<SEC-DOCUMENT>0001694665-20-000090.txt : 20201030
<SEC-HEADER>0001694665-20-000090.hdr.sgml : 20201030
<ACCEPTANCE-DATETIME>20201030083225
ACCESSION NUMBER:		0001694665-20-000090
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201030
DATE AS OF CHANGE:		20201030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evelo Biosciences, Inc.
		CENTRAL INDEX KEY:			0001694665
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465594527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38473
		FILM NUMBER:		201274858

	BUSINESS ADDRESS:	
		STREET 1:		620 MEMORIAL DRIVE
		STREET 2:		SUITE 200 WEST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 870 8281

	MAIL ADDRESS:	
		STREET 1:		620 MEMORIAL DRIVE
		STREET 2:		SUITE 200 WEST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evlo-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645,d:9309152dc4244de88c025672033625d7--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:evlo="http://evelobio.com/20200930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evlo-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8wLTEtMS0xLTA_bd9d1a0b-a6c4-4ba3-9c20-08e653b73841">10-Q</ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8xLTEtMS0xLTA_1ee536f1-c44c-4007-8b4e-ff6e4dd73324">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8yLTEtMS0xLTA_64ac82ca-53c8-46c2-b63f-da813a0bb251">2020</ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8zLTEtMS0xLTA_075f0447-4ef5-436b-a53a-a68bad4a9a61">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV80LTEtMS0xLTA_12ce9de8-c126-4e9e-a159-e2cf762a7783">0001694665</ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV81LTEtMS0xLTA_4dc54251-41cf-4335-bfc9-69840823c712">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731" name="evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNjgz_88021ac0-a529-40c8-86cd-253480fcf249">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i66830987cfbc412d9cfa324492f94b6a_D20200101-20200930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjIzOA_2e4a7638-383d-483e-b76d-0a2a2f8a433f">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i74487ec4f652475ab2a3c41c29dd618f_D20200101-20200930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg1Nw_74d83430-6831-4482-96e0-5983d9562632">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evlo-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8035dace6d484723b9e2770358a9e763_I20201028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i727b59e9eee84ab2b82d2423972c1f46_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37bfa021020a483b81d3d7f71c17fb85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170f27bed555450a960ed8a017f930d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666052e6e37f48afb5a6aae763ccc94d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e9b2138c64436299d7617a15d49ea4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9553d87f4ea46a3b3319afd5329cb7f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c43f7c78574e1d872e60fa8ff6cb0e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40d9d3d244843f498894e71017e9d48_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a337c69309946809c3142def8201268_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b37e4af397a4118b204e37457dee732_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad2f0cc24a5462b9661d795b6339101_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152ecd16776946888e51ea675f74bd45_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4d24e8c5004e208a5aaa7c929381a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b35cb2611543e9a26804e2b4845eba_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9c460b18c9443e9a10e22f70b04a5d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1115a5ba283435ca2ee0679245344cb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd90a3f9d90649d18c4f0e247aaa9b1c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8749a7d111c4b6e80fb618dde5fec7a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae6a95b363a49f1b083c4c98235266a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia597a7a81815459388e53a54a6edae64_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19330d3a0e2b4f32884d8c8d7d4e52f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i772516e37d4348288bfb7ead82e084bf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84dcaeb2960441fb8320dc401c4122ce_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id838f29aebd2439fad0dad587f16912b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd50cbcea0a4661a3adca182198a047_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7bc7d267b74b9994877e72a000f9a5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623396ade16641e89475195261e0c3bb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie136aa58c43d4d94b9f15bed3514eb71_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f329a1ae7344c5a6ee59a259cb9c0d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a551ca740a46139c2913fdee05a4b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca79798a26c4655b0162e901ca8ef98_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35deec7c65a44019b54cb1521fcd2ba_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e6055b96cc46ef9c60a122ec8ca1b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6081422c67a4959affb382889e30181_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8f41a0ea8041d3a56d432d4f829798_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b973735904d462b9458f1b40f1cf9d0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805997da9a164a49be9d13b7e742afae_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297bd608c3da4046877c9279b8ac3205_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2df3854b70d4b358592d4b7bbeada9d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f527d367b242c68fd17edc1580165f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445472023dd84c71b2bc0455e0f1a754_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90e130811884145a23fd79af66e4710_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c64ec573a044acbc4a84c3cee5b65a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ca8c3e2a57b4525b59221196e30a8a2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2616efd03a3846519ef8667220526fbd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f84b883b10466597e570d856ada5ad_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445a000730914ae9ad67896329d69891_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dc7b1f83b6487d924cdc369232095c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6eb482d639489094b6f3423352160e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a049ceec50142168d6b7cdca6b55c5e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19506e2ff4b405a8e57e3b847319cef_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if000c9350a8f4fa3bae7dd8d649a04d7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6400c85258fa4dfdb84406f6886223fe_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31920876cef41fda8536f18e104d5d1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca398585add43b0bee79e80e690e333_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54ea87091b054e0ab14959f3bdb971df_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0be4b8af0d144c6a8a31a5aa72508935_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:JuneOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd3ed046380c402e916b73b4e3b00f00_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:JuneOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfb404ffb8f4796939c3c659d253923_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-14</xbrli:startDate><xbrli:endDate>2020-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evlo:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia38f09c6713544c7bdac7b4ef58e8230_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="id4d98a0593604e4db29e81ca0e1ed08e_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iea25c6e18d36425baa31be5ed904178a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e795277073a42ab9298318fbeb02b69_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac86fce0f21b41e996c6c3824f421637_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a65273c2fc747578248931d9beaed19_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i815d7bddf0dc463bad9464271644bbe6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142ceba3efcb45ea958d6e85b6db1bf4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ded15f9f634b35ab6d912652a390dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba7ce22ac4e412aaff058cba3436fcc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01995a7366b14ec2aeb7be9fad8b500a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b0c348e01a4c26922b187713bd5bf6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ed7412637b46c8a8dbfdfb42b69661_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11bd6b0b98e54b1f9d4b6e9d9dc8b0b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c2dc7dd1162441085728c89b9000072_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3254063206b34f168fff62c3216eaf37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c9f5c9ddad943ce8f82cc180c9a0533_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b67f0fe6a5740e398b3f31ff3dd1588_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164f6350f5e344edacb0e9a6b68a1844_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220d743ead6c44fd9305f7880abca00e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea1dda588544015980d719168da2fa6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff5b25883e8f43038b8df1042fc86276_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a81634a68840829977fa5b44a68d41_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8f58fdec814720a8bc0f6960a616b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fda17f67d6e4f98be456487782da379_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d0061ad4354ae29fd62e2b60137505_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69bb769acc2400e94f81dd3cfb5831b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45be461d034047e1880917ae93e7b605_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22371425da1041168cf343492f01c4fa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>evlo:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5888734b31a84abe9cd96515a54830d4_D20201001-20210115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic924efafb0664fcc9352ca108ea8fc1d_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6af8e2843d54b498ab6811a2bdb9e01_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714d2fe395864b4fa7d700a7d8555b24_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36512fd07785419f8c346218b88c3574_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497af9117217436086fed1b12ad3d7a9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec21311cae448859c4bf7db77fa683c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc03be1a9fa44fa9fad574644a033f2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52af12becc094820bd3f1230018cdaee_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b24ece8af454852802d95c232d20b4f_D20170806-20170806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-06</xbrli:startDate><xbrli:endDate>2017-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76eb2613df44ca0bf34544038de3c75_D20170806-20170806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-06</xbrli:startDate><xbrli:endDate>2017-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5765428e6dc9410ba812e1aa42d7c4c2_D20170806-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-06</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2705dcad5b24a6489673679a8b632af_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e883ac26644ef6a592b975350598ff_D20160310-20160310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-10</xbrli:startDate><xbrli:endDate>2016-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6455f87ca54808a728b425104feb45_D20160310-20160310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-10</xbrli:startDate><xbrli:endDate>2016-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3aacf5203e14a5cb0bcbc6335830341_D20160310-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-10</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a9eed2f1ed471496cc34819ec412d1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc919b216958484baadfbaf3a5579160_D20190701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435a8ae096ae4da6bf33a4093a05df20_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">evlo:ExclusivityAndCommitmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:BioseIndustrieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a20243cb8d84ef18f004aae73258da3_I20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2a5654b6754515818e140c5b08761a_D20190603-20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-03</xbrli:startDate><xbrli:endDate>2019-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21297bf18f09435c9c8903a7a0fe13d7_I20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:SalesAgreementCowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f994741045472492789b1f3256cad7_I20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0331b53ef2c94cbdb3540b9c8689c650_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d66e58adfb6442daaf1ba85feaf140e_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8a41ea4f4146b0aebd206e1f94d0e0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66830987cfbc412d9cfa324492f94b6a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7436d15f4ad5490d93c800ee4ae5d465_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e85e8eb3804e36b93c6a30043a30b2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id857f9eb771f41fa9395bb219b6db368_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74487ec4f652475ab2a3c41c29dd618f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4a44fb4e8b48ac915b62b55ebffe17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ffbe5b60b54ac58b8345b0c3ce8b6b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f3aba8c3af44db97c1de2f2eb7d95b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf913522ccab41a9a9d188138fdc0c2b_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea04ebdbabf44bda8de9e1db8bbf68cb_I20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3445cdc78926417abcbfd87995b2d7ad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice9ffd1c5890497b8ba9733f662871de_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f970dc30ff49bc95066276f19569ef_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia237cd66629540edb0fdf167fb187799_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9707f9de1ed24944bcc195fb5a28ab50_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab3a97dae834644890cbda892fe5002_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220c4df4a97e4803892c37ccdd46a4e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ae55ffcb5b4b38b1294a478dba4306_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851cd9abcdca4743b9d2ea90d5b4eeb4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee55ced3b34d4b52a1a1f852c64d2e67_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-18</xbrli:startDate><xbrli:endDate>2018-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8463191a45964196b29df202007afc9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id704a4dd15bd403ab0cac9fc81b19ebf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102115e148ba457a9e0f7b80f0e81eae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e341efe8ff445c5bfac11f2c9f50db8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id804b1ab406a45b386f84874e2f511e9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a534ca0c824a918ef5b0b5cfd144f6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8832142a8fd34e73a080e4c3c2df3b1c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f093b1b4c194114a2857f69750073f1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a12b5d775194c26a646d257a891b43f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cef482e496443fa58c3e279239e38f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8535ad7567824b5eb8061e3eb77bcea4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040867f309fd4a60b8b170d1d3f8cb1a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bd8f29cd6a448ba1d11baf833a3e94_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ebbc6067103474782dd50c5fad869dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-16</xbrli:startDate><xbrli:endDate>2019-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>evlo:installment</xbrli:measure></xbrli:unit><xbrli:context id="iece4b57622c64cce95e2a617bf90bcaa_I20190916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i810d7c9e6e614a82ad32d53275585c7d_D20201011-20201011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-11</xbrli:startDate><xbrli:endDate>2020-10-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9309152dc4244de88c025672033625d7_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ZDRiYWNiNzMwN2MxNDIwNDgwMmJjNjFlZTU1YjdlMWUvdGFibGVyYW5nZTpkNGJhY2I3MzA3YzE0MjA0ODAyYmM2MWVlNTViN2UxZV8wLTAtMS0xLTA_5c4c739e-db79-4ff1-b6e6-956204fc4625">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8xMjI_c056b99c-e522-4280-8fc3-2896c7c70290">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YTc2Y2JhZmFiODFkNGNlYmIyZGNmYThjOTBkYTMwNWIvdGFibGVyYW5nZTphNzZjYmFmYWI4MWQ0Y2ViYjJkY2ZhOGM5MGRhMzA1Yl8wLTAtMS0xLTA_1a53bf10-6d6b-4dd9-9b2a-6cc9f91649cd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDM0_6027b6e4-0bf9-46b0-a0a9-49570307f81a">001-38473</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDM1_10e74ff1-5085-4d17-9a5e-361a67ef8951">Evelo Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8wLTAtMS0xLTA_34586973-8cce-437a-8a2c-00d9a5a1294b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8wLTItMS0xLTA_c1dfac12-adbb-43b4-97e0-74f7f567a04d">46-5594527</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M180_58d80ee4-c1a8-47c7-961e-3625533469bc">620 Memorial Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M183_2958cd51-176c-42bf-9d24-9da896cd2e96">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M18xMQ_0fca5973-3809-43a7-88ca-81b346cab497">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTItMS0xLTA_f4af5a8f-b83e-4958-bcda-a8d42c7d88d7">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDI4_f3fa56bd-3601-419e-9b4e-bf2e2771c0e5">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDI5_bd4bfddd-bd7f-4752-8cb5-45a74375d878">577-0300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTAtMS0xLTA_6fffb2bb-d1db-408f-af3e-83be354b4ac0"><div style="margin-bottom:0.5pt;margin-top:2.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock,</span></div><div style="margin-bottom:0.5pt;margin-top:2.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.001 par value per share</span></div></ix:nonNumeric></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTItMS0xLTA_66e67b91-194b-4657-a0c2-72b363f6e668">EVLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTQtMS0xLTA_5ee8ac65-1f7e-4b35-80f8-76be06c385c6">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMw_e2e71b8c-682c-40d0-bb9f-c49a8c152cc9">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMx_496a36dc-b0ba-4e78-8959-e9058ebb84c7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl8wLTQtMS0xLTA_cc18b781-6e8b-4055-abb4-d91d811b6b81">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl8yLTYtMS0xLTA_f4112f47-8aac-4a76-8f51-ccb8342d8935">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl80LTYtMS0xLTA_34306a40-7acc-4ef9-97c2-10928e36203e">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMy_bd9547a0-142e-416a-b73b-ccb66efdf42b">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMz_e3eaa9a1-5273-43c7-808d-826629793762">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 28, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="i8035dace6d484723b9e2770358a9e763_I20201028" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMTk5MDIzMjU3NjI4_212e2890-616c-48e5-8f9d-fb88382e2884">46,189,236</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9309152dc4244de88c025672033625d7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, the anticipated impact of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic on our business, business strategy, prospective products, product approvals, research and development costs, timing and plans for clinical trials, expected timing of the release of clinical trial data, new formulations and product candidates, the scalability of manufacturing for EDP1815, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and Part II, Item 1A. &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. These forward-looking statements are subject to numerous risks, including, without limitation, the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our status as a development-stage company and our expectation to incur losses in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our ability to continue as a going concern, our future capital needs and our need to raise additional funds;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build a pipeline of product candidates and develop and commercialize drugs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our unproven approach to therapeutic intervention;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients and volunteers in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish our own manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce our intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of clinical trials and the likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and retain key executives and attract and retain qualified personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manage our growth.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not occur or be achieved, and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9309152dc4244de88c025672033625d7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q for the Quarterly Period Ended September 30, 2020 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:94.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_13">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_16">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_19">September</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_19"> 30, 2020 and December&#160;31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22">Condensed Consolidated Statements of Operations and Comprehensive Loss for the </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22">three</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22"> and</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22"> nine</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22"> months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22">September</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22">&#160;30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25">Condensed Consolidated Statements of Stockholders' Equity for the three and</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25"> nine</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25"> months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25">September</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28">nine</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28"> months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28">September</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28"> 30, 2020 and 2019 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_31">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_31">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_73">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_73">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_76">Item 3. Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_76">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_79">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_79">35</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_82">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_85">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_85">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_88">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_88">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_91">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_91">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_94">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_94">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_97">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_97">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_100">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_100">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_103">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_103">80</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_106">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_106">81</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9309152dc4244de88c025672033625d7_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i9309152dc4244de88c025672033625d7_16"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i9309152dc4244de88c025672033625d7_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except per share and share amounts)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMy0yLTEtMS0w_c08b4b10-c8c4-48a6-9c8a-bce1806f1066">81,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMy00LTEtMS0w_96d847d5-69b9-4cf4-9dc7-979880c52aec">77,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNC0yLTEtMS0w_c9211aba-448f-457a-b159-a05e426e279d">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNC00LTEtMS0w_646f2d6d-02e6-402b-a86e-9eec63fff1b7">3,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNS0yLTEtMS0w_9b94ad98-14ec-4f43-8a2e-388450c6a502">84,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNS00LTEtMS0w_7e370f94-a825-4c6a-b67c-ce29c2711f34">81,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNi0yLTEtMS0w_f205a456-633d-4a00-8cfe-d85d93953631">7,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNi00LTEtMS0w_0b12bb4c-c02e-402b-aff9-d64be8e72be3">8,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNy0yLTEtMS0w_bb9fac55-0486-451e-b75c-952e054d1f63">11,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOC0yLTEtMS0w_2ebbc2e7-6cd0-4900-a95d-b8b486e493f2">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOC00LTEtMS0w_b7584406-43b0-4b93-aa87-118a42ec61a9">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOS0yLTEtMS0w_84d364b0-dbb0-4ea0-b72d-ea64594efae9">104,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOS00LTEtMS0w_bd4bf287-cf94-4e0d-960b-fc0e0c8f60ae">90,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTItMi0xLTEtMA_c4eef4b7-c6bc-4120-aed4-b09a4fc74d38">2,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTItNC0xLTEtMA_074d8d86-3e2e-4db2-ad48-e1814fa1390c">620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTMtMi0xLTEtMA_be1f98c1-78e3-4a6a-b7fb-f3a6e1054faa">8,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTMtNC0xLTEtMA_6c5bd1a2-c1c3-47fe-a11b-eceeb15e4569">8,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTQtMi0xLTEtMA_b7e0e958-9a06-46ff-933b-ad6271f949b0">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTUtMi0xLTEtMA_de67bdf2-4624-498e-9033-b7600f697bff">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTUtNC0xLTEtMA_343e9e22-622f-42ef-82b4-79b998e9a620">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTYtMi0xLTEtMA_682faefb-7509-4fe1-bacf-02cc55532f31">13,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTYtNC0xLTEtMA_ba77e26d-2021-4427-9a09-89b11fffaf60">9,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTgtMi0xLTEtMA_15fab411-66da-4bcb-b410-8e875603818e">29,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTgtNC0xLTEtMA_69712207-51d6-4201-9431-816fe0182b72">19,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTktMi0xLTEtMA_1cd50d75-f886-4bb3-94df-2b515006d0a3">10,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjAtNC0xLTEtMA_38adec06-e067-4a22-9ea3-2202f51daa9d">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjEtMi0xLTEtMA_414ac4b7-9a58-4718-bc3e-e673dc7e40c2">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjEtNC0xLTEtMA_ab0028cb-07ff-4c87-af7b-0dab631d2a3c">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjItMi0xLTEtMA_bcc3bb75-b099-4015-93b9-5462961ad55c">54,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjItNC0xLTEtMA_e8b69e3b-7d9e-486d-a89e-de27e159331c">30,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjMtMi0xLTEtMA_d2b756f3-1d87-47bf-96c3-f52ace944f50"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjMtNC0xLTEtMA_bab4da22-188d-44c5-9176-a9896f632201"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholder&#8217;s equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzIy_51349efa-f4c9-4b8d-a7d0-4716596866da"><ix:nonFraction unitRef="usdPerShare" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzIy_dffb5c48-88e5-4c9b-a914-36664887b95c">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzM2_3e2ee142-488b-4d33-afab-47c2d5034de8"><ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzM2_9d746aeb-c326-4242-8de9-66444869d099">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_386d7ee9-6670-4c9b-9d32-b0c09aab3923"><ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_703e21bb-2984-404a-b246-2b076d27756c"><ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_7884222e-0ef2-49dd-8a2e-aa3586465c95"><ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_b08e692b-70cd-4fd6-8b1a-3f48d6e65f93">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMi0xLTEtMA_730900d7-3028-427e-9b84-4b9a84fbf89c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtNC0xLTEtMA_502983b4-5501-4b81-a403-d2b15b53e3d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzE5_12c5e9ac-8c1d-4273-b535-9d7ee81d0c2b"><ix:nonFraction unitRef="usdPerShare" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzE5_c4d79dbc-f893-4035-ba5b-5d44e987f27d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzMz_4edefc1a-557f-4376-8139-b7ce8b557560"><ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzMz_a26d32b4-f8a7-4bcc-82e6-31389c1fccc5">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzU1_8dea5dc3-ed8f-4210-bfe2-64b68ea010f8">46,220,859</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzYy_602634e8-c1e4-4fb9-83ca-34289bc3b270">32,232,258</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzgz_8458e5ea-1c0b-4b8b-bd03-2e09c85023a3">46,184,087</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzkw_89bcb3b0-bdbd-4eb9-b614-93852d6e55db">32,170,605</ix:nonFraction> shares outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMi0xLTEtMA_f1de77b2-e859-4f7a-a0be-7c02871a27db">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtNC0xLTEtMA_0162c745-6be5-4375-a708-708adaf6777d">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjctMi0xLTEtMA_b692cec1-31c9-4a04-b6bc-c7d481bbefed">313,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjctNC0xLTEtMA_12babccd-5ab9-4526-9894-6a42b8402a5c">259,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjgtMi0xLTEtMA_97a8c418-0834-4084-8777-a8dfe3ad5648">263,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjgtNC0xLTEtMA_bde82bea-7d21-4c43-a08a-0beb7fefe61f">198,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjktMi0xLTEtMA_e92a8435-13d8-4f2f-a978-d9f08f6ff1bc">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjktNC0xLTEtMA_23d8e3ed-a455-4730-bee5-afa91c42db04">60,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMzAtMi0xLTEtMA_2389b484-5468-4da6-a6f7-ed9240b3ed8c">104,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMzAtNC0xLTEtMA_35264bca-1f62-4aee-9f53-6ad1e89a31ed">90,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy0yLTEtMS0w_a47d3b50-53c5-4fd8-9489-78f6abddedd9">14,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy00LTEtMS0w_3a6f371b-6ba2-425e-a244-0a73910aa4e7">15,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy02LTEtMS0w_54fca9e7-d88b-4027-83dd-01b52cd644b9">47,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy04LTEtMS0w_b4c0c407-b719-46ce-91fb-aa65a78b0785">46,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC0yLTEtMS0w_217d400a-f458-44ce-a664-e41e04c45c69">5,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC00LTEtMS0w_2a2c3907-8dd5-410f-b039-dce35a539d15">5,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC02LTEtMS0w_980318e7-571d-4eec-8a38-485a03018075">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC04LTEtMS0w_539547d7-b26c-44a1-8b8c-3c18edb1a613">16,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS0yLTEtMS0w_489fbae4-5fba-4222-ac27-584b99d3dbbf">20,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS00LTEtMS0w_16bcf49f-b083-4ca0-8399-89e33f025587">21,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS02LTEtMS0w_443f8753-20c8-4bb6-84d2-48f894c5bd4f">63,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS04LTEtMS0w_f2399d38-0c2a-41a3-bfd0-57a9903ed15c">63,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi0yLTEtMS0w_01935444-28a2-4519-acd7-4a6a728dbe24">20,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi00LTEtMS0w_8b1d0be8-ee97-44b4-bc53-8c943d348ac7">21,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi02LTEtMS0w_ea2b263e-8eb4-4f37-950c-1c1611488048">63,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi04LTEtMS0w_7ea647c3-9c84-4830-ac12-24a9d2b5e8e4">63,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC0yLTEtMS0w_cc7ebf33-07f4-43d3-b64f-a5d98536d641">713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC00LTEtMS0w_66e18d94-a68c-4678-ba6b-c02d703591f3">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC02LTEtMS0w_10bac847-193a-4150-9ddd-cccd6dec9194">1,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC04LTEtMS0w_d2cf3385-323e-49d4-8862-7db969b51a3f">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS0yLTEtMS0w_050a6cd4-9b88-476f-ad6b-94ffacbd529c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS00LTEtMS0w_decd80a2-7993-4b66-a3ad-2be3fee8fac8">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS02LTEtMS0w_de846662-672b-481d-a1b6-0da5bc98f754">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS04LTEtMS0w_f9ed6003-b7db-4bcf-b3d3-6c9fa4301098">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtMi0xLTEtMA_deb532d6-1fbf-4000-8200-15fc38543102">674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtNC0xLTEtMA_e5e14561-a974-4cd1-82d5-ebc31e17f333">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtNi0xLTEtMA_d0bfb0f6-28b1-4a87-a99d-a53d06fca097">707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtOC0xLTEtMA_8634c9f9-bef3-4cab-a1d5-f474ad5927c7">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtMi0xLTEtMA_5fab4b1a-c65e-4a9f-8ec8-4423b10f7ed7">20,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtNC0xLTEtMA_bf21de4c-7df5-4965-a092-ec55c1ae12f4">21,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtNi0xLTEtMA_88c2471c-4722-4ed2-beef-652a82113d9d">64,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtOC0xLTEtMA_d526120f-3c32-4f2c-a33a-61c5cfa17216">62,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItMi0xLTEtMA_67537611-e5bf-4fb2-b77c-a326131edbf5">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItNC0xLTEtMA_c07289cb-a471-4219-b67f-5128fbcd04c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItNi0xLTEtMA_e7e2d557-da83-4b36-80ff-e10e0144e92a">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItOC0xLTEtMA_e1455faa-d883-41c8-ae10-4a72a9aa41eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtMi0xLTEtMA_3d73ce16-c463-4236-89f2-5708408c9c49">20,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtNC0xLTEtMA_369fb1d1-320c-43a1-9a50-a74d2f7cc87e">21,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtNi0xLTEtMA_d1a6f8bb-f2f3-41df-96fb-67a8b80769ee">64,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtOC0xLTEtMA_391ec466-dab5-42d2-b35b-7b33b98b77c5">62,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtMi0xLTEtMA_e28abb5e-2a0a-474c-b753-6a0137d1f28a">0.45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtNC0xLTEtMA_49fb0a10-4b4a-49c6-beaf-678925c64dd0">0.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtNi0xLTEtMA_471b9862-c82b-400f-9b57-352a2a3252ad">1.74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtOC0xLTEtMA_a0360078-dd32-409a-a1f0-c7ada5b5f607">1.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtMi0xLTEtMA_f4b0f458-1b43-4b59-ab3a-aac42ebdd998">46,168,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtNC0xLTEtMA_eecb60fd-b9b9-4938-adb9-3dea091af871">32,060,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtNi0xLTEtMA_68ef445b-5feb-413f-9348-cfe6202afbeb">37,050,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtOC0xLTEtMA_4b3394e1-4416-4523-90d6-162d586ccdc8">32,009,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktMi0xLTEtMA_72f85ce8-5259-46c1-8c9a-f53407686d1f">20,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktNC0xLTEtMA_cd774acd-d1b1-49b8-9f68-6ce200f41daf">21,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktNi0xLTEtMA_0d879663-93ca-4bae-94d6-c601c70855ea">64,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktOC0xLTEtMA_95e0ca63-f2ef-42df-a88c-4f6a7b917d24">62,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_26d7db5e-1b8c-4d01-8f70-8b4231af7a7a"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_3d187d3f-f9a9-460d-bbfe-cc82d25d6fdb"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_958bb253-f675-4d0b-b386-86565836cdeb"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="INF" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_fcffb56d-a3d3-4ffb-8563-1dc048e55a37">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMi0xLTEtMA_02aada7b-bb0b-4ad4-827c-011b42e55e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtNC0xLTEtMA_36696629-1e03-49ae-be87-00dde532a7de">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtNi0xLTEtMA_aeca1359-6305-4247-94db-08d34de4aa41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtOC0xLTEtMA_0f5fcd11-aabc-4f0f-895e-0bd3bdeb680e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItMi0xLTEtMA_3fed857a-07d2-44f7-af10-72cf30baee05">20,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItNC0xLTEtMA_b22dec40-e285-46fd-a867-bcb4651308e4">21,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItNi0xLTEtMA_ba086f5b-b40b-4f4c-b2c4-b481cd8cd8c2">64,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItOC0xLTEtMA_3c781867-9f50-4eb5-8f4d-d263b2e22050">62,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i170f27bed555450a960ed8a017f930d8_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xLTEtMS0w_57c6d9a1-c49e-43a0-896b-32d0716fe844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170f27bed555450a960ed8a017f930d8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0zLTEtMS0w_806823bd-5b8c-4112-9bc1-037037f88df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i666052e6e37f48afb5a6aae763ccc94d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy02LTEtMS0w_8eb5a0cd-56d6-46eb-9c8c-b3cffdf73ad2">32,170,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666052e6e37f48afb5a6aae763ccc94d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy04LTEtMS0w_49466311-0201-41c9-8ac8-3d03eb980935">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e9b2138c64436299d7617a15d49ea4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xMC0xLTEtMA_79685ea8-b40b-4878-8687-ba34e4e16aac">259,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9553d87f4ea46a3b3319afd5329cb7f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xMi0xLTEtMA_b85d4bbf-2d3a-4d46-81ad-4a9b31848367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6c43f7c78574e1d872e60fa8ff6cb0e_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xNC0xLTEtMA_ef125ce3-f276-43ff-bd47-2ecbd23e0bb8">198,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xNi0xLTEtMA_9a2e5c55-bc5f-4f45-b424-07c6468ce147">60,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id40d9d3d244843f498894e71017e9d48_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC02LTEtMS0w_4a709a10-4db7-42e3-8229-f9f17570ba27">13,390</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC0xMC0xLTEtMA_b9df2100-775f-4c93-9771-b0803cc1e86b">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC0xNi0xLTEtMA_a5a68591-69a3-4dae-8d4f-b0c5c5907115">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id40d9d3d244843f498894e71017e9d48_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS02LTEtMS0w_585e9010-815c-419d-8021-3ae24389eab3">137,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS0xMC0xLTEtMA_aa9f6022-09e7-4b70-8e65-156ba37ff8ae">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS0xNi0xLTEtMA_37d7b416-c29f-4b3d-aa78-95ea7d44415d">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNi0xMC0xLTEtMA_d4cdf666-60fd-4a78-942a-ebe7b4756346">1,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNi0xNi0xLTEtMA_20914ea1-ca04-469f-a4a0-13a7390c947e">1,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b37e4af397a4118b204e37457dee732_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOC0xNC0xLTEtMA_8d280d97-51a2-470f-9f15-bd92dab80084">23,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOC0xNi0xLTEtMA_69354b96-4c20-4a7f-8e41-c34441ab854b">23,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-March 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ad2f0cc24a5462b9661d795b6339101_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xLTEtMS0w_5caf534c-c97a-46c2-95b1-0165dcd3010c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad2f0cc24a5462b9661d795b6339101_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0zLTEtMS0w_62d983aa-3836-4728-926d-597f57fa4139">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i152ecd16776946888e51ea675f74bd45_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS02LTEtMS0w_9f256518-e01d-472c-91b4-41ee39f04f1c">32,321,208</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152ecd16776946888e51ea675f74bd45_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS04LTEtMS0w_f986083d-50e4-40a1-9cbe-efeadb310e0b">32</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4d24e8c5004e208a5aaa7c929381a3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xMC0xLTEtMA_42673d3f-cbe6-4e01-8c99-3ba4c54893db">261,206</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b35cb2611543e9a26804e2b4845eba_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xMi0xLTEtMA_53eabdf4-b2f0-4003-b9af-a6f87ea0a346">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c9c460b18c9443e9a10e22f70b04a5d_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xNC0xLTEtMA_f5812516-4fa2-4056-9475-813eec5c8c57">221,894</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1115a5ba283435ca2ee0679245344cb_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xNi0xLTEtMA_5b441f60-8749-4ed9-83a6-f38fcfaffcc2">39,344</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in public offering, net of fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtNi0xLTEtMA_ac84eeec-f9ae-4ab6-a581-9ee761f8eec9">13,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtOC0xLTEtMA_99d42ac7-2e57-4498-87c5-468a0f11b823">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtMTAtMS0xLTA_d0b67908-7480-405a-9ca4-a8a792925bd3">48,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtMTYtMS0xLTA_74726a05-043c-453c-ab26-22afdc8626c4">48,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtNi0xLTEtMA_26ae76f4-d00f-4b10-b59a-3d14e1ac95d0">11,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtMTAtMS0xLTA_6b347bc6-3893-4350-a14a-f8753eed469f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtMTYtMS0xLTA_03de940a-3774-48b8-9a89-7dd380159066">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItNi0xLTEtMA_ac53eafd-f3ca-43e6-924b-88c0bb8ec390">3,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItMTAtMS0xLTA_dd9f2383-a62c-4089-acf5-24e8bc8fa5f7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItMTYtMS0xLTA_d17a8a51-3205-4f8a-9820-7d83b56746f2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTMtMTAtMS0xLTA_f7070bdb-07b7-4234-afe5-a0930eb718cb">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTMtMTYtMS0xLTA_c23c8c7f-001b-4797-b4d4-5234980f4242">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd90a3f9d90649d18c4f0e247aaa9b1c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTUtMTQtMS0xLTA_f99d4cbb-8d4a-4acf-a490-e4409df5cec4">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTUtMTYtMS0xLTA_7cf19059-8baf-4503-86a5-bfd4c22f8cc2">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8749a7d111c4b6e80fb618dde5fec7a_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMS0xLTEtMA_447c6824-a2ce-4116-943c-d81b593a839b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8749a7d111c4b6e80fb618dde5fec7a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMy0xLTEtMA_fe9a5299-5630-4b29-81ed-6761488f3c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ae6a95b363a49f1b083c4c98235266a_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtNi0xLTEtMA_853a8454-4bd7-4a6c-8944-fe51f49671de">46,136,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae6a95b363a49f1b083c4c98235266a_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtOC0xLTEtMA_d4635855-5257-493f-b2dc-c9b9683d39fb">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia597a7a81815459388e53a54a6edae64_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTAtMS0xLTA_956266c9-b01d-4c5f-affe-c308ba3d3701">311,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19330d3a0e2b4f32884d8c8d7d4e52f1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTItMS0xLTA_41f378dd-d734-4ac1-bc0a-8dd8cca15fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i772516e37d4348288bfb7ead82e084bf_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTQtMS0xLTA_36d149ec-5b43-4da4-8531-432ff18a4d4c">242,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84dcaeb2960441fb8320dc401c4122ce_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTYtMS0xLTA_a724c781-5f73-4d43-9525-804c751ed36a">69,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctNi0xLTEtMTU4_104e324e-6bf7-441f-9457-d62652cb738a">28,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctMTAtMS0xLTE1OA_9b164b51-d77a-4826-92eb-5e70e3302a0c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctMTYtMS0xLTE1OA_358d4904-011b-45e4-b195-6a33384d4586">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktNi0xLTEtNDA_1c26bd55-5d43-40bb-afef-f14a2f33b378">18,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktMTAtMS0xLTQ0_3db47e04-2ff6-4f44-a124-277f10c5c59d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktMTYtMS0xLTQ2_cd5ae94c-2c99-468f-b121-0c5b95aab8c1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTAtMS0xLTQ0_1b3498f6-91b3-4a44-8354-2ab166311b40">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTYtMS0xLTQ2_da241b90-8c90-48a6-96d9-1f7f5ee3629b">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fees associated with public offering of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTAtMS0xLTE2Nw_974d5211-8ac0-4ad9-8935-949464782a8e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTYtMS0xLTE2Nw_4b76eaf2-9619-4577-8397-d9501123bc8e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id838f29aebd2439fad0dad587f16912b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjItMTQtMS0xLTUw_ea856dc8-9d2c-4dcb-a07f-b9baac20dec6">20,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjItMTYtMS0xLTQ4_fa3cb6c8-1d1e-42ac-b3a1-f7d2765f9df9">20,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfd50cbcea0a4661a3adca182198a047_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMS0xLTEtNTI_724e52d3-c659-49c4-887c-4a966d369d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd50cbcea0a4661a3adca182198a047_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMy0xLTEtNTQ_664f1086-e812-41aa-9345-c3ce0c009328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d7bc7d267b74b9994877e72a000f9a5_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtNi0xLTEtNTY_d6c3685d-1734-46f9-a09b-1d5e5df39f07">46,184,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7bc7d267b74b9994877e72a000f9a5_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtOC0xLTEtNTg_9e401616-e7c2-4ade-bdf2-c1af3dae59ff">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i623396ade16641e89475195261e0c3bb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTAtMS0xLTYw_ec119a38-2f09-42e8-9efd-1a4d9537c670">313,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie136aa58c43d4d94b9f15bed3514eb71_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTItMS0xLTYy_5959e604-ff72-4d94-aaaa-44af4649b1ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f329a1ae7344c5a6ee59a259cb9c0d_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTQtMS0xLTUw_4fc85ff6-871b-490e-bf26-e4de45c01dbb">263,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTYtMS0xLTQ4_24d33b0a-deff-47cb-afce-ffe46bcdbf8a">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except share amounts)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:29.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5a551ca740a46139c2913fdee05a4b8_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xLTEtMS0w_61ebdd7f-ff7d-462b-9bda-3bd484726f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5a551ca740a46139c2913fdee05a4b8_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0zLTEtMS0w_b1d75aaf-aadd-493f-b21c-2382092abac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy02LTEtMS0w_3e15cacc-c358-43c0-af80-cf0be3c430c5">31,825,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy04LTEtMS0w_02d6db21-b16d-4313-9204-2aacc7d5ab23">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca79798a26c4655b0162e901ca8ef98_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xMC0xLTEtMA_f000d3af-4ce5-4f9f-84f1-874176ae16c8">250,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie35deec7c65a44019b54cb1521fcd2ba_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xMi0xLTEtMA_3049e8fa-88ca-4cd4-b912-2fe6105b01dc">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4e6055b96cc46ef9c60a122ec8ca1b1_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xNC0xLTEtMA_e74fa391-7253-4c4b-8325-50c8aa5dd7d1">113,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xNi0xLTEtMA_4ed3e191-23b6-4233-9fab-f251309471a4">136,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC02LTEtMS0w_4d1c9c10-281d-4566-8dcd-8c0bb2d5a596">23,345</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC0xMC0xLTEtMA_6397ef29-a0bb-4921-a81c-1a7802a8107a">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC0xNi0xLTEtMA_8497a107-8f1f-45fc-b298-bd222dfbce5b">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS02LTEtMS0w_a206f4b9-8df0-4d7c-b4d0-3c9c141ee69d">181,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS0xMC0xLTEtMA_d8b59165-5efc-46a1-8666-3a8e0504397e">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS0xNi0xLTEtMA_132b8f19-d3d3-4194-bc3b-f39b3030ae7f">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNi0xMC0xLTEtMA_b9f9dabb-c2af-4bd3-8cc4-8641c852863a">1,953</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNi0xNi0xLTEtMA_df611752-25df-46e9-b89e-57047b6dbfca">1,953</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8f41a0ea8041d3a56d432d4f829798_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNy0xMi0xLTEtMA_3b60523c-fc37-4e62-a30d-3b7edad44d6c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNy0xNi0xLTEtMA_f11408af-5cc4-4571-8e6f-2b827ac40c1b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b973735904d462b9458f1b40f1cf9d0_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOC0xNC0xLTEtMA_1f364f8e-6389-4843-a40a-947d43be624a">20,299</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOC0xNi0xLTEtMA_b8fd1cf5-189c-4adf-9a81-077e71c70075">20,299</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i805997da9a164a49be9d13b7e742afae_I20190331" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xLTEtMS0w_87935daf-68d4-484e-8bc8-c2b7ff457a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805997da9a164a49be9d13b7e742afae_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0zLTEtMS0w_0d6dc5ea-6f19-4fbd-8edf-b2b1b5404257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i297bd608c3da4046877c9279b8ac3205_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS02LTEtMS0w_6f4de162-c734-436d-b197-fa0f41ff3467">32,030,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i297bd608c3da4046877c9279b8ac3205_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS04LTEtMS0w_55c47969-c964-4781-b333-d2396dbcf207">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2df3854b70d4b358592d4b7bbeada9d_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xMC0xLTEtMA_aa153f2e-4da7-48db-95c9-87866ff7c566">252,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f527d367b242c68fd17edc1580165f_I20190331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xMi0xLTEtMA_db07fc42-b5aa-4e03-83ff-e2b50424751f">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i445472023dd84c71b2bc0455e0f1a754_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xNC0xLTEtMA_1f10e8c6-8403-45b3-97ea-dd298b42de2a">133,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90e130811884145a23fd79af66e4710_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xNi0xLTEtMA_c6a0141e-506f-4b6c-b2b2-ee9ab5f13a7b">118,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtNi0xLTEtMA_03c52afc-ba84-4e6e-8b8a-4af4b0dacf1f">13,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtMTAtMS0xLTA_51b5e4fe-cf57-490a-9b08-f45bec8fa467">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtMTYtMS0xLTA_dbc4fb03-6e64-4648-bed1-54d1762a555a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtNi0xLTEtMA_205c31ed-ed62-4d74-9899-eb21e0569aef">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtMTAtMS0xLTA_19441f0c-4826-4133-a287-297be1266019">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtMTYtMS0xLTA_0827da59-46e0-49d2-a01a-c4160340b08c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTItMTAtMS0xLTA_d14a4ea6-e9e0-4a08-85ca-ccf823256409">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTItMTYtMS0xLTA_8d1b512e-e278-4b84-a3e3-2cf02222a0d3">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c64ec573a044acbc4a84c3cee5b65a_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTMtMTItMS0xLTA_9afb20cc-c17f-4fbd-993a-0a266819d74a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTMtMTYtMS0xLTA_1d99904e-204b-45f7-9e28-de61b58ddc8a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca8c3e2a57b4525b59221196e30a8a2_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTQtMTQtMS0xLTA_b12a8b2e-e495-47f6-bc9e-d1294c9039e3">20,941</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTQtMTYtMS0xLTA_71dba778-6ab7-4f4c-869a-95990bc61b5c">20,941</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2616efd03a3846519ef8667220526fbd_I20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMS0xLTEtMA_10e24c4e-dea2-498d-934f-f9903b726c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2616efd03a3846519ef8667220526fbd_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMy0xLTEtMA_e81ae37c-c241-49d5-b6f8-a1cadd764c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39f84b883b10466597e570d856ada5ad_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtNi0xLTEtMA_4752f943-abfd-48d9-833f-7e6b91b4b933">32,045,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f84b883b10466597e570d856ada5ad_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtOC0xLTEtMA_584a0b44-ef07-4382-b33d-343e37809a8a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445a000730914ae9ad67896329d69891_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTAtMS0xLTA_c7411d2d-3bf5-4899-a0be-f5bbc0aa9d62">254,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38dc7b1f83b6487d924cdc369232095c_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTItMS0xLTA_d6c79caf-b618-448f-996c-3520404b385d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6eb482d639489094b6f3423352160e_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTQtMS0xLTA_e01bc829-2294-466d-b6af-f84dcf5b8a47">154,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a049ceec50142168d6b7cdca6b55c5e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTYtMS0xLTA_4c7b17b8-3ef3-4a2f-868a-2e8139965649">100,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtNi0xLTEtNjQ_43b326b1-5a21-4b8c-b44a-51e8babe9c71">13,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtMTAtMS0xLTY2_a1552ffa-a26b-4482-8110-ed25d5dfcfc6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtMTYtMS0xLTY4_7bab4e03-9313-46c9-92b8-30286d06467d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctNi0xLTEtNjQ_e9b9ddbd-e708-4f2d-aead-e61bccbda4b0">12,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctMTAtMS0xLTY2_138f1c13-3f1a-4447-b99c-99be57f0cf85">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctMTYtMS0xLTY4_eb5e4a78-801d-4158-9fd3-12692469083f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTgtMTAtMS0xLTY2_d32351f1-aaa1-41a6-bfbe-5cca6ed88e40">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTgtMTYtMS0xLTY4_d556cb4e-be95-457c-a584-f9da2dcc5a70">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id19506e2ff4b405a8e57e3b847319cef_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTktMTItMS0xLTcy_d6fc493f-9c71-4651-b1f9-ddb18c341970">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTktMTYtMS0xLTY4_64f425d4-93f3-4f52-8873-3b7f74f36cb4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if000c9350a8f4fa3bae7dd8d649a04d7_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjAtMTQtMS0xLTcw_5eb47347-1d1b-4a9b-88ad-fc17776ad8a9">21,633</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjAtMTYtMS0xLTY4_2f9a7225-2847-4448-8c84-429b0a1f3c27">21,633</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance-September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6400c85258fa4dfdb84406f6886223fe_I20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMS0xLTEtODQ_0a0dfeba-2cae-4d78-b9d0-5c0f95b3ed5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6400c85258fa4dfdb84406f6886223fe_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMy0xLTEtODI_b37d7320-e356-4d14-8c7d-b5b8577fd466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtNi0xLTEtODA_de8c9cbf-8e67-4afe-adfa-faca040dde2e">32,072,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtOC0xLTEtNzg_f576f79d-2b34-48d8-8259-289bd3f7a89e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31920876cef41fda8536f18e104d5d1_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTAtMS0xLTc2_deb3ffcb-7041-44c2-b22b-c01c638ca4f7">256,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca398585add43b0bee79e80e690e333_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTItMS0xLTc0_d5ac4c90-40a8-40f3-933c-723075b68dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54ea87091b054e0ab14959f3bdb971df_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTQtMS0xLTcw_9163124d-540f-48f1-b789-13fb780d08e4">176,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be4b8af0d144c6a8a31a5aa72508935_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTYtMS0xLTY4_83cb3e2f-397f-44ac-a69d-5c149ac08d7f">80,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMy0yLTEtMS0w_992c196e-a8df-4c2c-abc6-96aac1a19cd0">64,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMy00LTEtMS0w_f0348bf9-7ce7-4388-88aa-9b7f937389e7">62,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNS0yLTEtMS0w_f56612d6-e6d8-489d-84b1-ce9d36d6ef51">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNS00LTEtMS0w_65f0e332-e974-4588-8ca4-9dc5309eb280">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNi0yLTEtMS0w_a30fc9b2-9d94-46bf-b33d-999ec96939ec">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNi00LTEtMS0w_8123cbcd-eb25-4bd1-a7a3-ac4e4ca002e2">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net accretion of discount marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNy0yLTEtMS0w_bfa22839-ffa3-4daf-800e-3befdb396b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNy00LTEtMS0w_49550273-9be8-4ab7-bf31-641f0200cfd1">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="evlo:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOC0yLTEtMS0w_0b5e40eb-14cb-409e-a9ce-2e454cbdc0c6">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="evlo:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOC00LTEtMS0w_1351e04f-1363-452d-94c7-dc92d1b10594">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="evlo:NonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOS0yLTEtMS0w_fa77ccd9-cbc0-44b3-9b49-b2be2d25881c">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of fixed assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTAtMi0xLTEtMA_fafbbd02-40f9-4eca-aedf-546b26b22723">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTAtNC0xLTEtMA_057a64da-4f3d-4c14-9982-26a6d48f8c94">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTItMi0xLTEtMA_1944f654-76ef-4bf4-954e-ad9dfbcb8e9d">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTItNC0xLTEtMA_d0598e1c-5749-4b78-9c87-f321d2a46607">633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTMtMi0xLTEtMA_988bf271-4e6c-4f5b-bcbb-d5d1ec123234">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTMtNC0xLTEtMA_d12a5d2b-0785-48d5-b434-1c5bf28b3763">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTQtMi0xLTEtMA_33b115ca-8206-46eb-ada6-1d23e323d569">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTQtNC0xLTEtMA_8813d25c-5ed5-46a1-9aef-3592020df8ed">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evlo:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTUtMi0xLTEtMA_6d51e923-6677-4d82-a155-e4f62167ae3d">1,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="evlo:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTUtNC0xLTEtMA_2e091e78-f554-48fd-b372-1fc73e928d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTYtMi0xLTEtMA_d6f88607-2801-488f-a3b8-ab1813fe97b5">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTYtNC0xLTEtMA_85b4bdab-8b89-4e00-8fda-c2d7ecd36595">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTctMi0xLTEtMA_00d82e93-e91f-4224-9473-eee96966997d">54,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTctNC0xLTEtMA_2a555a86-75e0-45f7-b97c-27709b2038cc">52,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTktMi0xLTEtMA_4eab0728-21c1-473f-abcb-616b7ecc6bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTktNC0xLTEtMA_c8e519f6-79bb-4baf-8fa3-bb8a285e533b">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjAtMi0xLTEtMA_c5a550bc-2c5d-438d-b107-aefb5b7572e3">912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjAtNC0xLTEtMA_776d6492-2f91-48b4-8d7c-a972e4460ff7">2,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjEtMi0xLTEtMA_5f0a6ef4-1caf-4bb3-85f4-ef85049d221b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjEtNC0xLTEtMA_118593c1-e163-427a-b30b-09647c363c09">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in)/provided by  investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjItMi0xLTEtMA_3f4a0564-040d-4b01-b34f-1dbf74384839">906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjItNC0xLTEtMA_9b94a865-329a-4137-ab75-d1b13f667736">52,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from the issuance of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjQtMi0xLTEtMA_525c749f-1488-4c59-9ff0-f216c2741cfc">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjQtNC0xLTEtMA_92433e3e-5cc6-4251-839e-b67fd2869a63">19,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtMi0xLTEtMjEw_37f14d6f-058c-4ec0-9268-13923d3ea152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtNC0xLTEtMjE0_4dc2a880-c2af-4727-8482-16d84cb6fda6">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtMi0xLTEtMA_f010a158-6fe3-46ba-8ea1-60671fbfd0d8">48,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtNC0xLTEtMA_50fafbf2-ec91-45a6-8626-0f524047c6c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjYtMi0xLTEtMA_3c897ecd-9b53-4963-b7fd-e50e06977099">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjYtNC0xLTEtMA_bbcbcd79-2393-4694-b2a2-2acb86862ac7">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjctMi0xLTEtMA_175dc62a-3a31-4df7-adf0-0896731687a3">58,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjctNC0xLTEtMA_1f438928-65c4-4657-ba20-ddd74699c629">4,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjgtMi0xLTEtMA_3967bcd2-bb3f-4fc7-b7ac-94e7dd7371d9">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjgtNC0xLTEtMA_17cbac85-69cd-4943-8065-18a29b967a06">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8211; beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjktMi0xLTEtMA_b1fe98d0-1910-4a8c-9e0f-a0f8c5736f2e">79,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjktNC0xLTEtMA_e66e3891-bca2-46c1-87e0-94920abb8531">94,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8211; end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzAtMi0xLTEtMA_1b9d9e63-dcf8-422c-869f-dc514624f92b">83,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be4b8af0d144c6a8a31a5aa72508935_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzAtNC0xLTEtMA_d5a70720-0619-40fe-8a5d-2b402d8f1cda">98,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzItMi0xLTEtMA_7de713cd-958b-4b78-bc63-231f694a5caa">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzItNC0xLTEtMA_f2a62df2-73a8-4e21-88a8-aabde5d21e10">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzMtMi0xLTEtMA_dbcb0dc3-698d-4373-9eb1-391d432f8617">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzMtNC0xLTEtMA_1749431c-64d9-4363-be8b-9bc15ddac75d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing and public offering costs in accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzUtMi0xLTEtMA_b88307fb-30be-44e4-9463-984e7134fec4">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzUtNC0xLTEtMA_95c36bf2-c714-40b5-93bc-54461e835d0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment additions in accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzYtMi0xLTEtMA_4df2063f-bf0c-4687-a181-f07000c3e796">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzYtNC0xLTEtMA_6620a1f4-1cdc-4ef7-b489-3fcec751e1c4">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVELO BIOSCIENCES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i9309152dc4244de88c025672033625d7_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfNDU5OQ_4cea0626-a38a-4c5a-b77c-1ccb84cdb769" continuedAt="ica576871bd6840059d42f058238a6402" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="ica576871bd6840059d42f058238a6402"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences, Inc. ("Evelo" or the "Company&#8221;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing oral biologics designed to act on cells in the small intestine with systemic therapeutic effects. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTEzNA_16912fb4-69ae-4d0e-b7b3-1744c79f1812">13,800,000</ix:nonFraction> shares of its common stock in an underwritten public offering at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icd3ed046380c402e916b73b4e3b00f00_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTIyOQ_71f9dfa2-da28-4df6-848f-b06753ac1107">3.75</ix:nonFraction> per share, including the underwriters' exercise of their option to purchase <ix:nonFraction unitRef="shares" contextRef="i4bfb404ffb8f4796939c3c659d253923_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTMwOA_3bdf985d-d86d-464f-b1b4-430bff9d1df6">1,800,000</ix:nonFraction> shares to cover over-allotment, generating gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTM3Mg_373d7586-95a0-4574-a994-81b590987f00">51.8</ix:nonFraction> million and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTQwNQ_5967417a-5034-4a57-9c15-bc17ac052ce9">48.4</ix:nonFraction> million, after deducting underwriting discounts and commission and other offering expenses payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 14, 2020, the Company drew down the second tranche of $<ix:nonFraction unitRef="usd" contextRef="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTA5OTUxMTY2NTQxOQ_5ce86f55-c5d9-4564-9a00-17703e40cee7">10.0</ix:nonFraction> million available under the 2019 Credit Facility. Refer to Note 6 to these unaudited condensed consolidated financial statements for more information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of September 30, 2020, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMjA3MA_77c63195-bf17-4926-8556-b5da8c388c1b">81.6</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMjEwMw_e6169e5d-d901-4c51-9ee2-a69a7bf8b71c">263.5</ix:nonFraction> million. </span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="evlo:SubstantialDoubtAboutGoingConcernPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfNDYwMA_90e8f8ea-484b-456b-a3a8-6a3924c64c97" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. The transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure. Based on the Company&#8217;s current operating plan and due to the uncertainty related to the impact of the COVID-19 pandemic and the nature of Evelo's business, the Company has substantial doubt that its cash and cash equivalents at September 30, 2020 will be sufficient to fund operations and capital expenditures for at least the twelve months following the filing of this Quarterly Report on Form 10-Q, and the Company will need to obtain additional funding. The Company intends to pursue strategic partnerships and collaborations, or obtain additional funding through its available financing sources which include, additional public offerings of common stock and private financing of debt or equity. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. There can be no assurance that the Company will be able to obtain additional funding on acceptable terms, if at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources at September 30, 2020, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTA_9a194f17-f603-4eb4-8eff-d3142b3eadd1" continuedAt="i90aa8a1ffc8c4b4eae010c22aba825db" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i90aa8a1ffc8c4b4eae010c22aba825db" continuedAt="if00aeecb301f4ace94edb2bef6b92997"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTg_50b6cd6a-6ffc-4a19-9200-dd370ba208f1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of September 30, 2020, the results of its operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results for the year ending December 31, 2020, or for any future period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTk_3a1b61ff-ba50-4eb9-9962-a5ff76a56628" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYzMDA_8e925b1b-9a69-4126-86aa-e4d2c1fefd48" continuedAt="i7b72e29cb89e417da2c012820c8312fe" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b72e29cb89e417da2c012820c8312fe">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTE_965fbcec-e406-4913-b6cb-074547181dd7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Event Considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the unaudited condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure in this Quarterly Report on Form 10-Q.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="evlo:EmergingGrowthCompanyStatusPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTI_ffa6b560-a947-41dd-937b-1a87dce4a4f7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><ix:continuation id="if00aeecb301f4ace94edb2bef6b92997" continuedAt="i4c6d533c1a674db5960173fe80bb61c3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODc_0217ce7b-4505-4399-8af3-e14bf26564a8" continuedAt="i338bfd170a624684b8cb84a0a592ed17" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i338bfd170a624684b8cb84a0a592ed17">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss.</ix:continuation> The Company's only element of other comprehensive loss is unrealized gains on available-for-sale investments, which the Company held in 2019. Comprehensive loss totaled $<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDg1OQ_f67bcf21-d058-4ea0-b882-4dd12b155d23">20.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDg2Ng_40868913-662d-429b-a825-a43a006d021a">64.6</ix:nonFraction> million, respectively, for the three and nine months ended September 30, 2020. For the three and nine months ended September 30, 2019 comprehensive loss was $<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDk4NA_f447f970-41db-4dbf-905f-578379f3c6cf">21.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDk5MQ_9c316ca5-8e8d-4feb-aa0e-a87b79c8bee0">62.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTM_5122f0a2-8f34-4ce5-954d-5e1b4b250990" continuedAt="ibad0456dfb3d4e988219cddc1448e09e" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibad0456dfb3d4e988219cddc1448e09e">Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility.</ix:continuation> Restricted cash totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNTYxNA_44e72804-411c-4074-985a-4b6c15848819"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNTYxNA_ef6f1bdc-eb87-485e-bbcc-a5896a63838f">1.5</ix:nonFraction></ix:nonFraction> million at September 30, 2020 and December 31, 2019, and is classified within other assets on the accompanying condensed consolidated balance sheet. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODg_e7680694-17b3-4984-8589-9e66c84fd63f" continuedAt="ia4da1faf9d2e40689acc15ff5592915f" escape="true"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMjE5OTAyMzI3MTg1Nw_f25a262b-6589-47fe-b9f3-6450e5d77933" continuedAt="ia5e29cde77fd47cc9dcd39bc510bb88c" escape="true">The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><ix:continuation id="ia4da1faf9d2e40689acc15ff5592915f"><ix:continuation id="ia5e29cde77fd47cc9dcd39bc510bb88c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMi0yLTEtMS0w_b05adfa6-226e-402b-b0ba-1d8faf158010">6,830</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMi00LTEtMS0w_d622900d-96d3-4adc-8831-6482fb44983a">1,634</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMy0yLTEtMS0w_fce03112-76c1-4c9c-957a-7fd561f94041">74,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMy00LTEtMS0w_d1760329-6be3-40ac-a8fd-fa4f97728dfc">76,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNC0yLTEtMS0w_41f244ae-2283-41be-9689-4b3c3fb34a3e">81,580</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNC00LTEtMS0w_2733d3bd-f624-479d-9651-c00a4353846b">77,833</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNS0yLTEtMS0w_d621522a-5fc2-486c-91c5-50273b38a1ef">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNS00LTEtMS0w_43e6ba7e-b2b0-4e72-af07-6bba6eca4671">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNi0yLTEtMS0w_e4192c6f-16ad-459f-9c72-933d755e3770">83,080</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNi00LTEtMS0w_e00c5048-abb3-4916-b8ef-a347a59f7492">79,333</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYzMDE_11f399a2-6bc1-44d2-9c3c-879806273e45" continuedAt="ibf7799f62b8f40bdb4f3cc5bd2e87ff2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><ix:continuation id="i4c6d533c1a674db5960173fe80bb61c3" continuedAt="ie7e9a51cd55c48a1bc66f4defb66a7ae"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf7799f62b8f40bdb4f3cc5bd2e87ff2">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</ix:continuation></span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODk_bc3b07fe-f329-4e24-943e-6981616670e0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMzI5ODUzNDg5OTYzMQ_26469262-3763-4115-b767-2db42c5f23ee" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for options granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMzI5ODUzNDg5OTYzMg_f9bb88f1-5fc6-426d-9522-1255df5e1a07" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTExNjk_6e99d281-9d1c-4f41-9412-77472b1569ba">one</ix:nonFraction> operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><ix:continuation id="ie7e9a51cd55c48a1bc66f4defb66a7ae"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTU_222c9a22-70ee-4c7c-b847-f7042a17dd57" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;), which supersedes the guidance in former ASC 840, Leases. The new accounting guidance requires recognition of all long-term lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. It requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The FASB subsequently issued several ASUs amending the new standard. This guidance is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018 for most public entities. The Company adopted this new standard on January 1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2016-02 provides a number of optional practical expedients in transition. The Company elected to adopt the 'package of practical expedients', which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, and (iii) not to reassess initial direct costs for any existing leases. The Company will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#8217;s January 1, 2020 condensed consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="ia38f09c6713544c7bdac7b4ef58e8230_I20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTM0NDM_9fbed6b1-0912-4707-ab09-ba069a98f87d">12.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia38f09c6713544c7bdac7b4ef58e8230_I20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTM0NTA_cb08a7b4-c75e-48ad-8128-cd21e9494273">13.9</ix:nonFraction> million, respectively. There was no material impact resulting from the adoption on the Company&#8217;s unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2020. For leases with terms greater than 12 months, the Company records the related right-of-use asset and lease liability at the present value of lease payments over the term. As the Company&#8217;s leases do not provide readily determinable implicit interest rates, the Company utilized its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The application of the new standard required netting of unamortized balance of lease incentives and deferred lease obligation to the right-of-use asset at the adoption date. The Company&#8217;s operating leases include rental escalation clauses that are factored into the determination of lease payments when appropriate. The Company does not separate lease and non-lease components of contracts. Refer to Note 3, Leases within these unaudited condensed consolidated financial statements for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting (Topic 718) ("ASU 2018-07"), which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. Entities will apply the ASU by recognizing a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the annual period of adoption. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of this standard did not have a material impact on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September 30, 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTQ1MA_1e395ad4-a9f0-4784-9381-7275c3a35768" continuedAt="i3c21e96de5094a6389350209b6873e15" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i3c21e96de5094a6389350209b6873e15"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="id4d98a0593604e4db29e81ca0e1ed08e_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTE0_53446e3a-2292-40b9-b1a7-bc21510041c7">40,765</ix:nonFraction> square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfNzY3_fa856df0-6816-4f17-b730-03f97b2a4381">0.2</ix:nonFraction> million for the nine months ended September 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, the Company recorded rent expense of $<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTY0OTI2NzQ0NTA2Mg_66aba4ed-1208-4c61-84c8-77a6aa192ab5">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTAzNg_04536600-523e-4498-9867-88287bb12e67">2.1</ix:nonFraction> million, respectively. Rent expense for the nine months ended September 30, 2020 is net of sublease rental income of $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMTAyMg_8ea8c70e-bd37-436c-bf27-e04de661f07b">0.3</ix:nonFraction> million. There was <ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMjE5OTAyMzI1ODkxNQ_523275fd-9621-49e5-bd21-45afa2b4bd4e">no</ix:nonFraction> sublease rental income for the three months ended September 30, 2020. For the three and nine months ended September 30, 2019, the Company recorded rent expense of $<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA0NDUzNjA0NjczMDI_b139049b-cba1-41e4-92a4-b90196ecd0db">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMTA1OA_6cc449cb-188a-4abf-ad06-b150f8028a3c">2.0</ix:nonFraction> million, respectively, which is net of sublease rental income of $<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMDE5MA_84a70367-d7e2-44ad-93fc-3a1a3c3da0a4">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMDA1Mw_fff810e2-65be-4a3b-8b7b-c7c846d32364">0.4</ix:nonFraction> million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.</span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTQ1MQ_eaa093fa-8724-42d2-a5bc-507427d5e531" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments, exclusive of any offsetting sublease rental payments, at September 30, 2020, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding payments made as of September 30, 2020)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMS0yLTEtMS0w_438c4959-2566-461c-9bac-9d434492dc1a">493</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMi0yLTEtMS0w_0b8f33c3-5c17-4689-b18b-cae23ad6a869">2,973</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMy0yLTEtMS0w_0f9df962-cc9a-4c1c-b903-df2597bc6753">3,062</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNC0yLTEtMS0w_285bb605-d43e-4bd2-8c43-e4485d22b357">3,154</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNS0yLTEtMS0w_7584d919-b575-4226-b044-f23c507a941c">3,249</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNi0yLTEtMS0w_e0bf19b4-f537-49ba-a97e-36754b0d676a">2,491</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNy0yLTEtMS0w_7eb5390a-7038-47cb-b0c1-d5c8668fe458">15,422</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfOC0yLTEtMS0w_2397358a-1662-4c8e-9bbb-dfa7a1b11e09">3,312</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfOS0yLTEtMS0w_7385d387-d7e9-453d-850e-957b15addc57">12,110</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTItMi0xLTEtMA_ed982c9e-d016-4117-84f5-7ef7a4336363">2,596</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTMtMi0xLTEtMA_c0026859-4d2c-44a1-8c1c-a0b84ea173d7">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTQtMi0xLTEtMA_f0151ac3-5ef0-47cc-89bd-dd4f0d992c84">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RleHRyZWdpb246Y2ZiOWEyNGRlOTYwNGM0MDllNDE4ZDNjNWEyNDRkYjlfNTMw_d2cb5ca1-7937-4aa4-8470-ef259dc7c0eb" continuedAt="ibef20dd85ba44e088f0aec0c11715f3a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ibef20dd85ba44e088f0aec0c11715f3a"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RleHRyZWdpb246Y2ZiOWEyNGRlOTYwNGM0MDllNDE4ZDNjNWEyNDRkYjlfNTMx_ddfef71c-1c0b-4d51-afe6-f27e4a7a942b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea25c6e18d36425baa31be5ed904178a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi0yLTEtMS0w_8ed9a021-1635-4e72-ab7f-fa4bba0af731">74,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e795277073a42ab9298318fbeb02b69_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi00LTEtMS0w_130a76fd-99aa-4791-b74c-92ff2b54de54">74,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac86fce0f21b41e996c6c3824f421637_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi02LTEtMS0w_b95eac8b-3251-430b-bf6e-293e289775ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a65273c2fc747578248931d9beaed19_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi04LTEtMS0w_999f00f4-449c-4340-8487-1508bfdcb136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy0yLTEtMS0w_894b0f58-0111-4f89-a271-97b78a16ee97">74,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815d7bddf0dc463bad9464271644bbe6_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy00LTEtMS0w_3a6de927-3807-45c9-baf2-d71282cc7877">74,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ceba3efcb45ea958d6e85b6db1bf4_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy02LTEtMS0w_03e7de29-870e-4586-ad02-80bae07ed308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ded15f9f634b35ab6d912652a390dc_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy04LTEtMS0w_871e61c5-f796-49d5-a2b1-602e5ee93445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba7ce22ac4e412aaff058cba3436fcc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi0yLTEtMS0w_05a7a6ca-a57c-4a89-a60b-2b9ffd0eb45e">76,199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01995a7366b14ec2aeb7be9fad8b500a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi00LTEtMS0w_5cd76028-66be-435f-a119-dc6304feed9b">76,199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b0c348e01a4c26922b187713bd5bf6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi02LTEtMS0w_c046f68b-b3ab-4797-a5c0-7a312d8067fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ed7412637b46c8a8dbfdfb42b69661_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi04LTEtMS0w_d1ba9a05-3744-47f1-a497-9f1f6adc5f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy0yLTEtMS0w_ad16d93b-a231-4b9b-b7e1-a3d8754d4da6">76,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11bd6b0b98e54b1f9d4b6e9d9dc8b0b1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy00LTEtMS0w_50ae48f1-ec60-419c-ab72-7c9566e0cb78">76,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2dc7dd1162441085728c89b9000072_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy02LTEtMS0w_df52b260-accd-4ef1-aea5-b369400947e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3254063206b34f168fff62c3216eaf37_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy04LTEtMS0w_bf3f152a-600e-42bc-ad16-15cd42d819e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September 30, 2020&#160;and&#160;December 31, 2019, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.</span></div></ix:continuation><div id="i9309152dc4244de88c025672033625d7_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjU1_83f48a98-4aff-4170-a774-18f6277aa7ad" continuedAt="ifdf8c62d76bf45acaed29e10dfb8407a" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="ifdf8c62d76bf45acaed29e10dfb8407a"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjU2_a2040336-e952-4bd1-91a7-07827177fd03" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c9f5c9ddad943ce8f82cc180c9a0533_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMi0yLTEtMS0w_6bc2e94f-6e4c-4c82-acd6-4f295b69e25f">8,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b67f0fe6a5740e398b3f31ff3dd1588_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMi00LTEtMS0w_1b1423de-0492-45e1-954d-67261a5045a1">7,479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164f6350f5e344edacb0e9a6b68a1844_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMy0yLTEtMS0w_73d6c360-4498-4e2b-99ab-ef118b13962a">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i220d743ead6c44fd9305f7880abca00e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMy00LTEtMS0w_24f27f10-ae9b-4047-abe7-488a4c16f511">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea1dda588544015980d719168da2fa6_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNC0yLTEtMS0w_7318e2ab-2072-4d62-899f-f2ab8ee1f5f5">822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5b25883e8f43038b8df1042fc86276_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNC00LTEtMS0w_051356aa-ed02-446e-8ed3-bd210e3a10cd">750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a81634a68840829977fa5b44a68d41_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNS0yLTEtMS0w_fc79cea5-3e05-4c65-8b5d-592aa5edc1ed">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8f58fdec814720a8bc0f6960a616b6_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNS00LTEtMS0w_a1714f6d-7370-47d2-a032-4c6d1c6b580e">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fda17f67d6e4f98be456487782da379_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNi0yLTEtMS0w_c1a25d66-697a-4c2b-aaa5-60b1eae5a74e">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d0061ad4354ae29fd62e2b60137505_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNi00LTEtMS0w_724b5724-8364-44dd-a7de-eaef9ff39c64">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69bb769acc2400e94f81dd3cfb5831b_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNy0yLTEtMS0w_ff249c46-1bdf-4b5e-8991-ff1ebd89a5a3">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45be461d034047e1880917ae93e7b605_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNy00LTEtMS0w_140e33c2-89ea-46a2-80d7-33363476e481">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOC0yLTEtMS0w_cb70c377-8e9c-43d7-883f-df8c35e7438b">12,695</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOC00LTEtMS0w_e0c28579-e624-43de-b371-726cdbfbf6c3">12,050</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOS0yLTEtMS0w_d35a09e5-4a99-4e6a-90fa-f7c00ba79ad2">5,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOS00LTEtMS0w_09c6b085-f853-4bec-be13-21ff7eaa9983">3,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMTAtMi0xLTEtMA_9533de16-3b5a-4e64-bd5e-965a67dc9c16">7,586</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMTAtNC0xLTEtMA_c56170d5-9a69-44b3-a1f8-e3a13f8d44b3">8,341</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMTI2_3779388f-a601-4fdb-b27a-c721eb18a132">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMTMz_0992c7dd-2216-4bda-93a6-a958159f05db">1.5</ix:nonFraction> million of depreciation expense for the three and nine months ended September 30, 2020, respectively and $<ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjA1_d9aa8c92-0e12-4052-9770-dbc533ad7faa">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjEy_0d56243b-3bc8-4979-9f5c-525a00080a46">1.3</ix:nonFraction> million for the three and nine months ended September 30, 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjE5OTAyMzI2MDcwMw_01b3b6f8-aa95-4736-bef7-ae42dc6d7ea9" continuedAt="if473e1672a9845ae949bbe401fb84290" escape="true">Loan and Security Agreements</ix:nonNumeric></span></div><ix:continuation id="if473e1672a9845ae949bbe401fb84290" continuedAt="ic647e6b60f5446cb8190dd2375bf2b5a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a credit facility (the &#8220;2016 Credit Facility&#8221;) with a bank that allowed the Company to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i22371425da1041168cf343492f01c4fa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTky_b6c8f5f6-80c8-43f6-a6d6-4b9959db92ac">15.0</ix:nonFraction> million. Borrowings under the 2016 Credit Facility were secured by a lien on all Company assets, excluding intellectual property. The Company borrowed the entire $<ix:nonFraction unitRef="usd" contextRef="i22371425da1041168cf343492f01c4fa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzQ5_b6c8f5f6-80c8-43f6-a6d6-4b9959db92ac">15.0</ix:nonFraction> million available under the 2016 Credit Facility prior to its extinguishment in July 2019 as discussed in further detail below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Credit Facility contained negative covenants restricting the Company&#8217;s activities, including limitations on cash deposits, dispositions, mergers or acquisitions, incurring indebtedness or liens, paying dividends or making investments and certain other business transactions. There were no financial covenants associated with the agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTExMw_c46843d2-f983-4bcc-b7b6-6d5bd2a27a0d">45.0</ix:nonFraction> million available to the Company in <ix:nonFraction unitRef="tranche" contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719" decimals="INF" format="ixt-sec:numwordsen" name="evlo:SecurityAndLoanAgreementNumberOfTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE0NA_a56290f9-41d6-420c-97f7-f7832ba4887f">three</ix:nonFraction> tranches. The initial tranche of $<ix:nonFraction unitRef="usd" contextRef="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE4MA_f427ad79-8062-44c6-8937-344630aa9389">20.0</ix:nonFraction> million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $<ix:nonFraction unitRef="usd" contextRef="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTI3NQ_5ce86f55-c5d9-4564-9a00-17703e40cee7">10.0</ix:nonFraction> million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The third tranche of $<ix:nonFraction unitRef="usd" contextRef="i5888734b31a84abe9cd96515a54830d4_D20201001-20210115" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTQwNA_48570b22-1a38-4d02-a267-0a17b313a3a4">15.0</ix:nonFraction> million is available to be funded at the Company's election on or before January 15, 2021, subject to certain customary conditions and the achievement of certain clinical development milestones. Borrowings under the 2019 Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTk5Mg_ebec6a9c-e8ff-4db4-a1ac-31cb77a281ad">8.65</ix:nonFraction>% and (ii) the prime rate plus <ix:nonFraction unitRef="number" contextRef="ic924efafb0664fcc9352ca108ea8fc1d_D20190719-20190719" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjAyNA_cb027ab0-bdf8-4df3-9d54-65c5282997c3">3.15</ix:nonFraction>%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2022. If the Company elects to draw the third tranche, the interest-only period will be extended through August 31, 2022. Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to <ix:nonFraction unitRef="number" contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719" decimals="INF" name="evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjUxNg_50087962-e280-41d2-9fad-da34310b588a">4.3</ix:nonFraction>% of the loans borrowed, which is being accrued to interest expense over the term of the loan using the effective-interest method. The Company incurred fees associated with establishing the 2019 Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjczMQ_25a8763b-5384-4839-87fe-6a2eab590eef">0.4</ix:nonFraction> million. The Company has an option to prepay the loans in whole, subject to a prepayment fee of <ix:nonFraction unitRef="number" contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjgyMg_6172ff5d-edea-4490-bce1-2113a5e1b0a5">2</ix:nonFraction>% of the amount prepaid or, if the prepayment occurs after the <ix:nonNumeric contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719" format="ixt-sec:durmonth" name="evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjg4Ng_0900a6f8-d601-4064-bf60-59fa300c847e">18</ix:nonNumeric>-month anniversary of the funding date of the loans, <ix:nonFraction unitRef="number" contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjk0MQ_f7b1e6dd-4e07-414f-a6f8-80f4cbd555b7">1</ix:nonFraction>% of the amount prepaid.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2019 Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional <ix:nonFraction unitRef="number" contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentDebtDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzU0NQ_3e77b4e6-d021-4ea7-a9e7-6ade4a6106b8">5</ix:nonFraction>% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the 2019 Credit Facility and under applicable law. As of September 30, 2020, the Company was in compliance with all covenants under the 2019 Credit Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the proceeds from the initial $<ix:nonFraction unitRef="usd" contextRef="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzk4Nw_9f4aa52b-0724-4097-b822-6212b2f21204">20.0</ix:nonFraction> million tranche to prepay on July 19, 2019 the full $<ix:nonFraction unitRef="usd" contextRef="if6af8e2843d54b498ab6811a2bdb9e01_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDAzNA_fad20a4c-c820-47d4-aa79-c48e0121e027">15.0</ix:nonFraction> million loan balance outstanding under the 2016 Credit Facility.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ic647e6b60f5446cb8190dd2375bf2b5a"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDYyNA_7bbe9e1b-ecfb-4c58-8944-849b9c60632e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has the following minimum aggregate future loan payments at September 30, 2020 (in thousands). </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve month period ending September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMS0yLTEtMS0w_1803f275-b5db-467f-a3da-8d67e3544acd">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMi0yLTEtMS0w_7351f901-4c4f-4459-9830-36716a5c85bd">8,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMy0yLTEtMS0w_6109f59d-8f4d-4cee-b669-9357e5581f68">13,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNC0yLTEtMS0w_3d29ec49-9864-447e-920b-419c2305bee5">13,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:zerodash" name="evlo:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNS0yLTEtMS0w_fd5ab049-e6e9-42ef-9946-4494c77b1335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNi0yLTEtMS0w_49ab356e-7638-48cd-ab77-a774a313b35f">38,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNy0yLTEtMS0w_56ce413a-7b00-4cc5-8b48-6b511633b74c">8,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfOC0yLTEtMS0w_2ff47e9a-7df0-4705-b921-2843e90014f8">29,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Company's 2016 Credit Facility was approximately $<ix:nonFraction unitRef="usd" contextRef="i36512fd07785419f8c346218b88c3574_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDQ3NQ_90b1c44d-a2aa-4b6b-a02d-aacacd4a33d9">0.5</ix:nonFraction> million for the nine months ended September 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Company's 2019 Credit Facility was approximately $<ix:nonFraction unitRef="usd" contextRef="i497af9117217436086fed1b12ad3d7a9_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDU4Nw_27bf1ec2-c800-4875-981a-6531ce54c388">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ec21311cae448859c4bf7db77fa683c_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDU5NA_73905457-2a4f-4c15-a2e5-fffce5b6ecd5">1.5</ix:nonFraction> million for the three and nine months ended September 30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i1cc03be1a9fa44fa9fad574644a033f2_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE1NDQ4NzIwOTYzNDM_04a81b8b-9a75-4155-9fc7-1aa1f974bb9b"><ix:nonFraction unitRef="usd" contextRef="i52af12becc094820bd3f1230018cdaee_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE1NDQ4NzIwOTYzNDM_7bec8fa0-8920-4ab7-97bd-12251a28878e">0.4</ix:nonFraction></ix:nonFraction> million for both the three and nine months ended September 30, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMzAxMw_44d66fd4-f2a1-469b-be92-dacf9ba1be80" continuedAt="ibbe08fbb75594b1991088970e72cd3e5" escape="true">In-License Agreements</ix:nonNumeric></span></div><ix:continuation id="ibbe08fbb75594b1991088970e72cd3e5" continuedAt="i64a2a84d935549588d9dad41385dbe9a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education and Research</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 10, 2016, the Company entered into a Research and License Agreement, (the &#8220;2016 Mayo License Agreement&#8221;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#8220;Mayo Clinic&#8221;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#8217;s public offering and warrants which were issued in 2016 and exercised in 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#8220;2017 Mayo License Agreement&#8221;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#8217;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i9b24ece8af454852802d95c232d20b4f_D20170806-20170806" decimals="-5" format="ixt:numdotdecimal" name="evlo:NonRefundableUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTE4NA_ca01bbdc-dd24-42e7-a7fe-e53f6072fe0a">0.2</ix:nonFraction> million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ib76eb2613df44ca0bf34544038de3c75_D20170806-20170806" decimals="INF" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTU2MQ_d9d8bab9-2ac2-4724-abb3-b57ee066ffc4">56.0</ix:nonFraction> million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i5765428e6dc9410ba812e1aa42d7c4c2_D20170806-20200930" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTc1NQ_f97081b5-344a-4d5b-ae9a-be212ce4811e">0.2</ix:nonFraction> million under the agreement of which <ix:nonFraction unitRef="usd" contextRef="ia2705dcad5b24a6489673679a8b632af_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTc4Nw_2d9ea167-a96e-4636-92a3-d2f69266b34f">no</ix:nonFraction></span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Chicago</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i64a2a84d935549588d9dad41385dbe9a"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#8220;2016 University of Chicago Agreement&#8221;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the Licensed Patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize Licensed Products. As consideration, the Company paid a nonrefundable upfront fee of less than $<ix:nonFraction unitRef="usd" contextRef="i04e883ac26644ef6a592b975350598ff_D20160310-20160310" decimals="-5" format="ixt:numdotdecimal" name="evlo:NonRefundableUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjQwMA_535667fa-7165-4cde-a23e-8f9c02a06b7c">0.5</ix:nonFraction> million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i8f6455f87ca54808a728b425104feb45_D20160310-20160310" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjczMw_f9dc5774-ad1e-4938-a278-308b6729f560">60.9</ix:nonFraction> million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ia3aacf5203e14a5cb0bcbc6335830341_D20160310-20200930" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMzAxMQ_7e3870b7-d32c-430b-b355-3628825ab053">0.4</ix:nonFraction> million under the agreement of which <ix:nonFraction unitRef="usd" contextRef="i39a9eed2f1ed471496cc34819ec412d1_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjE5OTAyMzI1OTE3OA_dae2992c-492c-45aa-bb99-089d75f574db">no</ix:nonFraction></span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span></ix:continuation><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMzI5ODUzNDg4NjIzMw_c3c9cb8e-1c3b-458d-bea6-029b1980f84c" continuedAt="i3a0994ad6dc74b03b4bc77945e4300c0" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i3a0994ad6dc74b03b4bc77945e4300c0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Collaboration Agreement with Sacco S.r.l.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#8217;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of <ix:nonNumeric contextRef="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731" format="ixt-sec:durwordsen" name="evlo:CollaborationArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNTQ0_f0d21211-c0f4-4751-b84f-c779ab68e6c3">five years</ix:nonNumeric>. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNjgz_88021ac0-a529-40c8-86cd-253480fcf249">six</span> consecutive months. The Company has agreed to pay Sacco an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731" decimals="-5" format="ixt:numdotdecimal" name="evlo:AggregateAmountDueUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNzU4_30bdb264-212f-4a1d-a4f1-809469bd28ac">3.0</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731" decimals="-5" format="ixt:numdotdecimal" name="evlo:AnnualAmountDueUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNzYy_220ec25e-8fd9-4e62-89b6-4a224cc81dc8">0.6</ix:nonFraction> million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="ifc919b216958484baadfbaf3a5579160_D20190701-20200930" decimals="-5" format="ixt:numdotdecimal" name="evlo:FeeIncurredUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMTA5OTUxMTYzMDcwOA_8f9c01ac-0b89-4b6a-8b11-a78e9546f323">1.2</ix:nonFraction> million, and no amounts are currently due as of September 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement with Biose Industrie</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2018, the Company entered into an agreement with Biose Industrie (&#8220;Biose&#8221;), a French corporation, in which Biose has agreed to exclusively manufacture certain microbial biotherapeutic products for the Company and reserve agreed upon manufacturing resources to conduct manufacturing runs for such products. Under the terms of this agreement, the Company agreed to annual fees in the mid-six digits in consideration of both exclusivity for the manufacture of those microbial biotheraputics and for a set minimum number of manufacturing runs per year. Exclusivity fees paid and any minimum commitments are expensed as incurred. As of September 30, 2020, aggregate minimum payments over the remaining contract life total approximately $<ix:nonFraction unitRef="usd" contextRef="i435a8ae096ae4da6bf33a4093a05df20_I20200930" decimals="-5" format="ixt:numdotdecimal" name="evlo:AggregateAmountDueUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMTY4NQ_6ec61992-9576-4619-be2e-a85f6d61d669">0.8</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Other Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the United States Patent and Trademark Office ("USPTO"), granted a third-party petition to initiate a post-grant review of a patent issued to the University of Chicago, to which the Company has an exclusive license from the University of Chicago. In April 2020, the USPTO issued its decision in the post-grant review, finding unpatentable all of the current claims in the patent. In June 2020, the University of Chicago filed a re-issue application to seek narrowed claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Importantly, the USPTO decision does not hinder the Company's ability to continue developing its oncology or other product candidates. Under the terms of our license agreement, the Company has been responsible for reimbursing the University of Chicago for patent defense costs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMTA0Ng_55a1e722-40d1-4717-afef-5910e3bd0b27" continuedAt="i56234e285b134f75b5e694102a13ec3b" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i56234e285b134f75b5e694102a13ec3b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#8220;Shelf&#8221;) with the U.S. Securities and Exchange Commission (the "SEC") in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i5a20243cb8d84ef18f004aae73258da3_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMzI4_b7bfa0ec-ad7b-4256-b91e-8a6baed5f9ee">200.0</ix:nonFraction> million for a period of up to <ix:nonNumeric contextRef="i2b2a5654b6754515818e140c5b08761a_D20190603-20190603" format="ixt-sec:durwordsen" name="evlo:SaleOfStockConsiderationReceivedTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMzUz_b5e69f71-cdb9-4f42-9fcd-da98722f04b9">three years</ix:nonNumeric> from the date of the filing. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $<ix:nonFraction unitRef="usd" contextRef="i21297bf18f09435c9c8903a7a0fe13d7_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfNTc2_64ba36aa-d181-4776-92d0-1e5b07de2051">50.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of September 30, 2020, no securities have been issued pursuant to the sales agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfNzY4_16912fb4-69ae-4d0e-b7b3-1744c79f1812">13,800,000</ix:nonFraction> shares of its common stock pursuant to the Shelf in an underwritten public offering at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icd3ed046380c402e916b73b4e3b00f00_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfODY5_71f9dfa2-da28-4df6-848f-b06753ac1107">3.75</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfOTA1_373d7586-95a0-4574-a994-81b590987f00">51.8</ix:nonFraction> million and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfOTM4_5967417a-5034-4a57-9c15-bc17ac052ce9">48.4</ix:nonFraction> million, after deducting underwriting discounts and commission and other offering expenses payable by the Company.</span></div></ix:continuation><div id="i9309152dc4244de88c025672033625d7_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5MQ_eddec206-a464-4432-80ed-252747950dc2" continuedAt="i637acc2ca024462bb7a886ff482ca1e9" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i637acc2ca024462bb7a886ff482ca1e9" continuedAt="i2a7db00d8e414e16ad246ad579f4420e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Incentive Award Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;), which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to <ix:nonFraction unitRef="shares" contextRef="i37f994741045472492789b1f3256cad7_I20180508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjEz_80c57634-8c41-4964-88a0-d2c0c6c3c25c">1,344,692</ix:nonFraction>&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of <ix:nonFraction unitRef="number" contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930" decimals="INF" name="evlo:CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTE3MQ_a015fcbf-b413-449c-a8b1-44886d444ae8">4</ix:nonFraction>% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#8217;s board of directors. Accordingly, on January 1, 2019, the number of shares authorized for issuance under the 2018 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="i0331b53ef2c94cbdb3540b9c8689c650_D20190101-20190101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTQ1MQ_b624ff82-697a-4786-97cc-28b7d795578a">1,273,031</ix:nonFraction> shares, and on January 1, 2020 this number was further increased by <ix:nonFraction unitRef="shares" contextRef="i7d66e58adfb6442daaf1ba85feaf140e_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTUyMg_4f8247a3-6516-4dce-9354-46db410383de">1,286,824</ix:nonFraction> shares. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the 2018 Plan is not less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a <ix:nonNumeric contextRef="i9d8a41ea4f4146b0aebd206e1f94d0e0_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5Mg_3810d404-654c-4c97-a3b2-ec522a6a0d4a">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control.  Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjIzOA_2e4a7638-383d-483e-b76d-0a2a2f8a433f">one</span> to <ix:nonNumeric contextRef="i7436d15f4ad5490d93c800ee4ae5d465_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjI0NA_9db7b716-7040-4d1a-bbaf-0e66f2705579">four years</ix:nonNumeric>. Stock options granted under the 2018 Plan expire no more than <ix:nonNumeric contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjMxMA_ebb51663-4c0e-4a58-9695-c24c6186ce73">10</ix:nonNumeric> years from the date of grant. As of September 30, 2020,&#160;equity-based incentive awards covering up to <ix:nonFraction unitRef="shares" contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjM5OA_9e03eac2-9bd9-4c9f-b972-e8eaa9ed0701">4,243,544</ix:nonFraction> shares of the Company&#8217;s common stock have been issued under the 2018 Plan, of which <ix:nonFraction unitRef="shares" contextRef="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjE5OTAyMzI2MjA3Nw_626b457b-0ba5-4bc3-94c0-c4009faa4ce7">none</ix:nonFraction> have been exercised and  <ix:nonFraction unitRef="shares" contextRef="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjQ4NQ_af4b4342-da0a-43dc-8cd6-e87a5e382021">818,084</ix:nonFraction> have been canceled. As of September 30, 2020, <ix:nonFraction unitRef="shares" contextRef="id3e85e8eb3804e36b93c6a30043a30b2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjU0NQ_b3f274dc-9914-4148-90c2-05d5c0f687a4">1,304,183</ix:nonFraction> shares of common stock are available for future grant under the 2018 Plan, which includes <ix:nonFraction unitRef="shares" contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjYzOA_24ac9743-f8b6-4c14-baf5-47041df1745b">825,096</ix:nonFraction> shares subject to awards that were originally granted, and have, since the effective date of the 2018 Plan, been canceled or repurchased under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants and advisors.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><ix:continuation id="i2a7db00d8e414e16ad246ad579f4420e" continuedAt="i3903bcb3b6e44cfaae68851a0249b042"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a <ix:nonNumeric contextRef="id857f9eb771f41fa9395bb219b6db368_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5Mw_b58d1ee8-8ef7-402f-beb3-7e852d96a062">four-year</ix:nonNumeric> period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg1Nw_74d83430-6831-4482-96e0-5983d9562632">one</span> to <ix:nonNumeric contextRef="ief4a44fb4e8b48ac915b62b55ebffe17_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg2Mw_f27f053e-535a-4c47-a1de-4116dfda19ce">four years</ix:nonNumeric>. Stock options issued under the 2015 Plan expire no more than <ix:nonNumeric contextRef="ia6ffbe5b60b54ac58b8345b0c3ce8b6b_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzkyOA_bcd9c6e2-a359-419d-8366-fa36bf4bc2f4">10</ix:nonNumeric> years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i83f3aba8c3af44db97c1de2f2eb7d95b_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDE1MA_7d5fc19e-dc53-452d-9e45-f71df5f1944a">5,417,044</ix:nonFraction> shares of common stock.&#160;As of September 30, 2020, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDIwMw_61fbda05-5f97-4f27-be1f-4c57f5289243">5,758,518</ix:nonFraction> options and other equity awards had been granted under the 2015 Plan, of which <ix:nonFraction unitRef="shares" contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDI4NQ_da8edd7f-8d16-40b9-89ec-364ddd9a7211">1,345,266</ix:nonFraction> have been exercised, <ix:nonFraction unitRef="shares" contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDMwOQ_7891e0cc-c5b3-4a27-83e3-b9ffda84e5c4">1,261,105</ix:nonFraction> have been canceled and <ix:nonFraction unitRef="shares" contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDMzNQ_8baed25c-0654-4870-ac8b-6079c70816fa">18,468</ix:nonFraction> have been repurchased as of September 30, 2020. A total of <ix:nonFraction unitRef="shares" contextRef="iaf913522ccab41a9a9d188138fdc0c2b_D20180508-20180508" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDM4MQ_fd6eb4e3-446a-4648-b55f-7b25300dc987">113,006</ix:nonFraction> shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were <ix:nonFraction unitRef="shares" contextRef="iea04ebdbabf44bda8de9e1db8bbf68cb_I20180508" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDUyMQ_9a182d62-953f-4f3d-9269-3e302b94831b">no</ix:nonFraction> longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5NA_0651e79d-7348-427f-be2b-57b7f4a1f64b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3445cdc78926417abcbfd87995b2d7ad_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi0yLTEtMS0w_90feafab-d5b3-4a38-a132-08b8bad22e6e">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9ffd1c5890497b8ba9733f662871de_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi00LTEtMS0w_adaef3b1-06ac-4118-a611-9a70580118ad">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f970dc30ff49bc95066276f19569ef_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi02LTEtMS0w_be3600b1-945e-4d94-9b66-811e246eb53b">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia237cd66629540edb0fdf167fb187799_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi04LTEtMS0w_69b55d54-9871-487d-bc99-4961ff99c41b">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9707f9de1ed24944bcc195fb5a28ab50_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy0yLTEtMS0w_2ef429bb-54f6-4e75-bd64-942d192732c1">1,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab3a97dae834644890cbda892fe5002_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy00LTEtMS0w_a6220bc7-e9a3-4a11-a763-3077a1c6aee1">980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i220c4df4a97e4803892c37ccdd46a4e3_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy02LTEtMS0w_8b299929-70a4-46b6-a229-5824d21c2044">3,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ae55ffcb5b4b38b1294a478dba4306_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy04LTEtMS0w_2344827b-b3ea-4fc6-9981-6b0c87b120f0">2,844</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC0yLTEtMS0w_83b13756-b591-4ea4-ab8e-ab64a5458003">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC00LTEtMS0w_dde286c7-d93c-498e-9e2e-039cffb5e6e6">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC02LTEtMS0w_18d61d0a-065c-44cf-8604-ebec67bb3628">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC04LTEtMS0w_e2d02c37-989f-4ebd-8742-0812039a492a">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5NQ_2318608e-768c-4e97-8c5f-5ad1d568c18b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMS0yLTEtMS0w_87ad3f03-4ad0-4736-ad6a-96d921ca31f5">5,691,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMS00LTEtMS0w_bd1f1ee8-dc25-4691-bd20-755c16708893">6.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMi0yLTEtMS0w_ce70027c-20e8-4662-a6ae-a6399696129e">2,028,718</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMi00LTEtMS0w_856055ff-c487-4d57-8936-9c6a0704e60c">6.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMy0yLTEtMS0w_ec9ffb7e-5eaa-4db0-b5d7-4dbd2bdc0daa">159,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMy00LTEtMS0w_9726f227-5aaa-4304-af9c-44ca689bc65f">1.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNC0yLTEtMS0w_71cd3ec5-585e-403f-abe6-e8bf6cb71d2a">982,574</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNC00LTEtMS0w_f7ad6174-76f7-420c-a6b8-d2c7aa9d6ea7">8.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNS0yLTEtMS0w_4e44e132-7d18-4643-84b1-c0d2961afb1c">6,577,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNS00LTEtMS0w_ba63b66b-4ffa-486f-bcb2-d23d96bea121">6.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNi0yLTEtMS0w_37e1de14-e875-4d10-8acd-b3e5ca1a5945">3,363,541</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNi00LTEtMS0w_5662b121-05a8-4e35-bc86-acdd09df0b96">5.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the nine months ended September 30, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDk4Ng_20231ced-c8ec-4a3f-a177-b37e1ae8f0ef">4.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDk5Mw_31b08389-67d2-4522-8ab0-67f7896c6b48">7.66</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="i851cd9abcdca4743b9d2ea90d5b4eeb4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTExMg_3f37ae72-cd35-49e4-b683-710fe42c3027">16.5</ix:nonFraction> million. This amount is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iee55ced3b34d4b52a1a1f852c64d2e67_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTE5MQ_3f9036f2-7189-4a01-97b3-4a3d6bae43e2">2.61</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's board of directors adopted on April</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18, 2018, and the Company&#8217;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on May</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8, 2018. A total of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTQzMw_4a2376f1-ae94-42d8-96b7-581a6582c325">336,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTc1Ng_efd5a738-baeb-4330-b698-b059cfb63fd6">1</ix:nonFraction>%&#160;of the number of shares of the Company&#8217;s common stock outstanding on the last day of the applicable preceding calendar year and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><ix:continuation id="i3903bcb3b6e44cfaae68851a0249b042"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an amount determined by the Company&#8217;s board of directors. The Company's board of directors determined not to increase the number of shares that may be issued under the ESPP on January 1, 2020. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The compensation expense recognized related to the ESPP for the three and nine months ended September 30, 2020 was not material. There was a total of <ix:nonFraction unitRef="shares" contextRef="i8463191a45964196b29df202007afc9a_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfOTg5NTYwNDY1NjQzMA_47da7656-d2dc-47b3-958d-1199f92e6391"><ix:nonFraction unitRef="shares" contextRef="id704a4dd15bd403ab0cac9fc81b19ebf_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfOTg5NTYwNDY1NjQzMA_b8a4f74c-c383-488a-8ea4-2eada323b6d2">28,603</ix:nonFraction></ix:nonFraction> shares purchased under the ESPP during the three and nine months ended September 30, 2020.</span></div></ix:continuation><div id="i9309152dc4244de88c025672033625d7_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTYxNQ_c914e079-72a2-4f6f-956a-88c5af921d17" continuedAt="i46a5e5a83c674f5c92778384dfa7ef44" escape="true"><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTYxNg_2c4456b4-910e-498d-a785-af3b08b999c1" continuedAt="iea2beb969c514d9c8110c22cf5f725a2" escape="true">Income Taxes</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i46a5e5a83c674f5c92778384dfa7ef44"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea2beb969c514d9c8110c22cf5f725a2">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted on March 27, 2020. The CARES Act contains several key provisions including: (i) five year carryback of net operating losses (&#8220;NOLs&#8221;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of September 30, 2020, the Company had deferred $<ix:nonFraction unitRef="usd" contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930" decimals="-5" format="ixt:numdotdecimal" name="evlo:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTE5NA_98c55e8e-b661-4f25-9645-a25d6b6f9eeb">0.3</ix:nonFraction> million in employer payroll taxes pursuant to the CARES Act, which is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, the Company has recorded a tax provision of $<ix:nonFraction unitRef="usd" contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTQzNw_27a87cdf-f3d7-4f59-8411-2153a72f7b10">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTQ0NA_cc8328ff-e2b4-445b-a633-928bee72cabc">0.2</ix:nonFraction> million, respectively, primarily related to the Company's wholly-owned UK subsidiary. There were <ix:nonFraction unitRef="usd" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTUzNg_e73bd1df-5748-4c30-9c54-d5288ac418f5"><ix:nonFraction unitRef="usd" contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTUzNg_fe571bed-a87f-44d9-8a08-e03f9527ffb9">no</ix:nonFraction></ix:nonFraction> significant income tax provisions or benefits for the three and nine months ended September 30, 2019.</span></div></ix:continuation><div id="i9309152dc4244de88c025672033625d7_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RleHRyZWdpb246M2MxOTMwODExYWQyNDEyYmI2ZTY4MTQ5OWI2M2JiODdfMTA1NQ_b13ef13d-f483-4eb6-8f1e-c73d2a02d9c0" continuedAt="i9bb1f8b353e044e3bd44fe589ae6bcb8" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i9bb1f8b353e044e3bd44fe589ae6bcb8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.</span></div><ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RleHRyZWdpb246M2MxOTMwODExYWQyNDEyYmI2ZTY4MTQ5OWI2M2JiODdfMTA1Ng_8f169d4a-91f3-44e7-9138-3c5c30d0c591" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i102115e148ba457a9e0f7b80f0e81eae_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMi0yLTEtMS0w_8cfea0d9-cc78-452c-9d50-40d1823d46e3">36,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e341efe8ff445c5bfac11f2c9f50db8_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMi00LTEtMS0w_847c6571-2a7a-4ef7-a532-4388842b1fb4">75,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id804b1ab406a45b386f84874e2f511e9_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMy0yLTEtMS0w_5677ad3d-17ed-4122-9e3a-1060f91a5805">6,577,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40a534ca0c824a918ef5b0b5cfd144f6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMy00LTEtMS0w_c456ede9-5941-4910-8447-1a1ffa20b3db">5,892,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8832142a8fd34e73a080e4c3c2df3b1c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNC0yLTEtMS0w_95aff870-7648-4ffa-87be-9b5c6c49ef5b">12,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f093b1b4c194114a2857f69750073f1_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNC00LTEtMS0w_95af1429-91f4-42cc-8bcd-e43a84a812ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNS0yLTEtMS0w_1961e3ae-5639-45dd-bf4b-979ddaaff3f0">6,626,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNS00LTEtMS0w_0404e6b6-29d4-47c3-8469-faf1edd1c8e3">5,967,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjg2Mg_77d27404-8d7a-4d9c-b7b2-c2c1880670cc" continuedAt="i1543ecf8b7354019a0c09922d3e02544" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i1543ecf8b7354019a0c09922d3e02544"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives clinical advisory services from Weatherden Ltd. (&#8220;Weatherden&#8221;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#8217;s Chief Medical Officer, is a part owner of Weatherden. During the nine months ended September 30, 2020 and 2019, the Company paid Weatherden $<ix:nonFraction unitRef="usd" contextRef="i1a12b5d775194c26a646d257a891b43f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMzMx_2b009681-d77b-49d6-9e01-f60e2e878e5f">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie5cef482e496443fa58c3e279239e38f_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMzM4_55589550-6862-4dcd-b85f-22cdd4a4256a">0.7</ix:nonFraction> million, respectively. As of September 30, 2020 and 2019, the amounts due to Weatherden under the supply of service agreement were approximately $<ix:nonFraction unitRef="usd" contextRef="i8535ad7567824b5eb8061e3eb77bcea4_I20200930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNDQ2_2f63474c-e8a6-4e4d-991e-a130887e7aa3">30.0</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i040867f309fd4a60b8b170d1d3f8cb1a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNDUz_2815575a-45ce-4989-9c99-f2e7dd12fe57">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $<ix:nonFraction unitRef="usd" contextRef="i48bd8f29cd6a448ba1d11baf833a3e94_I20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNzI5_53b2f36a-74f4-4d4e-b2a2-21430e54e96d">0.9</ix:nonFraction> million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the nine-months ended September 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i9ebbc6067103474782dd50c5fad869dc_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTA5OTUxMTYzMDgxOA_68a1cc21-ca97-4c7a-aedc-874047cc117d">0.3</ix:nonFraction> million related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a consulting agreement with David Epstein (as amended, the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein will provide strategic advisory and other consulting services to the Company. As amended on October 15, 2020, the Consulting Agreement will continue until June 30, 2021 unless terminated earlier by either Mr. Epstein or the Company upon <ix:nonNumeric contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916" format="ixt-sec:durday" name="evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTU3Nw_4987ef0a-4fa9-45ca-905c-78db72a9c15c">30</ix:nonNumeric> days&#8217; notice, or <ix:nonNumeric contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916" format="ixt-sec:durhour" name="evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTU5Mg_1ac20aac-20e9-41c5-aba9-2afb0e38ae2c">24</ix:nonNumeric> hours&#8217; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase <ix:nonFraction unitRef="shares" contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTc2MA_e2af2a00-7b2d-4575-8c47-98dddd922185">75,000</ix:nonFraction> shares of the Company&#8217;s common stock, which award vests in <ix:nonFraction unitRef="installment" contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916" decimals="INF" name="evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTgyMg_950b064b-582e-4ded-a1b3-4c477e1ae43b">36</ix:nonFraction> equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $<ix:nonFraction unitRef="usd" contextRef="iece4b57622c64cce95e2a617bf90bcaa_I20190916" decimals="-5" format="ixt:numdotdecimal" name="evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjMwOQ_76332fc6-6986-45a0-99c9-b9fbc6582d76">0.2</ix:nonFraction> million, as determined by the Board in its discretion based on customary option pricing methodologies, which award vests in <ix:nonFraction unitRef="installment" contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916" decimals="INF" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjE5OTAyMzI2NjY2Nw_b0352c84-59d4-4f9a-956a-5d7c21fc7a80">12</ix:nonFraction> equal monthly installment following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $<ix:nonFraction unitRef="usd" contextRef="iece4b57622c64cce95e2a617bf90bcaa_I20190916" decimals="-5" format="ixt:numdotdecimal" name="evlo:RelatedPartyTransactionAnnualCashConsultingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjY3MQ_897b06f1-5aaf-43ec-bed6-7ee262faee63">0.3</ix:nonFraction> million for his consulting services. All of the foregoing options, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase <ix:nonFraction unitRef="shares" contextRef="i810d7c9e6e614a82ad32d53275585c7d_D20201011-20201011" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjE5OTAyMzI2NjY1OQ_d68947e9-b46e-4ef2-a2b9-6fd6bfbbf509">44,743</ix:nonFraction> shares of the Company&#8217;s common stock, which award vests in nine equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the year ended December 31, 2019 (the "2019 Annual Report"), including the audited consolidated financial statements and notes thereto contained in our 2019 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A. &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described, in or implied, by these forward-looking statements. In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to &#8220;Evelo,&#8221; &#8220;Evelo Biosciences,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Evelo Biosciences, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences is discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce systemic therapeutic effects throughout the body. The target cells in the small intestine play a central role in governing the immune, metabolic and neurological systems throughout the body. We refer to this biology as the small intestinal axis, or SINTAX&#8482;. We have built a platform to discover and develop novel oral medicines which target SINTAX. By harnessing SINTAX, we believe we can transform healthcare via medicines that have the potential to be effective, safe, convenient and affordable and thus able to treat patients at all stages of disease and to treat patients globally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product candidates are orally delivered pharmaceutical preparations derived from naturally occurring, specific single strains of microbes. In preclinical models, our product candidates have engaged immune cells in the small intestine and driven changes in systemic biology without systemic exposure and without colonizing the gut. We have observed in early clinical trials and in preclinical studies that specific product candidates modulated  immune responses throughout the body by acting on SINTAX. We currently have two product candidates in multiple clinical trials, EDP1815 for the treatment of inflammatory diseases and the treatment of individuals with COVID-19 and EDP1503 for the treatment of certain types of cancer. We have two additional product candidates for the treatment of inflammatory diseases: EDP1867 and EDP2939, and one additional product candidate for the treatment of cancer: EDP1908.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that orally delivered SINTAX medicines have the potential to address patient needs at all stages of disease due to their potentially superior characteristics over current therapies:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Each of our product candidates has been observed to act through multiple clinically relevant and validated biological pathways in preclinical models. By acting on multiple pathways simultaneously, we believe our product candidates could impact disease in ways that are not possible with current single-target or dual-target therapies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our data suggests that our product candidates for inflammatory diseases have the potential to resolve disease causing inflammation whilst preserving immunity, a significant potential benefit compared to other anti-inflammatory therapies that often cause significant immunosuppression.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our product candidates are likely to be well-tolerated given that they are derived from naturally occurring, specific single strains of human commensal microbes that engage immune cells in the small intestine and drive changes in systemic biology without systemic exposure and without colonizing the gut. Our initial clinical data supports this potential and, if we are able to validate this profile in future clinical trials, we believe our product candidates have the potential to be used at all stages of disease and in many more patients than current immunomodulatory drugs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:13.8pt">Our discovery and development of oral SINTAX medicine has the potential to be more efficient than other product classes such as cell therapy, monoclonal antibodies and small molecules. We believe our product candidates do not require the lengthy target validation and compound discovery requirements of conventional drug discovery.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization ("WHO") declared the COVID-19 outbreak a pandemic. The outbreak has resulted in governments around the world implementing stringent measures to help control the spread of the virus, including quarantines, &#8220;shelter in place&#8221; and &#8220;stay at home&#8221; orders, travel restrictions, business closures and curtailments, and school closures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had, and for an extended period of time is expected to have, negative impacts on our operations and supply chain. Our ability to continue to operate without any significant negative impacts will, in part, depend on our ability to protect our employees and our supply chain. We have endeavored to follow recommended actions of government and health authorities to protect our employees with particular measures in place for those working in our laboratories, such as staggered work shifts and flexible schedules, and telecommuting for office workers. We are working with our contract manufacturing organizations to minimize delays and disruptions to scheduled manufacturing batch runs for our product candidates and to ensure conformity to product specifications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted and continues to impact our enrollment of new patients into, and the retention of existing patients in, our ongoing clinical trials, due primarily to lower patient participation. The pandemic likely will impact enrollment and retention of patients in new clinical trials, such as our Phase 2 trial of EDP1815, for similar reasons.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to recruit individuals in line with the local and national guidelines of the clinical research sites. We are keeping in close contact with our contract research organization ("CRO") and clinical sites to provide support and guidance to ensure the safety of the patients in our clinical trials. We have prioritized our drug supply operations to secure the re-supply of patients currently enrolled in our clinical trials.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic impacts our business and finances will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States, the United Kingdom and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States, the United Kingdom and other countries to contain and treat the disease. See &#8220;Risk Factors &#8212; The outbreak of the novel coronavirus disease, COVID-19, has and may continue to adversely impact our business, including our preclinical studies and clinical trials and finances.&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Clinical Developments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1815</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1815 is an investigational oral biologic being developed for the treatment of inflammatory diseases. It is a strain of Prevotella histicola, selected for its specific pharmacology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1815 is being evaluated in two ongoing clinical studies for the treatment of hospitalized COVID-19 patients. The first is a Phase 2 double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of EDP1815 for the treatment of individuals diagnosed with COVID-19 early in the course of their disease. The trial initially will evaluate 60 individuals to determine if early intervention with EDP1815 can prevent the progression of COVID-19 symptoms and the development of COVID-Related Complications. Individuals who have presented at the emergency room of the Robert Wood Johnson University Hospital within the last 36 hours and tested positive for SARS-CoV-2 are randomized 1:1 to receive the enteric capsule formulation of EDP1815 or placebo for 14 days, along with the standard of care. The primary endpoint is reduced requirements for oxygen therapy, as measured by the ratio of oxygen saturation (SpO2) / fraction of inspired oxygen (FiO2). Key secondary endpoints include total symptom duration, progression along the WHO scale of disease severity, and mortality. The trial is led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1815 is also included as a treatment arm in the TACTIC-E clinical trial. TACTIC-E is a Phase 2/3 randomized trial, sponsored by Cambridge University Hospitals NHS Foundation Trust, that is expected to evaluate up to 469 patients per arm at Addenbrooke&#8217;s Hospital and other leading clinical centers in the United Kingdom. The trial is investigating the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized individuals at early stages of the disease. The trial is enrolling individuals with COVID-19 who have identified risk factors for developing severe complications and are at risk of progression to the intensive care unit or death. The primary outcome measure of the trial is time to incidence (up to day 14) of any one of the following: death, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), cardiovascular organ support, renal failure, hemofiltration or dialysis. Secondary outcome measures include duration of stay in hospital, duration of oxygen therapy, changes in biomarkers associated with COVID-19 progression, and time to clinical improvement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the varying infection rates that have occurred with the pandemic, we experienced slower than expected enrollment early on in both trials and now expect to report data from clinical trial conducted at the Robert Wood Johnson University Hospital and interim safety data and futility analysis from TACTIC-E in the second quarter of 2021. In order to expedite patient recruitment and expand access to potential therapies for COVID-19, new trial sites are being opened for TACTIC-E. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If EDP1815 is successfully developed and approved as a treatment for COVID-19, we believe that we could rapidly scale the manufacturing of EDP1815 to supply the drug at a reasonable cost. If approved and proven effective for early intervention, we expect that oral EDP1815 could also be useful in the outpatient setting to control the community impact of the COVID-19 pandemic. If the Phase 2 trials are successful in COVID-19, we plan to investigate EDP1815 as a potential therapy for other diseases, such as influenza infection, in which hyperinflammation and cytokine storm can play a key role. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Psoriasis and atopic dermatitis </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 clinical trial in psoriasis </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on previously reported positive clinical data in two cohorts of individuals with mild to moderate psoriasis in a Phase 1b clinical trial, we have advanced EDP1815 into a Phase 2 dose ranging trial, evaluating three doses of EDP1815 in enteric capsules versus placebo in approximately 225 individuals with mild to moderate psoriasis. The primary endpoint of the trial is the mean reduction in Psoriasis Area and Severity Index (PASI) score at 16 weeks. Other clinical measures of psoriasis are also being evaluated. We initiated the Phase 2 clinical trial in October 2020, and expect to announce interim data by the middle of 2021. Clinical data from this trial may enable us to advance directly into Phase 3 registrational trials in late 2021, subject to end of Phase 2 discussions with regulatory agencies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate EDP1815 in additional inflammatory disease indications, depending on the results from the interim data analysis of the Phase 2 trial. Potential indications include psoriatic arthritis, axial spondylarthritis and rheumatoid arthritis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1b clinical trial in atopic dermatitis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated our ongoing Phase 1b double-blind placebo-controlled dose-escalating safety and tolerability study of EDP1815 in healthy volunteers and individuals with mild to moderate psoriasis or atopic dermatitis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on previously reported positive clinical data in two cohorts of individuals with psoriasis, we are evaluating EDP1815 in a cohort of 24 patients with mild to moderate atopic dermatitis, randomized 2:1 to receive oral administration of 2.76g of the enteric capsule formulation of EDP1815 or placebo once daily, for 56 days. The primary endpoint is safety and tolerability. Secondary endpoints include key validated markers of atopic dermatitis, including the Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Dermatology Life Quality Index (DLQI), and Pruritis Numerical Rating Scale (Pruritis NRS). This cohort is fully recruited and we expect to announce initial data from this cohort in the first quarter of 2021.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1867</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1867 is a non-living investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1867 was selected from a broad screen of single strains of microbes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cellular assays and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">models of inflammation. In preclinical studies EDP1867 was shown to resolve multiple pathways of inflammation. This observed activity suggests a number of possible initial clinical indications for EDP1867, including TH2-dependent inflammation which underlies atopic diseases and a large spectrum of asthma. We expect to initiate our first Phase 1b clinical trial of EDP1867 in individuals with atopic dermatitis in the first quarter of 2021, and expect to announce initial data from this trial in mid-2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1503</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1503 is an investigational oral biologic being developed for the treatment of cancer. In December 2018, we initiated our ongoing Phase 1/2 open-label clinical trial of EDP1503 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in three cohorts of individuals: microsatellite stable colorectal cancer; triple-negative breast cancer; and individuals with multiple tumor types who have relapsed on prior PD-1/L1 inhibitor treatment. This trial is designed to evaluate the safety and tolerability, immune response markers and overall response rates achieved with EDP1503 in combination with KEYTRUDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we reported interim clinical data from the trial in a poster presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting. In addition to data in individuals with microsatellite stable colorectal cancer (&#8220;CRC&#8221;), the poster reported preliminary data on 11 individuals with triple-negative breast cancer (&#8220;TNBC&#8221;) (8 on high dose and 3 on low dose EDP1503). An overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) were observed across all individuals with TNBC receiving high dose EDP1503. Historic studies of anti-PD-1 monotherapy in heavily pretreated TNBC patients have yielded an ORR of 5-10%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have decided to prioritize the development of EDP1503 for the treatment of TNBC with a high dose regimen, based on early clinical response data with this regimen. We expect to announce further data from the TNBC cohort in the fourth quarter of 2020. Initial safety analyses have been performed on all three cohorts, and the CRC and TNBC cohorts have passed prespecified futility criteria. Because of the range of tumor types included within the PD-1/L1 relapsed cohort, we did not include a futility analysis for this cohort in the study protocol. We continue to monitor individuals in the three cohorts who remain on study.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our incorporation in 2014, we have devoted substantially all of our resources to developing our clinical and preclinical candidates, building our intellectual property portfolio and process development and manufacturing function, business planning, raising capital and providing general and administrative support for these operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage company and have not generated any revenue. All of our product candidates are in early clinical or preclinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since our inception, we have incurred significant operating losses and we continue to incur significant research and development and other expenses related to our operations. For the nine months ended September 30, 2020, our net loss was $64.6 million. As of September 30, 2020, we had an accumulated deficit of $263.5 million. We do not expect to generate revenue from sales of any products for the foreseeable future, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the ongoing trials for EDP1815 and EDP1503;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional clinical trials for EDP1815, EDP1867, EDP2939 and EDP1908;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate or advance the clinical development of any additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and continue preclinical development of potential product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make strategic investments in manufacturing capabilities, including potentially planning and building our own manufacturing facility;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain our current intellectual property portfolio and opportunistically acquire complementary intellectual property;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase employees and employee-related expenses including salaries, benefits, travel and stock-based compensation expense; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In June 2020, we sold 13,800,000 shares of our common stock in an underwritten public offering at a public offering price of $3.75 per share, for gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 14, 2020, we drew down the second tranche of $10.0 million available under the 2019 Credit Facility with K2HV.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, our principal source of liquidity is cash and cash equivalents, which totaled approximately $81.6 million. We expect that our existing cash and cash equivalents will enable us to fund our planned operating expenses and capital expenditure requirements into the beginning of the third quarter of 2021. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources."</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe we do not have sufficient cash and cash equivalents on hand to support current operations for at least one year from the date of issuance of the unaudited condensed consolidated financial statements appearing within this Quarterly Report on Form 10-Q without raising additional capital. To finance our operations beyond that point, we will need to raise additional capital. There can be no assurance that we will be able to obtain additional funding on acceptable terms, if at all. We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern for at least one year from the date that our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2020 were issued. As such, we plan&#160;to seek to raise capital from time to time&#160;through future equity financings, debt financings or partnerships to fund our future operations and remain as a going concern. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders will be diluted, which dilution may be significant. See Note 1 of the notes to our unaudited condensed consolidated condensed financial statements in this Quarterly Report on Form 10-Q for additional information on our assessment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts for our current product candidates or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted primarily of research and development activities and general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, including investigative sites, external laboratories and CROs that conduct research, preclinical activities and clinical trials on our behalf;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing process-development costs as well as technology transfer and other expenses incurred with contract manufacturing organizations ("CMOs") that manufacture drug substance and drug product for use in our preclinical activities and any current or future clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel in our research and development functions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses to acquire technologies to be used in research and development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus of research and development since inception has been building a platform to enable us to develop medicines based on an understanding that cells in the small intestine play a central role in governing the immune, metabolic and neurological systems and to show potential clinical utility. Our platform and program expenses consist principally of costs, such as preclinical research, clinical and preclinical manufacturing activity costs, clinical development costs, licensing expenses as well as an allocation of certain indirect costs, facility costs and depreciation expense. We do not allocate personnel costs, which primarily include salaries, discretionary bonus and stock-based compensation costs, as such costs are separately classified as research and development personnel costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase in the foreseeable future as we continue to implement our business strategy, continue our ongoing clinical trials for our product candidates, including EDP1815 and EDP1503, initiate additional clinical trials, including EDP1867, continue to discover and develop additional product candidates, seek regulatory approvals for any products that successfully complete clinical trials, build manufacturing capabilities, hire additional research and development personnel, and expand into additional therapeutic areas.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to add and retain key research and development personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our successful enrollment and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays in clinical trials as a result of the COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the development of our current product candidates and/or any additional product candidates we identify in-house or acquire through collaborations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish an appropriate safety profile with IND-enabling toxicology studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain agreements with CMOs and other entities for clinical trial supply and future commercial supply, if our product candidates are approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates if and when approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued acceptable safety profiles of the product candidates following approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. We expect our research and development expenses to increase at least over the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, identify and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; other professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur increased expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs and investor and public relations costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (expense), net primarily consists of interest earned on our cash, cash equivalents balances offset by interest expense incurred on our debt. During each of the three and nine months ended September 30, 2020 and 2019, interest income (expense), net consisted primarily of interest earned on institutional money market instruments and U.S. treasury securities offset by interest at the stated rate on borrowings under our loan and security agreements and amortization of deferred financing costs and interest expense related to the accretion of debt discount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the three and nine months ended September 30, 2020 primarily consists of foreign currency gains and government grants related to our operations in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the three and nine months ended September 30, 2020 reflects the provision for income taxes at our wholly owned UK subsidiary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2014, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2020 and 2019</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,496)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,856)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,633)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammation programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs (including stock-based compensation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $14.9 million for the three months ended September 30, 2020, compared to $15.6 million for the three months ended September 30, 2019. The decrease of $0.7 million was due to a $1.6 million decrease in our platform expenses and a $0.7 million decrease in our oncology programs primarily related to clinical trial recruitment delays, lower lab costs and fewer research and development related activities due to the COVID-19 pandemic. These decreases were partially offset by a $0.8 million increase in our inflammation programs due to EDP1815 progression to a Phase 2 trial, additional COVID-19 trials and EDP1815 Phase 1b trials, and costs incurred in clinical manufacturing to enable the EDP1867 Phase 1 clinical trial, partially offset by the closeout of the EDP1066 program. The $0.8 million increase in personnel related costs is primarily due to headcount increases in clinical development, technical operations and platform organization, which is in line with our strategy to maximize the potential of our platform. Overall, we expect that our research and development expenses will increase in the foreseeable future as we continue clinical trials for our product candidates, including EDP1815, EDP1503 and EDP1867, initiate new clinical trials, continue discovery and development efforts for additional product candidates, hire additional research and development personnel, seek to increase manufacturing capabilities and possibly expand into additional therapeutic areas.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility costs, office expense and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,272&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $5.3 million for the three months ended September 30, 2020, compared to $5.9 million for the three months ended September 30, 2019. The decrease of $0.6 million is due to lower personnel costs of $0.4 million associated with temporarily lower general and administrative headcount and lower professional fees of $0.4 million. These decreases were partially offset by a $0.2 million increase in facility and office costs due to the impact of the COVID-19 pandemic. We expect general and administrative expenses to increase as we hire personnel to fill open positions and incur professional expenses in support of the continued growth of the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended September 30, 2020 was $0.7 million compared to $0.1 million for the three months ended September 30, 2019. The $0.6 million increase in other expenses was primarily driven by a decrease in interest income as a result of lower interest rates and lower cash and cash equivalent balance and an increase in interest expense as a result of a higher interest rate on a greater principal balance from the 2019 Credit Facility, partially offset by foreign currency gains and a grant related to our operations in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended September 30, 2020 was $20.9 million, compared to $21.6 million for the three months ended September 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine months ended September 30, 2020 and 2019</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,688&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,687)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,395)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,873)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,616)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,873)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,743)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammation programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs (including stock-based compensation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses were $47.5 million for the nine months ended September 30, 2020, compared to $46.8 million for the nine months ended September 30, 2019. The increase of $0.8 million was primarily drive by higher personnel costs of $2.8 million due to increases in clinical development and technical operations headcount and due to higher inflammation programs cost of $1.0 million resulting from the progression of EDP1815 to a Phase 2 trial and the addition of COVID-19 trials, and costs incurred in contract manufacturing to enable the EDP1867 Phase 1 clinical trial, partially offset by the closeout of the EDP1066 program. These increases were partially offset by a $2.7 million decrease in our oncology programs primarily related to the clinical trial stage and the impact of the COVID-19 on patient recruitment and a decrease of $0.4 million in platform expenses due to lower lab costs as a result of the impact of COVID-19 pandemic. Overall, we expect that our research and development expenses will continue to increase in the foreseeable future as we continue our clinical trials for our product candidates, including EDP1815, EDP1503 and EDP1867, initiate new clinical trials, continue discovery and development efforts for additional product candidates, hire additional research and development personnel and seek to increase manufacturing capabilities and possibly expand into additional therapeutic areas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility costs, office expense and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $16.2 million for the nine months ended September 30, 2020, compared to $16.9 million for the nine months ended September 30, 2019. The decrease of $0.8 million  was primarily driven by lower personnel costs of $0.4 million due to temporarily lower general and administrative headcount, and lower professional fees of $0.5 million, partially offset by higher facility and office cost of $0.1 million due to the impact of the COVID-19 pandemic. We expect this decrease to be temporary and general and administrative expenses to increase due to higher personnel and related costs, professional, legal, and patent fees and consulting expenses in support of our continued growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses, net for the nine months ended September 30, 2020 was $0.7 million compared to income of $0.8 million for the nine months ended September 30, 2019. This $1.5 million decrease was primarily driven by a decrease in interest income as a result of lower interest rates and a lower cash and cash equivalent balance and an increase in interest expense as a result of a higher interest rate on a greater principal balance from the 2019 Credit Facility, partially offset by foreign currency gains and a grant related to our operations in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the nine months ended September 30, 2020 was $64.6 million, compared to $62.9 million for the nine months ended September 30, 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses and generated negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. We incurred net losses of approximately $64.6 million and $62.9 million for the nine months ended September 30, 2020 and 2019, respectively. To date, we have financed our operations primarily with proceeds from public offerings of our common stock, sales of our convertible preferred stock to our equity investors and borrowings under our debt facilities. From our inception through September 30, 2020, we have received gross proceeds of $325.0 million from such transactions, including a net $30.0&#160;million borrowed under our debt facilities. As of September 30, 2020, we had cash and cash equivalents of $81.6 million and an accumulated deficit of $263.5 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;11, 2018, we completed our IPO of 5,312,500 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the IPO were $85.0&#160;million and the net proceeds were approximately $75.8&#160;million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, we entered into a sales agreement with Cowen and Company, LLC, as sales agent, pursuant to which we may, from time to time, issue and sell up to an aggregate of $50.0 million of our common stock in &#8220;at-the-market&#8221; offerings. As of September 30, 2020, no securities had been issued pursuant to the sales agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we sold 13,800,000 shares of its common stock in an underwritten public offering at a public offering price of $3.75 per share, for gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, we entered into the 2019 Credit Facility with K2HV, as amended, providing for up to $45.0 million of current and future potential debt financing. The aggregate principal amount is available in three tranches of term loans of $20.0 million, $10.0 million, and $15.0 million, respectively. At closing on July 19, 2019, we withdrew initial proceeds of $20.0 million representing the first tranche under the 2019 Credit Facility. On July 14, 2020 we drew down the second tranche of $10.0 million. The third tranche will be available to us at our election through January 15, 2021, subject to certain customary conditions and the achievement of certain clinical development milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the outstanding loan balance will accrue at a variable rate equal to the greater of (i) 8.65% and (ii) the prime rate as published in the Wall Street Journal, plus 3.15%. We are required to make monthly interest-only payments through February 2022. If we elect to draw the third tranche, the interest-only period is extended through August 2022. Subsequent to the interest-only period, we are required to make equal monthly principal payments plus any accrued interest until the loans mature in August 2024. Upon final payment or prepayment of the loans, we are required to pay a final payment equal to 4.3% of the loans borrowed. We have an option to prepay the loans in whole, subject to a prepayment fee of 2% of the amount prepaid or, if the prepayment occurs after the 18-month anniversary of the funding date of the loans, 1% of the amount prepaid.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneous with the closing of the first tranche of funding described above, we repaid the entire $15.0 million loan balance outstanding under an existing loan and security agreement with a separate financial institution. In accordance with the agreement underlying the prior debt facility, we paid an additional 0.5% prepayment fee as additional expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash and cash equivalents will enable us to fund our planned operating expenses and capital expenditure requirements into the beginning of the third quarter of 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaborations, license and development agreements. To the extent that we raise additional capital through future equity offerings or debt financings, ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the common stockholders. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that such financings will be obtained on terms acceptable to us, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue our research and development programs or future commercialization efforts. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties for one or more of our current or future drug candidates, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,110)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September 30, 2020 was $54.1 million driven primarily by our net loss of $64.6 million. This was partially offset by non-cash charges including stock-based compensation expense of $6.1 million, non-cash lease expense of $1.5 million, depreciation expense of $1.5 million and changes in components of working capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September 30, 2019 was $53.0 million driven primarily by our net loss of $62.9 million. This was partially offset by non-cash charges including stock-based compensation expense of $6.2 million, depreciation expense of $1.3 million, and changes in components of working capital.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September 30, 2020 was $0.9 million, driven by the net purchase of capital equipment totaling $0.9 million during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the nine months ended September 30, 2019 was $52.4 million, primarily consisting of proceeds from maturity of investments totaling $55.0 million, which was partially offset by the purchase of capital equipment totaling $2.6 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September 30, 2020 was $58.8 million, consisting of proceeds from the issuance of common stock, net of issuance costs totaling $48.4 million, proceeds from the issuance of long-term debt  under our 2019 Credit Facility of $10.0 million  and proceeds from the issuance of common stock under the ESPP and the exercise of stock options totaling $0.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September 30, 2019 was $4.8 million, primarily due to net proceeds from the issuance of long-term debt under our 2019 Credit Facility of $19.5 million and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the issuance of common stock in connection with the exercise of stock options totaling $0.3 million, partially offset by the repayment of our prior debt facility of $15.0 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the loan and security agreement described in Note 6 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes to our contractual obligations and commitments included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted or issued accounting pronouncements please refer to Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. These items, including accrued research and development expenses and stock-based compensation, are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Except as described in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies during the three and nine months ended September 30, 2020 from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; included in our Annual Report on&#160;Form&#160;10-K&#160;that was filed with the SEC on February&#160;14, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Fluctuation Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of September 30, 2020, our cash and cash equivalents consisted of cash and money market accounts. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the nature of cash and cash equivalents, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our cash and cash equivalents or on our financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2020, we had $30.0 million outstanding under the 2019 Credit Facility. Amounts outstanding under the 2019 Credit Facility bear interest at a variable annual rate equal to the greater of (i) 8.65% and (ii) the prime rate plus 3.15%, thereby exposing us to interest rate risk. Based upon the prime rate at September 30, 2020 of 3.25% and considering the $30.0&#160;million of borrowings described above, an immediate 10% change in the prime rate would have no impact on our interest to be paid annually and therefore would not have a material impact on our debt-related obligations, financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Fluctuation Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors that are located in Europe and are to be paid in foreign currencies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Fluctuation Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three and nine months ended September 30, 2020, and 2019.</span></div><div id="i9309152dc4244de88c025672033625d7_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the most recent financial quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 2&#8212;OTHER INFORMATION</span></div><div id="i9309152dc4244de88c025672033625d7_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceeding</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to any material legal proceedings. From time to time we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously reported, the USPTO granted Genome &amp; Co.'s petition to initiate a post-grant review of a patent issued to the University of Chicago, to which we have an exclusive license from the University of Chicago. In April 2020, the USPTO issued its decision in the post-grant review, finding unpatentable all of the current claims in the patent. In June 2020, the University of Chicago filed a re-issue application to seek narrowed claims. Importantly, the USPTO decision does not hinder our ability to continue developing our oncology or other product candidates. Under the terms of our license agreement, we have been responsible for reimbursing the University of Chicago for patent defense costs.</span></div><div id="i9309152dc4244de88c025672033625d7_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes and Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a development-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net loss was $20.9 million and $64.6 million for the three and nine months ended September 30, 2020, and $85.5 million, $56.9 million, and $28.0 million for the years ended December 31, 2019, 2018 and 2017, respectively. As of September 30, 2020, we had an accumulated deficit of $263.5 million. Through September 30, 2020, we have financed our operations through private placements of our preferred stock, borrowings under loan and security agreements and proceeds from equity offerings of our common stock. We have devoted substantially all of our financial resources and efforts to developing our platform, identifying potential product candidates and conducting preclinical and clinical trials. We are in the early stages of developing our product candidates, and we have not completed the development of any product candidate. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to enhance our platform and discover and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we anticipate that our expenses will increase substantially if we experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or the European Medicines Agency (the &#8220;EMA&#8221;) or other regulatory authorities to perform preclinical studies or clinical trials in addition to those currently expected, or if there are any delays in completing our preclinical studies or clinical trials or the development of any of our product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or discontinue our product development programs or commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials, build manufacturing capacity and expand into additional therapeutic areas.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our existing cash and cash equivalents will enable us to fund our planned operating expenses and capital expenditure requirements into the beginning of the third quarter of 2021. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress and results of any ongoing and future clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing clinical supplies of our product candidates, including EDP1815, EDP1503,  EDP1867, EDP2939 and EDP1908;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for any other future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such transactions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Additionally, market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, or discontinue one or more of our research or product development programs or the commercialization of any product candidates or cease our operations. In addition, we may be unable to make milestone and royalty payments due under our intellectual property license agreements or other payments under our agreements with CROs and academic research collaborators, or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2014, we have devoted substantially all of our resources to identifying and developing our product candidates, building our intellectual property portfolio, process development and manufacturing function, planning our business, raising capital and providing general and administrative support for these operations. All of our product candidates are in clinical or preclinical development. We have not yet demonstrated our ability to successfully complete a Phase 2 clinical trial or a Phase 3 or other pivotal clinical trial, obtain regulatory approvals to commercialize a product, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our loan and security agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2019 Credit Facility with K2HV for $45.0 million is secured by a lien covering substantially all of our personal property, excluding intellectual property. Contemporaneous with the closing of the first tranche of funding under the 2019 Credit Facility, we repaid the entire $15.0 million loan balance outstanding under our prior loan and security agreement with Pacific Western Bank. As of September 30, 2020, the outstanding principal balance under the 2019 Credit Facility was $30.0 million, resulting from the closing of the first tranche of funding which occurred on July 19, 2019 and second tranche of funding which occurred on July 14, 2020. The 2019 Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default applicable to us and our subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we default under the 2019 Credit Facility, K2HV may accelerate all of our repayment obligations and exercise all of their rights and remedies under the 2019 Credit Facility and applicable law, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. K2HV could declare a default upon the occurrence of any event, among others, that they interpret as a material adverse effect or a change of control as delineated under the 2019 Credit Facility, payment defaults, or breaches of covenants thereby requiring us to repay the loan immediately or to attempt to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reverse the declaration of default through negotiation or litigation. Any declaration by the lenders of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be forced to delay or reduce the scope of our development programs, reduce our research and development costs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan. We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern. As of September 30, 2020, we had $81.6 million in cash and cash equivalents. Based on our available cash resources and based on our current operating plan, we believe we have sufficient cash and cash equivalents on hand to support current operations into the beginning of the third quarter of 2021.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty related to the impact of COVID-19 and the nature of our business, substantial doubt exists about our ability to continue as a going concern for at least one year from the date of issuance of the unaudited condensed consolidated financial statements appearing within this Quarterly Report on Form 10-Q, without raising additional capital. Nevertheless, our unaudited</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will need to raise additional capital to fund our future operations and remain as a going concern. There can be no assurance that we will be able to obtain additional funding on acceptable terms, if at all. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders will be diluted, which dilution may be significant. However, we cannot guarantee that we will be able to obtain any or sufficient additional funding or that such funding, if available, will be obtainable on terms satisfactory to us. In the event that we are unable to obtain any or sufficient additional funding, there can be no assurance that we will be able to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts and may not be successful in our efforts to use our platform to build a pipeline of product candidates and develop marketable drugs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our technology platform to harness the small intestinal axis, with an initial focus on developing therapies in immunology, specifically inflammatory diseases, and also oncology. While we believe our preclinical studies and clinical trials to date have validated our platform to a degree, we are at an early stage of development and our platform has not yet, and may never lead to, approvable or marketable products. We are developing these product candidates and additional product candidates that we intend to use to treat broader immunological diseases, respiratory diseases, neuro-inflammation and degeneration, liver diseases, type I diabetes, food allergy, neurobehavior, cardiovascular disease and diseases of metabolism. We may have problems applying our technologies to these other areas, and our new product candidates may not demonstrate a comparable ability in treating disease as our initial product candidates. Even if we are successful in identifying additional product candidates, they may not be suitable for clinical development as a result of our inability to manufacture more complex oral biologics, limited efficacy, unacceptable safety profiles or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. The success of our product candidates will depend on several factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical studies and clinical trials with positive results;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with CMOs, or establishing our own, commercial manufacturing capabilities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering into new collaborations throughout the development process as appropriate, from preclinical studies through to commercialization;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating without infringing or violating the valid and enforceable patents or other intellectual property of third parties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of the products following approval; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and growing an organization of scientists and business people who can develop and commercialize our products and technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not successfully develop and commercialize product candidates based upon our technological approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are intended to act on cells in the small intestine to produce systemic therapeutic effects with limited systemic exposure. This biological interaction between the small intestine and the rest of the body may not function in humans the way we have observed in mice and our drugs may not reproduce the systemic effects we have seen in preclinical data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our product candidates, including EDP1815, EDP1503, EDP1867, EDP2939 and EDP1908 work by modulating systemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">responses via interactions with cells in the small intestine. Dosing to achieve sufficient exposure may require an inconvenient dosing regimen. Even with successful formulation and delivery to achieve proper exposure of our microbes to the small intestine, we may not get sufficient or even any activity at the site of disease. This may be because our understanding of the mechanisms of the small intestine do not work in humans the way we believe they do. Despite there being strong academic literature to support the concept and our observations in preclinical studies in mice, these principles and the ability to use pharmaceutical preparations derived from single strains of microbes to modulate the immune system and other systems has not yet been proven in humans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are an unproven approach to therapeutic intervention.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are based on targeting SINTAX. We have not, nor to our knowledge has any other company, received regulatory approval for an oral therapeutic based on this approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our product candidates may have different safety profiles and efficacy in various indications. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on singe strains of microbes, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our platform relies on third parties for biological materials to expand our microbial library.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform relies on third parties for biological materials, including human samples containing bacteria, to expand our microbial library. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business and ability to build our pipeline of product candidates. For example, if any supplied biological materials are contaminated, we would not be able to use such biological materials. Although we have quality control processes and screening procedures, biological materials are susceptible to damage and contamination. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our raw materials or products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates do not cause off target adverse events, there may be immunotoxicity associated with the fundamental pharmacology of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, including EDP1815, EDP1503, EDP1867, EDP2939 and EDP1908 are designed to work by modulating the immune system. While we have observed in preclinical studies that our product candidates have limited systemic exposure, the pharmacological immune effects we induce are systemic. Systemic immunomodulation from taking our product candidates could lead to immunotoxicity in patients, which may cause us or regulatory authorities to delay, limit or suspend clinical development. Other immunomodulatory agents have shown immunotoxicity. This includes immune suppressive agents, such as HUMIRA or REMICADE, which have shown an increased risk of infection or in rare instances certain types of blood cancer. In the case of immune activating agents, such as YERVOY, induction of adverse auto-immune events has been observed in some patients. Immunotoxicity in one program could cause regulators to view these adverse events as a class effect of our product candidates which may impact the timing of the development of our pipeline of potential product candidates. Even if the adverse events are manageable, the profile of the drug may be such that it limits or diminishes the possible number of patients who could receive our therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. For example, some of our product candidates may consist of live biological material that may remain viable in humans, which carries a risk of causing infections in patients. Some infections may require treatment with antibiotics to eliminate the bacteria. All our product candidates are screened for antibiotic sensitivity but it is possible that if antibiotic therapy does not eliminate the live biological material, a resistant version of our strain could remerge. These events, while unlikely, could cause a delay in our clinical development and/or could increase the regulatory standards for the entire class of our product candidates. In an instance where the infection risk of taking our product candidates is high, this may cause the benefit risk profile of therapy to be non-competitive in the market and may lead to discontinuation of development of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it is possible that infections from our product candidates could be rare and not frequently observed in our clinical trials. In larger post marketing authorization trials, however, data could show that the infection risk, while small, does exist. If unacceptable side effects arise in the development of our product candidates, we, the FDA, EMA or comparable foreign regulatory authorities, the IRBs at the institutions in which our clinical trials are conducted, or ethics committees, or the data safety monitoring board ("DSMB") could suspend or terminate our clinical trials or the FDA, EMA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall a product or change the way such product is administered to patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies or clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8216;&#8216;black box&#8217;&#8217; warning or a contraindication;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Companies with microbiome products or differing microbial products may produce negative clinical data which will adversely affect public perception of our product candidates, and may negatively impact regulatory approval of, or demand for, our potential products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are pharmaceutical compositions of commensal microbes. While we believe our approach is distinct from microbiome therapies, negative data from clinical trials using microbiome-based therapies (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, fecal transplant) and other microbial therapies could negatively impact the perception of the therapeutic use of microbial-based products. This could negatively impact our ability to enroll patients in clinical trials. The clinical and commercial success of our potential products will depend in part on the public and clinical communities&#8217; acceptance of the use of therapeutic microbes. Moreover, our success depends upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing therapeutic microbes, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for our product candidates that are approved, if any, and a decrease in demand for any such products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Catastrophic loss of our master cell banks could significantly impair our ability to manufacture our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require that we manufacture from master cell banks ("MCBs") of our microbial strains. There is a possibility of a catastrophic failure or destruction of our MCBs. This could make it impossible for us to continue to manufacture a specific product. Recreating and recertifying our MCBs is possible but not certain and could put at risk the supply of our product candidates for preclinical studies or clinical trials or any products, if approved, to our customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are currently in clinical or preclinical development. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval, and the risk of failure through the product development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failed clinical trial can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, in our clinical trials, investigational drug products are being delivered in a capsule for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeted release in the small intestine. This formulation has not previously been clinically tested, nor are we able to dose mice with a capsule for targeted release in the small intestine. Our ongoing clinical trials will be the first time this formulation is tested, and we cannot assure you that the results of this formulation will be consistent with the observations from our preclinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results from early clinical trials of product candidates may not predict the results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate. For example, in August and November 2019, we announced positive Phase 1b interim clinical data, as measured using certain secondary and exploratory endpoints, from our ongoing clinical trial of EDP1815 in subjects with psoriasis. Although the interim clinical data from this trial may be encouraging, the data are preliminary in nature, based on a limited number of people with psoriasis, and the Phase 1 trial is not complete. There can be no assurance that this trial will ultimately be successful or support further clinical advancement of this product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be certain as to the type and number of clinical trials the FDA will require us to conduct before we may successfully gain approval, referred to as licensure in the United States, to market any of our product candidates. Prior to approving a new therapeutic product, the FDA generally requires that efficacy be demonstrated in two adequate and well-controlled clinical trials. In some situations, evidence from a Phase 2 trial and a Phase 3 trial or from a single Phase 3 trial can be sufficient for FDA approval, such as in cases where the trial or trials provide highly reliable and statistically strong evidence of an important clinical benefit. Additionally, the FDA requires that investigation include adequate tests to demonstrate the safety of the new therapeutic product. Additional clinical trials could cause us to incur significant development costs, delay or prevent the commercialization of our products or otherwise adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may demonstrate undesirable side effects or produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CROs, CMOs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to, or regulators, IRB or ethics committees may require that we or our investigators, suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regarding trials managed by any future collaborators, our collaborators may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but potentially suboptimal for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lose the support of any future collaborators, requiring us to bear more of the burden of developing certain microbial strains;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as we intend or desire;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States, such as the EMA. We are developing our product candidates, EDP1815 and EDP1867, to treat inflammatory diseases, beginning with psoriasis and atopic dermatitis, and EDP1503 to treat multiple types of cancer. There are a limited number of patients from which to draw for clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria for the trial in question;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of other treatments for the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of competing clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our payments for conducting clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients or volunteers for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials, and finances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, which causes COVID-19, was reported to have surfaced in Wuhan, China. Since then, the coronavirus has spread to multiple countries, including the United States and the United Kingdom, where we have planned or ongoing preclinical studies and clinical trials. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The pandemic and government measures taken in response have had and continue to have a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have adopted and continue to employ several temporary business practices, including telecommuting and staggered work shifts in our laboratories, to protect our employees while continuing business operations. In addition, due to the COVID-19 pandemic, enrollment of new patients into, and the retention of existing patients in, our on-going clinical trials have been and continue to be impacted, due primarily to lower patient participation. As a result of the COVID-19 pandemic, we may continue to experience disruptions and face new disruptions that could severely impact our business, preclinical studies and clinical trials, and finances including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments, employers and others or interruption of clinical trial subject visits and study procedures (such as skin biopsies that are deemed non-essential activities), which may impact the integrity of subject data and clinical trials endpoints;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions or delays in the operations of the FDA and EMA, which may impact review and approval timelines;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions of, or delays in receiving, supplies of our product candidates from our CMOs due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal of the FDA to accept data from clinical trials in affected geographies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.05pt">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties with equity offerings due to disruptions and uncertainties in securities markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. While the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, "topline" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates or will not be able to do so as soon as anticipated, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate in any jurisdiction will prevent us from commercializing the product candidate in that jurisdiction, and may affect our plans for commercialization in other jurisdictions as well. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy to such regulatory authorities&#8217; satisfaction. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years. The scope and amount of clinical data required to obtain marketing approvals can vary substantially from jurisdiction to jurisdiction, and it may be difficult to predict whether a particular regulatory body will require additional or different clinical trials than those conducted by a sponsor, especially for novel product candidates such as our product candidates. The FDA, EMA or other foreign regulatory authorities may delay, limit, or deny the approval of our product candidates for many reasons, including: our inability to demonstrate that the clinical benefits of our product candidates outweigh any safety or other perceived risks; the regulatory authority&#8217;s disagreement with the interpretation of data from nonclinical or clinical studies; the regulatory agency&#8217;s requirement that we conduct additional preclinical studies and clinical trials; changes in marketing approval policies during the development period; changes in or the enactment of additional statutes or regulations, or changes in regulatory review process for each submitted product application; or the regulatory authority&#8217;s failure to approve the manufacturing processes or third-party manufacturers with which we contract. Regulatory authorities have substantial discretion in the approval process and may refuse to accept a marketing application as deficient. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA or other regulatory approval processes and are commercialized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our product candidates may not receive marketing approval even if they achieve their specified endpoints in clinical trials. Clinical data are often susceptible to varying interpretations and many companies that have believed that their products performed satisfactorily in clinical trials have nonetheless failed to obtain FDA, EMA or the applicable foreign regulatory agency approval for their products. The FDA, EMA or foreign regulatory authorities may disagree with our trial design and our interpretation of data from nonclinical and clinical studies. Upon the review of data from any pivotal trial, the FDA, EMA or applicable foreign regulatory agency may request that the sponsor conduct additional analyses of the data and, if it believes the data are not satisfactory, could advise the sponsor to delay filing a marketing application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we eventually complete clinical testing and receive approval of a BLA or foreign marketing authorization for one of our product candidates, the FDA, EMA or applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA, EMA or the applicable foreign regulatory agency may also approve our products for a more limited indication and/or a narrower patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our products. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of SINTAX medicines and their interactions with cells in the small intestine is an emerging field, and it is possible that the FDA, EMA or other regulatory authorities could issue regulations or new policies in the future affecting our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for multiple initial indications that we identify as most likely to succeed, in terms of both regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and product development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements, in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek fast track designation for some of our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs for this condition, the drug or biologic sponsor may apply for FDA fast track designation. Fast track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. Fast track designation does not assure ultimate approval by the FDA. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our product development program.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation for our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the designation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global pandemic of COVID-19, on March 10, 2020 the FDA temporarily postponed most foreign inspections of manufacturing facilities and products. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Dependence on Third Parties and Manufacturing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, medical institutions, clinical investigators and potential pharmaceutical partners, to conduct and manage our clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, safety and welfare of trial participants are protected. Other countries&#8217; regulatory agencies also have requirements for clinical trials with which we must comply. We also may be required in certain instances to register ongoing clinical trials and post the results of completed clinical trials on government-sponsored databases, such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, do not meet expected deadlines, experience work stoppages, terminate their agreements with us or need to be replaced, or do not conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed, or terminated or may need to be repeated. If any of the foregoing occur, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to rely on other third parties to store and distribute drug product required by our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or that such quantities may not be available at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates on a timely basis or at all, or that such quantities will be available at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers on acceptable terms or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breach of manufacturing agreements by the third-party manufacturers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to manufacture our product according to our specifications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to manufacture our product according to our schedule or at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">misappropriation or disclosure of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of agreements by third-party manufacturers at times that are costly or inconvenient for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Some of the contract manufacturers we rely on to produce our product candidates have never produced a FDA-approved therapeutic. If our contract manufacturers are unable to comply with cGMP regulation or if the FDA does not approve their facility upon a pre-approval inspection, our product candidates may not be approved or may be delayed in obtaining approval. In addition, there are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products. Therefore, our product candidates and any future product candidates that we may develop may compete with other products for access to manufacturing facilities. Any failure to gain access to these limited manufacturing facilities could severely impact the clinical development, marketing approval and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant sources of clinical supplies for both drug substance and drug product. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products could delay, prevent or impair our development and commercialization efforts. Moreover, as a result of the COVID-19 pandemic, third-party manufacturers may be affected, which could disrupt their activities and, as a result, we could face difficulties and delays in the manufacture of our product candidates, which may negatively affect our preclinical and clinical development activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing our product candidates at commercial scale, and if we decide to establish our own manufacturing facility, we cannot assure you that we can manufacture our product candidates in compliance with regulations at a cost or in quantities necessary to make them commercially viable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may establish a manufacturing facility for our product candidates for production at a commercial scale. We have no experience in commercial-scale manufacturing of our product candidates. We currently intend to develop our manufacturing capacity in part by expanding our current facility or building additional facilities. This activity will require substantial additional funds and we would need to hire and train a significant number of qualified employees to staff these facilities. We may not be able to develop commercial-scale manufacturing facilities that are adequate to produce materials for additional later-stage clinical trials or commercial use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equipment and facilities employed in the manufacture of pharmaceuticals are subject to stringent qualification requirements by regulatory agencies, including validation of facility, equipment, systems, processes and analytics. We may be subject to lengthy delays and expense in conducting validation clinical trials, if we can meet the requirements at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current psoriasis treatment involves the use of steroids and biologics that are well established in the medical community, and physicians may continue to rely on these treatments. If our product candidates receive approval but do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our approved product candidates, if any, will depend on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">their efficacy, safety and other potential advantages compared to alternative treatments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which our products are approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer them for sale at competitive prices;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">their convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of their side effects and their overall safety profiles;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interactions of our products with other medicines patients are taking; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of certain types of patients to take our product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no sales organization. If we are unable to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of our product candidates. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish a sales and marketing organization or make arrangements with third parties to perform sales and marketing functions and we may not be successful in doing so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to build a focused sales and marketing infrastructure to market or promote our product candidates in the United States and potentially elsewhere, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain an adequate number of effective sales and marketing personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to or educate physicians on the benefits of our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we may rely on third parties to sell, market and distribute our product candidates. We may not be successful in entering into arrangements with such third parties or may be unable to do so on terms that are favorable to us. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug and biologic products is highly competitive and is characterized by rapid and substantial technological development and product innovations. We face competition with respect to our current product candidates and will face competition with respect to product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are aware of a number of large pharmaceutical and biotechnology companies, including AbbVie Inc., Agenus Inc., AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche A.G., Gilead Sciences, Inc., Incyte Corporation, Johnson &amp; Johnson, Merck, Novartis International A.G., Pfizer Inc. and Regeneron Pharmaceuticals, Inc., as well as smaller, early-stage companies, that are pursuing the development of products, including microbial-based therapeutics in some instances, for disease indications we are targeting. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others may be based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These third parties compete with us in recruiting and retaining qualified scientific, sales and marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could delay us from obtaining FDA approval to market our product candidates and result in our competitors establishing a strong market position before we are able to enter the market, especially for any competitor developing a microbial-based therapeutic which will likely share our same regulatory approval requirements. For more information, please see "Risk Factors-Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated, which may delay us from marketing our product candidates." In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic or biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, any of which could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and impact reimbursement levels.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain coverage and an adequate level of reimbursement for our products by third-party payors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. In addition, reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval, and the royalties resulting from the sales of those products may also be adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription drug pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries, will be considered medically necessary or cost-effective for a specific indication, or that coverage or an adequate level of reimbursement will be available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product liability insurance coverage and any product liability insurance coverage that we acquire in the future may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated, which may delay us from marketing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars. The BPCIA created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.  Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.  Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilars in other countries that could compete with our products. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our product candidates in the European Union and many other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval in foreign countries may differ substantially from that required to obtain FDA, EMA or other applicable regulatory approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA, EMA or other applicable regulatory approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals for our product candidates from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We and our contract manufacturers will also be subject to continual review and periodic inspections to assess compliance with cGMP. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to specific conditions of approval, including a requirement to implement a risk evaluation and mitigation strategy, which could include requirements for a medication guide, communication plan, or restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of drugs and biologics to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDA&#8217;s restrictions relating to the promotion of prescription drugs may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a regulatory agency or we later discover previously unknown problems with our products, such as adverse events of unanticipated severity or frequency, problems with manufacturers or manufacturing processes, or failure to comply with regulatory requirements, the regulatory agency may impose restrictions on the products or us, including requiring withdrawal of the product from the market. Any failure to comply with applicable regulatory requirements may yield various results, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation involving patients taking our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of products from the market;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of ongoing clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to relationships with potential collaborators;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable press coverage and damage to our reputation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with similar European Union requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. In addition, the FDA&#8217;s regulations, policies or guidance may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from governmental healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors, physicians and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may restrict the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program, such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate the statute to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (described below);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the false claims and civil monetary penalties laws, including the federal False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim or from knowingly or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians, certain other healthcare professionals beginning in 2022, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; manufacturers are required to submit reports to the government by the 90th day of each calendar year;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to our business practices, including but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, pricing information or marketing expenditures; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust system to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may violate one or more of the requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Affordable Care Act ("ACA") was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the ACA that are of importance to our potential product candidates are the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a new pathway for approval of lower cost biosimilars to compete with biologic products, such as those we are developing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the Tax Cuts and Jobs Acts (the "TCJA") was enacted, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court's decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how these decisions, subsequent appeals and other efforts to challenge, repeal or replace the ACA will affect the law or our business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Individual states in the United States have become increasingly aggressive in implementing regulations designed to contain pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various European Union member states and parallel distribution or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If coverage and reimbursement of our products are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials such as human stool. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. Prosecution of our patent portfolio is at an early stage, and we are beginning to reach the statutory deadlines for deciding whether and where to initiate prosecution in specific foreign jurisdictions by filing national stage applications based on our Patent Cooperation Treaty applications. As those deadlines come due, we will have to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decide whether and where to pursue patent protection for the various inventions claimed in our patent portfolio, and we will only have the opportunity to obtain patents in those jurisdictions where we pursue protection. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as, with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our current and future license agreements with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio is in the early stages of prosecution. We currently have eleven issued U.S. patents. Although we have numerous patent applications pending, substantive prosecution has begun in only a small number of those applications. We cannot provide any assurances that any of our pending patent applications will mature into issued patents and, if they do, that such patents or our current patents will include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. For example, we are pursuing claims to compositions of certain bacterial populations. Any claims that are issued may provide coverage for such compositions and/or their use. However, such claims would not prevent a third party from commercializing alternative compositions that do not include the bacterial populations claimed in pending applications, potential applications or patents that have or may issue. There can be no assurance that any such alternative composition will not be equally effective. These and other factors may provide opportunities for our competitors to design around our patents, should they issue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, other parties have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming similar methods or by claiming subject matter that could dominate our patent position. In addition, given the early stage of prosecution of our portfolio, it may be some time before we understand how patent offices react to our patent claims and whether they identify prior art of relevance that we have not already considered, which could be an impediment to our patents issuing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in any issued patents or pending patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we may license patents were the first to make the inventions claimed or were the first to file. For these and other reasons, the issuance, scope, validity, enforceability and commercial value of our patent rights are subject to a level of uncertainty. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in derivation, reexamination, inter partes review, ex partes reexamination, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third- party patent rights. For example, in April 2020, in a post grant review of a patent issued to the University of Chicago, to which we have an exclusive license from the University of Chicago, the USPTO found that all of the challenged claims are unpatentable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any limitation on the protection of the subject technology could hinder our ability to develop and commercialize applicable product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product candidates. The issuance, scope, validity, enforceability and commercial value of our patents are subject to a level of uncertainty.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering biotechnological and pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if issued, a patent&#8217;s validity, inventorship, ownership or enforceability is not conclusive. Accordingly, rights under any existing patent or any patents we might obtain or license may not cover our product candidates, or may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our product candidates or any other products or product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications will issue as patents;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to successfully commercialize our product candidates, if approved, before our relevant patents expire;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to make the inventions covered by any existing patent and pending patent applications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not develop similar or alternative technologies that do not infringe or design around our patents;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not use pre-existing technology to effectively compete against us;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our patents, if issued, will be found to ultimately be valid and enforceable;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties will not compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies or product candidates that are separately patentable; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial activities or products will not infringe upon the patents or proprietary rights of others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. Even if we are successful, domestic or foreign litigation, or USPTO or foreign patent office proceedings, may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or potential collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into and may be required to enter into in the future, intellectual property license agreements that are important to our business. These license agreements may impose various diligence, milestone payment, royalty and other obligations on us. For example, we have entered into exclusive license agreements with the University of Chicago and Mayo Clinic pursuant to which we are required to use efforts to engage in various development and commercialization activities with respect to licensed products and are required to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements with licensors, we may be subject to termination of the license agreement in whole or in part or increased financial obligations to our licensors, in which case our ability to develop or commercialize products covered by the license agreement will be impaired. Further, we may need to outsource and rely on third parties for many aspects of the clinical development, sales and marketing of our products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property which we have licensed from the University of Chicago and Mayo Clinic was discovered through government funded programs and thus may be subject to federal regulations such as "march-in" rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain intellectual property from the University of Chicago and Mayo Clinic. These agreements indicate that the rights licensed to us are subject to the obligations to and the rights of the U.S. government, including those set forth in the Bayh-Dole Act of 1980 (the "Bayh-Dole Act"). As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed intellectual property. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as "march-in rights." While the U.S. government has sparingly used, and to our knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position would be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also seek to enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, patent reform legislation could further increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the "Leahy-Smith Act") was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO has also developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular the first to file provisions, only became effective on March 16, 2013. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Thus, for our U.S. patent applications containing a priority claim after March 16, 2013, there is a greater level of uncertainty in the patent law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some of the patent applications in our portfolio will be subject to examination under the pre-Leahy-Smith Act law and regulations, while other patents applications in our portfolio will be subject to examination under the law and regulations, as amended by the Leahy-Smith Act. This introduces additional complexities into the prosecution and management of our portfolio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Leahy-Smith Act limits where a patentee may file a patent infringement suit and provides opportunities for third parties to challenge any issued patent in the USPTO. These provisions apply to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a federal court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims because it may be easier for them to do so relative to challenging the patent in a federal court action. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. From time to time, the U.S. Supreme Court, other federal courts, the United States Congress, or the USPTO, may change the standards of patentability and any such changes could have a negative impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cases decided by the Supreme Court have involved questions of when claims reciting abstract ideas, laws of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 569 U.S. 12-398 (2013) or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myriad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alice Corp. v. CLS Bank International</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 573 U.S. 13-298 (2014); and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Services v. Prometheus Laboratories, Inc.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prometheus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 566 U.S. 10-1150 (2012). In response to these cases, the USPTO has issued guidance to the examining corps.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of these decisions is not yet known. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myriad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision, issued on June 13, 2013, is the most recent Supreme Court decision to address patent eligibility of natural products. Our current product candidates include natural products, therefore, this decision and its interpretation by the courts and the USPTO may impact prosecution, defense and enforcement of our patent portfolio. In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myriad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Court held that claims to isolated genomic DNA are not patentable, but claims to complementary DNA, or cDNA, molecules, which are not genomic sequences, may be patent eligible because they are not a natural product. The effect of the decision on patents for other isolated natural products is uncertain. However, on March 4, 2014, the USPTO issued a memorandum to patent examiners providing guidance for examining claims that recite laws of nature, natural phenomena or natural products under the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myriad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prometheus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decisions. The guidance did not limit the application of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myriad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to DNA but, rather, applied the decision broadly to other natural products, which may include our product candidates. The March 4, 2014 memorandum and the USPTO&#8217;s interpretation of the cases and announced examination rubric received widespread criticism from stakeholders during a public comment period and was superseded by interim guidance published on December 15, 2014. The USPTO&#8217;s interpretation of the case law and new guidelines for examination may influence, possibly adversely, prosecution and defense of certain types of claims in our portfolio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in procedures in the USPTO or in courts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#8217;s intellectual property rights, we cannot guarantee that our technology, products or use of our products do not infringe third-party patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous patents and pending applications are owned by third parties in the fields in which we are developing product candidates, both in the United States and elsewhere. It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. We are aware of several pending patent applications containing one or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more claims that could be construed to cover some of our product candidates or technology, should those claims issue in their original form or in the form presently being pursued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may allege that our product candidates or the use of our technologies infringe patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future. If we were to challenge the validity of an issued U.S. patent in court, such as an issued U.S. patent of potential relevance to some of our product candidates or methods of use, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. There is no assurance that a court would find in our favor on questions of infringement or validity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found or believe there is a risk we may be found, to infringe a third party&#8217;s intellectual property rights, we could be required or may choose to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any such license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, intellectual property litigation or claims could force us to do one or more of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cease developing, selling or otherwise commercializing our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages for past use of the asserted intellectual property;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain a license from the holder of the asserted intellectual property, which license may not be available on reasonable terms, if at all; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of trademark claims, redesign or rename some or all of our product candidates or other brands to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if possible, could be costly and time-consuming.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable or could be interpreted narrowly if challenged in court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. If we initiated legal proceedings against a third party to enforce a patent, if and when issued, covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obviousness or non-enablement, or failure to claim patent eligible subject matter. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Moreover, even if not found invalid or unenforceable, the claims of our patents could be construed narrowly or in a manner that does not cover the allegedly infringing technology in question. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and, in some jurisdictions, during the pendency of a patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, contractors and advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may also engage advisors and consultants who are concurrently employed at universities or other organizations or who perform services for other entities. Although we try to ensure that our employees, advisors and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, advisors or consultants have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such party&#8217;s former or current employer or in violation of an agreement with another party. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants, advisors and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Similarly, we may be subject to claims that an employee, advisor or consultant performed work for us that conflicts with that person&#8217;s obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work performed for us. Litigation may be necessary to defend against these claims. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than in the United States, assuming that rights are obtained in the United States and assuming that rights are pursued outside the United States. The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications. For all of the patent families in our portfolio, including the families that may provide coverage for our lead product candidates, the relevant statutory deadlines have not yet expired. Therefore, for each of the patent families that we believe provide coverage for our lead product candidates, we will need to decide whether and where to pursue protection outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, even if we do elect to pursue patent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights outside the United States, we may not be able to obtain relevant claims and/or we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ability to obtain and, if obtained, enforce our patents to stop infringing activities is inadequate, third parties may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Accordingly, our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business</span></div><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on Balkrishan (Simba) Gill, our President and Chief Executive Officer, as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain "key person" insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time due to the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product development, regulatory affairs, clinical affairs and manufacturing and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with operating internationally could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited international operations, but our business strategy incorporates potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional potentially relevant third-party patent rights;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits in our ability to penetrate international markets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease (e.g. the COVID-19 pandemic), boycotts, curtailment of trade and other business restrictions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions, or other anti-bribery and anti-corruption laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, the United Kingdom of Great Britain and Northern Ireland (the &#8220;United Kingdom&#8221;) left the European Union (&#8220;Brexit&#8221;). The United Kingdom and the European Union have ratified the Agreement on the Withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community of October 19, 2019 (the &#8220;Withdrawal Agreement&#8221;), which provides for a transition period during which EU law will remain applicable in the United Kingdom as though the United Kingdom were still an EU Member State, with limited exceptions. The transition period is due to end on December 31, 2020. The United Kingdom can request an extension of the transition period for a further one or two years, but the British government has indicated that it will not extend the transition period beyond the end of 2020. The UK Parliament has passed the European Union (Withdrawal Agreement) Act of 2020, pursuant to which the various UK statutory instruments designed to ensure that current EU law operates effectively in the United Kingdom after Brexit now will come into effect at the end of the transition period. The terms of the United Kingdom&#8217;s trading relationship with the European Union after the conclusion of the transition period are subject to a complex and ongoing negotiation between the United Kingdom and the European Union whose result remains unclear and which has created significant political and economic uncertainty, including with respect to the laws and regulations that will apply as the United Kingdom determines which EU laws to replace or replicate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which could have a material adverse effect on our business, financial condition and results of operations and reduce the price of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of Brexit after the conclusion of the transition period, the United Kingdom could lose its present rights or terms of access to the single EU market and EU customs areas and to the global trade deals negotiated by the European Union on behalf of its members. The uncertainty regarding new or modified arrangements between the United Kingdom and other countries following Brexit may have a material adverse effect on the movement of goods between the United Kingdom and members of the European Union and the United States, including the interruption of or delays in imports into the United Kingdom of goods originating within the European Union and exports from the United Kingdom of goods originating there. For example, shipments into the United Kingdom of drug substance manufactured for us in the European Union may be interrupted or delayed and thereby prevent or delay the manufacture in the United Kingdom of drug product. Similarly, shipments out of the United Kingdom of drug product to the United States or the European Union may be interrupted or delayed and thereby prevent or delay the delivery of drug product to clinical sites. Such a situation could hinder our ability to conduct current and planned clinical trials and have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of information technology and other system failures or security breaches of or unauthorized access to our systems.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, or to attachments to emails and other security breaches or unauthorized access by persons inside our organization or with access to our internal systems. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusions, including by computer hackers, foreign governments and cyber terrorists, generally has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.  In addition, our systems safeguard important confidential personal data regarding patients enrolled in our clinical trials.  While we are not aware of any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our product development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a set of cloud-based software services and access these services via the Internet for the vast majority of our computing, storage, bandwidth, and other services. Any disruption of or interference with our use of our cloud-based services would negatively affect our operations and could seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several distributed computing infrastructure platforms for business operations, or what is commonly referred to as "cloud" computing services and we access these services via the Internet. Any transition of the cloud services currently provided by an existing vendor to another cloud provider would be difficult to implement and will cause us to incur significant time and expense. Given this, any significant disruption of or interference with our use of these cloud computing services would negatively impact our operations and our business would be seriously harmed. If our employees or partners are not able to access our cloud computing services or encounter difficulties in doing so, we may experience business disruption. The level of service provided by our cloud computing vendors, including the ability to secure our confidential information and the confidential information of third parties that is shared with us, may also impact the perception of our company and could seriously harm our business and reputation and create liability for us. If a cloud computing service that we use experiences interruptions in service regularly or for a prolonged basis, or other similar issues, our business could be seriously harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a cloud computing service may take actions beyond our control that could seriously harm our business, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discontinuing or limiting our access to its platform;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing pricing terms;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminating or seeking to terminate our contractual relationship altogether;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing more favorable relationships with one or more of our competitors; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifying or interpreting its terms of service or other policies in a manner that impacts our ability to run our business and operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cloud computing services have broad discretion to change and interpret its terms of service and other policies with respect to us, and those actions may be unfavorable to us. Our cloud computing services may also alter how we are able to process data on the platform. If a cloud computing services makes changes or interpretations that are unfavorable to us, our business could be seriously harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to protect the information shared with us may be unsuccessful due to the actions of third parties, software bugs, or other technical malfunctions, employee error or malfeasance, or other factors. In addition, third parties may attempt to fraudulently induce employees or users to disclose information to gain access to our data or third-party data entrusted to us. If any of these events occur, our or third-party information could be accessed or disclosed improperly. Some partners or collaborators may store information that we share with them on their own computing system. If these third parties fail to implement adequate data-security practices or fail to comply with our policies, our data may be improperly accessed or disclosed. And even if these third parties take all these steps, their networks may still suffer a breach, which could compromise our data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any incidents where our information is accessed without authorization, or is improperly used, or incidents that violate our policies, could damage our reputation and our brand and diminish our competitive position. In addition, affected parties or government authorities could initiate legal or regulatory action against us over those incidents, which could cause us to incur significant expense and liability or result in orders or consent decrees forcing us to modify our business practices. Concerns over our privacy practices, whether actual or unfounded, could damage our reputation and brand and deter users, advertisers, and partners from using our products and services. Any of these occurrences could seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to many federal, state, and foreign laws and regulations, including those related to privacy, rights of publicity, data protection, content regulation, intellectual property, health and safety, competition, protection of minors, consumer protection, employment, and taxation. By way of example, on June 28, 2018, California enacted the California Consumer Privacy Act (the "CCPA"), which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states. These laws and regulations are constantly evolving and may be interpreted, applied, created, or amended in a manner that could seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We have only made one acquisition to date, and our ability to do so successfully is unproven beyond this instance. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with future customers or with current or future distributors or suppliers as a result of such a transaction;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated liabilities related to acquired companies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to develop a sales force for any additional product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the anticipated benefit of any acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock, and we could be subject to securities class action litigation as a result.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is likely to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price at which you purchase the shares. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future collaborations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our preclinical studies or clinical trials, manufacturing or sales and marketing activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any adverse changes to our relationship with third party contractors or manufacturers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development of new product candidates that may address our markets and may make our existing product candidates less attractive;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or product development programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">press reports or other negative publicity, whether or not true, about our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this "Risk Factors" section.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may result in large and sudden changes in the volume and trading price of our common stock. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares of common stock outstanding as of September 30, 2020, our executive officers, directors and stockholders who own more than 5% of our outstanding common stock and their respective affiliates hold, in the aggregate, shares representing appr</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oximately 67% of our ou</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding voting stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. They may also have interests that differ from yours and may vote in a way with which you disagree, and which may be adverse to your interests. This concentration of ownership control may have the effect of delaying, deferring or preventing a change in control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might ultimately affect the market price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, holders of an aggregate of approxim</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately 18.4 million shares of our co</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mmon stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, including entities affiliated with Flagship Pioneering, until such shares can otherwise be sold without restriction under Rule 144 of the Securities Act or until the rights terminate pursuant to the terms of the investors&#8217; rights agreement between us and such holders. We have also registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an "emerging growth company" and a "smaller reporting company," and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an "emerging growth company" as that term is used in the JOBS Act and may remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the initial public offering of our common stock, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our outstanding common stock that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations" disclosure;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 ("Section 404") and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to take advantage of certain of the reduced reporting obligations. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an emerging growth company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to maintain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies or clinical trials and/or operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our restated certificate of incorporation and amended and restated bylaws could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated certificate of incorporation provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee or stockholder to us or our stockholders, any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or any action asserting a claim governed by the internal affairs doctrine. We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. The provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, and may have the effect of discouraging lawsuits, including those against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the operation and expansion of our business. Therefore, you should not rely on an investment in our common stock as a source for any future dividend income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has significant discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our common stock will likely depend entirely on any future capital appreciation, if any, of our common stock. There is no guarantee that our common stock will appreciate in value or even maintain the price at which you purchased our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, we had federal and state NOLs of $96.1 million and $90.4 million, respectively. The federal NOLs includes $49.9 million that will begin to expire at various dates through 2037 and $46.2 million that will carry forward indefinitely. The state NOLs will begin to expire at various dates through 2039. As of December 31, 2019, we also had federal research and development tax credit carryforwards of $3.4 million and state research and development tax credit carryforwards of $1.9 million, which begin to expire in 2034. A portion of these NOLs and the tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the "Code"), a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change NOLs or tax credits to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in the future, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. The reduction of the corporate tax rate under the TCJA may cause a reduction in the economic benefit of our net operating loss carryforwards and other deferred tax assets available to us. Furthermore, under the TCJA, although the treatment of NOLs generated before December 31, 2017 has generally not changed, NOLs generated in calendar year 2018 and beyond will not be subject to expiration but will only be able to offset 80% of taxable income. This change may require us to pay federal income taxes even if we have NOLs that could otherwise offset our taxable income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCJA has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as "orphan drugs"), adopting elements of a territorial tax system, imposing a one-time transition tax, or repatriation tax, on all undistributed earnings and profits of certain U.S.-owned foreign corporations, revising the rules governing net operating losses and the rules governing foreign tax credits, and introducing new anti-base erosion provisions. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While some of the changes made by the TCJA may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors and auditors to determine the full impact that the TCJA will have on us. We urge our investors to consult with their legal and tax advisors with respect to the TCJA.</span></div><div id="i9309152dc4244de88c025672033625d7_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9309152dc4244de88c025672033625d7_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9309152dc4244de88c025672033625d7_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9309152dc4244de88c025672033625d7_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i9309152dc4244de88c025672033625d7_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 5.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1694665/000119312518160865/d582561dex31.htm">Restated Certificate of Incorporation of Evelo Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/11/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 5.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1694665/000119312518160865/d582561dex32.htm">Amended and Restated Bylaws of Evelo Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/11/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1694665/000169466520000079/exhibit1022020q2.htm">Third Amendment to Loan and Security Agreement dated as of July 8, 2020 by and among Evelo Biosciences, Inc., the lenders party thereto and K2 HealthVentures LLC, as administrative agent for such lenders.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit1022020q3.htm">Letter Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit1022020q3.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit1032020q3.htm">Consulting Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit1032020q3.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 3.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq32020exhibit311.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 3.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq32020exhibit321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Instance Document- the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File&#160;No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9309152dc4244de88c025672033625d7_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i9309152dc4244de88c025672033625d7_106"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVELO BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Balkrishan (Simba) Gill, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Xiaoli (Jacqueline) Liu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xiaoli (Jacqueline) Liu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VP of Finance and Controller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exhibit1022020q3.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i54d820ec97c44c268b103b2b620bd23c_51"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><img alt="evelobioseciencesheaderexab.jpg" src="evelobioseciencesheaderexab.jpg" style="height:71px;width:428px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 16, 2019</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. David R. Epstein</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RE&#58; Compensation for Services as Chairman of Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear David,</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you for agreeing to serve as the Chairman (the &#34;Chairman&#34;) of the Board of Directors (the &#34;Board&#34;) of Evelo Biosciences, Inc. (the &#34;Company&#34;). This letter memorializes our recent discussion concerning your compensation for serving as the Chairman. The compensation described in this letter will become applicable upon your appointment by the Board as its Chairman.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While serving as the non-employee Chairman, you will be entitled to receive the following cash and equity compensation, unless otherwise determined by the Board&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. An annual retainer of $150,000 for your service on the Board and as the Chairman, and on any committees of the Board (as a member or the chair of any such committees) shall be payable to Remedii LLC, a limited liability company for which you are the managing member. The annual retainer shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event you do not serve as the Chairman for an entire calendar quarter, the annual retainer paid to you shall be prorated for the portion of such calendar quarter during which you actually served as the Chairman.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to approval by the Board, you shall receive (i) on your appointment as the Chairman, a single grant of options to purchase 75,000 shares of the Company&#8217;s common stock (the &#34;Initial Grant&#34;), and (ii) thereafter on the anniversary of the date of your appointment as the Chairman, annual grants of options to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $225,000, as determined by the Board in its discretion based on customary option pricing methodologies (&#34;Annual Grants&#34;). The Initial Grant and Annual Grants shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity incentive plan then maintained by the Company (the &#34;Equity Plan&#34;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. For the avoidance of doubt, the share numbers shall be subject to adjustment as provided in the Equity Plan. The per share exercise price of the Initial Grant and each Annual Grant shall equal the Fair Market Value (as defined in the Equity Plan) of a share of the Company&#8217;s common stock on the date the option is granted.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Initial Grant shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Grant shall be fully vested on the third anniversary of the date of grant, subject to you continuing in service as the Chairman through each such vesting date. Each Annual Grant shall vest and become exercisable on the first anniversary of the date of grant, subject to you continuing in service as the Chairman through each such vesting date. Unless the Board otherwise determines, any portion of the Initial Grant or an Annual Grant which is unvested or unexercisable at the time of your termination of service as the Chairman shall be immediately forfeited upon such termination of service and shall not thereafter become vested or exercisable. The Initial Grant and all Annual Grants shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time. The terms of the Initial Grant and each Annual Grant shall be ten (10) years from the date the option is granted.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation described above is in lieu of, and not in addition to, the compensation provided under the Company&#8217;s Non-Employee Director Compensation Program (the &#34;Compensation Program&#34;). You hereby decline the receipt from the Company of any cash or equity compensation provided pursuant to the Compensation Program while receiving the compensation described in this letter.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please indicate your agreement to and acceptance of the compensation arrangement described above, including without limitation your declination of cash and equity compensation pursuant to the Compensation Program, by signing your name where indicate below and returning this letter to me.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I look forward to working with you as the Chairman and to your continuing contributions to the success of the Company.</font></div><div><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:288pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:42.708%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Respectfully,</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan &#34;Simba&#34; Gill</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Balkrishan &#8220;Simba&#8221; Gill, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div></td></tr></table></div><div style="padding-left:288pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acknowledged and agreed as of September 16, 2019.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David R. Epstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David R. Epstein</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2020</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i54d820ec97c44c268b103b2b620bd23c_1"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><img alt="evelobioseciencesheaderexab.jpg" src="evelobioseciencesheaderexab.jpg" style="height:71px;width:428px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                     &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:396pt;text-align:right"><font><br></font></div><div style="padding-left:396pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> October 14, 2020</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mr. David R. Epstein</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Re&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Amendment to Letter Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dear David,</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reference is made to my letter dated as of September 16, 2019 addressed to you concerning your compensation for serving as the Chair of the Board of Directors of Evelo Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Letter Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;). This letter memorializes our recent discussion concerning an amendment to your compensation, and will become applicable upon your signature below (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Now, Therefore, the parties agree as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. The first and second paragraphs of Section B (Equity Compensation) of the Letter Agreement are hereby amended and restated in their entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Subject to approval by the Board, you shall receive (i) on your appointment as the Chairman, a single grant of options to purchase 75,000 shares of the Company&#8217;s common stock (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Initial Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;), and (ii) thereafter on the anniversary of the date of your appointment as the Chairman, annual grants of options to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair value equal to approximately $225,000, as determined by the Board in its discretion based on customary option pricing methodologies (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#34;Annual Grants&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). The Initial Grant and Annual Grants shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity incentive plan then maintained by the Company (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. For the avoidance of doubt, the share numbers shall be subject to adjustment as provided in the Equity Plan. The per share exercise price of the Initial Grant and each Annual Grant shall equal the Fair Market Value (as defined in the Equity Plan) of a share of the Company&#8217;s common stock on the date the option is granted.&#8221;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;The Initial Grant shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Grant shall be fully vested on the third anniversary of the date of grant, subject to you continuing in service as the Chairman through each such vesting date. Each Annual Grant shall vest and become exercisable in twelve (12) substantially equal monthly installments following the date of grant, such that each Annual Grant shall be fully vested on the first anniversary of the date of grant, subject to you continuing in service as the Chairman through each such vesting date. Unless the Board otherwise determines, any portion of the Initial Grant or an Annual Grant which is unvested or unexercisable at the time of your termination of service as the Chairman shall be immediately forfeited upon such termination of service and shall not thereafter become vested or exercisable. The Initial Grant and all Annual Grants shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time. The terms of the Initial Grant and each Annual Grant shall be ten (10) years from the date the option is granted.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. Except as expressly modified by this Amendment, the Letter Agreement shall remain unchanged and in full force and effect in accordance with its terms.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the foregoing accurately sets forth our agreement, please countersign this letter in the space provide below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Respectfully,</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan &#34;Simba&#34; Gill</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Balkrishan &#8220;Simba&#8221; Gill, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.404%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agreed and Accepted&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David R. Epstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David R. Epstein</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2020</font></div></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>exhibit1032020q3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i468b5e484c2241c1b27033641ed249e7_43"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.3</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consulting Agreement</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Consulting Agreement (the &#34;Agreement&#34;), made as of September 16, 2019, is entered into by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation with offices at 620 Memorial Drive, Cambridge, Massachusetts 02139 (the &#34;Company&#34;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">David R. Epstein</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an individual residing at &#91;***&#93; (the &#34;Consultant&#34;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, the Company and the Consultant desire to establish the terms and conditions under which the Consultant will provide services to the Company for the Company&#8217;s business, which presently includes the research, development and&#47;or commercialization of therapeutics and&#47;or diagnostics relating to microorganisms (including microbiota) associated with disease. For the sake of clarity, the Company&#8217;s business specifically includes the use of one or more microorganisms, progeny or derivatives thereof to prevent, treat or diagnose disease.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1    The Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably requested from time to time by the Company, including, but not limited to, the services specified on Schedule A to this Agreement (the &#34;Services&#34;). It is understood and agreed that you the Consultant will dedicate approximately 50 working days per year to the Company. During the Consultation Period (as defined below) and for a period of one year thereafter, the Consultant shall not engage in any activity that has a conflict of interest with the Company, including without limitation any competitive employment, business or other activity, and shall not assist any other person or organization that competes, or intends to compete, with the Company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2    The Consultant represents and warrants that the Consultant shall provide such Services in a timely manner in strict accordance with the terms of this Agreement and applicable business conduct, regulatory and health and safety guidelines, laws, statutes, rules, regulations, ordinances, and professional and industry codes of conduct which are applicable to the Services and the Consultant's or the Company&#8217;s business anywhere in the world, including, without limitation&#58; (i) laws and regulations governing the purchase and sale of securities while in possession of material, nonpublic information&#59; (ii) the federal anti-kickback statute (42 U.S.C. &#223;1320a-7b(b)) and state anti-kickback laws&#59; (iii) any applicable national, federal, and state privacy and data protections laws, including the Health Insurance Portability and Accountability Act of 1996, as amended (&#34;HIPAA&#34;)&#59; (iv) the U.S. Food, Drug and Cosmetic Act, as amended from time to time&#59; (v) any laws or regulation requiring disclosure of any payments made hereunder&#59; and (vi) any laws and regulations relating to anti-corruption, anti-bribery (including but not limited to the United States Foreign Corrupt Practices Act).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3    The Consultant represents and warrants that he has not (i) been excluded, debarred, suspended or otherwise made ineligible to exercise their profession and activities under the applicable laws or regulations of any country, or (ii) engaged in any act that would be grounds for such exclusion, debarment or suspension. Upon learning or acquiring knowledge of any facts or circumstances that may lead to actions relating to the representations above (including, without limitation, criminal actions), the Consultant will immediately disclose such facts or circumstances to the Company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall commence on the date hereof and shall continue until the first anniversary of the effective date of this Agreement, unless sooner terminated in accordance with the provisions of Section 4 herein (such period, as it may be extended, being referred to as the &#34;Consultation Period&#34;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consulting Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company shall pay to the Consultant an annual consulting fee of $300,000. The fee shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event the Consultant does </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not serve as a consultant to the Company pursuant to this Agreement for an entire calendar quarter, the fee paid shall be prorated for the portion of such calendar quarter during which the Consultant actually served as a consultant to the Company. This amount will be subject to periodic review and adjustment at the Company&#8217;s discretion.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to approval by the Board of Directors of the Company, the Company shall award to the Consultant (i) a single grant of options to purchase 75,000 shares of the Company&#8217;s common stock (the &#34;Initial Grant&#34;), and (ii) thereafter on the anniversary of the effective date of this Agreement annual grants of options to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $225,000, as determined by the Board in its discretion based on customary option pricing methodologies (&#34;Annual Grants&#34;). The Initial Grant and Annual Grants shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity plan then maintained by the Company (the &#34;Equity Plan&#34;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. For the avoidance of doubt, the share numbers shall be subject to adjustment as provided in the Equity Plan. The per share exercise price of the Initial Grant and each Annual Grant shall be equal to the Fair Market Value (as defined in the Equity Plan) of one share of the Company&#8217;s common stock on the date the option is granted. The Initial Grant shall vest and become exercisable in 36 substantially equal monthly installments following the date of grant, such that the Initial Grant shall be fully vested on the third anniversary of the date of grant, subject to the Consultant continuing to provide Service to the Company pursuant to this Agreement through each such vesting date. Each Annual Grant shall vest and become exercisable on the first anniversary of the date of grant, subject to the Consultant continuing to provide Services to the Company pursuant to this Agreement through each such vesting date. Unless the Board otherwise determines, any portion of the Initial Grant or an Annual Grant which is unvested or unexercisable at the time of the termination of this Agreement shall be immediately forfeited upon such termination and shall not thereafter become vested or exercisable. The Initial Grant and all Annual Grants shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time. The terms of the Initial Grant and each Annual Grant shall be ten (10) years from the date the option is granted.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company shall reimburse the Consultant for all reasonable and necessary documented out of pocket expenses incurred or paid by the Consultant in connection with, or related to, the performance of the Services. The Consultant shall submit to the Company itemized statements, in a form satisfactory to the Company, of such expenses incurred. The Company shall pay to the Consultant uncontested amounts shown on each such statement within thirty (30) days after receipt thereof.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Consultant shall not be entitled to any benefits, coverages or privileges, including, without limitation, health insurance, social security, unemployment, medical or pension payments, made available to employees of the Company.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement may be terminated in the following manner&#58; (a) by either the Company or the Consultant upon not less than thirty (30) days prior written notice to the other party&#59; (b) by the non-breaching party, upon twenty-four (24) hours prior written notice to the breaching party if one party has materially breached this Agreement&#59; or (c) at any time upon the mutual written consent of the parties hereto. In the event of termination, the Consultant shall be entitled to payment for the Services performed and (subject to the limitation in Section 3.2) for expenses paid or incurred prior to the effective date of termination that have not been previously paid. Such payment shall constitute full settlement of any and all claims of the Consultant of every description against the Company for the Consultant&#8217;s services under this Agreement. Notwithstanding the foregoing, the Company may terminate this Agreement effective immediately by giving written notice to the Consultant if the Consultant breaches or threatens to breach any provision of Section 1or 6.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Consultant shall use Consultant&#8217;s best efforts in the performance of Consultant&#8217;s obligations under this Agreement. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform the Consultant&#8217;s obligations hereunder. The Consultant shall cooperate with the Company&#8217;s personnel, shall not interfere with the conduct of the Company&#8217;s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Proprietary Information and Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Consultant acknowledges that Consultant&#8217;s relationship with the Company is one of high trust and confidence and that in the course of Consultant&#8217;s service to the Company, Consultant will have access to and contact with Proprietary Information (as defined below). The Consultant will not disclose any Proprietary Information to any person or entity other than employees or directors of the Company or use the same for any purposes (other than in the performance of the Services or as a member of the board of directors of the Company) without written approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become public knowledge without fault by the Consultant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b). For purposes of this Agreement, &#34;Proprietary Information&#34; shall mean, by way of illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned, possessed or used by the Company, concerning the Company's business, business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant in the course of Consultant&#8217;s service as a consultant to the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    The Consultant&#8217;s obligations under this Section 6.1 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.1, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)    The Consultant agrees that all files, documents, letters, memoranda, reports, records, data sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Consultant or others, which shall come into the Consultant&#8217;s custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant only in the performance of Consultant&#8217;s duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Consultant shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Consultant shall not retain any such materials or copies thereof or any such tangible property.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)    The Consultant agrees that the Consultant&#8217;s obligation not to disclose or to use information and materials of the types set forth in paragraphs (b) and (d) above, and the Consultant&#8217;s obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Consultant.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)    The Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions that are known to the Consultant and to take all action necessary to discharge the obligations of the Company under such agreements.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All inventions, ideas, creations, discoveries, computer programs, works of authorship, data, developments, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others or under the Consultant&#8217;s direction and whether during normal business hours or otherwise, (i) during the Consultation Period if related to the business of </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company or (ii) after the Consultation Period if resulting or directly derived from Proprietary Information (collectively under clauses (i) and (ii), &#34;Inventions&#34;), shall be the sole property of the Company. The Consultant hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as the Consultant&#8217;s duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Consultant not during normal working hours, not on the Company&#8217;s premises and not using the Company&#8217;s tools, devices, equipment or Proprietary Information. The Consultant further acknowledges that each original work of authorship which is made by the Consultant (solely or jointly with others) within the scope of the Agreement and which is protectable by copyright is a &#34;work made for hire,&#34; as that term is defined in the United States Copyright Act.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Upon the request of the Company and at the Company&#8217;s expense, the Consultant shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c). The Consultant shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and&#47;or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.    &#91;intentionally left blank&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Agreements&#59; Warranty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1    The Consultant hereby represents that, except as the Consultant has disclosed in writing to the Company, the Consultant is not bound by the terms of any agreement with any third party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of the Consultant&#8217;s consultancy with the Company, to refrain from competing, directly or indirectly, with the business of such third party or to refrain from soliciting employees, customers or suppliers of such third party. The Consultant further represents that the Consultant&#8217;s performance of all the terms of this Agreement and the performance of the Services as a consultant of the Company do not and will not breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any current or previous employer or others.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2    The Consultant hereby represents, warrants and covenants that the Consultant has the skills and experience necessary to perform the Services, that the Consultant will perform said Services in a professional, competent and timely manner, that the Consultant has the power to enter into this Agreement and that the Consultant&#8217;s performance hereunder will not infringe upon or violate the rights of any third party or violate any federal, state or municipal laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Contractor Status</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1    The Consultant shall perform all Services under this Agreement as an &#34;independent contractor&#34; and not as an employee or agent of the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2    The Consultant shall have the right to control and determine the time, place, methods, manner and means of performing the Services. In performing the Services, the amount of time devoted by the Consultant on any given day will be entirely within the Consultant's control, and the Company will rely on the Consultant to put in the amount of time necessary to fulfill the requirements of this Agreement. The </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consultant will provide all equipment and supplies required to perform the Services. The Consultant is not required to attend regular meetings at the Company. However, upon reasonable notice, the Consultant shall meet with representatives of the Company at a location to be designated by the parties to this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3    In the performance of the Services, the Consultant has the authority to control and direct the performance of the details of the Services, the Company being interested only in the results obtained. However, the Services contemplated by the Agreement must meet the Company's standards and approval and shall be subject to the Company's general right of inspection and supervision to secure their satisfactory completion.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4    The Consultant shall not use the Company's trade names, trademarks, service names or service marks without the prior approval of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5    The Consultant shall be solely responsible for all state and federal income taxes, unemployment insurance and social security taxes in connection with this Agreement and for maintaining adequate workers' compensation insurance coverage.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Consultant acknowledges that any breach of the provisions of Sections 1 or 6 of this Agreement shall result in serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy the Consultant may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Consultant and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.    &#91;intentionally left blank&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.    &#91;intentionally left blank&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 13.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pronouns</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement constitute the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement.</font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Amendmen</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Assignability of Contrac</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t. This Agreement is personal to the Consultant and the Consultant shall not have the right to assign any of the Consultant&#8217;s rights or delegate any of the Consultant&#8217;s duties without the express written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall constitute a breach and a default by the Consultant.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall not be assigned by the Consultant.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any restriction set forth in Section 1 or 6 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Sections 1.2, 4 through 22 and the last sentence of Section 1.1 shall survive the expiration or termination of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:103.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.1     No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:103.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.2    The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:103.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.3    In the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the date and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"><tr><td style="width:1.0%"></td><td style="width:3.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evelo Biosciences, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan &#34;Simba&#34; Gill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David R. Epstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Balkrishan &#8220;Simba&#8221; Gill, Ph.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Epstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule A</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Services</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strategic advice and guidance for the Company relating to the development and commercialization of biologic and pharmaceutical products, including advice and guidance to the chief executive officer and other executive officers of the Company. Specific areas of strategy may include product candidate selection, clinical trial development strategy, partnering, product launch activities, and portfolio optimization.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i468b5e484c2241c1b27033641ed249e7_1"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                                                  </font></div><div style="padding-left:360pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evelo Biosciences, Inc.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment to Consulting Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Amendment to that certain Consulting Agreement dated as of September 16, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) is entered into by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evelo Biosciences, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a Delaware corporation with a place of business located at 620 Memorial Drive, Cambridge, Massachusetts 02139, USA (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Epstein</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an individual residing at &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WHEREAS, the Company and the Consultant desire to modify and extend the term of the Agreement to enable to Consultant to continue to provide services to the Company&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged by the parties hereto, the parties agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Section 2 of the Agreement is amended to read as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;This Agreement shall commence on September 16, 2019 and shall continue until June 30, 2021, unless sooner terminated in accordance with the provisions of Section 4 herein (such period, as it may be extended, being referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consultation Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).&#8221;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  The second paragraph of Section 3.1 of the Agreement is amended to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Subject to approval by the Board of Directors of the Company, the Company shall award to the Consultant (i) a single grant of options to purchase 75,000 shares of the Company&#8217;s common stock (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Initial Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;), and (ii) thereafter on the anniversary of the effective date of this Agreement annual grants of options to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair value equal to approximately $225,000, as determined by the Board in its discretion based on customary option pricing methodologies (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Annual Grants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;). The Initial Grant and Annual Grants shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity plan then maintained by the Company (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. For the avoidance of doubt, the share numbers shall be subject to adjustment as provided in the Equity Plan. The per share exercise price of the Initial Grant and each Annual Grant shall be equal to the Fair Market Value (as defined in the Equity Plan) of one share of the Company&#8217;s common stock on the date the option is granted. The Initial Grant shall vest and become exercisable in 36 substantially equal monthly installments following the date of grant, such that the Initial Grant shall be fully vested on the third anniversary of the date of grant, subject to the Consultant continuing to provide Service to the Company pursuant to this Agreement through each such vesting date. Each Annual Grant shall vest and become exercisable in 12 substantially equal monthly installments following the date of grant, such that the each Annual Grant shall be fully vested on the first anniversary of the date of grant, subject to the Consultant continuing to provide Services to the Company pursuant to this Agreement through each such vesting date. Unless the Board otherwise determines, any portion of the Initial Grant or an Annual Grant which is unvested or unexercisable at the time of the termination of this Agreement shall be immediately forfeited upon such termination and shall not thereafter become vested or exercisable. The Initial Grant and all Annual Grants shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time. The terms of the Initial Grant and each Annual Grant shall be ten (10) years from the date the option is granted.  Notwithstanding the foregoing, in the event this Agreement is renewed for a term of less than one year, the aggregate grant date fair value of the corresponding Annual Grant and the resulting number of shares of Common Stock purchaseable under such Annual Grant and the vesting schedule shall be adjusted proportionately to the length of the renewal term.&#8221;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt;text-decoration:underline">No Other Changes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. All other provisions of the Agreement shall remain unchanged and in full force and effect.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date written below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.154%"><tr><td style="width:1.0%"></td><td style="width:6.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evelo Biosciences, Inc.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David R. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan &#34;Simba&#34; Gill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Balkrishan &#8220;Simba&#8221; Gill, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President &#38; Chief Executive Officer</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 15, 2020</font></td></tr></table></div><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.404%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>eveloq32020exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i161735f1d730478392a431605b76b15c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Balkrishan (Simba) Gill, Ph.D., certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Evelo Biosciences, Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 30, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>eveloq32020exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i541389b67a7440a5b613a904fb02e61c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Balkrishan (Simba) Gill, Ph.D., President and Chief Executive Officer of Evelo Biosciences, Inc. (the &#8220;Company&#8221;), hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:36.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.193%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 30, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>evlo-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evlo="http://evelobio.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://evelobio.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://evelobio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://evelobio.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://evelobio.com/role/OrganizationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Organization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://evelobio.com/role/Leases">
        <link:definition>2108103 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://evelobio.com/role/LeasesTables">
        <link:definition>2309302 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://evelobio.com/role/LeasesNarrativeDetails">
        <link:definition>2410404 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails">
        <link:definition>2411405 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1">
        <link:definition>2411405 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://evelobio.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://evelobio.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://evelobio.com/role/PropertyandEquipmentNet">
        <link:definition>2115105 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables">
        <link:definition>2316304 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
        <link:definition>2417407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativeDetails" roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails">
        <link:definition>2418408 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreements" roleURI="http://evelobio.com/role/LoanandSecurityAgreements">
        <link:definition>2119106 - Disclosure - Loan and Security Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsTables" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables">
        <link:definition>2320305 - Disclosure - Loan and Security Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsNarrativeDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails">
        <link:definition>2421409 - Disclosure - Loan and Security Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails">
        <link:definition>2422410 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InLicenseAgreements" roleURI="http://evelobio.com/role/InLicenseAgreements">
        <link:definition>2123107 - Disclosure - In-License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InLicenseAgreementsNarrativeDetails" roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails">
        <link:definition>2424411 - Disclosure - In-License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://evelobio.com/role/CommitmentsandContingencies">
        <link:definition>2125108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2426412 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://evelobio.com/role/StockholdersEquity">
        <link:definition>2127109 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://evelobio.com/role/StockholdersEquityDetails">
        <link:definition>2428413 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://evelobio.com/role/StockBasedCompensation">
        <link:definition>2129110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://evelobio.com/role/StockBasedCompensationTables">
        <link:definition>2330306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2431414 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails">
        <link:definition>2432415 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2433416 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://evelobio.com/role/IncomeTaxes">
        <link:definition>2134111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://evelobio.com/role/IncomeTaxesDetails">
        <link:definition>2435417 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://evelobio.com/role/NetLossPerShare">
        <link:definition>2136112 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://evelobio.com/role/NetLossPerShareTables">
        <link:definition>2337307 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails">
        <link:definition>2438418 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://evelobio.com/role/RelatedPartyTransactions">
        <link:definition>2139113 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2440419 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evlo_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" abstract="false" name="RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" abstract="false" name="RelatedPartyTransactionConsultingContractTerminationNoticeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementNumberOfTranches" abstract="false" name="SecurityAndLoanAgreementNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" abstract="false" name="MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" abstract="false" name="MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_AggregateAmountDueUnderCollaborativeArrangement" abstract="false" name="AggregateAmountDueUnderCollaborativeArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_BioseIndustrieMember" abstract="true" name="BioseIndustrieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_SalesAgreementCowenAndCompanyLLCMember" abstract="true" name="SalesAgreementCowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evlo_SaccoS.r.l.Member" abstract="true" name="SaccoS.r.l.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_VL46Member" abstract="true" name="VL46Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_UniversityOfChicagoMember" abstract="true" name="UniversityOfChicagoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" abstract="false" name="RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheOneMember" abstract="true" name="SecurityAndLoanAgreementTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTranchesAxis" abstract="true" name="SecurityAndLoanAgreementTranchesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evlo_CollaborationArrangementTerm" abstract="false" name="CollaborationArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_TwoThousandAndEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_CommitmentAndContingenciesTable" abstract="true" name="CommitmentAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="evlo_DebtInstrumentDebtDefaultPercentage" abstract="false" name="DebtInstrumentDebtDefaultPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_EmergingGrowthCompanyStatusPolicyTextBlock" abstract="false" name="EmergingGrowthCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheTwoMember" abstract="true" name="SecurityAndLoanAgreementTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_ComputersAndSoftwareMember" abstract="true" name="ComputersAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" abstract="false" name="SaleOfStockMaximumValueOfSharesIssuedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_NonEmployeeOptionsMember" abstract="true" name="NonEmployeeOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_UnvestedCommonStockMember" abstract="true" name="UnvestedCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" abstract="false" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" abstract="false" name="DebtInstrumentRepaymentOrPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" abstract="false" name="SubstantialDoubtAboutGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" abstract="false" name="DebtInstrumentPrepaymentFeePercentageOnPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="evlo_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheThreeMember" abstract="true" name="SecurityAndLoanAgreementTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SaleOfStockConsiderationReceivedTerm" abstract="false" name="SaleOfStockConsiderationReceivedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_NonRefundableUpfrontFee" abstract="false" name="NonRefundableUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_FeeIncurredUnderCollaborativeArrangement" abstract="false" name="FeeIncurredUnderCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SocialSecurityTaxEmployerDeferralCARESAct" abstract="false" name="SocialSecurityTaxEmployerDeferralCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionAnnualCashConsultingFee" abstract="false" name="RelatedPartyTransactionAnnualCashConsultingFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTranchesDomain" abstract="true" name="SecurityAndLoanAgreementTranchesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" abstract="false" name="DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" abstract="false" name="DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="evlo_JuneOfferingMember" abstract="true" name="JuneOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_RegistrationStatementMember" abstract="true" name="RegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_CommitmentAndContingenciesLineItems" abstract="true" name="CommitmentAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" abstract="false" name="CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="evlo_A2016CreditFacilityMember" abstract="true" name="A2016CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_A2019CreditFacilityMember" abstract="true" name="A2019CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" abstract="false" name="CollaborativeArrangementPeriodOfInactiveManufacturingServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_WeatherdenLtdMember" abstract="true" name="WeatherdenLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_AnnualAmountDueUnderCollaborativeArrangement" abstract="false" name="AnnualAmountDueUnderCollaborativeArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_NonCashOperatingLeaseExpense" abstract="false" name="NonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_MayoClinicMember" abstract="true" name="MayoClinicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_TwoThousandAndFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="evlo_ExclusivityAndCommitmentAgreementMember" abstract="true" name="ExclusivityAndCommitmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>evlo-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://evelobio.com/role/CoverPage" xlink:type="simple" xlink:href="evlo-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1a62b47-c7f7-4e41-a836-a75dd8435d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3a5519ef-49ea-46d1-b52b-e680313d501f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1a62b47-c7f7-4e41-a836-a75dd8435d73" xlink:to="loc_us-gaap_AccountsPayableCurrent_3a5519ef-49ea-46d1-b52b-e680313d501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cab58a3c-e633-4aca-8ffd-6ac277b3ee61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1a62b47-c7f7-4e41-a836-a75dd8435d73" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cab58a3c-e633-4aca-8ffd-6ac277b3ee61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_200192f8-5dbe-4c5e-816f-da187fee8a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1a62b47-c7f7-4e41-a836-a75dd8435d73" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_200192f8-5dbe-4c5e-816f-da187fee8a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0899d768-3c9e-40d8-acd5-a5fb03d12da5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1a62b47-c7f7-4e41-a836-a75dd8435d73" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0899d768-3c9e-40d8-acd5-a5fb03d12da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9302fde3-52f5-46cb-b7e7-7c8b4cf58e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d29838b-535e-4420-92b3-29f9476bc501" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9302fde3-52f5-46cb-b7e7-7c8b4cf58e87" xlink:to="loc_us-gaap_AssetsCurrent_8d29838b-535e-4420-92b3-29f9476bc501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d3e84493-1ec7-4b72-8347-8c96a4b34a23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9302fde3-52f5-46cb-b7e7-7c8b4cf58e87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d3e84493-1ec7-4b72-8347-8c96a4b34a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dd6b3b60-4bd7-4b0d-b05f-744f8eb59881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9302fde3-52f5-46cb-b7e7-7c8b4cf58e87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dd6b3b60-4bd7-4b0d-b05f-744f8eb59881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f40bf2c7-8baf-4186-b6c9-77191ae7f58b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9302fde3-52f5-46cb-b7e7-7c8b4cf58e87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f40bf2c7-8baf-4186-b6c9-77191ae7f58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e6781ba2-06cf-4dbe-b38e-d23d34116a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e6781ba2-06cf-4dbe-b38e-d23d34116a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d5a1558c-e729-420f-b1e2-cbe6606dc3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d5a1558c-e729-420f-b1e2-cbe6606dc3e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bde696e-bf4f-4259-91fb-2cec2c4ab7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bde696e-bf4f-4259-91fb-2cec2c4ab7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_cb281c52-e2f8-4b27-a764-48cf2d1129ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_cb281c52-e2f8-4b27-a764-48cf2d1129ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_741f9deb-8543-4966-a42b-cf23c6646adf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47e826ae-df69-4581-a813-0df5280336b2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_741f9deb-8543-4966-a42b-cf23c6646adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37fb469d-ade5-4ed5-ab23-ecbd32357318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38b2603b-1284-457a-8887-afc7c9cc0e05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37fb469d-ade5-4ed5-ab23-ecbd32357318" xlink:to="loc_us-gaap_Liabilities_38b2603b-1284-457a-8887-afc7c9cc0e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18fc0977-2256-4685-ac71-77845eede209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37fb469d-ade5-4ed5-ab23-ecbd32357318" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18fc0977-2256-4685-ac71-77845eede209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db00764c-2f90-4e7c-a1f8-d964d62ff139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37fb469d-ade5-4ed5-ab23-ecbd32357318" xlink:to="loc_us-gaap_StockholdersEquity_db00764c-2f90-4e7c-a1f8-d964d62ff139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41a3cad5-c5c9-471e-8af5-9f9ad19ed955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dbb7110-9c90-4036-85af-a7f9b02b9645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_41a3cad5-c5c9-471e-8af5-9f9ad19ed955" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dbb7110-9c90-4036-85af-a7f9b02b9645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e9c298f3-60ff-418c-be04-4461f9954ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_41a3cad5-c5c9-471e-8af5-9f9ad19ed955" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e9c298f3-60ff-418c-be04-4461f9954ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70aec1ee-9d1f-44f7-a5cd-545acd178320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ee51df7f-d4d2-44e4-9c5b-1237ebe9dccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70aec1ee-9d1f-44f7-a5cd-545acd178320" xlink:to="loc_us-gaap_PreferredStockValue_ee51df7f-d4d2-44e4-9c5b-1237ebe9dccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4af1f21-0928-475e-a990-5f79f050edf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70aec1ee-9d1f-44f7-a5cd-545acd178320" xlink:to="loc_us-gaap_CommonStockValue_f4af1f21-0928-475e-a990-5f79f050edf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a22bda-bdd9-467b-a482-35443b2ce476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70aec1ee-9d1f-44f7-a5cd-545acd178320" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a22bda-bdd9-467b-a482-35443b2ce476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba1ba946-8ed0-4709-96c1-51cdb2cf53e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70aec1ee-9d1f-44f7-a5cd-545acd178320" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba1ba946-8ed0-4709-96c1-51cdb2cf53e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75ceafe6-c0ec-4dd1-a876-ee55e3484eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f566c4bb-2aaf-4f80-8c22-74d93cdce202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75ceafe6-c0ec-4dd1-a876-ee55e3484eea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f566c4bb-2aaf-4f80-8c22-74d93cdce202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5930e4b1-002b-4e8d-b3f8-fb23de9c0ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75ceafe6-c0ec-4dd1-a876-ee55e3484eea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5930e4b1-002b-4e8d-b3f8-fb23de9c0ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2983a704-2e14-4271-9cb0-e66d6e843911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c96ac4e6-291b-4652-9794-674012919672" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2983a704-2e14-4271-9cb0-e66d6e843911" xlink:to="loc_us-gaap_NetIncomeLoss_c96ac4e6-291b-4652-9794-674012919672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_76a869af-e375-44a3-92c7-800f62f30e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2983a704-2e14-4271-9cb0-e66d6e843911" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_76a869af-e375-44a3-92c7-800f62f30e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cb195ebd-e74c-4be3-81af-ba0a2f92bca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_06673c77-cfbb-4819-a3d4-2dd5ae7a8890" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cb195ebd-e74c-4be3-81af-ba0a2f92bca2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_06673c77-cfbb-4819-a3d4-2dd5ae7a8890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8f38df3b-d448-4597-baa4-f16143e53054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cb195ebd-e74c-4be3-81af-ba0a2f92bca2" xlink:to="loc_us-gaap_OperatingIncomeLoss_8f38df3b-d448-4597-baa4-f16143e53054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fb193331-24fb-4ced-9a45-7260441a26f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e606377-387c-427c-8c7f-916c751c245e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fb193331-24fb-4ced-9a45-7260441a26f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e606377-387c-427c-8c7f-916c751c245e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b427c0fb-d29b-413f-8686-eaa94c3d18ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fb193331-24fb-4ced-9a45-7260441a26f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b427c0fb-d29b-413f-8686-eaa94c3d18ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6462a17e-a691-4f0a-99f6-bc9074ea0aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7de22b36-726e-42fd-bf0d-775b1581b448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6462a17e-a691-4f0a-99f6-bc9074ea0aaf" xlink:to="loc_us-gaap_InvestmentIncomeNet_7de22b36-726e-42fd-bf0d-775b1581b448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3f717485-27df-4b7f-9c7d-b86e07337727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6462a17e-a691-4f0a-99f6-bc9074ea0aaf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3f717485-27df-4b7f-9c7d-b86e07337727" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9186892f-116e-4ea6-95ab-5e133738d4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5257736-de90-41c9-8fa0-caef78309a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9186892f-116e-4ea6-95ab-5e133738d4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5257736-de90-41c9-8fa0-caef78309a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c972fa7f-223f-47a4-935a-0c4820aadeea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9186892f-116e-4ea6-95ab-5e133738d4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c972fa7f-223f-47a4-935a-0c4820aadeea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d778637b-f580-420a-9fc7-1a3d33b87f08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9186892f-116e-4ea6-95ab-5e133738d4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d778637b-f580-420a-9fc7-1a3d33b87f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bfbe8b6-3362-4034-ac17-4e0a7205e67b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_NetIncomeLoss_1bfbe8b6-3362-4034-ac17-4e0a7205e67b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a22022fd-3146-4e52-a793-7e593038b691" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_ShareBasedCompensation_a22022fd-3146-4e52-a793-7e593038b691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b74ea66d-a777-4295-ac1e-3028b3777a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_Depreciation_b74ea66d-a777-4295-ac1e-3028b3777a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_23608550-c84f-4d9a-a6a9-4b3d268f7928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_23608550-c84f-4d9a-a6a9-4b3d268f7928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense_d993df06-07fe-4323-a1e6-6f618a88c5fc" xlink:href="evlo-20200930.xsd#evlo_NonCashInterestExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_evlo_NonCashInterestExpense_d993df06-07fe-4323-a1e6-6f618a88c5fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense_85cc5112-06a1-4ab9-a53f-b9fce968b10b" xlink:href="evlo-20200930.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_evlo_NonCashOperatingLeaseExpense_85cc5112-06a1-4ab9-a53f-b9fce968b10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c18aff10-8158-4830-8304-0d3570c40633" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c18aff10-8158-4830-8304-0d3570c40633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3d8057a-dfac-4310-9cd9-348c98039702" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3d8057a-dfac-4310-9cd9-348c98039702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9b211871-41bd-4c40-8810-9665f117e5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9b211871-41bd-4c40-8810-9665f117e5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_5540a494-9ab3-4ab3-8c72-07ed7953db7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_5540a494-9ab3-4ab3-8c72-07ed7953db7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability_2d4e7aad-45b5-447b-aa4b-8013bf5fc1f4" xlink:href="evlo-20200930.xsd#evlo_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability_2d4e7aad-45b5-447b-aa4b-8013bf5fc1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0ea40cce-1277-4e4b-8c86-05f0132e50a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97ae50e5-9b41-4b8a-a9fd-10e87e9e419d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0ea40cce-1277-4e4b-8c86-05f0132e50a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91cd5b7d-35fa-4888-8431-f4de806cb2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7670c197-bae4-48d5-90be-9f7ccc904a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91cd5b7d-35fa-4888-8431-f4de806cb2d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7670c197-bae4-48d5-90be-9f7ccc904a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_accc758f-4a09-457a-af19-d5cbb24953a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91cd5b7d-35fa-4888-8431-f4de806cb2d7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_accc758f-4a09-457a-af19-d5cbb24953a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a66025f4-543c-419d-8cc0-f5bc509fdb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91cd5b7d-35fa-4888-8431-f4de806cb2d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a66025f4-543c-419d-8cc0-f5bc509fdb9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ba0eb5ae-e101-49c0-a82b-b7b8e861a33c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91cd5b7d-35fa-4888-8431-f4de806cb2d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ba0eb5ae-e101-49c0-a82b-b7b8e861a33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_845fcea5-c564-4404-8ebb-bf002802a0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ff7e74d5-2b3f-47d1-8f72-7bbabdbd9a39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_845fcea5-c564-4404-8ebb-bf002802a0c2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ff7e74d5-2b3f-47d1-8f72-7bbabdbd9a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85ba4801-2445-46ad-9bf2-5cd1aee46daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_845fcea5-c564-4404-8ebb-bf002802a0c2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85ba4801-2445-46ad-9bf2-5cd1aee46daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c77d5f80-1c44-47b9-bc2b-8ac336647251" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_845fcea5-c564-4404-8ebb-bf002802a0c2" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c77d5f80-1c44-47b9-bc2b-8ac336647251" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Organization" xlink:type="simple" xlink:href="evlo-20200930.xsd#Organization"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#OrganizationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ac807bf-2b72-4f32-9fc9-ebfe9432bd30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_f49abea9-0ef6-4fd5-9dc1-2b4a162a03eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ac807bf-2b72-4f32-9fc9-ebfe9432bd30" xlink:to="loc_us-gaap_Cash_f49abea9-0ef6-4fd5-9dc1-2b4a162a03eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_7cdcd10a-924c-4a37-882d-d42c5e41ae7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ac807bf-2b72-4f32-9fc9-ebfe9432bd30" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_7cdcd10a-924c-4a37-882d-d42c5e41ae7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_599a4b1c-3f09-4f45-b203-6b03602ab6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5860e382-b583-4870-b1ea-897ad3fd069c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_599a4b1c-3f09-4f45-b203-6b03602ab6f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5860e382-b583-4870-b1ea-897ad3fd069c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ae337e1b-082f-48f6-ae4e-5f17a676fb16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_599a4b1c-3f09-4f45-b203-6b03602ab6f3" xlink:to="loc_us-gaap_RestrictedCash_ae337e1b-082f-48f6-ae4e-5f17a676fb16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Leases" xlink:type="simple" xlink:href="evlo-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c80e8848-be3a-40b7-a057-4fe36e031bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_82683404-b7a2-400a-94d6-ede1dc66896e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c80e8848-be3a-40b7-a057-4fe36e031bde" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_82683404-b7a2-400a-94d6-ede1dc66896e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b32c6553-c0f4-4c85-a6ef-00d2797d48c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c80e8848-be3a-40b7-a057-4fe36e031bde" xlink:to="loc_us-gaap_OperatingLeaseLiability_b32c6553-c0f4-4c85-a6ef-00d2797d48c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_31501449-2f04-40b4-ab46-8927008349e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_31501449-2f04-40b4-ab46-8927008349e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82dac3b9-1725-41a8-8c27-89fd7a25040e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82dac3b9-1725-41a8-8c27-89fd7a25040e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ff8413a-1772-4604-8523-8e88f50da064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ff8413a-1772-4604-8523-8e88f50da064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aa482032-eb44-4ade-9000-e3ee0f53aa75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aa482032-eb44-4ade-9000-e3ee0f53aa75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd11fa4-1d2e-46c5-91db-2d842e44de2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd11fa4-1d2e-46c5-91db-2d842e44de2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a793f330-b1a1-4d7d-a400-fcfa1afc5cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2f643bc-a526-4827-9997-0e5e2b6a604b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a793f330-b1a1-4d7d-a400-fcfa1afc5cd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ddc969ab-acdc-495e-b84b-76d53f616564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8764283-0f94-4eff-a791-acc0bcac0aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ddc969ab-acdc-495e-b84b-76d53f616564" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8764283-0f94-4eff-a791-acc0bcac0aba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNet"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0581fce-16d8-4b5e-bd8d-7595f0d8c1da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_59fcb42c-fabb-4c94-9e96-9b6b5878f8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b0581fce-16d8-4b5e-bd8d-7595f0d8c1da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_59fcb42c-fabb-4c94-9e96-9b6b5878f8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5430792-36d1-4da3-bd8b-97e648b2cfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b0581fce-16d8-4b5e-bd8d-7595f0d8c1da" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5430792-36d1-4da3-bd8b-97e648b2cfa5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreements"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5a66275e-646d-4667-9c29-30a57945ad9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4199eeba-8d2c-4b7c-856c-c0f4d5fc0141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_5a66275e-646d-4667-9c29-30a57945ad9e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4199eeba-8d2c-4b7c-856c-c0f4d5fc0141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_299d3075-b345-4c08-9b83-849115d97a68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_5a66275e-646d-4667-9c29-30a57945ad9e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_299d3075-b345-4c08-9b83-849115d97a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_a4722f6f-bf64-4a82-b4e7-320952a10a12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_a4722f6f-bf64-4a82-b4e7-320952a10a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_61e6c327-333a-4c42-a85a-dce98614f609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_61e6c327-333a-4c42-a85a-dce98614f609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_a0543d08-1037-4629-89ce-a35bc92f2783" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_a0543d08-1037-4629-89ce-a35bc92f2783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_cb3a2999-b8a1-4231-bf69-fa49fad24132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_cb3a2999-b8a1-4231-bf69-fa49fad24132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_2c11ff07-8893-430f-b2a1-1dc0505d6469" xlink:href="evlo-20200930.xsd#evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_13f256d2-8334-48a7-9f64-2b43cbe5cc58" xlink:to="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_2c11ff07-8893-430f-b2a1-1dc0505d6469" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreements"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/InLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>evlo-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://evelobio.com/role/CoverPage" xlink:type="simple" xlink:href="evlo-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CoverPage" xlink:type="extended" id="i42b4ea914fff40f89cc8a5a0162ea581_CoverPage"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i2c84131f903848a78b8c971b61796f80_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i5c9623bae790473a9134701321f68280_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ib58622c1ccd548eea33813981c20853c_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended" id="ia81f5ff97c904cac9f14027e3234b6c1_CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i930d4e76d3de42378dab333aae294cf6_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5a531f38-62b9-41d1-9131-91abad799b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_SharesOutstanding_5a531f38-62b9-41d1-9131-91abad799b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98dbac0f-af73-4468-b8e9-f870967ba02d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockholdersEquity_98dbac0f-af73-4468-b8e9-f870967ba02d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5159ab3-295b-48b8-835d-0d6501fa5bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5159ab3-295b-48b8-835d-0d6501fa5bb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95aa0a32-669d-49b4-b908-0c70429155ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95aa0a32-669d-49b4-b908-0c70429155ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_00f20500-4854-4081-b1db-eadd0d4c3393" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_00f20500-4854-4081-b1db-eadd0d4c3393" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d72e7d4f-d658-462b-a78e-82b1d1ea8496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d72e7d4f-d658-462b-a78e-82b1d1ea8496" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_597cc203-9182-4288-b6b7-9b78966d75ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_597cc203-9182-4288-b6b7-9b78966d75ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d541b8eb-7110-4420-afbf-c6c82c122b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d541b8eb-7110-4420-afbf-c6c82c122b3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_945ef087-32db-41a1-84f8-f461c0044c80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_945ef087-32db-41a1-84f8-f461c0044c80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d50a5751-39ef-4683-90c3-3da67ac56819" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d50a5751-39ef-4683-90c3-3da67ac56819" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88b4d916-49cf-4033-8912-81fe7ecfd83d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88b4d916-49cf-4033-8912-81fe7ecfd83d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_11b4b90a-2e36-4053-b7ba-9611febfe80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_11b4b90a-2e36-4053-b7ba-9611febfe80e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_71c5bb46-c1e2-4207-a6ae-41ebf90df479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_71c5bb46-c1e2-4207-a6ae-41ebf90df479" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3adff8e0-bf19-4481-a358-f0f548336818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_NetIncomeLoss_3adff8e0-bf19-4481-a358-f0f548336818" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a857872-c9bc-4ceb-beb3-5098ce1cdabf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1613d4b-44ff-4cb9-a288-3d70475e7b99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:to="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_096faeec-9d03-4677-807a-55d2e55f9745_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:to="loc_us-gaap_EquityComponentDomain_096faeec-9d03-4677-807a-55d2e55f9745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:to="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_13d923f0-aa63-4112-8fe6-e6b0c4ac9e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_PreferredStockMember_13d923f0-aa63-4112-8fe6-e6b0c4ac9e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc080b80-036a-404c-b8ee-391209ff9b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_CommonStockMember_bc080b80-036a-404c-b8ee-391209ff9b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_263233dd-b67d-4525-9c18-94ba3ea58ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_263233dd-b67d-4525-9c18-94ba3ea58ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d0f2448-2270-4b22-8d49-9418a2af5c47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d0f2448-2270-4b22-8d49-9418a2af5c47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6e1c9884-0aff-4ae1-951f-f9e3bd2493c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_RetainedEarningsMember_6e1c9884-0aff-4ae1-951f-f9e3bd2493c7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i4e90fc0efd774235a3007bbbb23dd77b_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://evelobio.com/role/Organization" xlink:type="simple" xlink:href="evlo-20200930.xsd#Organization"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/Organization" xlink:type="extended" id="icc8fc0fae38a494f8e61a70af6479a3e_Organization"/>
  <link:roleRef roleURI="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="i0e26f8637c804c6c88a9ba3a53d6fba0_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a27ab7e-0ac6-421a-afe5-7011847efbae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a27ab7e-0ac6-421a-afe5-7011847efbae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9787f519-07f7-4438-b5b1-3d73618ba417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9787f519-07f7-4438-b5b1-3d73618ba417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a52b4ba1-1c2c-40b8-be3e-a219bb1010c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a52b4ba1-1c2c-40b8-be3e-a219bb1010c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19470506-f2c9-4d8e-a58a-8053a943ce73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19470506-f2c9-4d8e-a58a-8053a943ce73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8d4014b4-3598-499d-af5f-a12b91e1d7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8d4014b4-3598-499d-af5f-a12b91e1d7cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_46b8dfc5-8e90-4f15-ad6a-9f1490d43573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_46b8dfc5-8e90-4f15-ad6a-9f1490d43573" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4feaf6f9-0476-4981-abcf-2ca3b0adc030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4feaf6f9-0476-4981-abcf-2ca3b0adc030" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_JuneOfferingMember_b4e4ae31-7836-4008-80a1-9a9957e67f4a" xlink:href="evlo-20200930.xsd#evlo_JuneOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:to="loc_evlo_JuneOfferingMember_b4e4ae31-7836-4008-80a1-9a9957e67f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_050ae67f-50a3-4de8-a10b-46d19e918fde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:to="loc_us-gaap_OverAllotmentOptionMember_050ae67f-50a3-4de8-a10b-46d19e918fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_2dcde5a3-2512-4a12-ab71-f483adcc5d0c_default" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_2dcde5a3-2512-4a12-ab71-f483adcc5d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_bd60a553-e673-449b-a7d6-4f1abdd635c3" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_bd60a553-e673-449b-a7d6-4f1abdd635c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8ae8e221-9438-4010-bb47-2264f9e598f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:to="loc_us-gaap_CreditFacilityDomain_8ae8e221-9438-4010-bb47-2264f9e598f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:to="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dac7fde5-b22e-434c-8148-26e3e54417c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:to="loc_us-gaap_LineOfCreditMember_dac7fde5-b22e-434c-8148-26e3e54417c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_976e5f22-26ab-46e4-b8ec-8f6c62965956_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_976e5f22-26ab-46e4-b8ec-8f6c62965956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_2c606edc-c405-4feb-a06e-ec602eb48276" xlink:href="evlo-20200930.xsd#evlo_A2019CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:to="loc_evlo_A2019CreditFacilityMember_2c606edc-c405-4feb-a06e-ec602eb48276" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i8e536ea02cc048208aab92a635ef461b_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i6de47260f2aa4ebdbf6f290b94b2cee6_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i13c1e633b9804df1958448f8e6511be1_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i5e309d64c1a7414e82bb14e9bbc65794_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5a7f547-2740-41aa-88dd-aed0b568563f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5a7f547-2740-41aa-88dd-aed0b568563f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7bc2a35a-2ce2-4af9-a594-3f994f2a9bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:to="loc_us-gaap_OperatingLeaseLiability_7bc2a35a-2ce2-4af9-a594-3f994f2a9bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8028c2a6-c0e5-4d9e-b495-1f189c8cb437_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8028c2a6-c0e5-4d9e-b495-1f189c8cb437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:to="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_32eb1a47-5215-4118-9914-0df46e1edd91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_32eb1a47-5215-4118-9914-0df46e1edd91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i2f8f4ffc669345a596d0bbc5ba8fff7a_SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/Leases" xlink:type="simple" xlink:href="evlo-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/Leases" xlink:type="extended" id="ic16b862617f54b90b206a46f5a75c817_Leases"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LeasesTables" xlink:type="extended" id="iada3d497c6aa4befa51c75c703e053df_LeasesTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i600c4e463b964ea2854dfb7a7a0cbd7b_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended" id="i7d81486d8dff400db6e97eead897dfab_LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/FairValueMeasurements" xlink:type="extended" id="i62938b09ede24487ac2fb4624389b755_FairValueMeasurements"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="id66a1cee047042e79c0a7f5003d09abc_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i93026d23b4714d62a494f634e45491b9_FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d89db1ea-6bfb-475d-98db-f6226f273f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d89db1ea-6bfb-475d-98db-f6226f273f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c8e5b9eb-1793-4821-987e-766939a0b14a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c8e5b9eb-1793-4821-987e-766939a0b14a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6ff014e-3bbd-41d4-acaf-90dd45dfa575_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6ff014e-3bbd-41d4-acaf-90dd45dfa575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48499d06-365d-4731-9492-a7562e0cb8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48499d06-365d-4731-9492-a7562e0cb8e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50b97bd1-e9b8-41a9-ace6-f2b48dc5b9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50b97bd1-e9b8-41a9-ace6-f2b48dc5b9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5355b787-be9d-428a-948d-7bd6ac9d7eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5355b787-be9d-428a-948d-7bd6ac9d7eef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64331a80-6ffc-4e5d-8989-50704fca8df8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64331a80-6ffc-4e5d-8989-50704fca8df8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b8c0686d-f4d7-4c7b-8c2f-2e891bdf64b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b8c0686d-f4d7-4c7b-8c2f-2e891bdf64b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNet"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="extended" id="iad9f17f15c7449199058710147585bf2_PropertyandEquipmentNet"/>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="extended" id="i7613c5c3ae5041dcad56bfecc8438648_PropertyandEquipmentNetTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="id35ca0d098a148c3b4d90dccad75cfba_PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6a1ddc42-4f69-482b-87ba-16bbe4d38a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6a1ddc42-4f69-482b-87ba-16bbe4d38a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_078ba8d5-775f-4ef8-b9e8-951724801339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_078ba8d5-775f-4ef8-b9e8-951724801339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de50988e-1856-49c3-af36-33d202edb2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de50988e-1856-49c3-af36-33d202edb2c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c9265a4a-0961-4cac-a059-bc9015ca0305" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_EquipmentMember_c9265a4a-0961-4cac-a059-bc9015ca0305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e5c90b58-3454-4b37-9f77-5177d0f5d2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e5c90b58-3454-4b37-9f77-5177d0f5d2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_91a65d90-20f0-43f7-9238-f6fcaf6cdcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_91a65d90-20f0-43f7-9238-f6fcaf6cdcbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember_70c0bddc-92b3-4c9e-aaec-b0c067c11a39" xlink:href="evlo-20200930.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_evlo_ComputersAndSoftwareMember_70c0bddc-92b3-4c9e-aaec-b0c067c11a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3b451cab-2ac6-4f9a-8cfe-3819d2ba1794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_OfficeEquipmentMember_3b451cab-2ac6-4f9a-8cfe-3819d2ba1794" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fed3c4da-d372-4a1c-aa0b-39849f9529de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_ConstructionInProgressMember_fed3c4da-d372-4a1c-aa0b-39849f9529de" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended" id="i15692c051a4140308cd5ba530b0bafeb_PropertyandEquipmentNetNarrativeDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreements"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="extended" id="i3f533e45d43740ef9e9aa089678bb23e_LoanandSecurityAgreements"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="extended" id="ie5f3ee75bc764199b432dbf7babce289_LoanandSecurityAgreementsTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="extended" id="i30275894d8f647888a8e190302fff8b0_LoanandSecurityAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3c36bb3a-ecc3-4ea9-a8d5-01b5cfd4c554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3c36bb3a-ecc3-4ea9-a8d5-01b5cfd4c554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_19004df3-acfc-4d6c-8c53-ac80c8a9c6aa" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_19004df3-acfc-4d6c-8c53-ac80c8a9c6aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_333b1d98-2c47-473a-82ba-65e98e3fb7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_333b1d98-2c47-473a-82ba-65e98e3fb7f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16fd7ec0-cabb-438c-85b9-ded4d4fae53e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16fd7ec0-cabb-438c-85b9-ded4d4fae53e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_300c2bd3-399f-4f3e-8084-fb6556b67d69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_300c2bd3-399f-4f3e-8084-fb6556b67d69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_c2a54b5f-7922-436c-860a-6404fc27522d" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_c2a54b5f-7922-436c-860a-6404fc27522d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_fac5224d-211c-4ddc-8bb7-aa86d5df7708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_fac5224d-211c-4ddc-8bb7-aa86d5df7708" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_94c432ab-e981-40e5-bb22-25be26aa1c1c" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_94c432ab-e981-40e5-bb22-25be26aa1c1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_3b2bbbc5-ce45-4440-a444-1f84a81b1fe9" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_3b2bbbc5-ce45-4440-a444-1f84a81b1fe9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_10203e03-a55d-4051-a475-483f74755efa" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_10203e03-a55d-4051-a475-483f74755efa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage_2da8736c-679f-43b2-a765-b3c33cab2c52" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentDebtDefaultPercentage_2da8736c-679f-43b2-a765-b3c33cab2c52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9f8993c3-c5d7-4fb0-9ff3-f92c85f02ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_InterestExpenseDebt_9f8993c3-c5d7-4fb0-9ff3-f92c85f02ccf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e041614e-d43c-4f3f-914a-619806e42457_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:to="loc_us-gaap_CreditFacilityDomain_e041614e-d43c-4f3f-914a-619806e42457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:to="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e1ec7b0d-a86c-4bb6-89c0-24637483dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:to="loc_us-gaap_LineOfCreditMember_e1ec7b0d-a86c-4bb6-89c0-24637483dc08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e3cd3025-06d9-4a5d-bb65-03e3171a3afd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:to="loc_us-gaap_VariableRateDomain_e3cd3025-06d9-4a5d-bb65-03e3171a3afd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:to="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_74d96e17-ebee-4445-a8cd-193ba91e7340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:to="loc_us-gaap_PrimeRateMember_74d96e17-ebee-4445-a8cd-193ba91e7340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_91c15bd7-006a-4c73-97e6-6925f2c5bcb4_default" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_91c15bd7-006a-4c73-97e6-6925f2c5bcb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_648f0092-72c1-4b6d-80fc-c908477b02d6" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_648f0092-72c1-4b6d-80fc-c908477b02d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_7b2c3999-35fb-446a-abdb-a9cd2cb470e6" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_7b2c3999-35fb-446a-abdb-a9cd2cb470e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_c3202678-549c-4cb2-a19e-dce02c5a7d00" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_c3202678-549c-4cb2-a19e-dce02c5a7d00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2016CreditFacilityMember_7e6b620f-7fdb-480f-8292-606542081de4" xlink:href="evlo-20200930.xsd#evlo_A2016CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:to="loc_evlo_A2016CreditFacilityMember_7e6b620f-7fdb-480f-8292-606542081de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_1e1cfe77-7297-4b29-a6f6-0fc065480964" xlink:href="evlo-20200930.xsd#evlo_A2019CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:to="loc_evlo_A2019CreditFacilityMember_1e1cfe77-7297-4b29-a6f6-0fc065480964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2b06d525-c4b0-4f63-aee1-5aafdc4169f7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2b06d525-c4b0-4f63-aee1-5aafdc4169f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_015284bb-fb1c-46a2-81c0-394843718a68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:to="loc_srt_ScenarioForecastMember_015284bb-fb1c-46a2-81c0-394843718a68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended" id="i3046a9f32e134f24843549431c71fd06_LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_0a020433-3d51-4cf6-aa8e-c07e6a533c98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_0a020433-3d51-4cf6-aa8e-c07e6a533c98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_e61258a5-2cbf-42e1-93f0-8ccc3e28f8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_e61258a5-2cbf-42e1-93f0-8ccc3e28f8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_c406f3c7-5476-403e-8aa0-0af0391e2d87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_c406f3c7-5476-403e-8aa0-0af0391e2d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_4eae2de5-ea22-47be-a0d5-ccdc04807266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_4eae2de5-ea22-47be-a0d5-ccdc04807266" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_3a4d6533-4e4d-48ae-b1e0-eefcec1b7215" xlink:href="evlo-20200930.xsd#evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_3a4d6533-4e4d-48ae-b1e0-eefcec1b7215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_39ac0d30-f824-4099-85c9-0018f954ded6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_39ac0d30-f824-4099-85c9-0018f954ded6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_044b0b6c-47a0-4bf8-a309-336dc5a1199c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_044b0b6c-47a0-4bf8-a309-336dc5a1199c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_41149b39-b790-4f68-a7df-74d711c010db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_41149b39-b790-4f68-a7df-74d711c010db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:to="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e6787241-b022-4630-b5ad-fa1ad850b212_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:to="loc_us-gaap_CreditFacilityDomain_e6787241-b022-4630-b5ad-fa1ad850b212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:to="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_98e9d686-f68a-49db-ba7d-5b0c9f0ceab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:to="loc_us-gaap_LineOfCreditMember_98e9d686-f68a-49db-ba7d-5b0c9f0ceab2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreements"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/InLicenseAgreements" xlink:type="extended" id="i3fc5bb7b078041d0aced590944d5fab1_InLicenseAgreements"/>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="extended" id="i9b5c8ec4146c43a8be934ba912fd0958_InLicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee_c163bd71-b5f0-49e7-9a7a-f661cd63784c" xlink:href="evlo-20200930.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_NonRefundableUpfrontFee_c163bd71-b5f0-49e7-9a7a-f661cd63784c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_d6902d9f-7be7-44c0-8e36-8e8e56a6cf0c" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_d6902d9f-7be7-44c0-8e36-8e8e56a6cf0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8593ba25-8bac-4381-8f26-aeb6380d57e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_us-gaap_ContractualObligation_8593ba25-8bac-4381-8f26-aeb6380d57e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_17b1ea2d-5c9e-45a0-911d-ebecd039031d" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_17b1ea2d-5c9e-45a0-911d-ebecd039031d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:to="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6f72091-d4ae-477d-9c2c-867db174e2a6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6f72091-d4ae-477d-9c2c-867db174e2a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember_397859f6-e085-4605-adb3-fe037211511f" xlink:href="evlo-20200930.xsd#evlo_MayoClinicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:to="loc_evlo_MayoClinicMember_397859f6-e085-4605-adb3-fe037211511f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember_0d3bb798-363c-4c50-b11a-acb8faece4af" xlink:href="evlo-20200930.xsd#evlo_UniversityOfChicagoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:to="loc_evlo_UniversityOfChicagoMember_0d3bb798-363c-4c50-b11a-acb8faece4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:to="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a0e1fc6-d267-4401-8d88-152712fd1b9a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:to="loc_srt_RangeMember_0a0e1fc6-d267-4401-8d88-152712fd1b9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:to="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_02673c1d-e0a9-4349-9014-712a1652d465" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:to="loc_srt_MaximumMember_02673c1d-e0a9-4349-9014-712a1652d465" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="extended" id="i4dc1a6db714341e29e53645f2f29944e_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ib8a009534f47439e8021f264ad7b8a97_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm_f216fbef-d9ca-4f86-a0e3-ae489b720b28" xlink:href="evlo-20200930.xsd#evlo_CollaborationArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_CollaborationArrangementTerm_f216fbef-d9ca-4f86-a0e3-ae489b720b28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_ee70ddd3-cb46-4faf-8634-8c2fe4c89c6f" xlink:href="evlo-20200930.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_ee70ddd3-cb46-4faf-8634-8c2fe4c89c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_b64ed350-052e-49ca-87e2-39834a562615" xlink:href="evlo-20200930.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_b64ed350-052e-49ca-87e2-39834a562615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_1ae878e1-060a-44bd-873f-952c0dfb2f4e" xlink:href="evlo-20200930.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_1ae878e1-060a-44bd-873f-952c0dfb2f4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement_58a728a4-18a4-4845-b774-236a1dec4d8e" xlink:href="evlo-20200930.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_FeeIncurredUnderCollaborativeArrangement_58a728a4-18a4-4845-b774-236a1dec4d8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:to="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_362c7cb2-d454-4d6f-b986-feffdd025e7b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_362c7cb2-d454-4d6f-b986-feffdd025e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member_6eeff049-da10-465a-9157-c2990b12728e" xlink:href="evlo-20200930.xsd#evlo_SaccoS.r.l.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:to="loc_evlo_SaccoS.r.l.Member_6eeff049-da10-465a-9157-c2990b12728e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_BioseIndustrieMember_b49966f1-97b5-4708-aa2a-ea091d12b1a7" xlink:href="evlo-20200930.xsd#evlo_BioseIndustrieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:to="loc_evlo_BioseIndustrieMember_b49966f1-97b5-4708-aa2a-ea091d12b1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6573c0cc-7888-4367-a584-52f4274405c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6573c0cc-7888-4367-a584-52f4274405c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_257f8d78-2ae3-443b-a0bd-19103a480cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:to="loc_us-gaap_CollaborativeArrangementMember_257f8d78-2ae3-443b-a0bd-19103a480cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ExclusivityAndCommitmentAgreementMember_7d90fe9f-ce8d-47c6-be56-06932cbde017" xlink:href="evlo-20200930.xsd#evlo_ExclusivityAndCommitmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:to="loc_evlo_ExclusivityAndCommitmentAgreementMember_7d90fe9f-ce8d-47c6-be56-06932cbde017" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockholdersEquity" xlink:type="extended" id="ia188d70b715545339adf199dab36f081_StockholdersEquity"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="extended" id="i5139cd91a91f4bc0933e354766340b06_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_59c86c2d-c630-4ccb-a556-29fda401594e" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_59c86c2d-c630-4ccb-a556-29fda401594e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_3b12c691-a8dd-4aea-9e88-464d7f586b9c" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_3b12c691-a8dd-4aea-9e88-464d7f586b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_acb180ed-276d-49f4-994c-a9ce2cca26de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_acb180ed-276d-49f4-994c-a9ce2cca26de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40130f2f-851e-4301-ac1a-483e6608d913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40130f2f-851e-4301-ac1a-483e6608d913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51872114-b65e-44a6-a490-af4b0f37c516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51872114-b65e-44a6-a490-af4b0f37c516" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec0bd04f-9354-4416-8e5f-3bf0c4dfd448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec0bd04f-9354-4416-8e5f-3bf0c4dfd448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85ade207-dcd3-4a79-bb0c-f09058fa250c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85ade207-dcd3-4a79-bb0c-f09058fa250c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_6aed6a25-9763-48b5-8fc8-93ad633ea707" xlink:href="evlo-20200930.xsd#evlo_RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_RegistrationStatementMember_6aed6a25-9763-48b5-8fc8-93ad633ea707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SalesAgreementCowenAndCompanyLLCMember_6a66ecd3-b06b-4826-a584-1b96e4b0007b" xlink:href="evlo-20200930.xsd#evlo_SalesAgreementCowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_SalesAgreementCowenAndCompanyLLCMember_6a66ecd3-b06b-4826-a584-1b96e4b0007b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_JuneOfferingMember_83d44737-4c43-4244-af8f-524c8c42a323" xlink:href="evlo-20200930.xsd#evlo_JuneOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_JuneOfferingMember_83d44737-4c43-4244-af8f-524c8c42a323" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensation" xlink:type="extended" id="i84b7b85e9ad2437fa0a5f9f6ef9dc14a_StockBasedCompensation"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="extended" id="i7b0d4a12b5fb422ba6c9f467bfdb9278_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ic08dc691a49e480b94abc24d150b9d91_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43796b57-4300-4ae3-a8c6-de18a9906b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43796b57-4300-4ae3-a8c6-de18a9906b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_8776cd04-d23a-45e7-aa3d-266953db6214" xlink:href="evlo-20200930.xsd#evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_8776cd04-d23a-45e7-aa3d-266953db6214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91af385c-0f6b-4f20-834d-a5845a3603a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91af385c-0f6b-4f20-834d-a5845a3603a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a44e42c-f314-435f-9bd2-fbc04fbc3d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a44e42c-f314-435f-9bd2-fbc04fbc3d8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f8f94110-69fa-4681-aa5e-fc28dfda23d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f8f94110-69fa-4681-aa5e-fc28dfda23d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_afe1a2d2-4258-4e2a-9781-4c19801ea2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_afe1a2d2-4258-4e2a-9781-4c19801ea2c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d1e3cd2-364e-473e-9c63-04d060589027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d1e3cd2-364e-473e-9c63-04d060589027" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bc82ceea-17db-4085-a4ad-efddbebf5742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bc82ceea-17db-4085-a4ad-efddbebf5742" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fcfd7ffe-14b7-4245-86f2-c58fa338feec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fcfd7ffe-14b7-4245-86f2-c58fa338feec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_756f6150-36e0-422b-9206-92ee3967eccd" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_756f6150-36e0-422b-9206-92ee3967eccd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_bad601ab-feb0-4cad-9b13-2e89181c860e" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_bad601ab-feb0-4cad-9b13-2e89181c860e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_4a662b80-af98-4b8d-bd27-29d302256d47" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_4a662b80-af98-4b8d-bd27-29d302256d47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_b97c4c55-9631-4148-8952-e072e3477efd" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_b97c4c55-9631-4148-8952-e072e3477efd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_208c7b36-a473-4167-a72a-97e89e3f51ce" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_208c7b36-a473-4167-a72a-97e89e3f51ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bf91f68-4558-41af-bf9f-0c11b2813e84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bf91f68-4558-41af-bf9f-0c11b2813e84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4dace152-7425-45d1-b38f-4defc27da072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4dace152-7425-45d1-b38f-4defc27da072" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08c9b3fa-2dcb-4d6d-b3a0-ce41807a03c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08c9b3fa-2dcb-4d6d-b3a0-ce41807a03c5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3140b2a6-2673-4d3c-982a-daae29b30066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3140b2a6-2673-4d3c-982a-daae29b30066" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:to="loc_us-gaap_PlanNameDomain_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:to="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_418f4eae-b668-400d-9312-52e3229ee824" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:to="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_418f4eae-b668-400d-9312-52e3229ee824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_91cd1f25-bc65-4e77-b493-69495179d503" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:to="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_91cd1f25-bc65-4e77-b493-69495179d503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:to="loc_srt_RangeMember_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:to="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8fa1843-0479-4d4a-90f3-8be57abf39fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:to="loc_srt_MinimumMember_d8fa1843-0479-4d4a-90f3-8be57abf39fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8b0abad-e6f2-4ef6-9681-f540dc725727" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:to="loc_srt_MaximumMember_a8b0abad-e6f2-4ef6-9681-f540dc725727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_309c70b7-e468-4336-82a5-ab50655acf56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_309c70b7-e468-4336-82a5-ab50655acf56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21969412-8030-4a7d-b02d-1b5eaa9f3e23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21969412-8030-4a7d-b02d-1b5eaa9f3e23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonEmployeeOptionsMember_5c78233a-67bd-4fbc-816f-a39b529e342e" xlink:href="evlo-20200930.xsd#evlo_NonEmployeeOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_evlo_NonEmployeeOptionsMember_5c78233a-67bd-4fbc-816f-a39b529e342e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_14cf6206-738d-4261-af1c-10e05b47efed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_us-gaap_EmployeeStockMember_14cf6206-738d-4261-af1c-10e05b47efed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i96077f40768f476d9db25d846391eefb_StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9eff611c-bc98-42cf-9482-ce303c9c55d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9eff611c-bc98-42cf-9482-ce303c9c55d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d6edc62-bea2-4317-9484-27f082b0133b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d6edc62-bea2-4317-9484-27f082b0133b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_71bdb541-20fb-4818-bd2d-da50a8c7ddd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_71bdb541-20fb-4818-bd2d-da50a8c7ddd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_132a189d-b774-48c0-9129-e123bb01450b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_132a189d-b774-48c0-9129-e123bb01450b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended" id="iafae4afd02be4d7b87e25242646b2d86_StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/IncomeTaxes" xlink:type="extended" id="i3e01c0e0ce57401aa5d77ddf7a50670c_IncomeTaxes"/>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="extended" id="i0d58831e6930413cbc3ff4fe6f6f5bd2_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/NetLossPerShare" xlink:type="extended" id="iaf36f11860ee4ebeae06a0a0ca27d4f6_NetLossPerShare"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/NetLossPerShareTables" xlink:type="extended" id="ica512763d3c44cff8e5620304cc16ce8_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="extended" id="ie3dd46c1a1994c01bb59e8f2dc2daec0_NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ab2cdac-64a9-4656-99e0-f4623aa8b5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ab2cdac-64a9-4656-99e0-f4623aa8b5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a261c910-aef6-4f16-bc65-42631e6c03c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a261c910-aef6-4f16-bc65-42631e6c03c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember_c8471b8b-2c99-4e3f-a92e-809484513199" xlink:href="evlo-20200930.xsd#evlo_UnvestedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_evlo_UnvestedCommonStockMember_c8471b8b-2c99-4e3f-a92e-809484513199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b2364b7-6050-41ae-90c9-148992f630d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b2364b7-6050-41ae-90c9-148992f630d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_91aaa704-39eb-4a8f-87b9-a98ce90b3317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_us-gaap_EmployeeStockMember_91aaa704-39eb-4a8f-87b9-a98ce90b3317" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="extended" id="i967bc803534e4acbb4bab539df707499_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="ia260eddae38a4cccabb2757d4c2f9d56_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1612b9aa-3e80-4d6f-8f83-95634b125510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1612b9aa-3e80-4d6f-8f83-95634b125510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a33ba9-1c4d-4793-80c6-098cbddb29db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a33ba9-1c4d-4793-80c6-098cbddb29db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ce08443-a692-4f83-811d-a1545ea4baf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ce08443-a692-4f83-811d-a1545ea4baf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_60915b18-e5b0-4311-b900-56e402df3347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_OperatingExpenses_60915b18-e5b0-4311-b900-56e402df3347" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_5de220ef-8f58-48be-afc4-b44e990ee251" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_5de220ef-8f58-48be-afc4-b44e990ee251" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_abaea5b8-62ca-4071-a83e-75186869b889" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_abaea5b8-62ca-4071-a83e-75186869b889" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bcf5817c-2bcb-4ed9-ab9f-fa43116c88f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bcf5817c-2bcb-4ed9-ab9f-fa43116c88f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_045c740a-1048-4782-8654-928aafa4891f" xlink:href="evlo-20200930.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_045c740a-1048-4782-8654-928aafa4891f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_1e5765c5-fa7a-4579-8621-45829b278304" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_1e5765c5-fa7a-4579-8621-45829b278304" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_e25ead26-13b7-40c5-b798-6babc106213e" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_e25ead26-13b7-40c5-b798-6babc106213e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_67df2620-206b-4bcf-9e4a-3674ac5825ad" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_67df2620-206b-4bcf-9e4a-3674ac5825ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9dc2fc6f-2d0a-47be-aad2-0b694c4758c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_SubleaseIncome_9dc2fc6f-2d0a-47be-aad2-0b694c4758c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_981b7bc7-f31e-4359-a621-987531be1c02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:to="loc_us-gaap_RelatedPartyDomain_981b7bc7-f31e-4359-a621-987531be1c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:to="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember_fdb228e2-d4dc-48ab-9ba8-c9709d98c73c" xlink:href="evlo-20200930.xsd#evlo_WeatherdenLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_evlo_WeatherdenLtdMember_fdb228e2-d4dc-48ab-9ba8-c9709d98c73c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member_bc92e270-4062-4d93-ad20-ec35656c0051" xlink:href="evlo-20200930.xsd#evlo_VL46Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_evlo_VL46Member_bc92e270-4062-4d93-ad20-ec35656c0051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_a47a54c4-fa15-4793-b5e3-74998cb1909c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_a47a54c4-fa15-4793-b5e3-74998cb1909c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ca10797a-b34d-4253-952a-0a26cc71eb3d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ca10797a-b34d-4253-952a-0a26cc71eb3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember_c340432c-ca6d-4811-8d31-855e7ed6c434" xlink:href="evlo-20200930.xsd#evlo_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:to="loc_evlo_ConsultingAgreementMember_c340432c-ca6d-4811-8d31-855e7ed6c434" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d50aaea2-6d8f-4791-8474-16b4992873cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d50aaea2-6d8f-4791-8474-16b4992873cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ed5871ff-b245-4379-96f4-bb47bf311d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:to="loc_us-gaap_SubsequentEventMember_ed5871ff-b245-4379-96f4-bb47bf311d9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>evlo-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_dc7c3840-4369-4dc4-86f2-709467a5a13c_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period of consulting arrangement</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice, Term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:to="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_e754e6f2-68dd-4ea3-ba93-3e624098afb1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1bd880af-0299-40ed-9719-96b5c2c19387_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cdb376b9-9995-4c87-b22c-07026cd84241_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f635fee2-e033-48ff-bf01-fce987fa05ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3f3a45d9-ae62-43bb-938c-09223af33567_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_cfae6516-5d94-4e9d-971b-7b5cecdd6489_terseLabel_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments for development and commercialization of licensed products</link:label>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_label_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Development And Commercialization Of Licensed Products</link:label>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_documentation_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Development And Commercialization Of Licensed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:to="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_81ff6ffc-2923-48ec-9ae2-852c34989a6c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8e7e7007-d69f-4119-b2cb-656e68c06cca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_fa19292b-8e98-40a8-a2f5-034ae801cf37_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate grant date fair value</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:to="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9d34bfcb-724a-49d9-a67c-f4ad80f13144_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_1196e022-7720-43aa-a416-8f78d3855503_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards exercised (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_A2019CreditFacilityMember_4de721e7-d96b-4309-acff-b1622601a0ca_terseLabel_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility</link:label>
    <link:label id="lab_evlo_A2019CreditFacilityMember_label_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility [Member]</link:label>
    <link:label id="lab_evlo_A2019CreditFacilityMember_documentation_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember" xlink:href="evlo-20200930.xsd#evlo_A2019CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_A2019CreditFacilityMember" xlink:to="lab_evlo_A2019CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3864c184-a326-4641-9e15-21c02099e9fb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79cff1c7-f696-4056-bde8-0e1e17181fef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a1950eff-072f-4e46-98ce-0fa4d0dda3d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability_215c63df-29d1-4a2f-9781-533734dd8294_terseLabel_en-US" xlink:label="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="evlo-20200930.xsd#evlo_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_evlo_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f2ffbcc2-4cf7-4944-85e9-87d4905537ef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5d3612c3-7263-4ec7-abd7-bfb8964c1067_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_222a1e43-d623-445d-a13a-039f3de0db1a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ccb3dd99-41a5-47b8-bec6-612d41f9beac_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_bbf38f28-6664-4fe6-b370-99a41a9eeb44_terseLabel_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of inactive manufacturing services causing termination under collaborative arrangement</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_label_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Inactive Manufacturing Services</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_documentation_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Inactive Manufacturing Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:href="evlo-20200930.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:to="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_520e6e07-605b-4f2e-bb20-a4c04e1f3335_terseLabel_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing and public offering costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="evlo-20200930.xsd#evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_eb76d022-84fc-4143-ac15-312bbf5c13b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees associated with public offering of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2f9d902-a42c-4b91-b0e8-7fd076a7e192_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0d13b4fa-5066-4c28-9e42-b88507efcc7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f392636f-324a-4eba-8c07-033dec814acc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of fees</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fb79a4ba-8435-41a5-89c5-8649e9bd1b4b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9c0ea825-4c32-4e33-9113-347988e368ec_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest and discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ad84537d-d8c5-48c3-80dc-3e96aa061c23_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c153ec4b-fc5e-4bcc-a41e-6fb08255c638_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f47d706-075b-416f-8cac-192864cc9e03_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4a1b1501-0425-42a3-8193-f08a700db41d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and security agreement, basis spread on interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_72d64b91-f925-4d45-8632-715b66d31a4e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4e252178-7e7a-46cf-9b47-9059b5cc4d91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5e250d42-806e-4210-82bf-80b642d689d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2b3f2f0e-7261-4a49-b7c9-d660078c65ff_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cee36c3e-856d-4e30-9dc5-41e57387e927_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6aa432fd-9a55-469e-8b6d-66a079518213_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a7ef3999-d4a7-4f2f-a4eb-2a47367b9fc0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ff52b651-3e87-4c9a-94ac-6898e52aa738_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_9ffc36b4-dfd8-440c-84ab-b51c4f8f563e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_76136796-76bc-45e7-8cd6-1cb33093a19a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9730f428-02cd-4e34-8ff4-2023c162af15_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ae9e26cd-6965-4ed3-8bdf-b26b92a06745_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2067db3e-e056-4dc6-8bb1-49440ddbe4f6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cad0e262-45a6-4fa1-aa3b-4c2a834925ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2afb938c-9fd4-4df8-bca8-7453b36c6d2a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesAxis_ac33bbd3-698d-427e-bb1a-f1463260ccdd_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranches [Axis]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesAxis_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranches [Axis]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesAxis_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranches [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:to="lab_evlo_SecurityAndLoanAgreementTranchesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_768f9946-8933-410a-849b-759152cfe526_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8814cd4c-d403-47a8-adf7-042f9e2737c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1dd11deb-cd92-4ff5-a277-128b34298c93_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_7a188f42-8cfc-4eff-b468-82535f4cf41e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_a09f608c-1fe2-4fd7-b6bb-435ccaf220ee_terseLabel_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, term</link:label>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_label_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received, Term</link:label>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_documentation_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaleOfStockConsiderationReceivedTerm" xlink:to="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_dfb4b90d-3332-4907-83e0-73c46ab5a71b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0d50ab5b-39d4-4f23-b819-93796a402867_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_47c69a2b-b964-410d-8dfc-65d21a46686b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd6dccdd-614d-45cd-93e4-fc8d80b6faa4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8211; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f495233c-a3b8-49d3-b4f4-850f71395ba6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8211; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce1520a2-cfd1-4d6a-b2ed-8867a2071078_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a5be9a97-c9d4-455b-aee4-66e2790dae19_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fbfdb3c7-e577-4475-bb34-704b61fcae43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_85da98b0-8fe1-4935-82bc-5730a5499ac0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9edacae3-f21e-4179-bace-da88ebfda960_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_7c5a26a6-d846-44c1-8120-ec48c4eb2f7f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold in public offering (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bba89dbd-d95b-4bd1-81f3-3bc0cfe08b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_e928406c-5352-4f43-8cd0-0d80edc5f369_terseLabel_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Stock Incentive Plan</link:label>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fifteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:to="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_d6fd64b0-447b-4287-85ae-c499d524e020_terseLabel_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amount due under collaborative arrangement</link:label>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amount Due Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amount Due Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:href="evlo-20200930.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:to="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_58194da4-389a-4399-b4c8-170ea07d57f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_67e6f601-c79d-496c-b570-db063421ccb0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_596484f2-802e-4a6a-a04f-088308789e42_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_WeatherdenLtdMember_7b308eea-4947-4d1e-88d4-efd8a47f8792_terseLabel_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd</link:label>
    <link:label id="lab_evlo_WeatherdenLtdMember_label_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd [Member]</link:label>
    <link:label id="lab_evlo_WeatherdenLtdMember_documentation_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember" xlink:href="evlo-20200930.xsd#evlo_WeatherdenLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_WeatherdenLtdMember" xlink:to="lab_evlo_WeatherdenLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f432e5f-8a1e-4c7e-b716-9d383c724fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_35bc7495-d5e1-4455-8783-f95be7bd7046_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e8f64e0b-451d-4b8c-8f4a-f7d169d48bc9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_b8eadddd-8a20-4216-83f1-90e413c7cd70_terseLabel_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee incurred under collaborative arrangement</link:label>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Incurred Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Incurred Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:href="evlo-20200930.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:to="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_JuneOfferingMember_8f4e4b13-951f-4fe2-a7c5-338af88b99c9_terseLabel_en-US" xlink:label="lab_evlo_JuneOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Offering</link:label>
    <link:label id="lab_evlo_JuneOfferingMember_label_en-US" xlink:label="lab_evlo_JuneOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Offering [Member]</link:label>
    <link:label id="lab_evlo_JuneOfferingMember_documentation_en-US" xlink:label="lab_evlo_JuneOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_JuneOfferingMember" xlink:href="evlo-20200930.xsd#evlo_JuneOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_JuneOfferingMember" xlink:to="lab_evlo_JuneOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9785be8a-e1f3-46bf-83bb-c08c879853fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d25b8094-2023-4abc-afbb-c4bc23bbb55e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_f28ee6d1-a03b-4352-b019-1472d5223ece_terseLabel_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payroll taxes related to CARES Act</link:label>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_label_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_documentation_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:href="evlo-20200930.xsd#evlo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:to="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_59af4967-5f97-4d3c-9e3a-0b5ad36e7ab6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7aaadb08-372d-4953-ae7f-6a3a91ed96de_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_53ebefe4-5e61-4859-971c-a2881a07623a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e971ac58-f3cb-47dd-a17e-6e2d131d7ab3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_3cb72328-8369-445d-a129-e9220ee425e9_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt default interest rate per annum</link:label>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentDebtDefaultPercentage" xlink:to="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_e26e4220-6f50-4670-a55c-bed0e6c95c1d_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards canceled (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_20047bf5-baf4-46a2-9cd0-a1c28ae4ff52_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e985116f-55c7-4ad7-b41e-58ed8e235fae_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2686e8f3-2285-444c-bac5-b22e831294b7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_70bd40dc-2173-4025-9875-eef95204b225_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bb127e51-2ea7-4fdd-a9cd-6fe12fd97d09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_01334f30-8123-4307-95a5-ff1deed8c28a_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1bc0eee0-3504-492f-b147-56e8a5144e3e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0df2089-7df0-4e13-972a-164a193fc805_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_aa275f33-ea21-4379-8a99-9eb96805e62a_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_919f97ac-e96f-4099-bca9-77c10a764231_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_459f02b3-f4ff-4b13-b64d-b7e133c39882_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ca25b923-65b8-46ca-89b4-26455dec3703_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_56c1498b-3597-4a43-ba9b-70d34e9ea01b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_f1ed1032-9215-4de9-973a-39b9b8a65a12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3bd87a30-be9a-4682-9285-6bec8a3e142b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f2a9cf2f-15f5-4a5e-af71-86e11c21c671_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f5da114-716b-4d42-b092-cdfb678e4d88_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_40b769a0-8c3a-4558-9aaa-27401c06a12d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8abf3a80-29ae-46ae-9596-88aff0cdd1b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f5aa06fe-bfb5-4c7b-9ed7-6f50ea8882c8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_57e241ef-24cb-4ca8-b650-e0403073c3c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_51b46110-853f-46a8-b3e3-a7dafbf89c3e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3c2b945c-4a53-43ec-a7da-adeca3338e27_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_c7b9768b-442f-4f2f-b0fd-3af312315635_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_34a51038-469a-4520-b928-f3bbac03cd0e_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Number Of Tranches</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:to="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_6af428d6-3728-43f2-8fd6-105b80ff55b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_eed1334b-dd42-43b3-b849-4cced1e082ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_2c943ae7-4ad0-4f35-ac65-f021e85a6688_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_49150e60-05c2-4b55-b296-06f469ea991c_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_840ab5ce-b691-4c2c-8f31-3475f3a58dd6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_479bbc18-b0fb-4d8d-b8d0-a6040add40c9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_43b2fd33-1632-4a88-95f7-8c4662beb555_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3649d6c3-f99f-4e49-a0b5-36982ad9bb82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_7199d55f-f020-49f3-8d56-6fc5450dd6c0_terseLabel_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount due under collaborative arrangement</link:label>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Due Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Due Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:href="evlo-20200930.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:to="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_49474bf0-bb8c-4b1b-8ee6-0fa0b4f8ccd0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a98890a5-f9da-45fc-9607-1c648593bcc0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4539e669-3335-4046-a08e-2a380c5f28e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7a9d707d-e8ca-4339-8064-b954317e6240_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b8a9c2b-55ce-4af5-9e18-06f62d794ac8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b18dd4d3-ec9d-41d6-bc2a-fc01f843a6a1_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_40d783a3-e6eb-4ece-bed3-92cc812d3e30_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b9d0194a-d766-4fe5-9fab-20eae67935d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a40a4c43-7acc-4e13-b45c-bf288175cd49_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4189532b-944b-41e6-8931-3c3893155996_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_20ff4fab-2b3a-4023-a51e-251b672f4fee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5929df82-8b76-495a-b0aa-8ced0e179a36_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bc3530f6-cd59-4f2d-a71b-d6f6515a4af9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1f8fe24a-bf1e-40e3-b9e4-5d83f0efb82b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_87be09bc-07b6-4a7b-8b0a-547157a1c442_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9f76fd9f-246e-4943-8144-b74e82cb40c0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e4824b04-2166-46a8-8874-a069950d6e5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec26bd31-78d4-414e-9406-376d2bd6ef1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_2c231173-445f-40d1-b350-06baf8d87871_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3fde3cc0-085e-479b-b15b-30a0f77c8b97_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c67720c2-5199-4aa4-ad39-caaa24c24dac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e067417c-5912-4fce-a226-322eae10e775_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_548d4ea0-ab87-4d3b-ad51-eaf23a68677f_terseLabel_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_label_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_documentation_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CommitmentAndContingenciesTable" xlink:to="lab_evlo_CommitmentAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_a0db125e-5aba-404f-85c6-829f4a0ff6b6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_1b767589-9cff-49b5-8381-23ce44431794_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_891dc46c-deab-49de-9781-3a7fc71e4021_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_dbd6a479-8a43-4cec-9fe1-e3460e3762b3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_07ef9246-2310-4780-9809-13123f0cb224_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment:</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_28dad62c-bfba-4e5d-b81e-1db2fcf1921a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_884ac86f-71e1-4206-9c57-0ef986ab27b4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1830328d-ecff-4b16-984e-be21504afb25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_VL46Member_99f2ef4e-35ac-4275-9eeb-275b6b905b21_terseLabel_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VL46</link:label>
    <link:label id="lab_evlo_VL46Member_label_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">V- L- 46 [Member]</link:label>
    <link:label id="lab_evlo_VL46Member_documentation_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VL46.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member" xlink:href="evlo-20200930.xsd#evlo_VL46Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_VL46Member" xlink:to="lab_evlo_VL46Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_5cda3a0f-d023-40f0-bbf2-74be8537ee60_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_37244a25-0607-46e9-979e-4e878b5b74e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5fe55d8a-3d51-4534-bbe1-a42a0eccbc04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_04ee234f-c5af-41f3-9c1c-a5f5668292db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6a7f61c3-4bf1-48b7-a86b-4979226c146b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_506aff69-1e71-405e-bb83-5e6531c04777_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1879e2e-4866-4773-9ccc-215114c19d53_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_a958713f-35b9-489d-abe8-e0e500af4c74_terseLabel_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of certain development, regulatory, and commercial events</link:label>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_label_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments of Development, Regulatory, and Commercial Event</link:label>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_documentation_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments of development, regulatory, and commercial event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:to="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_286d1ee4-ca50-4155-af22-fa8eb8fd971b_terseLabel_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_label_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers And Software [Member]</link:label>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_documentation_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember" xlink:href="evlo-20200930.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ComputersAndSoftwareMember" xlink:to="lab_evlo_ComputersAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_83061dd7-0ddf-4eb0-a03c-a7d4c329816f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholder&#8217;s equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5bfda87a-9a4b-444a-9127-ea6188131633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63aeb15c-63c2-42fc-9cd8-1403aa3be39a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold in public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b6634fb-b72e-494e-af63-16d719286c81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock_1d164ee3-e28c-4d31-81f6-6c906a515e05_terseLabel_en-US" xlink:label="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt About Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt About Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:href="evlo-20200930.xsd#evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:to="lab_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ed8393e3-b0cb-42df-adcf-95f4220e087f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a0b84127-39ef-4a6c-a949-529b536a5c8e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_881c50bd-d4f7-4d9e-ae5a-b7b7b460ab5f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_33652fc1-d941-49aa-a5d4-c60be749d955_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b1de63c3-a906-4bb1-8fd8-b9eb58291ae2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b556fb47-ad73-4bff-b5f8-09b95d07b887_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9239c15a-e269-436e-a277-94f861a18bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_bda8c1d4-63b4-487e-af8a-775a16dc5848_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_135b1f33-cdf5-4367-9b9c-117c9cb57457_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ddb55008-0a35-4eac-bcea-ede0cbd32fab_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e520ec97-8ecc-4df8-b573-448e1c4938bd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_e0a7bede-3b4a-46e9-85c7-bc2912dcb38c_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment under agreement as a percentage of loans borrowed</link:label>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repayment Or Prepayment Fee Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repayment Or Prepayment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:to="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1728b4f3-c234-4672-82d6-2e71e8b6bd89_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d4e4490a-a4cc-4195-8566-f72dc01f01be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_638aec1e-209b-4b3a-bc6f-77686befb97c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ca276871-4e48-48fd-8520-947cf6d8a326_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment additions in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bd40cbd1-b773-4a49-8f6f-29184a6390d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_20981e53-a036-413f-b63f-96d25dcf75ae_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual equity award, vesting period, number of equal monthly installments</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_3422c80c-92e7-4b24-8d6d-cde4ae599103_terseLabel_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_label_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_documentation_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems" xlink:to="lab_evlo_CommitmentAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c4cc6103-0988-45a0-91d8-8aedaba890c5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32e92b31-76bc-4055-88e2-dc681d7e2f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares originally authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6281a28f-38d1-4898-8019-781a8f8c8e29_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_04d4f99e-8884-4ec0-b131-c9c2db700974_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_98f8cee8-a637-43fe-b551-1b2d152c2ec1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c4563efa-173e-4daa-b089-7734618886e8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3011043-235d-4667-8cd2-37cd989dfbbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7b2602ec-0700-4e8f-8a3a-e7c6670cb957_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_9bfb7e9b-165d-4397-8703-8a4f1ce4beaa_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased office and research development space (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4242a5fe-aea3-4550-b118-45d1c3ea6f75_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_daba54a4-bb86-40ab-90fd-a898f12888d1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a9c21a1d-ecf7-4816-b53b-5b68ae2835c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e3bff3bb-d56c-4706-a812-db0c4e227384_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8b22f221-8c76-4c37-82c7-ba495914c57b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_1b08a783-a15d-4059-9ece-ea9dff6c7a1b_terseLabel_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_label_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Operating Lease Expense</link:label>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense" xlink:href="evlo-20200930.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonCashOperatingLeaseExpense" xlink:to="lab_evlo_NonCashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1a785f2c-fe49-4cab-bb23-98c57b73360c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_02f9af4f-f067-40b2-90a2-d132435d555a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_c4e1878c-e07f-46df-822c-7ef5c3371c04_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Epstein</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_acbc5e3a-5cbc-49d3-9375-95f8daa32b26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e5b13126-d915-4ae7-9bb5-2850657eac1d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_A2016CreditFacilityMember_35191965-be85-468b-b9fb-273f9f3391b5_terseLabel_en-US" xlink:label="lab_evlo_A2016CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Credit Facility</link:label>
    <link:label id="lab_evlo_A2016CreditFacilityMember_label_en-US" xlink:label="lab_evlo_A2016CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Credit Facility [Member]</link:label>
    <link:label id="lab_evlo_A2016CreditFacilityMember_documentation_en-US" xlink:label="lab_evlo_A2016CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2016CreditFacilityMember" xlink:href="evlo-20200930.xsd#evlo_A2016CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_A2016CreditFacilityMember" xlink:to="lab_evlo_A2016CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5028c87f-ef46-4064-80f0-2979fbfae1e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6178774a-08ff-4766-a793-9d63bef4c15c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_582b78f8-372a-4ee0-961d-3958b3286534_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5a0f9c0b-37f1-4177-b52d-5faa15a7038b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80258a13-fe43-4185-bd6e-971280f944d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1c971202-f562-4fc9-9f04-a1deebb997c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c362fa3-af57-4ce9-b502-846af73d30d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_98b9ccf2-8f5f-42c1-a2a3-2bbe8c959a37_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_a1f93b81-ac13-4b04-aa53-569fcba8fcce_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Plus</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8e9626f8-027d-48e7-8767-887532b1b47c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_5e0d89e3-907c-4cfa-8d51-e820fc143d7b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Considerations</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4635c2a9-1a96-4f70-a71b-4931ecf422a2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b81a72ad-9767-44a5-8c27-a5d1e7428d5c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8f03b7b0-a7c6-42d5-8cc1-8c92540f782f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_61820d84-ed7a-482b-ac74-e652b9552913_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2035f683-621b-418b-a453-abb42d7018cc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ef63d432-7893-4aa7-8786-00fc7c95121f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f637bb07-6acb-461e-9881-0c6f1619a176_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_41ed14ba-07a8-4ab9-9f9e-cc55c3677717_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0fe8efb1-033b-4c1f-a745-2ddd91e373fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Aggregate Future Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_73c587bd-fae7-4d5a-86d1-d0285dabdc03_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6ad4e12f-4825-4ab0-95a0-6e60163ce822_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_3cd411d9-e86b-4986-91bc-a10901ab904a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a06ec042-00ba-4862-a788-a17ef2b9ed76_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_622222e3-83a2-463e-8ac0-f8f2b170f5c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_eb68ab8b-cab6-444d-afa7-9513d0c4104f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_23651766-2c18-4043-a942-96d1a6d605cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d3ee9100-f8db-4611-a709-92d7a12e8d1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_aac107aa-e86b-4bdb-84bc-988e5155e048_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_d35da6de-a9c6-4f71-896d-88ef3da1bf58_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b409eb3e-929a-4d9f-85c9-b08d3b3d3103_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8bad95d2-eecd-4ed2-8268-0c42c327a64c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_968fbfa1-7f72-4bcf-9529-8e6b572022d9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_75dc0437-04ba-4262-91bc-47acfff3ccc1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_eb501e6e-7911-404a-92d9-b53df6fea9f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to operating expense from sublease agreement</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_55143d9a-8e30-4107-b1ab-ab052f1ecb85_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards granted (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_79b935ae-da8e-47c3-83aa-28110ff6fdf8_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SalesAgreementCowenAndCompanyLLCMember_bc09aafa-201f-47b6-83c3-ba1936be8e43_terseLabel_en-US" xlink:label="lab_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement, Cowen And Company, LLC</link:label>
    <link:label id="lab_evlo_SalesAgreementCowenAndCompanyLLCMember_label_en-US" xlink:label="lab_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement, Cowen And Company, LLC [Member]</link:label>
    <link:label id="lab_evlo_SalesAgreementCowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement, Cowen And Company, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:href="evlo-20200930.xsd#evlo_SalesAgreementCowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:to="lab_evlo_SalesAgreementCowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c2bd1e3a-5873-491b-87f2-a76d0f10d3c2_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40409487-66ad-498e-a914-2eedd583ec6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3e6e7b7d-0862-4609-8dfc-f4a3eab9e7ed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8bdbd5de-7db5-47ed-a0b5-a5ab9e3514d2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ConsultingAgreementMember_84920674-7c50-45ef-a0b0-644cf7d4a55a_terseLabel_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_evlo_ConsultingAgreementMember_label_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_evlo_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember" xlink:href="evlo-20200930.xsd#evlo_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ConsultingAgreementMember" xlink:to="lab_evlo_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_64253e47-51dd-414c-8f37-f8bc797e0868_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum rental payments received</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9cc74015-5c9b-4563-9835-7f2c5829ac49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2923ea6a-3936-43ed-8e9f-cc5d85387a13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Aggregate Future Loan Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_1ae73b78-cfec-4ad5-8abf-f7744a4d0ea9_terseLabel_en-US" xlink:label="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding percentage to be declared as an increase in grants</link:label>
    <link:label id="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_label_en-US" xlink:label="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding percentage to be declared as an increase in grants</link:label>
    <link:label id="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_documentation_en-US" xlink:label="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding percentage to be declared as an increase in grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:href="evlo-20200930.xsd#evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:to="lab_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3da4a316-ec9f-4daa-b7bd-0126027f68aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d72621d7-28c7-4d32-9b25-f906fe137682_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a67bd7bd-26df-43d1-9c82-ca895bdf4824_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b6f906e1-ccab-43dd-8337-fbef97e59818_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6424946f-33ca-449a-815b-030ba8229959_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_248dbc2d-802c-42a1-b725-56c941dadc8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of fixed assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_41b7bd15-31cb-4aca-9143-acfd7f5c162e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_abb7df6c-9358-4782-8a27-df246c4c85bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_ff532957-9953-4370-84a5-7caa19d6a51e_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a1928ca-3fba-43e6-8fb3-686a43ce9402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6066d238-a7e9-4321-9e37-e0b70626d31b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0288fe94-49cd-48e1-8530-d0bafe5bf5a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_591bd11c-0c8e-4baa-b38d-5ef1e91e9540_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_09859513-4b71-48ad-acb9-f25cabf17dac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_cd88a08d-e673-4a01-8587-23038050578a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_1ceb3828-68fa-477a-9733-bcb57d9ae913_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8918f849-44c5-4cc0-90d6-60d05e41d232_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and Security Agreements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6f87b2c6-a351-4f32-bc5f-ffcbb0361817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_01d53b73-2ac5-4d3f-a1b9-faf993b65650_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MayoClinicMember_fcdaf182-d3b0-4a54-a227-4e1e9c043c7e_terseLabel_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic</link:label>
    <link:label id="lab_evlo_MayoClinicMember_label_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic [Member]</link:label>
    <link:label id="lab_evlo_MayoClinicMember_documentation_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember" xlink:href="evlo-20200930.xsd#evlo_MayoClinicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MayoClinicMember" xlink:to="lab_evlo_MayoClinicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_99a9938a-320d-40d7-ad3d-3a010dff44aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_1de9af4c-530e-409d-a541-8e0a7ff18432_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_61aacdfd-5a39-4195-ba43-b6c96c5a96f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3d32c044-09af-43ad-8772-fc6ae04bedf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonEmployeeOptionsMember_90922374-3081-4f80-802f-b23bfc863bd7_terseLabel_en-US" xlink:label="lab_evlo_NonEmployeeOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Options</link:label>
    <link:label id="lab_evlo_NonEmployeeOptionsMember_label_en-US" xlink:label="lab_evlo_NonEmployeeOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Options [Member]</link:label>
    <link:label id="lab_evlo_NonEmployeeOptionsMember_documentation_en-US" xlink:label="lab_evlo_NonEmployeeOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonEmployeeOptionsMember" xlink:href="evlo-20200930.xsd#evlo_NonEmployeeOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonEmployeeOptionsMember" xlink:to="lab_evlo_NonEmployeeOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_ea9de597-df1e-4d3c-9c71-210f4ba79fba_terseLabel_en-US" xlink:label="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_label_en-US" xlink:label="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling After Year Four</link:label>
    <link:label id="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_documentation_en-US" xlink:label="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:href="evlo-20200930.xsd#evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:to="lab_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ExclusivityAndCommitmentAgreementMember_4989e2bf-3190-4abb-9b0b-c15b5b003e45_terseLabel_en-US" xlink:label="lab_evlo_ExclusivityAndCommitmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusivity and Commitment Agreement</link:label>
    <link:label id="lab_evlo_ExclusivityAndCommitmentAgreementMember_label_en-US" xlink:label="lab_evlo_ExclusivityAndCommitmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusivity and Commitment Agreement [Member]</link:label>
    <link:label id="lab_evlo_ExclusivityAndCommitmentAgreementMember_documentation_en-US" xlink:label="lab_evlo_ExclusivityAndCommitmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusivity and commitment agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ExclusivityAndCommitmentAgreementMember" xlink:href="evlo-20200930.xsd#evlo_ExclusivityAndCommitmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ExclusivityAndCommitmentAgreementMember" xlink:to="lab_evlo_ExclusivityAndCommitmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonCashInterestExpense_3e377fea-97e1-441f-b9bb-1de904301033_terseLabel_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_evlo_NonCashInterestExpense_label_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_evlo_NonCashInterestExpense_documentation_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense" xlink:href="evlo-20200930.xsd#evlo_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonCashInterestExpense" xlink:to="lab_evlo_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c3f0e8c0-69ec-4274-8863-caa72758ae15_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2b1d149f-8300-43ca-bffc-d8f4fa725c8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_68b66eda-1533-4d8d-ba52-edc4ee41b83f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_319fcaf1-687f-4314-81db-39f1aa622421_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bbe357e3-1a1d-454e-b1ff-2835c9eb8bc9_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d1cc0a2c-9893-4caf-bf5c-44b4ff2e6251_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d7c8079f-aeb9-463e-8856-2349dfd24b1b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_dda333e7-33f3-43a8-a437-a6fc962c7eb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2315e481-38cf-4755-a976-a67ac6e8a2f2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b15f0919-7987-40da-b1e9-4d2f7489a5fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding payments made as of September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5557d1b0-0753-435d-8bd6-0cb1c14bdf80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1de931ae-a260-4611-a3de-d7317942af46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbbd1434-f8ca-4948-9674-79d7d6b897e7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_aec70bc7-10bb-448a-9c9d-859472b346ce_terseLabel_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration of equity instruments, aggregate authorized amount</link:label>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued In Transaction</link:label>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:to="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f0d68d91-5346-41b7-a05b-cf69c58ebfac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4c0d56bc-10ef-4cc7-99de-3d9b7d4dcf16_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b7fe8e6a-a778-4cd1-ab44-dd6bc00b4dcd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22364874-7869-45cc-b84c-aaf867f90b24_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3c89a558-9bd3-46c2-9cc5-088c0cc29346_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_a2d89bbb-f243-40e3-bc63-0229eab8d018_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period by non-breaching party in event of a breach</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:to="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_56c8d220-5cba-4634-9f9a-6418b606d380_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent due from sublease agreement</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a3dab8bf-2c3e-4185-9f01-fa4d1850ce61_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments, net of tax of $0</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b3dfd918-38f2-4b4c-bcb3-83d22f6e5aa4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1b482f46-58d2-4558-8dd9-00447044c624_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ebbaaa19-66e3-4f74-b08c-17a1059a41d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_e32b8ccc-9577-4644-8e40-230a042a7edc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e9cfa7f-712d-4f0b-898d-616013936e16_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_5e32e109-f845-41c6-b7cf-f5ef18affda5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_b2c58a48-2111-44ca-ba6a-e0e36b8884ac_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_712ae28d-9904-4333-ad22-0e11fade6640_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_94b950d9-7006-4037-b63c-2027b813d293_terseLabel_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status</link:label>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_label_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</link:label>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_documentation_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging growth company status.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="evlo-20200930.xsd#evlo_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75154d97-67e2-4312-97f9-46d31acae1b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_98ff1c2e-cada-4652-b5da-3a445884ca8e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7bf593f1-cb77-420e-8195-c485ecd536cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9dd24bb0-be89-499f-9564-38e8c8760e41_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e314bfff-271f-46cf-9bf0-714c0b9cabbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_06875697-8fe0-4371-8705-41ad9e15aaf6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e91ad0a3-b3f6-4e4e-9669-b297c05e3656_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9e15cee8-1950-4b13-b0db-589a03538f66_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0b7f4ac4-712d-4579-9008-d976d01d6ee8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2cfffcf4-53b5-4de3-b197-3a3a9f3c0c95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dec6d256-000b-4410-b8fd-eabeb891099b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_46b43719-0551-4d58-a5ef-dec51c166cdf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax portion of unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_26148e3d-c81f-4b64-8f02-a0e460948bab_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_label_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage On Principal</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percentage on principal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:to="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2016215a-3872-4536-a4ef-eede8fcad6f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e883c023-7eeb-481c-b244-b7f40ddadcd2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_UniversityOfChicagoMember_5194f1d5-11de-40e3-ae0d-2a461f0686dd_terseLabel_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago Agreement</link:label>
    <link:label id="lab_evlo_UniversityOfChicagoMember_label_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago [Member]</link:label>
    <link:label id="lab_evlo_UniversityOfChicagoMember_documentation_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember" xlink:href="evlo-20200930.xsd#evlo_UniversityOfChicagoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_UniversityOfChicagoMember" xlink:to="lab_evlo_UniversityOfChicagoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_c1ed818f-dfe6-4fc4-b55d-8b7c9a34dc4a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a37d99d6-c1a1-42bd-9a23-2c70db2800d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and security agreement, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7c7fa988-85bd-4345-b871-6e2b9c26da73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a78ca2bc-ab5c-4942-833c-db460bdfd76a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborationArrangementTerm_62261c73-378f-4163-8b5d-155b486e6456_terseLabel_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration arrangement</link:label>
    <link:label id="lab_evlo_CollaborationArrangementTerm_label_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Term</link:label>
    <link:label id="lab_evlo_CollaborationArrangementTerm_documentation_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm" xlink:href="evlo-20200930.xsd#evlo_CollaborationArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborationArrangementTerm" xlink:to="lab_evlo_CollaborationArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5add96c9-61e5-4282-b950-f161c37d1227_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d82fe1e0-d421-4239-970f-1f93d6e1708c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_0f60b46e-9912-4731-9101-9ff2cc5cd5cd_terseLabel_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront fee</link:label>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_label_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Upfront Fee</link:label>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_documentation_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee" xlink:href="evlo-20200930.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonRefundableUpfrontFee" xlink:to="lab_evlo_NonRefundableUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_13eeb12a-e752-4b48-ad51-0c67e20fc5cf_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate annual cash consulting fee</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Cash Consulting Fee</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Cash Consulting Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:to="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a43f74e8-83af-4037-a09a-7bec22d582af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_a9c28977-4193-4197-94ed-5cd28397d4b7_terseLabel_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to purchase shares, vesting period, number of equal monthly installments</link:label>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:href="evlo-20200930.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:to="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_160eddf2-d658-40b5-a628-f47f50bee7ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, maximum expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4c21940e-8c2b-4898-b3e0-40f4a7093cf6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in)/provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_19381ca2-89f5-40ef-94a7-287a0df048d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8d40eb08-7bb1-45fa-9f21-3869a55aab60_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2c949c4a-d1d7-41cd-afc3-b8b9af3d6ccb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_94f3c082-c666-4ae4-a3b4-e91a40d9049f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d3bbd1ec-a087-4cab-9bce-ee4ffec620de_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_615034d1-30cd-4911-9608-04c0b5f88aa2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4c34e850-1917-4eef-94f8-51ccc33fd560_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_99472bb4-2452-4881-82b2-d3298a3a9836_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_09110918-1bf1-4438-9005-2dd890e10008_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e8bbb424-0edc-4490-8ace-1eb3edcc7f18_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1ff7a68a-46cf-4ccb-9bb9-deed674fe8f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_35f725e4-b533-4e4e-8ef0-ee244e0a9b62_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_80abf9e7-4939-48f1-a87e-99e86434776d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_BioseIndustrieMember_91e88932-64fc-4778-9a69-2d8f6ca8cf67_terseLabel_en-US" xlink:label="lab_evlo_BioseIndustrieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biose Industrie</link:label>
    <link:label id="lab_evlo_BioseIndustrieMember_label_en-US" xlink:label="lab_evlo_BioseIndustrieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biose Industrie [Member]</link:label>
    <link:label id="lab_evlo_BioseIndustrieMember_documentation_en-US" xlink:label="lab_evlo_BioseIndustrieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biose Industrie.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_BioseIndustrieMember" xlink:href="evlo-20200930.xsd#evlo_BioseIndustrieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_BioseIndustrieMember" xlink:to="lab_evlo_BioseIndustrieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_ba30ee18-a114-421f-92ea-fc0dae4673fe_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary of funding date for determining prepayment fee percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:to="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_02b31355-e3fa-4d4d-8604-84646870351f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3f114bad-da96-44a7-982a-378c9cacc1ed_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_344d120d-c25e-4670-b11c-4f9fc51817bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bbbab5f1-7f27-404a-a94f-5c928fec7ffa_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe0e5cc5-9e9f-4c49-9ab7-57b9e67ac6ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ffce1f8-8c2d-49a1-8b29-f580029136d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_01a8c88c-2ef4-4640-840a-49f33d64f2b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7c6ef59e-3aea-4e86-9bf8-ce5b472c9636_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a2f0b036-6428-4631-b148-748ab82bfef9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b1630c9-0b19-42e0-b391-26b418099fdc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of fees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_8e582add-5ed8-4f74-a37a-28c8b272ce3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaccoS.r.l.Member_be3a1a85-e243-47c5-adf7-84e509b0c8e8_terseLabel_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco</link:label>
    <link:label id="lab_evlo_SaccoS.r.l.Member_label_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco S.r.l. [Member]</link:label>
    <link:label id="lab_evlo_SaccoS.r.l.Member_documentation_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco S.r.l. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member" xlink:href="evlo-20200930.xsd#evlo_SaccoS.r.l.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaccoS.r.l.Member" xlink:to="lab_evlo_SaccoS.r.l.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_981893b7-66c5-43e7-b387-8aac8e49e85e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aff6054-23b5-4bf8-adb7-5368aa384887_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_04ffba4c-f2aa-421b-aed2-54548b368089_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0a86c9c4-2546-4bbd-8923-60dd57ebe6f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized; 46,220,859 and 32,232,258 shares issued and 46,184,087 and 32,170,605 shares outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06cfa097-353c-4811-a862-f0a64dafd4f3_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_154e98a2-a4b1-472b-988d-50464d375811_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_82d9bf58-ef7f-48cb-9b96-abb028ba866d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_47d49be4-61a9-4e42-ac3a-4d600d68701a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e689a8eb-6f88-4831-a636-74ba35436c01_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e285ad7b-387a-44f6-a92e-2ae9b8a9507c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1981580c-68b3-4beb-9007-1b8a14be18ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a67151a5-88f6-40dc-801d-39d787c4773a_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d2b62d6e-e8a4-442a-af75-e3a4062b0272_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c8784a14-f3b7-4360-9474-dc79266763ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset - operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4803873f-96b1-4ec1-aa3a-874ea954b4ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_8e68ceb9-bdb5-4e90-9c6e-cc926a2ecfee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9d7ee154-44e9-4947-a821-10a7dcaa3ca7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_24e418da-23cf-456c-8a08-e3ac80b2fd8d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_68cfe106-4b19-419c-b69f-d9397e3fde92_terseLabel_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Stock Incentive Plan</link:label>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e449dda8-d3fc-400e-a117-0ef7ed3222f8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e4d2884b-8f4c-4db5-8bcc-b281cc302abb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bc9a16b4-8368-45aa-807a-acb258c87f5f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f95eab58-49f6-4c3e-9d72-e68c744dd10e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_6e7a33f5-7de0-4f79-93f6-77d3e9c158ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_260af62e-a93b-4697-abed-64808f4ee68e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_72242dfc-24e6-4bc1-bba4-512fb71f5bb3_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares no longer authorized (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dd5c1b26-05ea-443d-9b17-e0599be4a911_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of discount marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a00481d6-e9a2-4228-8fce-85ac6200af80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a072f25a-34b5-410d-9006-1cf978d729e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7df3066f-5df9-43d7-81fb-bfbe2950370a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RegistrationStatementMember_c6323214-a85b-4790-addf-4234b815e2e4_terseLabel_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement</link:label>
    <link:label id="lab_evlo_RegistrationStatementMember_label_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Member]</link:label>
    <link:label id="lab_evlo_RegistrationStatementMember_documentation_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember" xlink:href="evlo-20200930.xsd#evlo_RegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RegistrationStatementMember" xlink:to="lab_evlo_RegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9f9d4ba4-a947-4582-8e47-8c0054ed9b21_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_330678cd-2626-40cf-bfd9-e141b726b71a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e1b33640-f9d6-4e6c-bf52-0cc8b5e21d2b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_bf16115b-a111-464a-b7d8-be16759c3f6e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_de558b8a-b17c-46c1-9852-2006f3987d2c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e42cc7cd-44db-4ead-9d18-2afb668e7cdc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b6b9adf-19b6-4976-8ee6-4e1b680f19c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_946d9ebc-bc4e-48f9-89c0-0493fe842209_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_23394eb8-9af1-48b9-befb-38151dd28ec1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_79f05dd8-6b97-49f4-ae04-7c5271ee218f_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_f8be901a-9954-4de7-99c4-90ecf1e73572_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f3e55bcd-da0d-42b0-bf02-e98d43653b24_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4c6e97c-25f6-498a-80d6-b16a285f60f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6a72f2cf-055f-4aee-8439-6c54e0cdca08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_593e0918-2b3a-4ce6-85d6-d7cc88286a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_ad41cee3-9b69-44ee-ad99-5ee13adcf83d_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9ca80107-7b08-42e1-87d6-ab4b631ae427_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_86634461-d2cb-42e2-ac74-173608ecb349_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_93a639b3-4c9b-413f-8738-a4a7e5bbebad_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_ae536826-312e-41c3-85c5-4124d44b81aa_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_6b85e674-2fc7-419d-b61f-bc400382c24b_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage after specified period</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_label_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage After Specified Period One</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percentage after specified period one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:to="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_6108425d-9fc8-455d-8dc5-c2bb2ab8585d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees incurred to establish facility</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_cb1d839b-9720-44ef-86fe-84de229b20da_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_UnvestedCommonStockMember_291877aa-f9b2-4cd1-baff-5f2cabb144a5_terseLabel_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested common stock from early exercise of options</link:label>
    <link:label id="lab_evlo_UnvestedCommonStockMember_label_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Common Stock [Member]</link:label>
    <link:label id="lab_evlo_UnvestedCommonStockMember_documentation_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember" xlink:href="evlo-20200930.xsd#evlo_UnvestedCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_UnvestedCommonStockMember" xlink:to="lab_evlo_UnvestedCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e4d7c274-a92f-474b-b87a-4d1373dfb1db_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_24a22f15-2870-4f5a-9725-afea4deac7b3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering from ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_ba413e9e-6841-47e2-8e57-467c6bf40962_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due under license agreement</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6eefbd6b-ea66-4737-a6f1-92ab158dd7d8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_fb1e5180-77b7-4697-a31b-0282b7fd76b7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesDomain_5d7abb8f-9496-49bf-a65f-1531fb135440_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranches [Domain]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesDomain_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranches [Domain]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTranchesDomain_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Security And Loan Agreement, Tranches [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:to="lab_evlo_SecurityAndLoanAgreementTranchesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9fbad7d8-a48b-40cc-bbad-e392e21ea460_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>evlo-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d32fa321-7720-4179-bf7f-cadb33059357,g:173a9105-6fcb-4758-8b54-b36293998645-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://evelobio.com/role/CoverPage" xlink:type="simple" xlink:href="evlo-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ab53990d-ea62-490e-8db3-b8e2bfa38156" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentType_ab53990d-ea62-490e-8db3-b8e2bfa38156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bd8608bc-bae8-4988-b44c-945d133a0172" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentQuarterlyReport_bd8608bc-bae8-4988-b44c-945d133a0172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_99b0002d-2f4d-4853-879d-97b87c70a7b9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentPeriodEndDate_99b0002d-2f4d-4853-879d-97b87c70a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_02c6723f-4fe8-4b20-92ae-a294cb6dd214" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentTransitionReport_02c6723f-4fe8-4b20-92ae-a294cb6dd214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6420add7-76ac-48a3-8cac-15734ac91c86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityFileNumber_6420add7-76ac-48a3-8cac-15734ac91c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dc2b1ca2-788f-4c15-b73b-5a1c091ad878" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityRegistrantName_dc2b1ca2-788f-4c15-b73b-5a1c091ad878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2d9725c1-6853-43b0-8766-cc48e2e1aa2d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2d9725c1-6853-43b0-8766-cc48e2e1aa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_91ee5c86-9e20-4624-b5a3-47fabce957e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityTaxIdentificationNumber_91ee5c86-9e20-4624-b5a3-47fabce957e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_91aeea48-1f5f-424d-957a-eb52e531db87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityAddressAddressLine1_91aeea48-1f5f-424d-957a-eb52e531db87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_79a23d23-a458-4cae-b0fc-d044c2c235e4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityAddressCityOrTown_79a23d23-a458-4cae-b0fc-d044c2c235e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ed730729-3b61-4141-9723-0c64d124daa4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityAddressStateOrProvince_ed730729-3b61-4141-9723-0c64d124daa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5f6940aa-147a-4420-8db1-9bbe7101b1a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityAddressPostalZipCode_5f6940aa-147a-4420-8db1-9bbe7101b1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_77c52b20-d9a1-48dc-84d8-fc82ca3edb50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_CityAreaCode_77c52b20-d9a1-48dc-84d8-fc82ca3edb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_857232b2-d38f-40e7-9da3-23926d4208cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_LocalPhoneNumber_857232b2-d38f-40e7-9da3-23926d4208cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b6cf101e-e662-4ceb-b293-81da5fc64253" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_Security12bTitle_b6cf101e-e662-4ceb-b293-81da5fc64253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_67624a32-9e21-44a2-bb49-d2312bd4d827" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_TradingSymbol_67624a32-9e21-44a2-bb49-d2312bd4d827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b1524873-daed-4723-829e-2b913295c1f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_SecurityExchangeName_b1524873-daed-4723-829e-2b913295c1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e8b4563d-45ee-4098-963e-1184ffc4c938" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityCurrentReportingStatus_e8b4563d-45ee-4098-963e-1184ffc4c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f27cdba9-da7a-48b2-8964-b4fc5902a240" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityInteractiveDataCurrent_f27cdba9-da7a-48b2-8964-b4fc5902a240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_596ac37c-dd43-4988-8dae-4bf195413ff0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityFilerCategory_596ac37c-dd43-4988-8dae-4bf195413ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_894c3b03-2c1e-47c5-97c1-218143605ee1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntitySmallBusiness_894c3b03-2c1e-47c5-97c1-218143605ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f9073021-8683-4d64-b974-6c473c587095" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityEmergingGrowthCompany_f9073021-8683-4d64-b974-6c473c587095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9b170ba0-89dc-4dc1-b360-50fe300aa985" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityExTransitionPeriod_9b170ba0-89dc-4dc1-b360-50fe300aa985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38d45485-1122-4d9a-b6d6-3dc7446581c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityShellCompany_38d45485-1122-4d9a-b6d6-3dc7446581c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_db97d3df-16a0-4842-ba7b-6cdf3ced4219" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_db97d3df-16a0-4842-ba7b-6cdf3ced4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d6604d36-5690-4438-922e-ffb0c570d7fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_AmendmentFlag_d6604d36-5690-4438-922e-ffb0c570d7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9b0d9042-9ca7-42a9-812b-6f986edee837" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentFiscalYearFocus_9b0d9042-9ca7-42a9-812b-6f986edee837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_24cbbd8a-cabd-4329-bb1c-c103e6dbe92c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_24cbbd8a-cabd-4329-bb1c-c103e6dbe92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a7a7b309-2b10-41a7-8352-13f1f02388a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_EntityCentralIndexKey_a7a7b309-2b10-41a7-8352-13f1f02388a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ea773d83-bb50-48da-868d-9ec1f328bda3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fd43bc27-60e5-40a4-95dd-a9fad079bfb7" xlink:to="loc_dei_CurrentFiscalYearEndDate_ea773d83-bb50-48da-868d-9ec1f328bda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e4da6f84-0d7c-4942-a662-9a8d80056dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4da6f84-0d7c-4942-a662-9a8d80056dcb" xlink:to="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b0e9314d-b552-4d6a-b0f6-9a7fe80ae7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b0e9314d-b552-4d6a-b0f6-9a7fe80ae7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_654e37a1-5ca7-4a5f-9f58-2a82bc7b9de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0e9314d-b552-4d6a-b0f6-9a7fe80ae7b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_654e37a1-5ca7-4a5f-9f58-2a82bc7b9de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0a73ef7-1560-42ea-a332-5be693b0f934" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0e9314d-b552-4d6a-b0f6-9a7fe80ae7b3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0a73ef7-1560-42ea-a332-5be693b0f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c05b0180-6473-4b77-94bc-461586192c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0e9314d-b552-4d6a-b0f6-9a7fe80ae7b3" xlink:to="loc_us-gaap_AssetsCurrent_c05b0180-6473-4b77-94bc-461586192c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_af04c808-3529-4229-865d-e90ac957cb94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_af04c808-3529-4229-865d-e90ac957cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c081422-224a-4173-bfa7-66bf6a798f08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c081422-224a-4173-bfa7-66bf6a798f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36789ddf-7c39-416c-9507-5c659f9cc317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_36789ddf-7c39-416c-9507-5c659f9cc317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67ab6eef-1ebf-4807-970f-9c01f317eff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0ec374c8-a5e9-46e5-850a-52a09c932815" xlink:to="loc_us-gaap_Assets_67ab6eef-1ebf-4807-970f-9c01f317eff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4da6f84-0d7c-4942-a662-9a8d80056dcb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8395eb89-ae04-4483-ac79-4ba3a2101270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:to="loc_us-gaap_AccountsPayableCurrent_8395eb89-ae04-4483-ac79-4ba3a2101270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_994b9608-e5c6-4998-a152-d08f59ec943a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_994b9608-e5c6-4998-a152-d08f59ec943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3612afe-69e4-4dc5-876d-7e533997ed51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3612afe-69e4-4dc5-876d-7e533997ed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_81a133dc-892f-4eee-aa78-532472451da2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_81a133dc-892f-4eee-aa78-532472451da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_410878d7-4005-4403-98a3-8f3a4ee5933d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a303ce7-427c-4188-9d4c-126c3155223e" xlink:to="loc_us-gaap_LiabilitiesCurrent_410878d7-4005-4403-98a3-8f3a4ee5933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e185fbb4-feec-42bd-9966-421cc1e63b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e185fbb4-feec-42bd-9966-421cc1e63b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_345a3379-9abe-4ad7-ba3c-a563994b0d41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_345a3379-9abe-4ad7-ba3c-a563994b0d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_b1b9926a-7444-4a0a-8868-34fffa6f73c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_b1b9926a-7444-4a0a-8868-34fffa6f73c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5ff2db13-7d3e-4107-944e-6e5d7e036951" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_10beb3c8-85ab-40a8-84b4-640498b1406b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5ff2db13-7d3e-4107-944e-6e5d7e036951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a6e3f1f-eaba-49bc-958b-4a7d8143c112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_Liabilities_7a6e3f1f-eaba-49bc-958b-4a7d8143c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_aab4089e-cd59-48c7-b438-b3bdcd9508cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_aab4089e-cd59-48c7-b438-b3bdcd9508cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_020d3184-81fa-480d-b384-434bd483a8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:to="loc_us-gaap_PreferredStockValue_020d3184-81fa-480d-b384-434bd483a8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_315336ca-be1a-470e-9afc-3b448888b972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:to="loc_us-gaap_CommonStockValue_315336ca-be1a-470e-9afc-3b448888b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3f176395-fb34-41e3-8fee-9d69cfd13711" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3f176395-fb34-41e3-8fee-9d69cfd13711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d60e14e8-140f-4fbf-a50e-b315c5de0f16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d60e14e8-140f-4fbf-a50e-b315c5de0f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac25ecc3-c68d-4b0f-b15b-35bd240e953b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1aa8623f-0eb4-416d-8f9a-17f16a8b52f1" xlink:to="loc_us-gaap_StockholdersEquity_ac25ecc3-c68d-4b0f-b15b-35bd240e953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ae67a6f-ef2d-4e76-8fbb-dd64ecfbf971" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c091ec6c-9b3c-47a9-b413-7d689746bfc5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ae67a6f-ef2d-4e76-8fbb-dd64ecfbf971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4a25b31b-ae23-4c8f-9624-24f20d67c786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4a25b31b-ae23-4c8f-9624-24f20d67c786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f4b0ead3-13ac-4384-a1fc-38c1b413d59f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f4b0ead3-13ac-4384-a1fc-38c1b413d59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f6f099e4-41ef-412e-8688-9247b54bdadb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f6f099e4-41ef-412e-8688-9247b54bdadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d150254d-a175-4dcb-a8ab-111e0d6e5b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d150254d-a175-4dcb-a8ab-111e0d6e5b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cfd0754-c930-432b-abd9-3c1b7ffc5d37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cfd0754-c930-432b-abd9-3c1b7ffc5d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b13d532f-5c9c-491e-bf4a-0fa7a4874b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b13d532f-5c9c-491e-bf4a-0fa7a4874b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7dfbdf1d-988b-4c7e-bbf6-e8c735ddd440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7dfbdf1d-988b-4c7e-bbf6-e8c735ddd440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b46a8bd1-5ebe-4d06-bf5a-57d7122c5839" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb3f4699-fbca-45d7-a2ab-d12224817cd2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b46a8bd1-5ebe-4d06-bf5a-57d7122c5839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_90b8a126-443a-479b-9ebc-6700c13ca5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_90b8a126-443a-479b-9ebc-6700c13ca5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c82e5e16-d862-45ff-b19d-ba6b9b4fd9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90b8a126-443a-479b-9ebc-6700c13ca5d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c82e5e16-d862-45ff-b19d-ba6b9b4fd9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_86d89049-f272-4a8b-8ab1-bb5b6042ce4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90b8a126-443a-479b-9ebc-6700c13ca5d8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_86d89049-f272-4a8b-8ab1-bb5b6042ce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d645231c-7f7c-482d-82b6-a8302b64e599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90b8a126-443a-479b-9ebc-6700c13ca5d8" xlink:to="loc_us-gaap_OperatingExpenses_d645231c-7f7c-482d-82b6-a8302b64e599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b3716ee4-335c-413f-81a1-a72421ee112b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_OperatingIncomeLoss_b3716ee4-335c-413f-81a1-a72421ee112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e72e0bb4-69e0-48cf-a529-1c42cc10e768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_e72e0bb4-69e0-48cf-a529-1c42cc10e768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_3d7a81c6-7e3c-4a55-a248-f96192e25eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e72e0bb4-69e0-48cf-a529-1c42cc10e768" xlink:to="loc_us-gaap_InvestmentIncomeNet_3d7a81c6-7e3c-4a55-a248-f96192e25eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_28090b5c-85f6-461d-8a2d-c5c2bcefa495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e72e0bb4-69e0-48cf-a529-1c42cc10e768" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_28090b5c-85f6-461d-8a2d-c5c2bcefa495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f8ec6016-097a-423d-82dc-417fc21b26f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e72e0bb4-69e0-48cf-a529-1c42cc10e768" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f8ec6016-097a-423d-82dc-417fc21b26f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3ff1e10f-6d09-45ea-ba42-abc451e3c535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3ff1e10f-6d09-45ea-ba42-abc451e3c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3406339-ff37-43ae-893c-80bcb2a2f681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3406339-ff37-43ae-893c-80bcb2a2f681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cafa36bf-3b0a-43ed-b2ed-318450f63465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_NetIncomeLoss_cafa36bf-3b0a-43ed-b2ed-318450f63465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9ab6f85-d43a-46af-8fc0-65f9e02be99c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9ab6f85-d43a-46af-8fc0-65f9e02be99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a4b7ed7e-998a-447b-9066-6327b0923291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a4b7ed7e-998a-447b-9066-6327b0923291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ccc8f0db-524a-46b5-8e68-275aaa48975e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_139d3bb1-6a50-432a-a20d-16ac1b797fd0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ccc8f0db-524a-46b5-8e68-275aaa48975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5a492f29-ddc7-4bc4-8f40-298a63871f32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ccc8f0db-524a-46b5-8e68-275aaa48975e" xlink:to="loc_us-gaap_NetIncomeLoss_5a492f29-ddc7-4bc4-8f40-298a63871f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f88bf7f1-740d-427d-8216-8e008f00079a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ccc8f0db-524a-46b5-8e68-275aaa48975e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f88bf7f1-740d-427d-8216-8e008f00079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fa13034c-4b94-43a3-9e09-dd75f33b738b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f88bf7f1-740d-427d-8216-8e008f00079a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fa13034c-4b94-43a3-9e09-dd75f33b738b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_610086c0-bc38-41d3-a8f9-e24abcbf19ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ccc8f0db-524a-46b5-8e68-275aaa48975e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_610086c0-bc38-41d3-a8f9-e24abcbf19ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4c7e943a-86c3-4fff-aa7a-686999b4b3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_c13aa276-08ea-40f8-abe6-b976f39e0fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4c7e943a-86c3-4fff-aa7a-686999b4b3bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_c13aa276-08ea-40f8-abe6-b976f39e0fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_36558a64-8171-4c6d-b227-50b6becc24b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_36558a64-8171-4c6d-b227-50b6becc24b7" xlink:to="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096faeec-9d03-4677-807a-55d2e55f9745" xlink:to="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_13d923f0-aa63-4112-8fe6-e6b0c4ac9e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_PreferredStockMember_13d923f0-aa63-4112-8fe6-e6b0c4ac9e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc080b80-036a-404c-b8ee-391209ff9b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_CommonStockMember_bc080b80-036a-404c-b8ee-391209ff9b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_263233dd-b67d-4525-9c18-94ba3ea58ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_263233dd-b67d-4525-9c18-94ba3ea58ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d0f2448-2270-4b22-8d49-9418a2af5c47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d0f2448-2270-4b22-8d49-9418a2af5c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6e1c9884-0aff-4ae1-951f-f9e3bd2493c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14f1e4a2-67b0-4cbc-a746-fa20b98fa2c6" xlink:to="loc_us-gaap_RetainedEarningsMember_6e1c9884-0aff-4ae1-951f-f9e3bd2493c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57f0b4d1-b9e4-4822-b387-555ae3ac6654" xlink:to="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8d351ff-7203-4b09-9a95-ed9bfddaf174" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5a531f38-62b9-41d1-9131-91abad799b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_SharesOutstanding_5a531f38-62b9-41d1-9131-91abad799b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98dbac0f-af73-4468-b8e9-f870967ba02d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockholdersEquity_98dbac0f-af73-4468-b8e9-f870967ba02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5159ab3-295b-48b8-835d-0d6501fa5bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5159ab3-295b-48b8-835d-0d6501fa5bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95aa0a32-669d-49b4-b908-0c70429155ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_95aa0a32-669d-49b4-b908-0c70429155ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_00f20500-4854-4081-b1db-eadd0d4c3393" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_00f20500-4854-4081-b1db-eadd0d4c3393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d72e7d4f-d658-462b-a78e-82b1d1ea8496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d72e7d4f-d658-462b-a78e-82b1d1ea8496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_597cc203-9182-4288-b6b7-9b78966d75ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_597cc203-9182-4288-b6b7-9b78966d75ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d541b8eb-7110-4420-afbf-c6c82c122b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d541b8eb-7110-4420-afbf-c6c82c122b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_945ef087-32db-41a1-84f8-f461c0044c80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_945ef087-32db-41a1-84f8-f461c0044c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d50a5751-39ef-4683-90c3-3da67ac56819" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d50a5751-39ef-4683-90c3-3da67ac56819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88b4d916-49cf-4033-8912-81fe7ecfd83d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88b4d916-49cf-4033-8912-81fe7ecfd83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_11b4b90a-2e36-4053-b7ba-9611febfe80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_11b4b90a-2e36-4053-b7ba-9611febfe80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_71c5bb46-c1e2-4207-a6ae-41ebf90df479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_71c5bb46-c1e2-4207-a6ae-41ebf90df479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3adff8e0-bf19-4481-a358-f0f548336818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_NetIncomeLoss_3adff8e0-bf19-4481-a358-f0f548336818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a857872-c9bc-4ceb-beb3-5098ce1cdabf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_SharesOutstanding_9a857872-c9bc-4ceb-beb3-5098ce1cdabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1613d4b-44ff-4cb9-a288-3d70475e7b99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c63ef9c-20ac-48fd-85c8-883fd4c566f2" xlink:to="loc_us-gaap_StockholdersEquity_d1613d4b-44ff-4cb9-a288-3d70475e7b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="evlo-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55fc41bf-3fad-4e26-a3c5-426785fd1556" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55fc41bf-3fad-4e26-a3c5-426785fd1556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ddeb8fa4-4fff-48c0-a6fc-abaa76098fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55fc41bf-3fad-4e26-a3c5-426785fd1556" xlink:to="loc_us-gaap_NetIncomeLoss_ddeb8fa4-4fff-48c0-a6fc-abaa76098fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55fc41bf-3fad-4e26-a3c5-426785fd1556" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8bc0bde2-8a57-45ba-b7d8-2e2f2b641fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_us-gaap_ShareBasedCompensation_8bc0bde2-8a57-45ba-b7d8-2e2f2b641fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_833660f0-67cb-4450-8acd-d51fcd450759" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_us-gaap_Depreciation_833660f0-67cb-4450-8acd-d51fcd450759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_41c42417-6732-43de-9a44-a63701bef38c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_41c42417-6732-43de-9a44-a63701bef38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense_29ab00ba-9ccb-4837-8a1f-12d63b51d2fc" xlink:href="evlo-20200930.xsd#evlo_NonCashInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_evlo_NonCashInterestExpense_29ab00ba-9ccb-4837-8a1f-12d63b51d2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense_cf7f18c9-9510-4963-8932-0ff20df1fdec" xlink:href="evlo-20200930.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_evlo_NonCashOperatingLeaseExpense_cf7f18c9-9510-4963-8932-0ff20df1fdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52598147-1b89-4081-be4d-93e5fb9bbf9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52598147-1b89-4081-be4d-93e5fb9bbf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f9a3accb-e938-40b9-b986-17701f7403b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af845974-6448-4aa7-a5ba-f6e6f4d92de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af845974-6448-4aa7-a5ba-f6e6f4d92de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4f9252c0-3fb6-40c6-89ad-b6eb705c6fda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4f9252c0-3fb6-40c6-89ad-b6eb705c6fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4b4e96fd-86c9-4081-8766-05805093c494" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4b4e96fd-86c9-4081-8766-05805093c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability_8950d08d-296d-4aa7-9690-98b83a0014dd" xlink:href="evlo-20200930.xsd#evlo_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:to="loc_evlo_IncreaseDecreaseInOperatingLeaseLiability_8950d08d-296d-4aa7-9690-98b83a0014dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c394ee34-c8f7-4e11-b1ee-9df0dc7538a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612d943-995c-40c6-bb22-215aead52d57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c394ee34-c8f7-4e11-b1ee-9df0dc7538a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a534ff45-8836-4f36-b2b9-aabaa5ce6812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55fc41bf-3fad-4e26-a3c5-426785fd1556" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a534ff45-8836-4f36-b2b9-aabaa5ce6812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_26509c29-1aa6-470f-b96c-190fcf5e1c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_26509c29-1aa6-470f-b96c-190fcf5e1c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d049434-6f37-4b8a-bf14-88bdd5977024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d049434-6f37-4b8a-bf14-88bdd5977024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9ef7901d-277c-412f-b7a6-b1eae079f601" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9ef7901d-277c-412f-b7a6-b1eae079f601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4302164e-b42f-4a8b-b966-d9debde9e1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c3aeea2-e4cb-4ae9-acca-30fe07482563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4302164e-b42f-4a8b-b966-d9debde9e1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ca2c0ede-5630-4f67-8f2c-8d918bfba935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ca2c0ede-5630-4f67-8f2c-8d918bfba935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0f5390ef-99cf-411c-894e-9dfb17ac217f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0f5390ef-99cf-411c-894e-9dfb17ac217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d973be8a-ca4d-4bf5-90ac-16151156bd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d973be8a-ca4d-4bf5-90ac-16151156bd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a3a2d7c3-f4b2-456c-86dd-b6c0b404ab91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a3a2d7c3-f4b2-456c-86dd-b6c0b404ab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_46051499-3855-4e27-9249-f355b3a05d12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aa6dec6-e4d5-4491-a25e-7ba7db4b0335" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_46051499-3855-4e27-9249-f355b3a05d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18debc72-4cd8-4a33-9e01-98a1579d2737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18debc72-4cd8-4a33-9e01-98a1579d2737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6edfe1e7-5ee6-475d-b8c0-156e3a68f37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6edfe1e7-5ee6-475d-b8c0-156e3a68f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc1d3f1c-f5ea-472a-9320-9106aa6f0d40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc1d3f1c-f5ea-472a-9320-9106aa6f0d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd561f14-4677-426c-8468-0380244e3ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd561f14-4677-426c-8468-0380244e3ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_dae76731-0ca9-43c1-9853-00b779e49e97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd561f14-4677-426c-8468-0380244e3ff6" xlink:to="loc_us-gaap_InterestPaidNet_dae76731-0ca9-43c1-9853-00b779e49e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9e81c2e7-fff5-486d-924a-afe644842f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd561f14-4677-426c-8468-0380244e3ff6" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9e81c2e7-fff5-486d-924a-afe644842f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_256d8f0a-e2be-48c8-a1cb-553d4eea6fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30da2fd2-c9f8-45fd-aed3-f38084aaa49e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_256d8f0a-e2be-48c8-a1cb-553d4eea6fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_e540f371-09c9-4ae8-8ee9-578881fc4671" xlink:href="evlo-20200930.xsd#evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_256d8f0a-e2be-48c8-a1cb-553d4eea6fcd" xlink:to="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_e540f371-09c9-4ae8-8ee9-578881fc4671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_549c93e3-8a30-44ce-924d-dece37e2fa4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_256d8f0a-e2be-48c8-a1cb-553d4eea6fcd" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_549c93e3-8a30-44ce-924d-dece37e2fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Organization" xlink:type="simple" xlink:href="evlo-20200930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_094dbfb2-9bac-44a5-867a-5222337f8121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73855601-bf9d-4df5-8381-c15f7bb18df8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_094dbfb2-9bac-44a5-867a-5222337f8121" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73855601-bf9d-4df5-8381-c15f7bb18df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5e2fb63-7d4a-41d0-8d6f-9abdc1037a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e5e2fb63-7d4a-41d0-8d6f-9abdc1037a3a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd2980ae-d25e-4b02-9d5e-0925e0e3d8a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_JuneOfferingMember_b4e4ae31-7836-4008-80a1-9a9957e67f4a" xlink:href="evlo-20200930.xsd#evlo_JuneOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:to="loc_evlo_JuneOfferingMember_b4e4ae31-7836-4008-80a1-9a9957e67f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_050ae67f-50a3-4de8-a10b-46d19e918fde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_36a48cff-7c1a-4b1e-9353-c970f580fe77" xlink:to="loc_us-gaap_OverAllotmentOptionMember_050ae67f-50a3-4de8-a10b-46d19e918fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_2dcde5a3-2512-4a12-ab71-f483adcc5d0c" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_bd60a553-e673-449b-a7d6-4f1abdd635c3" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d7be1a91-2f71-4075-8b8a-6580d41370a7" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_bd60a553-e673-449b-a7d6-4f1abdd635c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8ae8e221-9438-4010-bb47-2264f9e598f1" xlink:to="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dac7fde5-b22e-434c-8148-26e3e54417c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3b600b8e-f565-4447-af7b-666bf28f2dea" xlink:to="loc_us-gaap_LineOfCreditMember_dac7fde5-b22e-434c-8148-26e3e54417c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_976e5f22-26ab-46e4-b8ec-8f6c62965956" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_2c606edc-c405-4feb-a06e-ec602eb48276" xlink:href="evlo-20200930.xsd#evlo_A2019CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_89c33276-cb10-4c1d-9c94-350d98c0d695" xlink:to="loc_evlo_A2019CreditFacilityMember_2c606edc-c405-4feb-a06e-ec602eb48276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce2ca1f3-38f3-42c2-a560-e42f13fb3734" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a27ab7e-0ac6-421a-afe5-7011847efbae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a27ab7e-0ac6-421a-afe5-7011847efbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9787f519-07f7-4438-b5b1-3d73618ba417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9787f519-07f7-4438-b5b1-3d73618ba417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a52b4ba1-1c2c-40b8-be3e-a219bb1010c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a52b4ba1-1c2c-40b8-be3e-a219bb1010c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19470506-f2c9-4d8e-a58a-8053a943ce73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_19470506-f2c9-4d8e-a58a-8053a943ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8d4014b4-3598-499d-af5f-a12b91e1d7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8d4014b4-3598-499d-af5f-a12b91e1d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_46b8dfc5-8e90-4f15-ad6a-9f1490d43573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_46b8dfc5-8e90-4f15-ad6a-9f1490d43573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4feaf6f9-0476-4981-abcf-2ca3b0adc030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7280b71d-c361-469b-841f-868afaa20f76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4feaf6f9-0476-4981-abcf-2ca3b0adc030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c78cadd7-c898-4728-8219-ea12f261bd30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_62b2baf4-4ddb-4e26-99db-5a95f5185f65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c78cadd7-c898-4728-8219-ea12f261bd30" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_62b2baf4-4ddb-4e26-99db-5a95f5185f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock_8bae51c5-d352-4ab2-864e-00caf36e731c" xlink:href="evlo-20200930.xsd#evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock_8bae51c5-d352-4ab2-864e-00caf36e731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_549c644b-16c4-4e43-b588-cb087bcc1a32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_549c644b-16c4-4e43-b588-cb087bcc1a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4dd1368a-a4c0-4f91-8a82-78a68c059caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_UseOfEstimates_4dd1368a-a4c0-4f91-8a82-78a68c059caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_5aa5c428-0a23-45a9-a098-f952ab422573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_5aa5c428-0a23-45a9-a098-f952ab422573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_6ad94abd-a89d-434c-bf6c-d52832eb98fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_6ad94abd-a89d-434c-bf6c-d52832eb98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_478f7c68-39c1-4f4c-8207-77b2b86d8eeb" xlink:href="evlo-20200930.xsd#evlo_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_478f7c68-39c1-4f4c-8207-77b2b86d8eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4573d307-bdc8-4f3d-b36d-f32b57f88531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4573d307-bdc8-4f3d-b36d-f32b57f88531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6b3f3266-4afd-49da-9a9c-7679a123be3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6b3f3266-4afd-49da-9a9c-7679a123be3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38fe5b12-4e46-4783-b4b6-3a49ba779cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_38fe5b12-4e46-4783-b4b6-3a49ba779cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_33238e70-f421-4b87-be71-e24a43d09fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_33238e70-f421-4b87-be71-e24a43d09fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_de73d067-9cc7-45ac-bdd4-37b197d053d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_de73d067-9cc7-45ac-bdd4-37b197d053d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a6ee39f6-65c0-455b-81ce-1d8012b16f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a6ee39f6-65c0-455b-81ce-1d8012b16f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d120f567-9c07-468c-80e4-c6b7ea8a30c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d120f567-9c07-468c-80e4-c6b7ea8a30c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_00e18e64-cba2-48ad-9dd7-da81a20f3bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_654f3bbb-5a6a-4f13-b7d5-ae7d84109898" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_00e18e64-cba2-48ad-9dd7-da81a20f3bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25c84e04-532e-4d22-8d6a-da03b94a8ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_157229bb-19a3-4508-8af9-1a889bff2be3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c84e04-532e-4d22-8d6a-da03b94a8ca8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_157229bb-19a3-4508-8af9-1a889bff2be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f14c7309-b6f9-4791-98f9-5f79e8ccc018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25c84e04-532e-4d22-8d6a-da03b94a8ca8" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f14c7309-b6f9-4791-98f9-5f79e8ccc018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c5b964c-3a34-4139-ab5f-e0eb3c4e7e61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1add72db-dcbf-4571-90c1-acd74af3d5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c5b964c-3a34-4139-ab5f-e0eb3c4e7e61" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1add72db-dcbf-4571-90c1-acd74af3d5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b44a40ab-597a-4290-8865-ccadfd847cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c5b964c-3a34-4139-ab5f-e0eb3c4e7e61" xlink:to="loc_us-gaap_RestrictedCash_b44a40ab-597a-4290-8865-ccadfd847cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e146689c-fecc-4f39-a729-a6332f3599ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c5b964c-3a34-4139-ab5f-e0eb3c4e7e61" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e146689c-fecc-4f39-a729-a6332f3599ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c5b964c-3a34-4139-ab5f-e0eb3c4e7e61" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8028c2a6-c0e5-4d9e-b495-1f189c8cb437" xlink:to="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_32eb1a47-5215-4118-9914-0df46e1edd91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_293fe08c-97d6-4e5a-8b97-fa6b3028f35f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_32eb1a47-5215-4118-9914-0df46e1edd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a0113f51-b9d6-4762-be6d-c50a6eab4bfa" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5a7f547-2740-41aa-88dd-aed0b568563f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5a7f547-2740-41aa-88dd-aed0b568563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7bc2a35a-2ce2-4af9-a594-3f994f2a9bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bf544f56-1ea2-4da0-9a3b-0f3b94401487" xlink:to="loc_us-gaap_OperatingLeaseLiability_7bc2a35a-2ce2-4af9-a594-3f994f2a9bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9f00182f-6370-4b18-8345-261616fd3fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fa52711f-d4bd-43df-8fff-65e641c4c2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f00182f-6370-4b18-8345-261616fd3fbd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fa52711f-d4bd-43df-8fff-65e641c4c2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ceda119c-70cc-400c-b796-b0e920bd04c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fa52711f-d4bd-43df-8fff-65e641c4c2a6" xlink:to="loc_us-gaap_Cash_ceda119c-70cc-400c-b796-b0e920bd04c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ca08518b-1616-472c-a731-93d62572643c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fa52711f-d4bd-43df-8fff-65e641c4c2a6" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ca08518b-1616-472c-a731-93d62572643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_245a80f7-244e-458c-9207-77ef1306ff77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fa52711f-d4bd-43df-8fff-65e641c4c2a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_245a80f7-244e-458c-9207-77ef1306ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b0e5ba8e-d6ca-4527-8dc4-e0abad70f60e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f00182f-6370-4b18-8345-261616fd3fbd" xlink:to="loc_us-gaap_RestrictedCash_b0e5ba8e-d6ca-4527-8dc4-e0abad70f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580213e9-da2a-4de5-9868-2c4637f25668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f00182f-6370-4b18-8345-261616fd3fbd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580213e9-da2a-4de5-9868-2c4637f25668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Leases" xlink:type="simple" xlink:href="evlo-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_af3ee805-0bfc-4dd7-bc40-540014be9027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2c6ade01-5711-4c2c-9564-b46145f9bbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3ee805-0bfc-4dd7-bc40-540014be9027" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2c6ade01-5711-4c2c-9564-b46145f9bbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36912344-0886-4c57-9887-5972424bc642" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8ee60a6f-629c-4ab3-8843-2edd40c41f68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36912344-0886-4c57-9887-5972424bc642" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8ee60a6f-629c-4ab3-8843-2edd40c41f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_219d9b87-9d73-4c21-8904-347d72cfe9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_AreaOfLand_219d9b87-9d73-4c21-8904-347d72cfe9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_170b94ba-4b29-44be-98f0-709d02268541" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_170b94ba-4b29-44be-98f0-709d02268541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9b0ea88f-8413-4860-8d21-a40b9561c694" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_OperatingLeaseExpense_9b0ea88f-8413-4860-8d21-a40b9561c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_31319589-1d4e-4c6d-b24a-df3b539cfdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_SubleaseIncome_31319589-1d4e-4c6d-b24a-df3b539cfdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_ad0a8a62-1f77-4cd1-83f3-b27a8991eb77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_LeaseAndRentalExpense_ad0a8a62-1f77-4cd1-83f3-b27a8991eb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_ef44ce85-7fb0-4ae0-abb3-01889937aa09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36cf8796-b2f2-4ce2-9fcc-367febf9437a" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_ef44ce85-7fb0-4ae0-abb3-01889937aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_575e7a0b-f940-4900-a437-dee62024d629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_575e7a0b-f940-4900-a437-dee62024d629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4afaf074-a1d6-424a-bdd4-7ba96172786e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4afaf074-a1d6-424a-bdd4-7ba96172786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50b9fadc-5d12-4b66-8be1-b6f5b16b8dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50b9fadc-5d12-4b66-8be1-b6f5b16b8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4cc9258e-6fe2-4365-a357-0a2fb8aaa170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4cc9258e-6fe2-4365-a357-0a2fb8aaa170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_45677884-7954-4eba-8a6e-c5c5ba651d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_45677884-7954-4eba-8a6e-c5c5ba651d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_39f1d2c4-7dd9-4b4e-9d88-535958e6e4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_39f1d2c4-7dd9-4b4e-9d88-535958e6e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f29db868-c3e0-4382-9d94-634264d00716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f29db868-c3e0-4382-9d94-634264d00716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a4473f1-76f8-424a-9118-f5e264e3139b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a4473f1-76f8-424a-9118-f5e264e3139b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1549637a-188a-4c0b-b979-b9bfa4dadad1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_OperatingLeaseLiability_1549637a-188a-4c0b-b979-b9bfa4dadad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_05e3df78-d756-4f94-8f87-4a3c7399dcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7debeb-6def-4c10-8944-aad711439674" xlink:to="loc_us-gaap_LeaseCostAbstract_05e3df78-d756-4f94-8f87-4a3c7399dcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3a07664d-04e0-4d7f-b059-8a79dd754f85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_05e3df78-d756-4f94-8f87-4a3c7399dcb1" xlink:to="loc_us-gaap_OperatingLeasePayments_3a07664d-04e0-4d7f-b059-8a79dd754f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_96ec4672-e2ce-4503-a7cc-4ee726383e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_05e3df78-d756-4f94-8f87-4a3c7399dcb1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_96ec4672-e2ce-4503-a7cc-4ee726383e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_03915b4e-35f8-494b-aca8-e201793012a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_05e3df78-d756-4f94-8f87-4a3c7399dcb1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_03915b4e-35f8-494b-aca8-e201793012a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="evlo-20200930.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f84870e-eeeb-4308-95c6-e7efdcc1be5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7a85e4eb-8a2e-41b7-9b43-961caec1ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f84870e-eeeb-4308-95c6-e7efdcc1be5b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7a85e4eb-8a2e-41b7-9b43-961caec1ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ebf28efc-f107-48e2-8b5b-1c5ee322b2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_dbf6ca13-e625-45b5-87a8-0646802e9dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ebf28efc-f107-48e2-8b5b-1c5ee322b2cb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_dbf6ca13-e625-45b5-87a8-0646802e9dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9d44f7b2-36d0-49a8-a892-155cf548b328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9d44f7b2-36d0-49a8-a892-155cf548b328" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d6ff014e-3bbd-41d4-acaf-90dd45dfa575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48499d06-365d-4731-9492-a7562e0cb8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48499d06-365d-4731-9492-a7562e0cb8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50b97bd1-e9b8-41a9-ace6-f2b48dc5b9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50b97bd1-e9b8-41a9-ace6-f2b48dc5b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5355b787-be9d-428a-948d-7bd6ac9d7eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19ac8b36-1cfe-459f-aee5-8ea846168f3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5355b787-be9d-428a-948d-7bd6ac9d7eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64331a80-6ffc-4e5d-8989-50704fca8df8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b8c0686d-f4d7-4c7b-8c2f-2e891bdf64b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0e7189ad-8ec2-48bd-82e7-1f48120d3180" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b8c0686d-f4d7-4c7b-8c2f-2e891bdf64b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7e50fe-ed54-4bef-be16-7ba6c3e19902" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f477e41-e021-47ef-a132-16c6cd850eef" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d89db1ea-6bfb-475d-98db-f6226f273f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d89db1ea-6bfb-475d-98db-f6226f273f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c8e5b9eb-1793-4821-987e-766939a0b14a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5f663b43-bec3-4611-9222-bd26ed841f5a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c8e5b9eb-1793-4821-987e-766939a0b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b016b480-4b9a-4c10-aea2-109f9af1b38d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_37417d9e-68c2-49bb-8e88-1e8548cab844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b016b480-4b9a-4c10-aea2-109f9af1b38d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_37417d9e-68c2-49bb-8e88-1e8548cab844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0547203b-20da-4f00-9e1b-d849e62eed30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a6a33a9-cb2b-48fb-95f1-eb6c3054db77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0547203b-20da-4f00-9e1b-d849e62eed30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a6a33a9-cb2b-48fb-95f1-eb6c3054db77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aeb07c0e-466d-4f8b-b378-bead6cfa8d40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aeb07c0e-466d-4f8b-b378-bead6cfa8d40" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6fde1d30-625e-40f7-8ca2-9fe17f22e5a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c9265a4a-0961-4cac-a059-bc9015ca0305" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_EquipmentMember_c9265a4a-0961-4cac-a059-bc9015ca0305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e5c90b58-3454-4b37-9f77-5177d0f5d2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e5c90b58-3454-4b37-9f77-5177d0f5d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_91a65d90-20f0-43f7-9238-f6fcaf6cdcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_91a65d90-20f0-43f7-9238-f6fcaf6cdcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember_70c0bddc-92b3-4c9e-aaec-b0c067c11a39" xlink:href="evlo-20200930.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_evlo_ComputersAndSoftwareMember_70c0bddc-92b3-4c9e-aaec-b0c067c11a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3b451cab-2ac6-4f9a-8cfe-3819d2ba1794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_OfficeEquipmentMember_3b451cab-2ac6-4f9a-8cfe-3819d2ba1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fed3c4da-d372-4a1c-aa0b-39849f9529de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bea4caab-0d10-4933-a99a-fc0c9854af4c" xlink:to="loc_us-gaap_ConstructionInProgressMember_fed3c4da-d372-4a1c-aa0b-39849f9529de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_344f63be-69dc-4f69-a9e2-9ccefdbdf6f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb31507f-f908-4efd-9fa1-1edf075bd6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6a1ddc42-4f69-482b-87ba-16bbe4d38a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6a1ddc42-4f69-482b-87ba-16bbe4d38a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_078ba8d5-775f-4ef8-b9e8-951724801339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_078ba8d5-775f-4ef8-b9e8-951724801339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de50988e-1856-49c3-af36-33d202edb2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_4940f144-c03a-4b6e-b8f4-0f961e65df11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de50988e-1856-49c3-af36-33d202edb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97d5b5b4-096b-4be4-ba8d-423f2dde6280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_685e15b1-0234-43d1-a261-e3214e5a7f59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97d5b5b4-096b-4be4-ba8d-423f2dde6280" xlink:to="loc_us-gaap_Depreciation_685e15b1-0234-43d1-a261-e3214e5a7f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f65586b-c19f-4a53-98d3-24020ab033c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fddf03d6-529d-445b-bf99-41d296e73a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f65586b-c19f-4a53-98d3-24020ab033c6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fddf03d6-529d-445b-bf99-41d296e73a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05649b4c-2d31-476f-8c77-18b2cdb42e13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c6fe8670-abbc-44d2-8fc4-04e446cf1bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05649b4c-2d31-476f-8c77-18b2cdb42e13" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c6fe8670-abbc-44d2-8fc4-04e446cf1bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_235dc4c3-346c-4d5b-9732-2e31c2bf9af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_235dc4c3-346c-4d5b-9732-2e31c2bf9af4" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e041614e-d43c-4f3f-914a-619806e42457" xlink:to="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e1ec7b0d-a86c-4bb6-89c0-24637483dc08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2ec4d98f-5d74-4a27-9f5c-40174985d231" xlink:to="loc_us-gaap_LineOfCreditMember_e1ec7b0d-a86c-4bb6-89c0-24637483dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e3cd3025-06d9-4a5d-bb65-03e3171a3afd" xlink:to="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_74d96e17-ebee-4445-a8cd-193ba91e7340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_71de12fd-8dd4-4e59-876c-337028184963" xlink:to="loc_us-gaap_PrimeRateMember_74d96e17-ebee-4445-a8cd-193ba91e7340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesAxis_91c15bd7-006a-4c73-97e6-6925f2c5bcb4" xlink:to="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_648f0092-72c1-4b6d-80fc-c908477b02d6" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_648f0092-72c1-4b6d-80fc-c908477b02d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_7b2c3999-35fb-446a-abdb-a9cd2cb470e6" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_7b2c3999-35fb-446a-abdb-a9cd2cb470e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_c3202678-549c-4cb2-a19e-dce02c5a7d00" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_SecurityAndLoanAgreementTranchesDomain_d2fa9a46-c25a-4565-8d75-515b6df7d400" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_c3202678-549c-4cb2-a19e-dce02c5a7d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_69c2ab03-4ddb-47af-b3c0-cb44d744c1d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2016CreditFacilityMember_7e6b620f-7fdb-480f-8292-606542081de4" xlink:href="evlo-20200930.xsd#evlo_A2016CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:to="loc_evlo_A2016CreditFacilityMember_7e6b620f-7fdb-480f-8292-606542081de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_1e1cfe77-7297-4b29-a6f6-0fc065480964" xlink:href="evlo-20200930.xsd#evlo_A2019CreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e58a1776-5a1f-463a-ab9e-9c71d33f2e10" xlink:to="loc_evlo_A2019CreditFacilityMember_1e1cfe77-7297-4b29-a6f6-0fc065480964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2b06d525-c4b0-4f63-aee1-5aafdc4169f7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_015284bb-fb1c-46a2-81c0-394843718a68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7bd9d2e2-48bf-47ac-81b5-95fb55079ae8" xlink:to="loc_srt_ScenarioForecastMember_015284bb-fb1c-46a2-81c0-394843718a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a003214f-65d4-404e-877a-abebdd144d17" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3c36bb3a-ecc3-4ea9-a8d5-01b5cfd4c554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3c36bb3a-ecc3-4ea9-a8d5-01b5cfd4c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_19004df3-acfc-4d6c-8c53-ac80c8a9c6aa" xlink:href="evlo-20200930.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_19004df3-acfc-4d6c-8c53-ac80c8a9c6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_333b1d98-2c47-473a-82ba-65e98e3fb7f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_333b1d98-2c47-473a-82ba-65e98e3fb7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16fd7ec0-cabb-438c-85b9-ded4d4fae53e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16fd7ec0-cabb-438c-85b9-ded4d4fae53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_300c2bd3-399f-4f3e-8084-fb6556b67d69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_300c2bd3-399f-4f3e-8084-fb6556b67d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_c2a54b5f-7922-436c-860a-6404fc27522d" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_c2a54b5f-7922-436c-860a-6404fc27522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_fac5224d-211c-4ddc-8bb7-aa86d5df7708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_fac5224d-211c-4ddc-8bb7-aa86d5df7708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_94c432ab-e981-40e5-bb22-25be26aa1c1c" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_94c432ab-e981-40e5-bb22-25be26aa1c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_3b2bbbc5-ce45-4440-a444-1f84a81b1fe9" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_3b2bbbc5-ce45-4440-a444-1f84a81b1fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_10203e03-a55d-4051-a475-483f74755efa" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_10203e03-a55d-4051-a475-483f74755efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage_2da8736c-679f-43b2-a765-b3c33cab2c52" xlink:href="evlo-20200930.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_evlo_DebtInstrumentDebtDefaultPercentage_2da8736c-679f-43b2-a765-b3c33cab2c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9f8993c3-c5d7-4fb0-9ff3-f92c85f02ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_579282f0-9edc-4b8c-b8e8-d5aed41b0396" xlink:to="loc_us-gaap_InterestExpenseDebt_9f8993c3-c5d7-4fb0-9ff3-f92c85f02ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a695971c-7584-4924-a6e1-5535acdf6e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a695971c-7584-4924-a6e1-5535acdf6e27" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:to="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e6787241-b022-4630-b5ad-fa1ad850b212" xlink:to="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_98e9d686-f68a-49db-ba7d-5b0c9f0ceab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4aec3538-52f8-4883-8853-e4d0c2e21a74" xlink:to="loc_us-gaap_LineOfCreditMember_98e9d686-f68a-49db-ba7d-5b0c9f0ceab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_219d0e05-abce-4a5c-83e4-bd73383bc3ee" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_0a020433-3d51-4cf6-aa8e-c07e6a533c98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_0a020433-3d51-4cf6-aa8e-c07e6a533c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_e61258a5-2cbf-42e1-93f0-8ccc3e28f8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_e61258a5-2cbf-42e1-93f0-8ccc3e28f8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_c406f3c7-5476-403e-8aa0-0af0391e2d87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_c406f3c7-5476-403e-8aa0-0af0391e2d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_4eae2de5-ea22-47be-a0d5-ccdc04807266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_4eae2de5-ea22-47be-a0d5-ccdc04807266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_3a4d6533-4e4d-48ae-b1e0-eefcec1b7215" xlink:href="evlo-20200930.xsd#evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour_3a4d6533-4e4d-48ae-b1e0-eefcec1b7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_39ac0d30-f824-4099-85c9-0018f954ded6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_39ac0d30-f824-4099-85c9-0018f954ded6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_044b0b6c-47a0-4bf8-a309-336dc5a1199c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_044b0b6c-47a0-4bf8-a309-336dc5a1199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_41149b39-b790-4f68-a7df-74d711c010db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_98db1945-da8a-434d-852a-57f3e2d077cd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_41149b39-b790-4f68-a7df-74d711c010db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreements" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/InLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_deca2639-19d4-483b-b3af-82c4c965dfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_73822c8b-a55b-4321-9785-b8602aa357ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_deca2639-19d4-483b-b3af-82c4c965dfe2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_73822c8b-a55b-4321-9785-b8602aa357ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#InLicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_e129411a-079f-49d6-bf98-2ca44d47e343" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e129411a-079f-49d6-bf98-2ca44d47e343" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:to="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a6f72091-d4ae-477d-9c2c-867db174e2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember_397859f6-e085-4605-adb3-fe037211511f" xlink:href="evlo-20200930.xsd#evlo_MayoClinicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:to="loc_evlo_MayoClinicMember_397859f6-e085-4605-adb3-fe037211511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember_0d3bb798-363c-4c50-b11a-acb8faece4af" xlink:href="evlo-20200930.xsd#evlo_UniversityOfChicagoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0dee611-6df1-4fcb-9df9-d0565bb298f3" xlink:to="loc_evlo_UniversityOfChicagoMember_0d3bb798-363c-4c50-b11a-acb8faece4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:to="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a0e1fc6-d267-4401-8d88-152712fd1b9a" xlink:to="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_02673c1d-e0a9-4349-9014-712a1652d465" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78f53f95-8f7a-4cdf-b0fe-a45c809ec29f" xlink:to="loc_srt_MaximumMember_02673c1d-e0a9-4349-9014-712a1652d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_103e47f9-59e8-44b2-9dcd-0cd74756e940" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee_c163bd71-b5f0-49e7-9a7a-f661cd63784c" xlink:href="evlo-20200930.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_NonRefundableUpfrontFee_c163bd71-b5f0-49e7-9a7a-f661cd63784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_d6902d9f-7be7-44c0-8e36-8e8e56a6cf0c" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_d6902d9f-7be7-44c0-8e36-8e8e56a6cf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8593ba25-8bac-4381-8f26-aeb6380d57e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_us-gaap_ContractualObligation_8593ba25-8bac-4381-8f26-aeb6380d57e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_17b1ea2d-5c9e-45a0-911d-ebecd039031d" xlink:href="evlo-20200930.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f6292484-4cc0-4786-bc2f-b0c7e1b6ec42" xlink:to="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_17b1ea2d-5c9e-45a0-911d-ebecd039031d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3c07013f-6350-46b2-a069-6c376618f82f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c9d54c7a-c4c5-4cb3-b6cc-86aedc7e7367" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3c07013f-6350-46b2-a069-6c376618f82f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c9d54c7a-c4c5-4cb3-b6cc-86aedc7e7367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8eb29945-fd13-4f14-81cb-a65c027d4677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8eb29945-fd13-4f14-81cb-a65c027d4677" xlink:to="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:to="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_362c7cb2-d454-4d6f-b986-feffdd025e7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member_6eeff049-da10-465a-9157-c2990b12728e" xlink:href="evlo-20200930.xsd#evlo_SaccoS.r.l.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:to="loc_evlo_SaccoS.r.l.Member_6eeff049-da10-465a-9157-c2990b12728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_BioseIndustrieMember_b49966f1-97b5-4708-aa2a-ea091d12b1a7" xlink:href="evlo-20200930.xsd#evlo_BioseIndustrieMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad210d83-5373-41ad-b798-7e660afd5c98" xlink:to="loc_evlo_BioseIndustrieMember_b49966f1-97b5-4708-aa2a-ea091d12b1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6573c0cc-7888-4367-a584-52f4274405c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_257f8d78-2ae3-443b-a0bd-19103a480cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:to="loc_us-gaap_CollaborativeArrangementMember_257f8d78-2ae3-443b-a0bd-19103a480cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ExclusivityAndCommitmentAgreementMember_7d90fe9f-ce8d-47c6-be56-06932cbde017" xlink:href="evlo-20200930.xsd#evlo_ExclusivityAndCommitmentAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c56e088-e95c-4c5a-8581-8880990438ef" xlink:to="loc_evlo_ExclusivityAndCommitmentAgreementMember_7d90fe9f-ce8d-47c6-be56-06932cbde017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:href="evlo-20200930.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_7ac4bc85-f4d9-4de0-b61d-73609e386506" xlink:to="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm_f216fbef-d9ca-4f86-a0e3-ae489b720b28" xlink:href="evlo-20200930.xsd#evlo_CollaborationArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_CollaborationArrangementTerm_f216fbef-d9ca-4f86-a0e3-ae489b720b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_ee70ddd3-cb46-4faf-8634-8c2fe4c89c6f" xlink:href="evlo-20200930.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_ee70ddd3-cb46-4faf-8634-8c2fe4c89c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_b64ed350-052e-49ca-87e2-39834a562615" xlink:href="evlo-20200930.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_b64ed350-052e-49ca-87e2-39834a562615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_1ae878e1-060a-44bd-873f-952c0dfb2f4e" xlink:href="evlo-20200930.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_1ae878e1-060a-44bd-873f-952c0dfb2f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement_58a728a4-18a4-4845-b774-236a1dec4d8e" xlink:href="evlo-20200930.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_ba56c810-bfe0-42dd-ab09-9203fd5ffced" xlink:to="loc_evlo_FeeIncurredUnderCollaborativeArrangement_58a728a4-18a4-4845-b774-236a1dec4d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_948da202-3bcb-4000-96e5-df953acfe91e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4349b80-fa47-428a-8b0c-b37fdf386569" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_948da202-3bcb-4000-96e5-df953acfe91e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4349b80-fa47-428a-8b0c-b37fdf386569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2b201f48-ac4d-4c58-b249-455159adcd86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2b201f48-ac4d-4c58-b249-455159adcd86" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85ade207-dcd3-4a79-bb0c-f09058fa250c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_6aed6a25-9763-48b5-8fc8-93ad633ea707" xlink:href="evlo-20200930.xsd#evlo_RegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_RegistrationStatementMember_6aed6a25-9763-48b5-8fc8-93ad633ea707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SalesAgreementCowenAndCompanyLLCMember_6a66ecd3-b06b-4826-a584-1b96e4b0007b" xlink:href="evlo-20200930.xsd#evlo_SalesAgreementCowenAndCompanyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_SalesAgreementCowenAndCompanyLLCMember_6a66ecd3-b06b-4826-a584-1b96e4b0007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_JuneOfferingMember_83d44737-4c43-4244-af8f-524c8c42a323" xlink:href="evlo-20200930.xsd#evlo_JuneOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdf67646-dd81-4aa5-9e9a-3d79cfd5256b" xlink:to="loc_evlo_JuneOfferingMember_83d44737-4c43-4244-af8f-524c8c42a323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dc4da6d3-08fe-410f-863a-673ae7f11b27" xlink:to="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_59c86c2d-c630-4ccb-a556-29fda401594e" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_59c86c2d-c630-4ccb-a556-29fda401594e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_3b12c691-a8dd-4aea-9e88-464d7f586b9c" xlink:href="evlo-20200930.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_3b12c691-a8dd-4aea-9e88-464d7f586b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_acb180ed-276d-49f4-994c-a9ce2cca26de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_acb180ed-276d-49f4-994c-a9ce2cca26de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_40130f2f-851e-4301-ac1a-483e6608d913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_40130f2f-851e-4301-ac1a-483e6608d913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51872114-b65e-44a6-a490-af4b0f37c516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51872114-b65e-44a6-a490-af4b0f37c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec0bd04f-9354-4416-8e5f-3bf0c4dfd448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27f6582e-aa7c-4911-b044-b61b4e51d0fd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec0bd04f-9354-4416-8e5f-3bf0c4dfd448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df7b7dd2-7044-4331-8f38-d8bc6701d72f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4ff8422-8018-4a2c-876a-895264ffb596" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df7b7dd2-7044-4331-8f38-d8bc6701d72f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4ff8422-8018-4a2c-876a-895264ffb596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f714c81-c795-4987-8e54-46dcdac05ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ede30acd-cb65-447a-ad51-e9724b78018c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f714c81-c795-4987-8e54-46dcdac05ab4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ede30acd-cb65-447a-ad51-e9724b78018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4d1b40b5-aeed-47ff-9ae9-da9cba3b0210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f714c81-c795-4987-8e54-46dcdac05ab4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4d1b40b5-aeed-47ff-9ae9-da9cba3b0210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8a3c346-89a4-41e3-94f1-eb45c309af98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8a3c346-89a4-41e3-94f1-eb45c309af98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_dc0bae1c-09f2-43fa-9724-2ddddcfe8ab0" xlink:to="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_418f4eae-b668-400d-9312-52e3229ee824" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:to="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_418f4eae-b668-400d-9312-52e3229ee824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_91cd1f25-bc65-4e77-b493-69495179d503" xlink:href="evlo-20200930.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8b195b8f-d6c5-4fb3-aa11-3dab5878b682" xlink:to="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_91cd1f25-bc65-4e77-b493-69495179d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d8dfe1f-e090-4ee5-b460-c8b3fc5d4739" xlink:to="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8fa1843-0479-4d4a-90f3-8be57abf39fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:to="loc_srt_MinimumMember_d8fa1843-0479-4d4a-90f3-8be57abf39fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8b0abad-e6f2-4ef6-9681-f540dc725727" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_51894cc8-4bc4-4c63-87c1-6cf114028d1c" xlink:to="loc_srt_MaximumMember_a8b0abad-e6f2-4ef6-9681-f540dc725727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_309c70b7-e468-4336-82a5-ab50655acf56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21969412-8030-4a7d-b02d-1b5eaa9f3e23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21969412-8030-4a7d-b02d-1b5eaa9f3e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonEmployeeOptionsMember_5c78233a-67bd-4fbc-816f-a39b529e342e" xlink:href="evlo-20200930.xsd#evlo_NonEmployeeOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_evlo_NonEmployeeOptionsMember_5c78233a-67bd-4fbc-816f-a39b529e342e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_14cf6206-738d-4261-af1c-10e05b47efed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_339cee8c-dd41-4c65-80e1-a7186e4cf9ee" xlink:to="loc_us-gaap_EmployeeStockMember_14cf6206-738d-4261-af1c-10e05b47efed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_26a671d0-df36-4ade-9f81-5119042c37b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43796b57-4300-4ae3-a8c6-de18a9906b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_43796b57-4300-4ae3-a8c6-de18a9906b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_8776cd04-d23a-45e7-aa3d-266953db6214" xlink:href="evlo-20200930.xsd#evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants_8776cd04-d23a-45e7-aa3d-266953db6214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91af385c-0f6b-4f20-834d-a5845a3603a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_91af385c-0f6b-4f20-834d-a5845a3603a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a44e42c-f314-435f-9bd2-fbc04fbc3d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a44e42c-f314-435f-9bd2-fbc04fbc3d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f8f94110-69fa-4681-aa5e-fc28dfda23d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f8f94110-69fa-4681-aa5e-fc28dfda23d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_afe1a2d2-4258-4e2a-9781-4c19801ea2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_afe1a2d2-4258-4e2a-9781-4c19801ea2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d1e3cd2-364e-473e-9c63-04d060589027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d1e3cd2-364e-473e-9c63-04d060589027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bc82ceea-17db-4085-a4ad-efddbebf5742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bc82ceea-17db-4085-a4ad-efddbebf5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fcfd7ffe-14b7-4245-86f2-c58fa338feec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fcfd7ffe-14b7-4245-86f2-c58fa338feec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_756f6150-36e0-422b-9206-92ee3967eccd" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_756f6150-36e0-422b-9206-92ee3967eccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_bad601ab-feb0-4cad-9b13-2e89181c860e" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_bad601ab-feb0-4cad-9b13-2e89181c860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_4a662b80-af98-4b8d-bd27-29d302256d47" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_4a662b80-af98-4b8d-bd27-29d302256d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_b97c4c55-9631-4148-8952-e072e3477efd" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_b97c4c55-9631-4148-8952-e072e3477efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_208c7b36-a473-4167-a72a-97e89e3f51ce" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_208c7b36-a473-4167-a72a-97e89e3f51ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bf91f68-4558-41af-bf9f-0c11b2813e84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1bf91f68-4558-41af-bf9f-0c11b2813e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4dace152-7425-45d1-b38f-4defc27da072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4dace152-7425-45d1-b38f-4defc27da072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08c9b3fa-2dcb-4d6d-b3a0-ce41807a03c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08c9b3fa-2dcb-4d6d-b3a0-ce41807a03c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3140b2a6-2673-4d3c-982a-daae29b30066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33e4fc6e-c467-4c62-b633-035d5086bb9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3140b2a6-2673-4d3c-982a-daae29b30066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bbab47f-6a84-4a92-ba58-3e8a0f844b56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bbab47f-6a84-4a92-ba58-3e8a0f844b56" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d6edc62-bea2-4317-9484-27f082b0133b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_71bdb541-20fb-4818-bd2d-da50a8c7ddd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_71bdb541-20fb-4818-bd2d-da50a8c7ddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_132a189d-b774-48c0-9129-e123bb01450b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_60fc1099-f83e-4adb-bb83-650a80f893d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_132a189d-b774-48c0-9129-e123bb01450b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60a0b08e-cd50-4e3b-9b6e-2b50279f035f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9eff611c-bc98-42cf-9482-ce303c9c55d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_da4d5d53-6298-41c3-a897-75b7c68e1d8d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9eff611c-bc98-42cf-9482-ce303c9c55d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef5db4f9-c8b9-4ea0-8cbc-98f0f6135bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef5db4f9-c8b9-4ea0-8cbc-98f0f6135bbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_caab3e0c-ebee-4af8-8672-974165776d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_caab3e0c-ebee-4af8-8672-974165776d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f5b151a-abab-4816-9e1d-acb505e194ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f5b151a-abab-4816-9e1d-acb505e194ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_987cecaf-1d64-4528-b640-c8527a649b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_987cecaf-1d64-4528-b640-c8527a649b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_00993ecb-d076-4128-ba44-6f1186770512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_00993ecb-d076-4128-ba44-6f1186770512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8a27f57-df4e-4633-b8f2-f4254df4a526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a7d8097-065d-478c-9511-616e4fdfa85f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8a27f57-df4e-4633-b8f2-f4254df4a526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_22f23b5b-a2de-4599-8d41-63dd4d0326e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef5db4f9-c8b9-4ea0-8cbc-98f0f6135bbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_22f23b5b-a2de-4599-8d41-63dd4d0326e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef5db4f9-c8b9-4ea0-8cbc-98f0f6135bbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7dbe8758-9123-4224-9f1e-d2e438f8099a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7dbe8758-9123-4224-9f1e-d2e438f8099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_423bf26e-3415-4ec0-b862-ebbba1f63287" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_423bf26e-3415-4ec0-b862-ebbba1f63287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fbb70c7a-4c7f-456d-8b18-dae0e20c8fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fbb70c7a-4c7f-456d-8b18-dae0e20c8fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fdb2bc2a-9749-4342-bf69-7be80231686b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fdb2bc2a-9749-4342-bf69-7be80231686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59c1eabf-bec7-4219-92ec-b3d1fbdb9a42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8460633a-d381-4959-b0dc-45eb60a99069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59c1eabf-bec7-4219-92ec-b3d1fbdb9a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d5f56777-90a1-4611-8049-83da09cc4f42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef5db4f9-c8b9-4ea0-8cbc-98f0f6135bbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d5f56777-90a1-4611-8049-83da09cc4f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d8027503-43e3-409d-b6c8-2e03a55654a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd2d5184-7273-4542-9f5d-b958ac72b286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8027503-43e3-409d-b6c8-2e03a55654a1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd2d5184-7273-4542-9f5d-b958ac72b286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87af28ca-6a81-47f9-b030-305a3f32eaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_e8df11b3-99e4-4f98-87ae-d3d7f69a8aef" xlink:href="evlo-20200930.xsd#evlo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87af28ca-6a81-47f9-b030-305a3f32eaaa" xlink:to="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_e8df11b3-99e4-4f98-87ae-d3d7f69a8aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aaa8cc23-8b70-481f-91c5-c709ccd05fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87af28ca-6a81-47f9-b030-305a3f32eaaa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aaa8cc23-8b70-481f-91c5-c709ccd05fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_20e4d40c-7322-4c12-b524-d93514767e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b4993b35-07ea-4d95-af9c-c4c8ba344bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_20e4d40c-7322-4c12-b524-d93514767e06" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b4993b35-07ea-4d95-af9c-c4c8ba344bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b87f55a9-10d4-4776-ab6b-6f56857a2cae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_99d7a8ad-420e-403a-877b-b3398af9d3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b87f55a9-10d4-4776-ab6b-6f56857a2cae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_99d7a8ad-420e-403a-877b-b3398af9d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0333190d-417d-4eab-839c-c2a274c12f20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0333190d-417d-4eab-839c-c2a274c12f20" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a261c910-aef6-4f16-bc65-42631e6c03c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember_c8471b8b-2c99-4e3f-a92e-809484513199" xlink:href="evlo-20200930.xsd#evlo_UnvestedCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_evlo_UnvestedCommonStockMember_c8471b8b-2c99-4e3f-a92e-809484513199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b2364b7-6050-41ae-90c9-148992f630d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b2364b7-6050-41ae-90c9-148992f630d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_91aaa704-39eb-4a8f-87b9-a98ce90b3317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85f00099-a5f0-4992-800b-b629cd2760df" xlink:to="loc_us-gaap_EmployeeStockMember_91aaa704-39eb-4a8f-87b9-a98ce90b3317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d8149cc-0913-42c9-bb1e-3b87c2e68896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ab2cdac-64a9-4656-99e0-f4623aa8b5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d772e264-ea00-4328-bff5-28f5cb79a106" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ab2cdac-64a9-4656-99e0-f4623aa8b5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_178e806f-034d-4782-af88-47bd8cf32742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1259bf76-d8d0-4ff5-8064-de514ee2d5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_178e806f-034d-4782-af88-47bd8cf32742" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1259bf76-d8d0-4ff5-8064-de514ee2d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20200930.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_fa393188-e2ae-4109-a2ac-224c94441057" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_fa393188-e2ae-4109-a2ac-224c94441057" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_981b7bc7-f31e-4359-a621-987531be1c02" xlink:to="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember_fdb228e2-d4dc-48ab-9ba8-c9709d98c73c" xlink:href="evlo-20200930.xsd#evlo_WeatherdenLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_evlo_WeatherdenLtdMember_fdb228e2-d4dc-48ab-9ba8-c9709d98c73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member_bc92e270-4062-4d93-ad20-ec35656c0051" xlink:href="evlo-20200930.xsd#evlo_VL46Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_evlo_VL46Member_bc92e270-4062-4d93-ad20-ec35656c0051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_a47a54c4-fa15-4793-b5e3-74998cb1909c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_59c3e7d2-45a7-4118-9678-f2707ab9bd9f" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_a47a54c4-fa15-4793-b5e3-74998cb1909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca10797a-b34d-4253-952a-0a26cc71eb3d" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember_c340432c-ca6d-4811-8d31-855e7ed6c434" xlink:href="evlo-20200930.xsd#evlo_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d45aca47-11b2-4359-89c5-2b506f83cc38" xlink:to="loc_evlo_ConsultingAgreementMember_c340432c-ca6d-4811-8d31-855e7ed6c434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d50aaea2-6d8f-4791-8474-16b4992873cb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ed5871ff-b245-4379-96f4-bb47bf311d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_110638c0-5f23-4019-9ff5-b39c96e3e83f" xlink:to="loc_us-gaap_SubsequentEventMember_ed5871ff-b245-4379-96f4-bb47bf311d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7431ee25-cb10-43b4-bbf5-75f5e6ee3e94" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1612b9aa-3e80-4d6f-8f83-95634b125510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1612b9aa-3e80-4d6f-8f83-95634b125510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a33ba9-1c4d-4793-80c6-098cbddb29db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a7a33ba9-1c4d-4793-80c6-098cbddb29db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ce08443-a692-4f83-811d-a1545ea4baf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ce08443-a692-4f83-811d-a1545ea4baf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_60915b18-e5b0-4311-b900-56e402df3347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_OperatingExpenses_60915b18-e5b0-4311-b900-56e402df3347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_5de220ef-8f58-48be-afc4-b44e990ee251" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_5de220ef-8f58-48be-afc4-b44e990ee251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_abaea5b8-62ca-4071-a83e-75186869b889" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_abaea5b8-62ca-4071-a83e-75186869b889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bcf5817c-2bcb-4ed9-ab9f-fa43116c88f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bcf5817c-2bcb-4ed9-ab9f-fa43116c88f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_045c740a-1048-4782-8654-928aafa4891f" xlink:href="evlo-20200930.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_045c740a-1048-4782-8654-928aafa4891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_1e5765c5-fa7a-4579-8621-45829b278304" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_1e5765c5-fa7a-4579-8621-45829b278304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_e25ead26-13b7-40c5-b798-6babc106213e" xlink:href="evlo-20200930.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_e25ead26-13b7-40c5-b798-6babc106213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_67df2620-206b-4bcf-9e4a-3674ac5825ad" xlink:href="evlo-20200930.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_67df2620-206b-4bcf-9e4a-3674ac5825ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9dc2fc6f-2d0a-47be-aad2-0b694c4758c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_601a2b4b-cb25-4de1-8755-9032d5c62d7f" xlink:to="loc_us-gaap_SubleaseIncome_9dc2fc6f-2d0a-47be-aad2-0b694c4758c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>evelobioseciencesheaderexab.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 evelobioseciencesheaderexab.jpg
M_]C_X  02D9)1@ ! 0   0 !  #__@ ?0V]M<')E<W-E9"!B>2!J<&5G+7)E
M8V]M<')E<W/_VP"$  0$! 0$! 0$! 0&!@4&!@@'!P<'" P)"0D)"0P3# X,
M# X,$Q$4$ \0%!$>%Q45%QXB'1L=(BHE)2HT,C1$1%P!! 0$! 0$! 0$! 8&
M!08&" <'!P<(# D)"0D)#!,,#@P,#@P3$100#Q 4$1X7%147'B(=&QTB*B4E
M*C0R-$1$7/_" !$( $\!VP,!(@ "$0$#$0'_Q  <  $  @,! 0$
M    !@<$!0@# 0+_V@ ( 0$     [^
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M',-;#K#U.VK_ ',GU/AO=9$;!@^?*:SG^:
M    /__$ !H! 0 # 0$!               ! @,%!@3_V@ ( 0(0
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M;UC=+/G.-+?%M>>Q83Z?YX-<?37&ONG:"2]99Q'[_:'4JGQV5Z#(C9:%L?\
MSUD_GE!['_''K2SE3UQZTAS])>24Y5>V;\BQYF(]5_NI77]5"TB3\3X7S5&#
MM'2LVZ91I!N-7SNQ5 OFV@F\7I/ZB8/A"N O/8KV;8!]#H.VI%E7 27M !
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MPN_S,\MT)!M:5V&TS7DB@JIXHF_E5A8:CN1%$+"YZD^I)[G^'/\ _\0 +1$
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-M , 1F1BN!_7S'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>evlo-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:evlo="http://evelobio.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evlo-20200930.xsd" xlink:type="simple"/>
    <context id="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8035dace6d484723b9e2770358a9e763_I20201028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-10-28</instant>
        </period>
    </context>
    <context id="i727b59e9eee84ab2b82d2423972c1f46_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i37bfa021020a483b81d3d7f71c17fb85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i170f27bed555450a960ed8a017f930d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i666052e6e37f48afb5a6aae763ccc94d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08e9b2138c64436299d7617a15d49ea4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9553d87f4ea46a3b3319afd5329cb7f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6c43f7c78574e1d872e60fa8ff6cb0e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id40d9d3d244843f498894e71017e9d48_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4a337c69309946809c3142def8201268_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b37e4af397a4118b204e37457dee732_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ad2f0cc24a5462b9661d795b6339101_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i152ecd16776946888e51ea675f74bd45_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7e4d24e8c5004e208a5aaa7c929381a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia7b35cb2611543e9a26804e2b4845eba_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1c9c460b18c9443e9a10e22f70b04a5d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia1115a5ba283435ca2ee0679245344cb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1a73310a701e434b86bec90132205ebc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd90a3f9d90649d18c4f0e247aaa9b1c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if8749a7d111c4b6e80fb618dde5fec7a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0ae6a95b363a49f1b083c4c98235266a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia597a7a81815459388e53a54a6edae64_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i19330d3a0e2b4f32884d8c8d7d4e52f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i772516e37d4348288bfb7ead82e084bf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84dcaeb2960441fb8320dc401c4122ce_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id838f29aebd2439fad0dad587f16912b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfd50cbcea0a4661a3adca182198a047_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0d7bc7d267b74b9994877e72a000f9a5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i623396ade16641e89475195261e0c3bb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie136aa58c43d4d94b9f15bed3514eb71_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie8f329a1ae7344c5a6ee59a259cb9c0d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if5a551ca740a46139c2913fdee05a4b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7ca79798a26c4655b0162e901ca8ef98_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie35deec7c65a44019b54cb1521fcd2ba_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie4e6055b96cc46ef9c60a122ec8ca1b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic6081422c67a4959affb382889e30181_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5a8f41a0ea8041d3a56d432d4f829798_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2b973735904d462b9458f1b40f1cf9d0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i805997da9a164a49be9d13b7e742afae_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i297bd608c3da4046877c9279b8ac3205_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic2df3854b70d4b358592d4b7bbeada9d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i89f527d367b242c68fd17edc1580165f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i445472023dd84c71b2bc0455e0f1a754_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic90e130811884145a23fd79af66e4710_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id1c64ec573a044acbc4a84c3cee5b65a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6ca8c3e2a57b4525b59221196e30a8a2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2616efd03a3846519ef8667220526fbd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i39f84b883b10466597e570d856ada5ad_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i445a000730914ae9ad67896329d69891_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i38dc7b1f83b6487d924cdc369232095c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4c6eb482d639489094b6f3423352160e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3a049ceec50142168d6b7cdca6b55c5e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id19506e2ff4b405a8e57e3b847319cef_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if000c9350a8f4fa3bae7dd8d649a04d7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6400c85258fa4dfdb84406f6886223fe_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib31920876cef41fda8536f18e104d5d1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ieca398585add43b0bee79e80e690e333_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i54ea87091b054e0ab14959f3bdb971df_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0be4b8af0d144c6a8a31a5aa72508935_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:JuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd3ed046380c402e916b73b4e3b00f00_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:JuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4bfb404ffb8f4796939c3c659d253923_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-14</startDate>
            <endDate>2020-07-14</endDate>
        </period>
    </context>
    <context id="ia38f09c6713544c7bdac7b4ef58e8230_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="id4d98a0593604e4db29e81ca0e1ed08e_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="iea25c6e18d36425baa31be5ed904178a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e795277073a42ab9298318fbeb02b69_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iac86fce0f21b41e996c6c3824f421637_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a65273c2fc747578248931d9beaed19_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i815d7bddf0dc463bad9464271644bbe6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i142ceba3efcb45ea958d6e85b6db1bf4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i14ded15f9f634b35ab6d912652a390dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2ba7ce22ac4e412aaff058cba3436fcc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01995a7366b14ec2aeb7be9fad8b500a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46b0c348e01a4c26922b187713bd5bf6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36ed7412637b46c8a8dbfdfb42b69661_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11bd6b0b98e54b1f9d4b6e9d9dc8b0b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c2dc7dd1162441085728c89b9000072_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3254063206b34f168fff62c3216eaf37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c9f5c9ddad943ce8f82cc180c9a0533_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5b67f0fe6a5740e398b3f31ff3dd1588_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i164f6350f5e344edacb0e9a6b68a1844_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i220d743ead6c44fd9305f7880abca00e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ea1dda588544015980d719168da2fa6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iff5b25883e8f43038b8df1042fc86276_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5a81634a68840829977fa5b44a68d41_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibc8f58fdec814720a8bc0f6960a616b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7fda17f67d6e4f98be456487782da379_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic1d0061ad4354ae29fd62e2b60137505_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib69bb769acc2400e94f81dd3cfb5831b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i45be461d034047e1880917ae93e7b605_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22371425da1041168cf343492f01c4fa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i5888734b31a84abe9cd96515a54830d4_D20201001-20210115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:SecurityAndLoanAgreementTranchesAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-01-15</endDate>
        </period>
    </context>
    <context id="ic924efafb0664fcc9352ca108ea8fc1d_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="if6af8e2843d54b498ab6811a2bdb9e01_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i714d2fe395864b4fa7d700a7d8555b24_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i36512fd07785419f8c346218b88c3574_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2016CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i497af9117217436086fed1b12ad3d7a9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ec21311cae448859c4bf7db77fa683c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cc03be1a9fa44fa9fad574644a033f2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52af12becc094820bd3f1230018cdaee_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9b24ece8af454852802d95c232d20b4f_D20170806-20170806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-06</startDate>
            <endDate>2017-08-06</endDate>
        </period>
    </context>
    <context id="ib76eb2613df44ca0bf34544038de3c75_D20170806-20170806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-06</startDate>
            <endDate>2017-08-06</endDate>
        </period>
    </context>
    <context id="i5765428e6dc9410ba812e1aa42d7c4c2_D20170806-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-06</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia2705dcad5b24a6489673679a8b632af_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i04e883ac26644ef6a592b975350598ff_D20160310-20160310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-10</startDate>
            <endDate>2016-03-10</endDate>
        </period>
    </context>
    <context id="i8f6455f87ca54808a728b425104feb45_D20160310-20160310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-10</startDate>
            <endDate>2016-03-10</endDate>
        </period>
    </context>
    <context id="ia3aacf5203e14a5cb0bcbc6335830341_D20160310-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-10</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39a9eed2f1ed471496cc34819ec412d1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ifc919b216958484baadfbaf3a5579160_D20190701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i435a8ae096ae4da6bf33a4093a05df20_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:BioseIndustrieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">evlo:ExclusivityAndCommitmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a20243cb8d84ef18f004aae73258da3_I20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-03</instant>
        </period>
    </context>
    <context id="i2b2a5654b6754515818e140c5b08761a_D20190603-20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-03</startDate>
            <endDate>2019-06-03</endDate>
        </period>
    </context>
    <context id="i21297bf18f09435c9c8903a7a0fe13d7_I20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:SalesAgreementCowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-03</instant>
        </period>
    </context>
    <context id="i37f994741045472492789b1f3256cad7_I20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-08</instant>
        </period>
    </context>
    <context id="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0331b53ef2c94cbdb3540b9c8689c650_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="i7d66e58adfb6442daaf1ba85feaf140e_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i9d8a41ea4f4146b0aebd206e1f94d0e0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66830987cfbc412d9cfa324492f94b6a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7436d15f4ad5490d93c800ee4ae5d465_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3e85e8eb3804e36b93c6a30043a30b2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id857f9eb771f41fa9395bb219b6db368_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74487ec4f652475ab2a3c41c29dd618f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief4a44fb4e8b48ac915b62b55ebffe17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evlo:NonEmployeeOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6ffbe5b60b54ac58b8345b0c3ce8b6b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83f3aba8c3af44db97c1de2f2eb7d95b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaf913522ccab41a9a9d188138fdc0c2b_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="iea04ebdbabf44bda8de9e1db8bbf68cb_I20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-08</instant>
        </period>
    </context>
    <context id="i3445cdc78926417abcbfd87995b2d7ad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice9ffd1c5890497b8ba9733f662871de_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i17f970dc30ff49bc95066276f19569ef_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia237cd66629540edb0fdf167fb187799_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9707f9de1ed24944bcc195fb5a28ab50_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ab3a97dae834644890cbda892fe5002_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i220c4df4a97e4803892c37ccdd46a4e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9ae55ffcb5b4b38b1294a478dba4306_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i851cd9abcdca4743b9d2ea90d5b4eeb4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee55ced3b34d4b52a1a1f852c64d2e67_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-18</startDate>
            <endDate>2018-04-18</endDate>
        </period>
    </context>
    <context id="i8463191a45964196b29df202007afc9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id704a4dd15bd403ab0cac9fc81b19ebf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i102115e148ba457a9e0f7b80f0e81eae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e341efe8ff445c5bfac11f2c9f50db8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id804b1ab406a45b386f84874e2f511e9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i40a534ca0c824a918ef5b0b5cfd144f6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8832142a8fd34e73a080e4c3c2df3b1c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f093b1b4c194114a2857f69750073f1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a12b5d775194c26a646d257a891b43f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5cef482e496443fa58c3e279239e38f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8535ad7567824b5eb8061e3eb77bcea4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i040867f309fd4a60b8b170d1d3f8cb1a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i48bd8f29cd6a448ba1d11baf833a3e94_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i9ebbc6067103474782dd50c5fad869dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-16</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="iece4b57622c64cce95e2a617bf90bcaa_I20190916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-16</instant>
        </period>
    </context>
    <context id="i810d7c9e6e614a82ad32d53275585c7d_D20201011-20201011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-11</startDate>
            <endDate>2020-10-11</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evlo:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>evlo:tranche</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="installment">
        <measure>evlo:installment</measure>
    </unit>
    <dei:DocumentType
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8wLTEtMS0xLTA_bd9d1a0b-a6c4-4ba3-9c20-08e653b73841">10-Q</dei:DocumentType>
    <dei:AmendmentFlag
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8xLTEtMS0xLTA_1ee536f1-c44c-4007-8b4e-ff6e4dd73324">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8yLTEtMS0xLTA_64ac82ca-53c8-46c2-b63f-da813a0bb251">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV8zLTEtMS0xLTA_075f0447-4ef5-436b-a53a-a68bad4a9a61">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV80LTEtMS0xLTA_12ce9de8-c126-4e9e-a159-e2cf762a7783">0001694665</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180L2ZyYWc6ZjdmOTM1NjBlMzAyNDZkZmEwM2JhZjM1MDU3NGZkN2MvdGFibGU6NTQ4ZDBkZTk5Yjk1NDA2M2EzZGEwMWY4NDI3ODk4ZjkvdGFibGVyYW5nZTo1NDhkMGRlOTliOTU0MDYzYTNkYTAxZjg0Mjc4OThmOV81LTEtMS0xLTA_4dc54251-41cf-4335-bfc9-69840823c712">--12-31</dei:CurrentFiscalYearEndDate>
    <evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices
      contextRef="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNjgz_88021ac0-a529-40c8-86cd-253480fcf249">P6M</evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i66830987cfbc412d9cfa324492f94b6a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjIzOA_2e4a7638-383d-483e-b76d-0a2a2f8a433f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i74487ec4f652475ab2a3c41c29dd618f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg1Nw_74d83430-6831-4482-96e0-5983d9562632">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentQuarterlyReport
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ZDRiYWNiNzMwN2MxNDIwNDgwMmJjNjFlZTU1YjdlMWUvdGFibGVyYW5nZTpkNGJhY2I3MzA3YzE0MjA0ODAyYmM2MWVlNTViN2UxZV8wLTAtMS0xLTA_5c4c739e-db79-4ff1-b6e6-956204fc4625">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8xMjI_c056b99c-e522-4280-8fc3-2896c7c70290">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YTc2Y2JhZmFiODFkNGNlYmIyZGNmYThjOTBkYTMwNWIvdGFibGVyYW5nZTphNzZjYmFmYWI4MWQ0Y2ViYjJkY2ZhOGM5MGRhMzA1Yl8wLTAtMS0xLTA_1a53bf10-6d6b-4dd9-9b2a-6cc9f91649cd">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDM0_6027b6e4-0bf9-46b0-a0a9-49570307f81a">001-38473</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDM1_10e74ff1-5085-4d17-9a5e-361a67ef8951">Evelo Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8wLTAtMS0xLTA_34586973-8cce-437a-8a2c-00d9a5a1294b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8wLTItMS0xLTA_c1dfac12-adbb-43b4-97e0-74f7f567a04d">46-5594527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M180_58d80ee4-c1a8-47c7-961e-3625533469bc">620 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M183_2958cd51-176c-42bf-9d24-9da896cd2e96">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmZjFhMjg4YTg4MGY0ZmY3YWY3MmRlYTc5MzhlNjM5M18xMQ_0fca5973-3809-43a7-88ca-81b346cab497">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6YjY4NGRiNGNiMjgxNGI0M2I5NDRjNTRlZWU4Yzk2NWIvdGFibGVyYW5nZTpiNjg0ZGI0Y2IyODE0YjQzYjk0NGM1NGVlZThjOTY1Yl8zLTItMS0xLTA_f4af5a8f-b83e-4958-bcda-a8d42c7d88d7">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDI4_f3fa56bd-3601-419e-9b4e-bf2e2771c0e5">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDI5_bd4bfddd-bd7f-4752-8cb5-45a74375d878">577-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTAtMS0xLTA_6fffb2bb-d1db-408f-af3e-83be354b4ac0">Common Stock,$0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTItMS0xLTA_66e67b91-194b-4657-a0c2-72b363f6e668">EVLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6ODA2OTdmMTk4YWI2NGI0YWEyZDg3NmVlZmVkODMwYTMvdGFibGVyYW5nZTo4MDY5N2YxOThhYjY0YjRhYTJkODc2ZWVmZWQ4MzBhM18yLTQtMS0xLTA_5ee8ac65-1f7e-4b35-80f8-76be06c385c6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMw_e2e71b8c-682c-40d0-bb9f-c49a8c152cc9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMx_496a36dc-b0ba-4e78-8959-e9058ebb84c7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl8wLTQtMS0xLTA_cc18b781-6e8b-4055-abb4-d91d811b6b81">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl8yLTYtMS0xLTA_f4112f47-8aac-4a76-8f51-ccb8342d8935">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGFibGU6NTVkMWUwNGQ0NzVlNDc5NGEzM2ViZGZkNDU4ZmM4MTIvdGFibGVyYW5nZTo1NWQxZTA0ZDQ3NWU0Nzk0YTMzZWJkZmQ0NThmYzgxMl80LTYtMS0xLTA_34306a40-7acc-4ef9-97c2-10928e36203e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMy_bd9547a0-142e-416a-b73b-ccb66efdf42b">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMDMz_e3eaa9a1-5273-43c7-808d-826629793762">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8035dace6d484723b9e2770358a9e763_I20201028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xL2ZyYWc6N2Q3ODUwNzA2YTA1NDBmYmFmMGZmZTI0YzNlMzBkOTkvdGV4dHJlZ2lvbjo3ZDc4NTA3MDZhMDU0MGZiYWYwZmZlMjRjM2UzMGQ5OV8yMTk5MDIzMjU3NjI4_212e2890-616c-48e5-8f9d-fb88382e2884"
      unitRef="shares">46189236</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMy0yLTEtMS0w_c08b4b10-c8c4-48a6-9c8a-bce1806f1066"
      unitRef="usd">81580000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMy00LTEtMS0w_96d847d5-69b9-4cf4-9dc7-979880c52aec"
      unitRef="usd">77833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNC0yLTEtMS0w_c9211aba-448f-457a-b159-a05e426e279d"
      unitRef="usd">2979000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNC00LTEtMS0w_646f2d6d-02e6-402b-a86e-9eec63fff1b7"
      unitRef="usd">3176000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNS0yLTEtMS0w_9b94ad98-14ec-4f43-8a2e-388450c6a502"
      unitRef="usd">84559000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNS00LTEtMS0w_7e370f94-a825-4c6a-b67c-ce29c2711f34"
      unitRef="usd">81009000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNi0yLTEtMS0w_f205a456-633d-4a00-8cfe-d85d93953631"
      unitRef="usd">7586000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNi00LTEtMS0w_0b12bb4c-c02e-402b-aff9-d64be8e72be3"
      unitRef="usd">8341000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfNy0yLTEtMS0w_bb9fac55-0486-451e-b75c-952e054d1f63"
      unitRef="usd">11192000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOC0yLTEtMS0w_2ebbc2e7-6cd0-4900-a95d-b8b486e493f2"
      unitRef="usd">1500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOC00LTEtMS0w_b7584406-43b0-4b93-aa87-118a42ec61a9"
      unitRef="usd">1570000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOS0yLTEtMS0w_84d364b0-dbb0-4ea0-b72d-ea64594efae9"
      unitRef="usd">104837000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfOS00LTEtMS0w_bd4bf287-cf94-4e0d-960b-fc0e0c8f60ae"
      unitRef="usd">90920000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTItMi0xLTEtMA_c4eef4b7-c6bc-4120-aed4-b09a4fc74d38"
      unitRef="usd">2729000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTItNC0xLTEtMA_074d8d86-3e2e-4db2-ad48-e1814fa1390c"
      unitRef="usd">620000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTMtMi0xLTEtMA_be1f98c1-78e3-4a6a-b7fb-f3a6e1054faa"
      unitRef="usd">8823000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTMtNC0xLTEtMA_6c5bd1a2-c1c3-47fe-a11b-eceeb15e4569"
      unitRef="usd">8758000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTQtMi0xLTEtMA_b7e0e958-9a06-46ff-933b-ad6271f949b0"
      unitRef="usd">1607000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTUtMi0xLTEtMA_de67bdf2-4624-498e-9033-b7600f697bff"
      unitRef="usd">389000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTUtNC0xLTEtMA_343e9e22-622f-42ef-82b4-79b998e9a620"
      unitRef="usd">365000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTYtMi0xLTEtMA_682faefb-7509-4fe1-bacf-02cc55532f31"
      unitRef="usd">13548000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTYtNC0xLTEtMA_ba77e26d-2021-4427-9a09-89b11fffaf60"
      unitRef="usd">9743000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTgtMi0xLTEtMA_15fab411-66da-4bcb-b410-8e875603818e"
      unitRef="usd">29924000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTgtNC0xLTEtMA_69712207-51d6-4201-9431-816fe0182b72"
      unitRef="usd">19634000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMTktMi0xLTEtMA_1cd50d75-f886-4bb3-94df-2b515006d0a3"
      unitRef="usd">10503000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjAtNC0xLTEtMA_38adec06-e067-4a22-9ea3-2202f51daa9d"
      unitRef="usd">1148000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjEtMi0xLTEtMA_414ac4b7-9a58-4718-bc3e-e673dc7e40c2"
      unitRef="usd">432000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjEtNC0xLTEtMA_ab0028cb-07ff-4c87-af7b-0dab631d2a3c"
      unitRef="usd">198000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjItMi0xLTEtMA_bcc3bb75-b099-4015-93b9-5462961ad55c"
      unitRef="usd">54407000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjItNC0xLTEtMA_e8b69e3b-7d9e-486d-a89e-de27e159331c"
      unitRef="usd">30723000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjMtMi0xLTEtMA_d2b756f3-1d87-47bf-96c3-f52ace944f50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjMtNC0xLTEtMA_bab4da22-188d-44c5-9176-a9896f632201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzIy_51349efa-f4c9-4b8d-a7d0-4716596866da"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzIy_dffb5c48-88e5-4c9b-a914-36664887b95c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzM2_3e2ee142-488b-4d33-afab-47c2d5034de8"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzM2_9d746aeb-c326-4242-8de9-66444869d099"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_386d7ee9-6670-4c9b-9d32-b0c09aab3923"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_703e21bb-2984-404a-b246-2b076d27756c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_7884222e-0ef2-49dd-8a2e-aa3586465c95"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjg2NjQ1NTM1Y2I4NjQxMGZiMDljZmZmYmJjN2ZhZmM3XzU4_b08e692b-70cd-4fd6-8b1a-3f48d6e65f93"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtMi0xLTEtMA_730900d7-3028-427e-9b84-4b9a84fbf89c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjUtNC0xLTEtMA_502983b4-5501-4b81-a403-d2b15b53e3d5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzE5_12c5e9ac-8c1d-4273-b535-9d7ee81d0c2b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzE5_c4d79dbc-f893-4035-ba5b-5d44e987f27d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzMz_4edefc1a-557f-4376-8139-b7ce8b557560"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzMz_a26d32b4-f8a7-4bcc-82e6-31389c1fccc5"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzU1_8dea5dc3-ed8f-4210-bfe2-64b68ea010f8"
      unitRef="shares">46220859</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzYy_602634e8-c1e4-4fb9-83ca-34289bc3b270"
      unitRef="shares">32232258</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzgz_8458e5ea-1c0b-4b8b-bd03-2e09c85023a3"
      unitRef="shares">46184087</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjA4N2QxMTM0NzBmNDRjMWRhNzY2ZjQ5NDJmMmY1MjcyXzkw_89bcb3b0-bdbd-4eb9-b614-93852d6e55db"
      unitRef="shares">32170605</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtMi0xLTEtMA_f1de77b2-e859-4f7a-a0be-7c02871a27db"
      unitRef="usd">46000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjYtNC0xLTEtMA_0162c745-6be5-4375-a708-708adaf6777d"
      unitRef="usd">32000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjctMi0xLTEtMA_b692cec1-31c9-4a04-b6bc-c7d481bbefed"
      unitRef="usd">313853000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjctNC0xLTEtMA_12babccd-5ab9-4526-9894-6a42b8402a5c"
      unitRef="usd">259018000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjgtMi0xLTEtMA_97a8c418-0834-4084-8777-a8dfe3ad5648"
      unitRef="usd">-263469000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjgtNC0xLTEtMA_bde82bea-7d21-4c43-a08a-0beb7fefe61f"
      unitRef="usd">-198853000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjktMi0xLTEtMA_e92a8435-13d8-4f2f-a978-d9f08f6ff1bc"
      unitRef="usd">50430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMjktNC0xLTEtMA_23d8e3ed-a455-4730-bee5-afa91c42db04"
      unitRef="usd">60197000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMzAtMi0xLTEtMA_2389b484-5468-4da6-a6f7-ed9240b3ed8c"
      unitRef="usd">104837000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18xOS9mcmFnOjI1MDcwZDNlZmRjNTQzNGZhMjQzN2Y4NWIwNzU2ZmUwL3RhYmxlOjgzY2NmN2Y1MjA3YzRiMWM5ODk3YWM2NDhjNDk4ZTViL3RhYmxlcmFuZ2U6ODNjY2Y3ZjUyMDdjNGIxYzk4OTdhYzY0OGM0OThlNWJfMzAtNC0xLTEtMA_35264bca-1f62-4aee-9f53-6ad1e89a31ed"
      unitRef="usd">90920000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy0yLTEtMS0w_a47d3b50-53c5-4fd8-9489-78f6abddedd9"
      unitRef="usd">14910000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy00LTEtMS0w_3a6f371b-6ba2-425e-a244-0a73910aa4e7"
      unitRef="usd">15610000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy02LTEtMS0w_54fca9e7-d88b-4027-83dd-01b52cd644b9"
      unitRef="usd">47503000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMy04LTEtMS0w_b4c0c407-b719-46ce-91fb-aa65a78b0785"
      unitRef="usd">46751000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC0yLTEtMS0w_217d400a-f458-44ce-a664-e41e04c45c69"
      unitRef="usd">5272000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC00LTEtMS0w_2a2c3907-8dd5-410f-b039-dce35a539d15"
      unitRef="usd">5886000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC02LTEtMS0w_980318e7-571d-4eec-8a38-485a03018075"
      unitRef="usd">16185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNC04LTEtMS0w_539547d7-b26c-44a1-8b8c-3c18edb1a613"
      unitRef="usd">16936000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS0yLTEtMS0w_489fbae4-5fba-4222-ac27-584b99d3dbbf"
      unitRef="usd">20182000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS00LTEtMS0w_16bcf49f-b083-4ca0-8399-89e33f025587"
      unitRef="usd">21496000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS02LTEtMS0w_443f8753-20c8-4bb6-84d2-48f894c5bd4f"
      unitRef="usd">63688000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNS04LTEtMS0w_f2399d38-0c2a-41a3-bfd0-57a9903ed15c"
      unitRef="usd">63687000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi0yLTEtMS0w_01935444-28a2-4519-acd7-4a6a728dbe24"
      unitRef="usd">-20182000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi00LTEtMS0w_8b1d0be8-ee97-44b4-bc53-8c943d348ac7"
      unitRef="usd">-21496000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi02LTEtMS0w_ea2b263e-8eb4-4f37-950c-1c1611488048"
      unitRef="usd">-63688000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfNi04LTEtMS0w_7ea647c3-9c84-4830-ac12-24a9d2b5e8e4"
      unitRef="usd">-63687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC0yLTEtMS0w_cc7ebf33-07f4-43d3-b64f-a5d98536d641"
      unitRef="usd">-713000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC00LTEtMS0w_66e18d94-a68c-4678-ba6b-c02d703591f3"
      unitRef="usd">81000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC02LTEtMS0w_10bac847-193a-4150-9ddd-cccd6dec9194"
      unitRef="usd">-1353000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOC04LTEtMS0w_d2cf3385-323e-49d4-8862-7db969b51a3f"
      unitRef="usd">1032000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS0yLTEtMS0w_050a6cd4-9b88-476f-ad6b-94ffacbd529c"
      unitRef="usd">39000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS00LTEtMS0w_decd80a2-7993-4b66-a3ad-2be3fee8fac8"
      unitRef="usd">-218000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS02LTEtMS0w_de846662-672b-481d-a1b6-0da5bc98f754"
      unitRef="usd">646000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfOS04LTEtMS0w_f9ed6003-b7db-4bcf-b3d3-6c9fa4301098"
      unitRef="usd">-218000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtMi0xLTEtMA_deb532d6-1fbf-4000-8200-15fc38543102"
      unitRef="usd">-674000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtNC0xLTEtMA_e5e14561-a974-4cd1-82d5-ebc31e17f333"
      unitRef="usd">-137000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtNi0xLTEtMA_d0bfb0f6-28b1-4a87-a99d-a53d06fca097"
      unitRef="usd">-707000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTAtOC0xLTEtMA_8634c9f9-bef3-4cab-a1d5-f474ad5927c7"
      unitRef="usd">814000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtMi0xLTEtMA_5fab4b1a-c65e-4a9f-8ec8-4423b10f7ed7"
      unitRef="usd">-20856000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtNC0xLTEtMA_bf21de4c-7df5-4965-a092-ec55c1ae12f4"
      unitRef="usd">-21633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtNi0xLTEtMA_88c2471c-4722-4ed2-beef-652a82113d9d"
      unitRef="usd">-64395000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTEtOC0xLTEtMA_d526120f-3c32-4f2c-a33a-61c5cfa17216"
      unitRef="usd">-62873000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItMi0xLTEtMA_67537611-e5bf-4fb2-b77c-a326131edbf5"
      unitRef="usd">67000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItNC0xLTEtMA_c07289cb-a471-4219-b67f-5128fbcd04c6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItNi0xLTEtMA_e7e2d557-da83-4b36-80ff-e10e0144e92a"
      unitRef="usd">221000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTItOC0xLTEtMA_e1455faa-d883-41c8-ae10-4a72a9aa41eb"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtMi0xLTEtMA_3d73ce16-c463-4236-89f2-5708408c9c49"
      unitRef="usd">-20923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtNC0xLTEtMA_369fb1d1-320c-43a1-9a50-a74d2f7cc87e"
      unitRef="usd">-21633000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtNi0xLTEtMA_d1a6f8bb-f2f3-41df-96fb-67a8b80769ee"
      unitRef="usd">-64616000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTMtOC0xLTEtMA_391ec466-dab5-42d2-b35b-7b33b98b77c5"
      unitRef="usd">-62873000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtMi0xLTEtMA_e28abb5e-2a0a-474c-b753-6a0137d1f28a"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtNC0xLTEtMA_49fb0a10-4b4a-49c6-beaf-678925c64dd0"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtNi0xLTEtMA_471b9862-c82b-400f-9b57-352a2a3252ad"
      unitRef="usdPerShare">-1.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTUtOC0xLTEtMA_a0360078-dd32-409a-a1f0-c7ada5b5f607"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtMi0xLTEtMA_f4b0f458-1b43-4b59-ab3a-aac42ebdd998"
      unitRef="shares">46168013</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtNC0xLTEtMA_eecb60fd-b9b9-4938-adb9-3dea091af871"
      unitRef="shares">32060747</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtNi0xLTEtMA_68ef445b-5feb-413f-9348-cfe6202afbeb"
      unitRef="shares">37050907</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTYtOC0xLTEtMA_4b3394e1-4416-4523-90d6-162d586ccdc8"
      unitRef="shares">32009571</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktMi0xLTEtMA_72f85ce8-5259-46c1-8c9a-f53407686d1f"
      unitRef="usd">-20923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktNC0xLTEtMA_cd774acd-d1b1-49b8-9f68-6ce200f41daf"
      unitRef="usd">-21633000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktNi0xLTEtMA_0d879663-93ca-4bae-94d6-c601c70855ea"
      unitRef="usd">-64616000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMTktOC0xLTEtMA_95e0ca63-f2ef-42df-a88c-4f6a7b917d24"
      unitRef="usd">-62873000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_26d7db5e-1b8c-4d01-8f70-8b4231af7a7a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_3d187d3f-f9a9-460d-bbfe-cc82d25d6fdb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_958bb253-f675-4d0b-b386-86565836cdeb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjU2NTViN2Y4MzM3ZTQ2N2RiOTIwOWJkNDU1OGUwNDI0XzU3_fcffb56d-a3d3-4ffb-8563-1dc048e55a37"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtMi0xLTEtMA_02aada7b-bb0b-4ad4-827c-011b42e55e10"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtNC0xLTEtMA_36696629-1e03-49ae-be87-00dde532a7de"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtNi0xLTEtMA_aeca1359-6305-4247-94db-08d34de4aa41"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjEtOC0xLTEtMA_0f5fcd11-aabc-4f0f-895e-0bd3bdeb680e"
      unitRef="usd">18000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItMi0xLTEtMA_3fed857a-07d2-44f7-af10-72cf30baee05"
      unitRef="usd">-20923000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItNC0xLTEtMA_b22dec40-e285-46fd-a867-bcb4651308e4"
      unitRef="usd">-21634000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItNi0xLTEtMA_ba086f5b-b40b-4f4c-b2c4-b481cd8cd8c2"
      unitRef="usd">-64616000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yMi9mcmFnOjBlYjI5NDBhMTNkNzQzNGFiYTgzZThkZjBmNWMzNWQ4L3RhYmxlOjI5NTdlZGQxMDhmMzQ3YmFiOWI2M2QxNDdkMGNlYzgzL3RhYmxlcmFuZ2U6Mjk1N2VkZDEwOGYzNDdiYWI5YjYzZDE0N2QwY2VjODNfMjItOC0xLTEtMA_3c781867-9f50-4eb5-8f4d-d263b2e22050"
      unitRef="usd">-62855000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i170f27bed555450a960ed8a017f930d8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xLTEtMS0w_57c6d9a1-c49e-43a0-896b-32d0716fe844"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i170f27bed555450a960ed8a017f930d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0zLTEtMS0w_806823bd-5b8c-4112-9bc1-037037f88df3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i666052e6e37f48afb5a6aae763ccc94d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy02LTEtMS0w_8eb5a0cd-56d6-46eb-9c8c-b3cffdf73ad2"
      unitRef="shares">32170605</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i666052e6e37f48afb5a6aae763ccc94d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy04LTEtMS0w_49466311-0201-41c9-8ac8-3d03eb980935"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08e9b2138c64436299d7617a15d49ea4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xMC0xLTEtMA_79685ea8-b40b-4878-8687-ba34e4e16aac"
      unitRef="usd">259018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9553d87f4ea46a3b3319afd5329cb7f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xMi0xLTEtMA_b85d4bbf-2d3a-4d46-81ad-4a9b31848367"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6c43f7c78574e1d872e60fa8ff6cb0e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xNC0xLTEtMA_ef125ce3-f276-43ff-bd47-2ecbd23e0bb8"
      unitRef="usd">-198853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMy0xNi0xLTEtMA_9a2e5c55-bc5f-4f45-b424-07c6468ce147"
      unitRef="usd">60197000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="id40d9d3d244843f498894e71017e9d48_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC02LTEtMS0w_4a709a10-4db7-42e3-8229-f9f17570ba27"
      unitRef="shares">13390</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC0xMC0xLTEtMA_b9df2100-775f-4c93-9771-b0803cc1e86b"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNC0xNi0xLTEtMA_a5a68591-69a3-4dae-8d4f-b0c5c5907115"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id40d9d3d244843f498894e71017e9d48_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS02LTEtMS0w_585e9010-815c-419d-8021-3ae24389eab3"
      unitRef="shares">137213</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS0xMC0xLTEtMA_aa9f6022-09e7-4b70-8e65-156ba37ff8ae"
      unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNS0xNi0xLTEtMA_37d7b416-c29f-4b3d-aa78-95ea7d44415d"
      unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief8c3841743140e2b9cab4c42f359417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNi0xMC0xLTEtMA_d4cdf666-60fd-4a78-942a-ebe7b4756346"
      unitRef="usd">1955000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfNi0xNi0xLTEtMA_20914ea1-ca04-469f-a4a0-13a7390c947e"
      unitRef="usd">1955000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2b37e4af397a4118b204e37457dee732_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOC0xNC0xLTEtMA_8d280d97-51a2-470f-9f15-bd92dab80084"
      unitRef="usd">-23041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4a337c69309946809c3142def8201268_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOC0xNi0xLTEtMA_69354b96-4c20-4a7f-8e41-c34441ab854b"
      unitRef="usd">-23041000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9ad2f0cc24a5462b9661d795b6339101_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xLTEtMS0w_5caf534c-c97a-46c2-95b1-0165dcd3010c"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ad2f0cc24a5462b9661d795b6339101_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0zLTEtMS0w_62d983aa-3836-4728-926d-597f57fa4139"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i152ecd16776946888e51ea675f74bd45_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS02LTEtMS0w_9f256518-e01d-472c-91b4-41ee39f04f1c"
      unitRef="shares">32321208</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i152ecd16776946888e51ea675f74bd45_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS04LTEtMS0w_f986083d-50e4-40a1-9cbe-efeadb310e0b"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e4d24e8c5004e208a5aaa7c929381a3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xMC0xLTEtMA_42673d3f-cbe6-4e01-8c99-3ba4c54893db"
      unitRef="usd">261206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7b35cb2611543e9a26804e2b4845eba_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xMi0xLTEtMA_53eabdf4-b2f0-4003-b9af-a6f87ea0a346"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c9c460b18c9443e9a10e22f70b04a5d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xNC0xLTEtMA_f5812516-4fa2-4056-9475-813eec5c8c57"
      unitRef="usd">-221894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1115a5ba283435ca2ee0679245344cb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfOS0xNi0xLTEtMA_5b441f60-8749-4ed9-83a6-f38fcfaffcc2"
      unitRef="usd">39344000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtNi0xLTEtMA_ac84eeec-f9ae-4ab6-a581-9ee761f8eec9"
      unitRef="shares">13800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtOC0xLTEtMA_99d42ac7-2e57-4498-87c5-468a0f11b823"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtMTAtMS0xLTA_d0b67908-7480-405a-9ca4-a8a792925bd3"
      unitRef="usd">48393000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTAtMTYtMS0xLTA_74726a05-043c-453c-ab26-22afdc8626c4"
      unitRef="usd">48407000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtNi0xLTEtMA_26ae76f4-d00f-4b10-b59a-3d14e1ac95d0"
      unitRef="shares">11491</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtMTAtMS0xLTA_6b347bc6-3893-4350-a14a-f8753eed469f"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTEtMTYtMS0xLTA_03de940a-3774-48b8-9a89-7dd380159066"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2a762158a164478b8bd8c9feb5019215_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItNi0xLTEtMA_ac53eafd-f3ca-43e6-924b-88c0bb8ec390"
      unitRef="shares">3944</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItMTAtMS0xLTA_dd9f2383-a62c-4089-acf5-24e8bc8fa5f7"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTItMTYtMS0xLTA_d17a8a51-3205-4f8a-9820-7d83b56746f2"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1892d3b61dae481fbc9606ddcdee884e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTMtMTAtMS0xLTA_f7070bdb-07b7-4234-afe5-a0930eb718cb"
      unitRef="usd">2093000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTMtMTYtMS0xLTA_c23c8c7f-001b-4797-b4d4-5234980f4242"
      unitRef="usd">2093000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ifd90a3f9d90649d18c4f0e247aaa9b1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTUtMTQtMS0xLTA_f99d4cbb-8d4a-4acf-a490-e4409df5cec4"
      unitRef="usd">-20652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a73310a701e434b86bec90132205ebc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTUtMTYtMS0xLTA_7cf19059-8baf-4503-86a5-bfd4c22f8cc2"
      unitRef="usd">-20652000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if8749a7d111c4b6e80fb618dde5fec7a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMS0xLTEtMA_447c6824-a2ce-4116-943c-d81b593a839b"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if8749a7d111c4b6e80fb618dde5fec7a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMy0xLTEtMA_fe9a5299-5630-4b29-81ed-6761488f3c99"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0ae6a95b363a49f1b083c4c98235266a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtNi0xLTEtMA_853a8454-4bd7-4a6c-8944-fe51f49671de"
      unitRef="shares">46136643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0ae6a95b363a49f1b083c4c98235266a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtOC0xLTEtMA_d4635855-5257-493f-b2dc-c9b9683d39fb"
      unitRef="usd">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia597a7a81815459388e53a54a6edae64_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTAtMS0xLTA_956266c9-b01d-4c5f-affe-c308ba3d3701"
      unitRef="usd">311706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19330d3a0e2b4f32884d8c8d7d4e52f1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTItMS0xLTA_41f378dd-d734-4ac1-bc0a-8dd8cca15fc3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i772516e37d4348288bfb7ead82e084bf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTQtMS0xLTA_36d149ec-5b43-4da4-8531-432ff18a4d4c"
      unitRef="usd">-242546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84dcaeb2960441fb8320dc401c4122ce_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTYtMTYtMS0xLTA_a724c781-5f73-4d43-9525-804c751ed36a"
      unitRef="usd">69206000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctNi0xLTEtMTU4_104e324e-6bf7-441f-9457-d62652cb738a"
      unitRef="shares">28603</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctMTAtMS0xLTE1OA_9b164b51-d77a-4826-92eb-5e70e3302a0c"
      unitRef="usd">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTctMTYtMS0xLTE1OA_358d4904-011b-45e4-b195-6a33384d4586"
      unitRef="usd">92000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0dd03a3bf38c44dba37b8d6b58da8953_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktNi0xLTEtNDA_1c26bd55-5d43-40bb-afef-f14a2f33b378"
      unitRef="shares">18841</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktMTAtMS0xLTQ0_3db47e04-2ff6-4f44-a124-277f10c5c59d"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMTktMTYtMS0xLTQ2_cd5ae94c-2c99-468f-b121-0c5b95aab8c1"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTAtMS0xLTQ0_1b3498f6-91b3-4a44-8354-2ab166311b40"
      unitRef="usd">2045000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTYtMS0xLTQ2_da241b90-8c90-48a6-96d9-1f7f5ee3629b"
      unitRef="usd">2045000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iaeced90e17c34a07ba7f7b2ba42386c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTAtMS0xLTE2Nw_974d5211-8ac0-4ad9-8935-949464782a8e"
      unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjAtMTYtMS0xLTE2Nw_4b76eaf2-9619-4577-8397-d9501123bc8e"
      unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="id838f29aebd2439fad0dad587f16912b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjItMTQtMS0xLTUw_ea856dc8-9d2c-4dcb-a07f-b9baac20dec6"
      unitRef="usd">-20923000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjItMTYtMS0xLTQ4_fa3cb6c8-1d1e-42ac-b3a1-f7d2765f9df9"
      unitRef="usd">-20923000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="idfd50cbcea0a4661a3adca182198a047_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMS0xLTEtNTI_724e52d3-c659-49c4-887c-4a966d369d87"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idfd50cbcea0a4661a3adca182198a047_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMy0xLTEtNTQ_664f1086-e812-41aa-9345-c3ce0c009328"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0d7bc7d267b74b9994877e72a000f9a5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtNi0xLTEtNTY_d6c3685d-1734-46f9-a09b-1d5e5df39f07"
      unitRef="shares">46184087</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0d7bc7d267b74b9994877e72a000f9a5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtOC0xLTEtNTg_9e401616-e7c2-4ade-bdf2-c1af3dae59ff"
      unitRef="usd">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i623396ade16641e89475195261e0c3bb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTAtMS0xLTYw_ec119a38-2f09-42e8-9efd-1a4d9537c670"
      unitRef="usd">313853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie136aa58c43d4d94b9f15bed3514eb71_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTItMS0xLTYy_5959e604-ff72-4d94-aaaa-44af4649b1ee"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8f329a1ae7344c5a6ee59a259cb9c0d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTQtMS0xLTUw_4fc85ff6-871b-490e-bf26-e4de45c01dbb"
      unitRef="usd">-263469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOjE5Y2Y2M2U1OTk5YTQzMzJiMTgxMjhhOTc0ZTk1N2NiL3RhYmxlcmFuZ2U6MTljZjYzZTU5OTlhNDMzMmIxODEyOGE5NzRlOTU3Y2JfMjMtMTYtMS0xLTQ4_24d33b0a-deff-47cb-afce-ffe46bcdbf8a"
      unitRef="usd">50430000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if5a551ca740a46139c2913fdee05a4b8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xLTEtMS0w_61ebdd7f-ff7d-462b-9bda-3bd484726f1c"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if5a551ca740a46139c2913fdee05a4b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0zLTEtMS0w_b1d75aaf-aadd-493f-b21c-2382092abac5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy02LTEtMS0w_3e15cacc-c358-43c0-af80-cf0be3c430c5"
      unitRef="shares">31825769</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd1609ce8f8f4247b3f84a86217c6cf6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy04LTEtMS0w_02d6db21-b16d-4313-9204-2aacc7d5ab23"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ca79798a26c4655b0162e901ca8ef98_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xMC0xLTEtMA_f000d3af-4ce5-4f9f-84f1-874176ae16c8"
      unitRef="usd">250316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie35deec7c65a44019b54cb1521fcd2ba_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xMi0xLTEtMA_3049e8fa-88ca-4cd4-b912-2fe6105b01dc"
      unitRef="usd">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4e6055b96cc46ef9c60a122ec8ca1b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xNC0xLTEtMA_e74fa391-7253-4c4b-8325-50c8aa5dd7d1"
      unitRef="usd">-113381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMy0xNi0xLTEtMA_4ed3e191-23b6-4233-9fab-f251309471a4"
      unitRef="usd">136949000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC02LTEtMS0w_4d1c9c10-281d-4566-8dcd-8c0bb2d5a596"
      unitRef="shares">23345</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC0xMC0xLTEtMA_6397ef29-a0bb-4921-a81c-1a7802a8107a"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNC0xNi0xLTEtMA_8497a107-8f1f-45fc-b298-bd222dfbce5b"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS02LTEtMS0w_a206f4b9-8df0-4d7c-b4d0-3c9c141ee69d"
      unitRef="shares">181521</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS0xMC0xLTEtMA_d8b59165-5efc-46a1-8666-3a8e0504397e"
      unitRef="usd">257000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNS0xNi0xLTEtMA_132b8f19-d3d3-4194-bc3b-f39b3030ae7f"
      unitRef="usd">257000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6081422c67a4959affb382889e30181_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNi0xMC0xLTEtMA_b9f9dabb-c2af-4bd3-8cc4-8641c852863a"
      unitRef="usd">1953000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNi0xNi0xLTEtMA_df611752-25df-46e9-b89e-57047b6dbfca"
      unitRef="usd">1953000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5a8f41a0ea8041d3a56d432d4f829798_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNy0xMi0xLTEtMA_3b60523c-fc37-4e62-a30d-3b7edad44d6c"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfNy0xNi0xLTEtMA_f11408af-5cc4-4571-8e6f-2b827ac40c1b"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i2b973735904d462b9458f1b40f1cf9d0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOC0xNC0xLTEtMA_1f364f8e-6389-4843-a40a-947d43be624a"
      unitRef="usd">-20299000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icaddf3d673e3464f8610126b04e74e3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOC0xNi0xLTEtMA_b8fd1cf5-189c-4adf-9a81-077e71c70075"
      unitRef="usd">-20299000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i805997da9a164a49be9d13b7e742afae_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xLTEtMS0w_87935daf-68d4-484e-8bc8-c2b7ff457a08"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i805997da9a164a49be9d13b7e742afae_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0zLTEtMS0w_0d6dc5ea-6f19-4fbd-8edf-b2b1b5404257"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i297bd608c3da4046877c9279b8ac3205_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS02LTEtMS0w_6f4de162-c734-436d-b197-fa0f41ff3467"
      unitRef="shares">32030635</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i297bd608c3da4046877c9279b8ac3205_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS04LTEtMS0w_55c47969-c964-4781-b333-d2396dbcf207"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2df3854b70d4b358592d4b7bbeada9d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xMC0xLTEtMA_aa153f2e-4da7-48db-95c9-87866ff7c566"
      unitRef="usd">252533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89f527d367b242c68fd17edc1580165f_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xMi0xLTEtMA_db07fc42-b5aa-4e03-83ff-e2b50424751f"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i445472023dd84c71b2bc0455e0f1a754_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xNC0xLTEtMA_1f10e8c6-8403-45b3-97ea-dd298b42de2a"
      unitRef="usd">-133680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic90e130811884145a23fd79af66e4710_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfOS0xNi0xLTEtMA_c6a0141e-506f-4b6c-b2b2-ee9ab5f13a7b"
      unitRef="usd">118883000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtNi0xLTEtMA_03c52afc-ba84-4e6e-8b8a-4af4b0dacf1f"
      unitRef="shares">13692</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtMTAtMS0xLTA_51b5e4fe-cf57-490a-9b08-f45bec8fa467"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTAtMTYtMS0xLTA_dbc4fb03-6e64-4648-bed1-54d1762a555a"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3852568bc5b947d7a86df07f8ef15e38_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtNi0xLTEtMA_205c31ed-ed62-4d74-9899-eb21e0569aef"
      unitRef="shares">1379</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtMTAtMS0xLTA_19441f0c-4826-4133-a287-297be1266019"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTEtMTYtMS0xLTA_0827da59-46e0-49d2-a01a-c4160340b08c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6143d9820444cd099ffd5f56c80eeff_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTItMTAtMS0xLTA_d14a4ea6-e9e0-4a08-85ca-ccf823256409"
      unitRef="usd">2135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTItMTYtMS0xLTA_8d1b512e-e278-4b84-a3e3-2cf02222a0d3"
      unitRef="usd">2135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id1c64ec573a044acbc4a84c3cee5b65a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTMtMTItMS0xLTA_9afb20cc-c17f-4fbd-993a-0a266819d74a"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTMtMTYtMS0xLTA_1d99904e-204b-45f7-9e28-de61b58ddc8a"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6ca8c3e2a57b4525b59221196e30a8a2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTQtMTQtMS0xLTA_b12a8b2e-e495-47f6-bc9e-d1294c9039e3"
      unitRef="usd">-20941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifb9e1e1c711d428c89794ef2714d4151_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTQtMTYtMS0xLTA_71dba778-6ab7-4f4c-869a-95990bc61b5c"
      unitRef="usd">-20941000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2616efd03a3846519ef8667220526fbd_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMS0xLTEtMA_10e24c4e-dea2-498d-934f-f9903b726c10"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2616efd03a3846519ef8667220526fbd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMy0xLTEtMA_e81ae37c-c241-49d5-b6f8-a1cadd764c9d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i39f84b883b10466597e570d856ada5ad_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtNi0xLTEtMA_4752f943-abfd-48d9-833f-7e6b91b4b933"
      unitRef="shares">32045706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i39f84b883b10466597e570d856ada5ad_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtOC0xLTEtMA_584a0b44-ef07-4382-b33d-343e37809a8a"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i445a000730914ae9ad67896329d69891_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTAtMS0xLTA_c7411d2d-3bf5-4899-a0be-f5bbc0aa9d62"
      unitRef="usd">254676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38dc7b1f83b6487d924cdc369232095c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTItMS0xLTA_d6c79caf-b618-448f-996c-3520404b385d"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c6eb482d639489094b6f3423352160e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTQtMS0xLTA_e01bc829-2294-466d-b6af-f84dcf5b8a47"
      unitRef="usd">-154621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a049ceec50142168d6b7cdca6b55c5e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTUtMTYtMS0xLTA_4c7b17b8-3ef3-4a2f-868a-2e8139965649"
      unitRef="usd">100088000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtNi0xLTEtNjQ_43b326b1-5a21-4b8c-b44a-51e8babe9c71"
      unitRef="shares">13691</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtMTAtMS0xLTY2_a1552ffa-a26b-4482-8110-ed25d5dfcfc6"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTYtMTYtMS0xLTY4_7bab4e03-9313-46c9-92b8-30286d06467d"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic2f2cf93875245d1ad9d7f2049fd148b_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctNi0xLTEtNjQ_e9b9ddbd-e708-4f2d-aead-e61bccbda4b0"
      unitRef="shares">12633</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctMTAtMS0xLTY2_138f1c13-3f1a-4447-b99c-99be57f0cf85"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTctMTYtMS0xLTY4_eb5e4a78-801d-4158-9fd3-12692469083f"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3f7fb8e2d990455ca54e938434ebf452_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTgtMTAtMS0xLTY2_d32351f1-aaa1-41a6-bfbe-5cca6ed88e40"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTgtMTYtMS0xLTY4_d556cb4e-be95-457c-a584-f9da2dcc5a70"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id19506e2ff4b405a8e57e3b847319cef_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTktMTItMS0xLTcy_d6fc493f-9c71-4651-b1f9-ddb18c341970"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMTktMTYtMS0xLTY4_64f425d4-93f3-4f52-8873-3b7f74f36cb4"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="if000c9350a8f4fa3bae7dd8d649a04d7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjAtMTQtMS0xLTcw_5eb47347-1d1b-4a9b-88ad-fc17776ad8a9"
      unitRef="usd">-21633000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjAtMTYtMS0xLTY4_2f9a7225-2847-4448-8c84-429b0a1f3c27"
      unitRef="usd">-21633000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6400c85258fa4dfdb84406f6886223fe_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMS0xLTEtODQ_0a0dfeba-2cae-4d78-b9d0-5c0f95b3ed5c"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6400c85258fa4dfdb84406f6886223fe_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMy0xLTEtODI_b37d7320-e356-4d14-8c7d-b5b8577fd466"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtNi0xLTEtODA_de8c9cbf-8e67-4afe-adfa-faca040dde2e"
      unitRef="shares">32072030</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4bccf8c5333d4e1b9f7d23efd0c47969_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtOC0xLTEtNzg_f576f79d-2b34-48d8-8259-289bd3f7a89e"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib31920876cef41fda8536f18e104d5d1_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTAtMS0xLTc2_deb3ffcb-7041-44c2-b22b-c01c638ca4f7"
      unitRef="usd">256768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieca398585add43b0bee79e80e690e333_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTItMS0xLTc0_d5ac4c90-40a8-40f3-933c-723075b68dd2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54ea87091b054e0ab14959f3bdb971df_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTQtMS0xLTcw_9163124d-540f-48f1-b789-13fb780d08e4"
      unitRef="usd">-176254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0be4b8af0d144c6a8a31a5aa72508935_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yNS9mcmFnOjJjNWE2NTBlOWU3NDRiNGI4YjJlNDFkNmFmMWFiMzdmL3RhYmxlOmE5N2I0NzUwM2MzNTQ3YjhiMmYwODVjMThlN2NjNWRmL3RhYmxlcmFuZ2U6YTk3YjQ3NTAzYzM1NDdiOGIyZjA4NWMxOGU3Y2M1ZGZfMjEtMTYtMS0xLTY4_83cb3e2f-397f-44ac-a69d-5c149ac08d7f"
      unitRef="usd">80546000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMy0yLTEtMS0w_992c196e-a8df-4c2c-abc6-96aac1a19cd0"
      unitRef="usd">-64616000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMy00LTEtMS0w_f0348bf9-7ce7-4388-88aa-9b7f937389e7"
      unitRef="usd">-62873000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNS0yLTEtMS0w_f56612d6-e6d8-489d-84b1-ce9d36d6ef51"
      unitRef="usd">6093000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNS00LTEtMS0w_65f0e332-e974-4588-8ca4-9dc5309eb280"
      unitRef="usd">6150000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNi0yLTEtMS0w_a30fc9b2-9d94-46bf-b33d-999ec96939ec"
      unitRef="usd">1493000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNi00LTEtMS0w_8123cbcd-eb25-4bd1-a7a3-ac4e4ca002e2"
      unitRef="usd">1264000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNy0yLTEtMS0w_bfa22839-ffa3-4daf-800e-3befdb396b65"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfNy00LTEtMS0w_49550273-9be8-4ab7-bf31-641f0200cfd1"
      unitRef="usd">164000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <evlo:NonCashInterestExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOC0yLTEtMS0w_0b5e40eb-14cb-409e-a9ce-2e454cbdc0c6"
      unitRef="usd">250000</evlo:NonCashInterestExpense>
    <evlo:NonCashInterestExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOC00LTEtMS0w_1351e04f-1363-452d-94c7-dc92d1b10594"
      unitRef="usd">263000</evlo:NonCashInterestExpense>
    <evlo:NonCashOperatingLeaseExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfOS0yLTEtMS0w_fa77ccd9-cbc0-44b3-9b49-b2be2d25881c"
      unitRef="usd">1541000</evlo:NonCashOperatingLeaseExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTAtMi0xLTEtMA_fafbbd02-40f9-4eca-aedf-546b26b22723"
      unitRef="usd">5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTAtNC0xLTEtMA_057a64da-4f3d-4c14-9982-26a6d48f8c94"
      unitRef="usd">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTItMi0xLTEtMA_1944f654-76ef-4bf4-954e-ad9dfbcb8e9d"
      unitRef="usd">-267000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTItNC0xLTEtMA_d0598e1c-5749-4b78-9c87-f321d2a46607"
      unitRef="usd">633000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTMtMi0xLTEtMA_988bf271-4e6c-4f5b-bcbb-d5d1ec123234"
      unitRef="usd">2105000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTMtNC0xLTEtMA_d12a5d2b-0785-48d5-b434-1c5bf28b3763"
      unitRef="usd">90000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTQtMi0xLTEtMA_33b115ca-8206-46eb-ada6-1d23e323d569"
      unitRef="usd">263000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTQtNC0xLTEtMA_8813d25c-5ed5-46a1-9aef-3592020df8ed"
      unitRef="usd">2907000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <evlo:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTUtMi0xLTEtMA_6d51e923-6677-4d82-a155-e4f62167ae3d"
      unitRef="usd">-1771000</evlo:IncreaseDecreaseInOperatingLeaseLiability>
    <evlo:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTUtNC0xLTEtMA_2e091e78-f554-48fd-b372-1fc73e928d65"
      unitRef="usd">0</evlo:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTYtMi0xLTEtMA_d6f88607-2801-488f-a3b8-ab1813fe97b5"
      unitRef="usd">270000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTYtNC0xLTEtMA_85b4bdab-8b89-4e00-8fda-c2d7ecd36595"
      unitRef="usd">12000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTctMi0xLTEtMA_00d82e93-e91f-4224-9473-eee96966997d"
      unitRef="usd">-54110000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTctNC0xLTEtMA_2a555a86-75e0-45f7-b97c-27709b2038cc"
      unitRef="usd">-52986000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTktMi0xLTEtMA_4eab0728-21c1-473f-abcb-616b7ecc6bdc"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMTktNC0xLTEtMA_c8e519f6-79bb-4baf-8fa3-bb8a285e533b"
      unitRef="usd">55000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjAtMi0xLTEtMA_c5a550bc-2c5d-438d-b107-aefb5b7572e3"
      unitRef="usd">912000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjAtNC0xLTEtMA_776d6492-2f91-48b4-8d7c-a972e4460ff7"
      unitRef="usd">2569000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjEtMi0xLTEtMA_5f0a6ef4-1caf-4bb3-85f4-ef85049d221b"
      unitRef="usd">6000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjEtNC0xLTEtMA_118593c1-e163-427a-b30b-09647c363c09"
      unitRef="usd">2000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjItMi0xLTEtMA_3f4a0564-040d-4b01-b34f-1dbf74384839"
      unitRef="usd">-906000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjItNC0xLTEtMA_9b94a865-329a-4137-ab75-d1b13f667736"
      unitRef="usd">52433000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjQtMi0xLTEtMA_525c749f-1488-4c59-9ff0-f216c2741cfc"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjQtNC0xLTEtMA_92433e3e-5cc6-4251-839e-b67fd2869a63"
      unitRef="usd">19481000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtMi0xLTEtMjEw_37f14d6f-058c-4ec0-9268-13923d3ea152"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtNC0xLTEtMjE0_4dc2a880-c2af-4727-8482-16d84cb6fda6"
      unitRef="usd">15000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtMi0xLTEtMA_f010a158-6fe3-46ba-8ea1-60671fbfd0d8"
      unitRef="usd">48424000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjUtNC0xLTEtMA_50fafbf2-ec91-45a6-8626-0f524047c6c5"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjYtMi0xLTEtMA_3c897ecd-9b53-4963-b7fd-e50e06977099"
      unitRef="usd">339000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjYtNC0xLTEtMA_bbcbcd79-2393-4694-b2a2-2acb86862ac7"
      unitRef="usd">282000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjctMi0xLTEtMA_175dc62a-3a31-4df7-adf0-0896731687a3"
      unitRef="usd">58763000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjctNC0xLTEtMA_1f438928-65c4-4657-ba20-ddd74699c629"
      unitRef="usd">4763000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjgtMi0xLTEtMA_3967bcd2-bb3f-4fc7-b7ac-94e7dd7371d9"
      unitRef="usd">3747000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjgtNC0xLTEtMA_17cbac85-69cd-4943-8065-18a29b967a06"
      unitRef="usd">4210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjktMi0xLTEtMA_b1fe98d0-1910-4a8c-9e0f-a0f8c5736f2e"
      unitRef="usd">79333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i16e5ea94e7c645e7a44ad2ceb3bc91d9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMjktNC0xLTEtMA_e66e3891-bca2-46c1-87e0-94920abb8531"
      unitRef="usd">94351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzAtMi0xLTEtMA_1b9d9e63-dcf8-422c-869f-dc514624f92b"
      unitRef="usd">83080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0be4b8af0d144c6a8a31a5aa72508935_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzAtNC0xLTEtMA_d5a70720-0619-40fe-8a5d-2b402d8f1cda"
      unitRef="usd">98561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzItMi0xLTEtMA_7de713cd-958b-4b78-bc63-231f694a5caa"
      unitRef="usd">1509000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzItNC0xLTEtMA_f2a62df2-73a8-4e21-88a8-aabde5d21e10"
      unitRef="usd">728000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzMtMi0xLTEtMA_dbcb0dc3-698d-4373-9eb1-391d432f8617"
      unitRef="usd">20000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzMtNC0xLTEtMA_1749431c-64d9-4363-be8b-9bc15ddac75d"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzUtMi0xLTEtMA_b88307fb-30be-44e4-9463-984e7134fec4"
      unitRef="usd">19000</evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzUtNC0xLTEtMA_95c36bf2-c714-40b5-93bc-54461e835d0f"
      unitRef="usd">0</evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzYtMi0xLTEtMA_4df2063f-bf0c-4687-a181-f07000c3e796"
      unitRef="usd">33000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18yOC9mcmFnOjg3Y2IzOGE1NmIyYTQxMTk4YzhjYWYzYjgyY2JhNGQwL3RhYmxlOmVkZGQ5NjBhNjMyNjQ0MzFhNDFjZGY2ZWE0NTNmNzNmL3RhYmxlcmFuZ2U6ZWRkZDk2MGE2MzI2NDQzMWE0MWNkZjZlYTQ1M2Y3M2ZfMzYtNC0xLTEtMA_6620a1f4-1cdc-4ef7-b489-3fcec751e1c4"
      unitRef="usd">290000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfNDU5OQ_4cea0626-a38a-4c5a-b77c-1ccb84cdb769">Organization&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo Biosciences, Inc. ("Evelo" or the "Company&#x201d;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing oral biologics designed to act on cells in the small intestine with systemic therapeutic effects. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, the Company sold 13,800,000 shares of its common stock in an underwritten public offering at a public offering price of $3.75 per share, including the underwriters' exercise of their option to purchase 1,800,000 shares to cover over-allotment, generating gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 14, 2020, the Company drew down the second tranche of $10.0 million available under the 2019 Credit Facility. Refer to Note 6 to these unaudited condensed consolidated financial statements for more information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of September 30, 2020, the Company had cash and cash equivalents of $81.6 million and an accumulated deficit of $263.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. The transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure. Based on the Company&#x2019;s current operating plan and due to the uncertainty related to the impact of the COVID-19 pandemic and the nature of Evelo's business, the Company has substantial doubt that its cash and cash equivalents at September 30, 2020 will be sufficient to fund operations and capital expenditures for at least the twelve months following the filing of this Quarterly Report on Form 10-Q, and the Company will need to obtain additional funding. The Company intends to pursue strategic partnerships and collaborations, or obtain additional funding through its available financing sources which include, additional public offerings of common stock and private financing of debt or equity. Management&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. There can be no assurance that the Company will be able to obtain additional funding on acceptable terms, if at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources at September 30, 2020, management has concluded that substantial doubt exists with respect to the Company&#x2019;s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTEzNA_16912fb4-69ae-4d0e-b7b3-1744c79f1812"
      unitRef="shares">13800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icd3ed046380c402e916b73b4e3b00f00_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTIyOQ_71f9dfa2-da28-4df6-848f-b06753ac1107"
      unitRef="usdPerShare">3.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4bfb404ffb8f4796939c3c659d253923_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTMwOA_3bdf985d-d86d-464f-b1b4-430bff9d1df6"
      unitRef="shares">1800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTM3Mg_373d7586-95a0-4574-a994-81b590987f00"
      unitRef="usd">51800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTQwNQ_5967417a-5034-4a57-9c15-bc17ac052ce9"
      unitRef="usd">48400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMTA5OTUxMTY2NTQxOQ_5ce86f55-c5d9-4564-9a00-17703e40cee7"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMjA3MA_77c63195-bf17-4926-8556-b5da8c388c1b"
      unitRef="usd">81600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfMjEwMw_e6169e5d-d901-4c51-9ee2-a69a7bf8b71c"
      unitRef="usd">-263500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <evlo:SubstantialDoubtAboutGoingConcernPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNC9mcmFnOjc4ZDQxMzFhNmY3ZDQ2ZGI5Y2NhNjdmMWRiZmVlOWM2L3RleHRyZWdpb246NzhkNDEzMWE2ZjdkNDZkYjljY2E2N2YxZGJmZWU5YzZfNDYwMA_90e8f8ea-484b-456b-a3a8-6a3924c64c97">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. The transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure. Based on the Company&#x2019;s current operating plan and due to the uncertainty related to the impact of the COVID-19 pandemic and the nature of Evelo's business, the Company has substantial doubt that its cash and cash equivalents at September 30, 2020 will be sufficient to fund operations and capital expenditures for at least the twelve months following the filing of this Quarterly Report on Form 10-Q, and the Company will need to obtain additional funding. The Company intends to pursue strategic partnerships and collaborations, or obtain additional funding through its available financing sources which include, additional public offerings of common stock and private financing of debt or equity. Management&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. There can be no assurance that the Company will be able to obtain additional funding on acceptable terms, if at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources at September 30, 2020, management has concluded that substantial doubt exists with respect to the Company&#x2019;s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;</evlo:SubstantialDoubtAboutGoingConcernPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTA_9a194f17-f603-4eb4-8eff-d3142b3eadd1">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#x2019;s financial position as of September 30, 2020, the results of its operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results for the year ending December 31, 2020, or for any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Event Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the unaudited condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss. The Company's only element of other comprehensive loss is unrealized gains on available-for-sale investments, which the Company held in 2019. Comprehensive loss totaled $20.9 million and $64.6 million, respectively, for the three and nine months ended September 30, 2020. For the three and nine months ended September 30, 2019 comprehensive loss was $21.6 million and $62.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#x2019;s restricted cash consists of restricted cash in connection with building leases for the Company&#x2019;s office and laboratory premises and deposits held in relation to the company's credit card facility. Restricted cash totaled approximately $1.5 million at September 30, 2020 and December 31, 2019, and is classified within other assets on the accompanying condensed consolidated balance sheet. The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#x2019;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock-based compensation for options granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the Company&#x2019;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;), which supersedes the guidance in former ASC 840, Leases. The new accounting guidance requires recognition of all long-term lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. It requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The FASB subsequently issued several ASUs amending the new standard. This guidance is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018 for most public entities. The Company adopted this new standard on January 1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASU 2016-02 provides a number of optional practical expedients in transition. The Company elected to adopt the 'package of practical expedients', which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, and (iii) not to reassess initial direct costs for any existing leases. The Company will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#x2019;s January 1, 2020 condensed consolidated balance sheet of $12.7 million and $13.9 million, respectively. There was no material impact resulting from the adoption on the Company&#x2019;s unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2020. For leases with terms greater than 12 months, the Company records the related right-of-use asset and lease liability at the present value of lease payments over the term. As the Company&#x2019;s leases do not provide readily determinable implicit interest rates, the Company utilized its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The application of the new standard required netting of unamortized balance of lease incentives and deferred lease obligation to the right-of-use asset at the adoption date. The Company&#x2019;s operating leases include rental escalation clauses that are factored into the determination of lease payments when appropriate. The Company does not separate lease and non-lease components of contracts. Refer to Note 3, Leases within these unaudited condensed consolidated financial statements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the FASB issued ASU No. 2018-07,&#160;Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting (Topic 718) ("ASU 2018-07"), which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. Entities will apply the ASU by recognizing a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the annual period of adoption. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of this standard did not have a material impact on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTg_50b6cd6a-6ffc-4a19-9200-dd370ba208f1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#x2019;s financial position as of September 30, 2020, the results of its operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results for the year ending December 31, 2020, or for any future period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTk_3a1b61ff-ba50-4eb9-9962-a5ff76a56628">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYzMDA_8e925b1b-9a69-4126-86aa-e4d2c1fefd48">Principles of ConsolidationThe unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTE_965fbcec-e406-4913-b6cb-074547181dd7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Event Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the unaudited condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure in this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <evlo:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTI_ffa6b560-a947-41dd-937b-1a87dce4a4f7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;</evlo:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODc_0217ce7b-4505-4399-8af3-e14bf26564a8">Comprehensive LossComprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDg1OQ_f67bcf21-d058-4ea0-b882-4dd12b155d23"
      unitRef="usd">-20900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDg2Ng_40868913-662d-429b-a825-a43a006d021a"
      unitRef="usd">-64600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDk4NA_f447f970-41db-4dbf-905f-578379f3c6cf"
      unitRef="usd">-21600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNDk5MQ_9c316ca5-8e8d-4feb-aa0e-a87b79c8bee0"
      unitRef="usd">-62900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTM_5122f0a2-8f34-4ce5-954d-5e1b4b250990">Cash, Cash Equivalents, and Restricted CashCash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#x2019;s restricted cash consists of restricted cash in connection with building leases for the Company&#x2019;s office and laboratory premises and deposits held in relation to the company's credit card facility.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNTYxNA_44e72804-411c-4074-985a-4b6c15848819"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfNTYxNA_ef6f1bdc-eb87-485e-bbcc-a5896a63838f"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODg_e7680694-17b3-4984-8589-9e66c84fd63f">The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMjE5OTAyMzI3MTg1Nw_f25a262b-6589-47fe-b9f3-6450e5d77933">The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:Cash
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMi0yLTEtMS0w_b05adfa6-226e-402b-b0ba-1d8faf158010"
      unitRef="usd">6830000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMi00LTEtMS0w_d622900d-96d3-4adc-8831-6482fb44983a"
      unitRef="usd">1634000</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMy0yLTEtMS0w_fce03112-76c1-4c9c-957a-7fd561f94041"
      unitRef="usd">74750000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfMy00LTEtMS0w_d1760329-6be3-40ac-a8fd-fa4f97728dfc"
      unitRef="usd">76199000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNC0yLTEtMS0w_41f244ae-2283-41be-9689-4b3c3fb34a3e"
      unitRef="usd">81580000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNC00LTEtMS0w_2733d3bd-f624-479d-9651-c00a4353846b"
      unitRef="usd">77833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNS0yLTEtMS0w_d621522a-5fc2-486c-91c5-50273b38a1ef"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNS00LTEtMS0w_43e6ba7e-b2b0-4e72-af07-6bba6eca4671"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNi0yLTEtMS0w_e4192c6f-16ad-459f-9c72-933d755e3770"
      unitRef="usd">83080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RhYmxlOmZhY2M5Y2VhYjc5YzQ5OGE4ZTlhOTJjZThkNWUwNTNjL3RhYmxlcmFuZ2U6ZmFjYzljZWFiNzljNDk4YThlOWE5MmNlOGQ1ZTA1M2NfNi00LTEtMS0w_e00c5048-abb3-4916-b8ef-a347a59f7492"
      unitRef="usd">79333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYzMDE_11f399a2-6bc1-44d2-9c3c-879806273e45">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyODk_bc3b07fe-f329-4e24-943e-6981616670e0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#x2019;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMzI5ODUzNDg5OTYzMQ_26469262-3763-4115-b767-2db42c5f23ee">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock-based compensation for options granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the Company&#x2019;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMzI5ODUzNDg5OTYzMg_f9bb88f1-5fc6-426d-9522-1255df5e1a07">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTExNjk_6e99d281-9d1c-4f41-9412-77472b1569ba"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTYyOTU_222c9a22-70ee-4c7c-b847-f7042a17dd57">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;), which supersedes the guidance in former ASC 840, Leases. The new accounting guidance requires recognition of all long-term lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. It requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The FASB subsequently issued several ASUs amending the new standard. This guidance is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018 for most public entities. The Company adopted this new standard on January 1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASU 2016-02 provides a number of optional practical expedients in transition. The Company elected to adopt the 'package of practical expedients', which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, and (iii) not to reassess initial direct costs for any existing leases. The Company will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#x2019;s January 1, 2020 condensed consolidated balance sheet of $12.7 million and $13.9 million, respectively. There was no material impact resulting from the adoption on the Company&#x2019;s unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2020. For leases with terms greater than 12 months, the Company records the related right-of-use asset and lease liability at the present value of lease payments over the term. As the Company&#x2019;s leases do not provide readily determinable implicit interest rates, the Company utilized its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The application of the new standard required netting of unamortized balance of lease incentives and deferred lease obligation to the right-of-use asset at the adoption date. The Company&#x2019;s operating leases include rental escalation clauses that are factored into the determination of lease payments when appropriate. The Company does not separate lease and non-lease components of contracts. Refer to Note 3, Leases within these unaudited condensed consolidated financial statements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the FASB issued ASU No. 2018-07,&#160;Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting (Topic 718) ("ASU 2018-07"), which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. Entities will apply the ASU by recognizing a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the annual period of adoption. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of this standard did not have a material impact on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of September 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia38f09c6713544c7bdac7b4ef58e8230_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTM0NDM_9fbed6b1-0912-4707-ab09-ba069a98f87d"
      unitRef="usd">12700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia38f09c6713544c7bdac7b4ef58e8230_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN18zNy9mcmFnOjlkMWFkYmNhNzllOTQ3NDE4N2JjODA2NGRiZGE1M2Q2L3RleHRyZWdpb246OWQxYWRiY2E3OWU5NDc0MTg3YmM4MDY0ZGJkYTUzZDZfMTM0NTA_cb08a7b4-c75e-48ad-8128-cd21e9494273"
      unitRef="usd">13900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTQ1MA_1e395ad4-a9f0-4784-9381-7275c3a35768">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately 40,765 square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $0.2 million for the nine months ended September 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2020, the Company recorded rent expense of $0.7 million and $2.1 million, respectively. Rent expense for the nine months ended September 30, 2020 is net of sublease rental income of $0.3 million. There was no sublease rental income for the three months ended September 30, 2020. For the three and nine months ended September 30, 2019, the Company recorded rent expense of $0.7 million and $2.0 million, respectively, which is net of sublease rental income of $0.1 million and $0.4 million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum aggregate future lease commitments, exclusive of any offsetting sublease rental payments, at September 30, 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding payments made as of September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,422&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,312)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,110&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="id4d98a0593604e4db29e81ca0e1ed08e_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTE0_53446e3a-2292-40b9-b1a7-bc21510041c7"
      unitRef="sqft">40765</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfNzY3_fa856df0-6816-4f17-b730-03f97b2a4381"
      unitRef="usd">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTY0OTI2NzQ0NTA2Mg_66aba4ed-1208-4c61-84c8-77a6aa192ab5"
      unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTAzNg_04536600-523e-4498-9867-88287bb12e67"
      unitRef="usd">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMTAyMg_8ea8c70e-bd37-436c-bf27-e04de661f07b"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMjE5OTAyMzI1ODkxNQ_523275fd-9621-49e5-bd21-45afa2b4bd4e"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA0NDUzNjA0NjczMDI_b139049b-cba1-41e4-92a4-b90196ecd0db"
      unitRef="usd">700000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMTA1OA_6cc449cb-188a-4abf-ad06-b150f8028a3c"
      unitRef="usd">2000000.0</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMDE5MA_84a70367-d7e2-44ad-93fc-3a1a3c3da0a4"
      unitRef="usd">100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTA5OTUxMTYzMDA1Mw_fff810e2-65be-4a3b-8b7b-c7c846d32364"
      unitRef="usd">400000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RleHRyZWdpb246MjJlZjg3NDcwMWQ5NGQ4ODkxYzBhZGZhZGMxNmU2Y2RfMTQ1MQ_eaa093fa-8724-42d2-a5bc-507427d5e531">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum aggregate future lease commitments, exclusive of any offsetting sublease rental payments, at September 30, 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding payments made as of September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,422&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,312)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,110&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMS0yLTEtMS0w_438c4959-2566-461c-9bac-9d434492dc1a"
      unitRef="usd">493000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMi0yLTEtMS0w_0b8f33c3-5c17-4689-b18b-cae23ad6a869"
      unitRef="usd">2973000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMy0yLTEtMS0w_0f9df962-cc9a-4c1c-b903-df2597bc6753"
      unitRef="usd">3062000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNC0yLTEtMS0w_285bb605-d43e-4bd2-8c43-e4485d22b357"
      unitRef="usd">3154000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNS0yLTEtMS0w_7584d919-b575-4226-b044-f23c507a941c"
      unitRef="usd">3249000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNi0yLTEtMS0w_e0bf19b4-f537-49ba-a97e-36754b0d676a"
      unitRef="usd">2491000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfNy0yLTEtMS0w_7eb5390a-7038-47cb-b0c1-d5c8668fe458"
      unitRef="usd">15422000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfOC0yLTEtMS0w_2397358a-1662-4c8e-9bbb-dfa7a1b11e09"
      unitRef="usd">3312000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfOS0yLTEtMS0w_7385d387-d7e9-453d-850e-957b15addc57"
      unitRef="usd">12110000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTItMi0xLTEtMA_ed982c9e-d016-4117-84f5-7ef7a4336363"
      unitRef="usd">2596000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTMtMi0xLTEtMA_c0026859-4d2c-44a1-8c1c-a0b84ea173d7">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180MC9mcmFnOjIyZWY4NzQ3MDFkOTRkODg5MWMwYWRmYWRjMTZlNmNkL3RhYmxlOjAzYTQzNzliNGIyYTQ1YWI4ZDViNzA4MTZlMDJiZTZhL3RhYmxlcmFuZ2U6MDNhNDM3OWI0YjJhNDVhYjhkNWI3MDgxNmUwMmJlNmFfMTQtMi0xLTEtMA_f0151ac3-5ef0-47cc-89bd-dd4f0d992c84"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RleHRyZWdpb246Y2ZiOWEyNGRlOTYwNGM0MDllNDE4ZDNjNWEyNDRkYjlfNTMw_d2cb5ca1-7937-4aa4-8470-ef259dc7c0eb">Fair Value Measurements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value as of September 30, 2020 and December 31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;September 30, 2020&#160;and&#160;December 31, 2019, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RleHRyZWdpb246Y2ZiOWEyNGRlOTYwNGM0MDllNDE4ZDNjNWEyNDRkYjlfNTMx_ddfef71c-1c0b-4d51-afe6-f27e4a7a942b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value as of September 30, 2020 and December 31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iea25c6e18d36425baa31be5ed904178a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi0yLTEtMS0w_8ed9a021-1635-4e72-ab7f-fa4bba0af731"
      unitRef="usd">74750000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e795277073a42ab9298318fbeb02b69_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi00LTEtMS0w_130a76fd-99aa-4791-b74c-92ff2b54de54"
      unitRef="usd">74750000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iac86fce0f21b41e996c6c3824f421637_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi02LTEtMS0w_b95eac8b-3251-430b-bf6e-293e289775ed"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a65273c2fc747578248931d9beaed19_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMi04LTEtMS0w_999f00f4-449c-4340-8487-1508bfdcb136"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy0yLTEtMS0w_894b0f58-0111-4f89-a271-97b78a16ee97"
      unitRef="usd">74750000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i815d7bddf0dc463bad9464271644bbe6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy00LTEtMS0w_3a6de927-3807-45c9-baf2-d71282cc7877"
      unitRef="usd">74750000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i142ceba3efcb45ea958d6e85b6db1bf4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy02LTEtMS0w_03e7de29-870e-4586-ad02-80bae07ed308"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14ded15f9f634b35ab6d912652a390dc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjViYmU5NmJmZDBmNzRiNGM5OGY1NDljNWE5NTY2ZWQ3L3RhYmxlcmFuZ2U6NWJiZTk2YmZkMGY3NGI0Yzk4ZjU0OWM1YTk1NjZlZDdfMy04LTEtMS0w_871e61c5-f796-49d5-a2b1-602e5ee93445"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2ba7ce22ac4e412aaff058cba3436fcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi0yLTEtMS0w_05a7a6ca-a57c-4a89-a60b-2b9ffd0eb45e"
      unitRef="usd">76199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01995a7366b14ec2aeb7be9fad8b500a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi00LTEtMS0w_5cd76028-66be-435f-a119-dc6304feed9b"
      unitRef="usd">76199000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i46b0c348e01a4c26922b187713bd5bf6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi02LTEtMS0w_c046f68b-b3ab-4797-a5c0-7a312d8067fb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i36ed7412637b46c8a8dbfdfb42b69661_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMi04LTEtMS0w_d1ba9a05-3744-47f1-a497-9f1f6adc5f67"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy0yLTEtMS0w_ad16d93b-a231-4b9b-b7e1-a3d8754d4da6"
      unitRef="usd">76199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i11bd6b0b98e54b1f9d4b6e9d9dc8b0b1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy00LTEtMS0w_50ae48f1-ec60-419c-ab72-7c9566e0cb78"
      unitRef="usd">76199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c2dc7dd1162441085728c89b9000072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy02LTEtMS0w_df52b260-accd-4ef1-aea5-b369400947e5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3254063206b34f168fff62c3216eaf37_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180My9mcmFnOmNmYjlhMjRkZTk2MDRjNDA5ZTQxOGQzYzVhMjQ0ZGI5L3RhYmxlOjlhZTVlMDljZmE1NzQ5MzE4NmQ0MTE2OWM5MmVhNGRkL3RhYmxlcmFuZ2U6OWFlNWUwOWNmYTU3NDkzMTg2ZDQxMTY5YzkyZWE0ZGRfMy04LTEtMS0w_bf3f152a-600e-42bc-ad16-15cd42d819e0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjU1_83f48a98-4aff-4170-a774-18f6277aa7ad">Property and Equipment, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $0.5 million and $1.5 million of depreciation expense for the three and nine months ended September 30, 2020, respectively and $0.5 million and $1.3 million for the three and nine months ended September 30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjU2_a2040336-e952-4bd1-91a7-07827177fd03">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4c9f5c9ddad943ce8f82cc180c9a0533_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMi0yLTEtMS0w_6bc2e94f-6e4c-4c82-acd6-4f295b69e25f"
      unitRef="usd">8606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b67f0fe6a5740e398b3f31ff3dd1588_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMi00LTEtMS0w_1b1423de-0492-45e1-954d-67261a5045a1"
      unitRef="usd">7479000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i164f6350f5e344edacb0e9a6b68a1844_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMy0yLTEtMS0w_73d6c360-4498-4e2b-99ab-ef118b13962a"
      unitRef="usd">2157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i220d743ead6c44fd9305f7880abca00e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMy00LTEtMS0w_24f27f10-ae9b-4047-abe7-488a4c16f511"
      unitRef="usd">2014000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7ea1dda588544015980d719168da2fa6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNC0yLTEtMS0w_7318e2ab-2072-4d62-899f-f2ab8ee1f5f5"
      unitRef="usd">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff5b25883e8f43038b8df1042fc86276_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNC00LTEtMS0w_051356aa-ed02-446e-8ed3-bd210e3a10cd"
      unitRef="usd">750000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5a81634a68840829977fa5b44a68d41_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNS0yLTEtMS0w_fc79cea5-3e05-4c65-8b5d-592aa5edc1ed"
      unitRef="usd">230000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc8f58fdec814720a8bc0f6960a616b6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNS00LTEtMS0w_a1714f6d-7370-47d2-a032-4c6d1c6b580e"
      unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7fda17f67d6e4f98be456487782da379_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNi0yLTEtMS0w_c1a25d66-697a-4c2b-aaa5-60b1eae5a74e"
      unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1d0061ad4354ae29fd62e2b60137505_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNi00LTEtMS0w_724b5724-8364-44dd-a7de-eaef9ff39c64"
      unitRef="usd">9000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib69bb769acc2400e94f81dd3cfb5831b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNy0yLTEtMS0w_ff249c46-1bdf-4b5e-8991-ff1ebd89a5a3"
      unitRef="usd">877000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i45be461d034047e1880917ae93e7b605_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfNy00LTEtMS0w_140e33c2-89ea-46a2-80d7-33363476e481"
      unitRef="usd">1594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOC0yLTEtMS0w_cb70c377-8e9c-43d7-883f-df8c35e7438b"
      unitRef="usd">12695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOC00LTEtMS0w_e0c28579-e624-43de-b371-726cdbfbf6c3"
      unitRef="usd">12050000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOS0yLTEtMS0w_d35a09e5-4a99-4e6a-90fa-f7c00ba79ad2"
      unitRef="usd">5109000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfOS00LTEtMS0w_09c6b085-f853-4bec-be13-21ff7eaa9983"
      unitRef="usd">3709000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMTAtMi0xLTEtMA_9533de16-3b5a-4e64-bd5e-965a67dc9c16"
      unitRef="usd">7586000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RhYmxlOjU5YmJjOWE4ZGE0NjRhYTNiMzg3OTc5NzFjMjQ3ZWMwL3RhYmxlcmFuZ2U6NTliYmM5YThkYTQ2NGFhM2IzODc5Nzk3MWMyNDdlYzBfMTAtNC0xLTEtMA_c56170d5-9a69-44b3-a1f8-e3a13f8d44b3"
      unitRef="usd">8341000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMTI2_3779388f-a601-4fdb-b27a-c721eb18a132"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMTMz_0992c7dd-2216-4bda-93a6-a958159f05db"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjA1_d9aa8c92-0e12-4052-9770-dbc533ad7faa"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180Ni9mcmFnOjZiY2IyYzBmODkwZjQyYWJhZTk3OWRiNjg1YjE0MWYwL3RleHRyZWdpb246NmJjYjJjMGY4OTBmNDJhYmFlOTc5ZGI2ODViMTQxZjBfMjEy_0d56243b-3bc8-4979-9f5c-525a00080a46"
      unitRef="usd">1300000</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjE5OTAyMzI2MDcwMw_01b3b6f8-aa95-4736-bef7-ae42dc6d7ea9">Loan and Security Agreements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into a credit facility (the &#x201c;2016 Credit Facility&#x201d;) with a bank that allowed the Company to borrow up to $15.0 million. Borrowings under the 2016 Credit Facility were secured by a lien on all Company assets, excluding intellectual property. The Company borrowed the entire $15.0 million available under the 2016 Credit Facility prior to its extinguishment in July 2019 as discussed in further detail below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Credit Facility contained negative covenants restricting the Company&#x2019;s activities, including limitations on cash deposits, dispositions, mergers or acquisitions, incurring indebtedness or liens, paying dividends or making investments and certain other business transactions. There were no financial covenants associated with the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $45.0 million available to the Company in three tranches. The initial tranche of $20.0 million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $10.0 million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The third tranche of $15.0 million is available to be funded at the Company's election on or before January 15, 2021, subject to certain customary conditions and the achievement of certain clinical development milestones. Borrowings under the 2019 Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) 8.65% and (ii) the prime rate plus 3.15%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2022. If the Company elects to draw the third tranche, the interest-only period will be extended through August 31, 2022. Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to 4.3% of the loans borrowed, which is being accrued to interest expense over the term of the loan using the effective-interest method. The Company incurred fees associated with establishing the 2019 Credit Facility of $0.4 million. The Company has an option to prepay the loans in whole, subject to a prepayment fee of 2% of the amount prepaid or, if the prepayment occurs after the 18-month anniversary of the funding date of the loans, 1% of the amount prepaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The 2019 Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the 2019 Credit Facility and under applicable law. As of September 30, 2020, the Company was in compliance with all covenants under the 2019 Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the proceeds from the initial $20.0 million tranche to prepay on July 19, 2019 the full $15.0 million loan balance outstanding under the 2016 Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has the following minimum aggregate future loan payments at September 30, 2020 (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve month period ending September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the Company's 2016 Credit Facility was approximately $0.5 million for the nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the Company's 2019 Credit Facility was approximately $0.6 million and $1.5 million for the three and nine months ended September 30, 2020 and $0.4 million for both the three and nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i22371425da1041168cf343492f01c4fa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTky_b6c8f5f6-80c8-43f6-a6d6-4b9959db92ac"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i22371425da1041168cf343492f01c4fa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzQ5_b6c8f5f6-80c8-43f6-a6d6-4b9959db92ac"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTExMw_c46843d2-f983-4bcc-b7b6-6d5bd2a27a0d"
      unitRef="usd">45000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <evlo:SecurityAndLoanAgreementNumberOfTranches
      contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE0NA_a56290f9-41d6-420c-97f7-f7832ba4887f"
      unitRef="tranche">3</evlo:SecurityAndLoanAgreementNumberOfTranches>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE4MA_f427ad79-8062-44c6-8937-344630aa9389"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i06bc5ceebeae4cc9b81437f800ee64fb_D20200714-20200714"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTI3NQ_5ce86f55-c5d9-4564-9a00-17703e40cee7"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5888734b31a84abe9cd96515a54830d4_D20201001-20210115"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTQwNA_48570b22-1a38-4d02-a267-0a17b313a3a4"
      unitRef="usd">15000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTk5Mg_ebec6a9c-e8ff-4db4-a1ac-31cb77a281ad"
      unitRef="number">0.0865</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic924efafb0664fcc9352ca108ea8fc1d_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjAyNA_cb027ab0-bdf8-4df3-9d54-65c5282997c3"
      unitRef="number">0.0315</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage
      contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjUxNg_50087962-e280-41d2-9fad-da34310b588a"
      unitRef="number">0.043</evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i7c4aa38b5d9b4bb9971733482e5942b8_I20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjczMQ_25a8763b-5384-4839-87fe-6a2eab590eef"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsGross>
    <evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal
      contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjgyMg_6172ff5d-edea-4490-bce1-2113a5e1b0a5"
      unitRef="number">0.02</evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal>
    <evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage
      contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjg4Ng_0900a6f8-d601-4064-bf60-59fa300c847e">P18M</evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage>
    <evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne
      contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMjk0MQ_f7b1e6dd-4e07-414f-a6f8-80f4cbd555b7"
      unitRef="number">0.01</evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne>
    <evlo:DebtInstrumentDebtDefaultPercentage
      contextRef="ie17ac7815b8c45329ca3a1f54e54967d_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzU0NQ_3e77b4e6-d021-4ea7-a9e7-6ade4a6106b8"
      unitRef="number">0.05</evlo:DebtInstrumentDebtDefaultPercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i56c8a7cca51442ae92613c0f57bb7f9f_D20190719-20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMzk4Nw_9f4aa52b-0724-4097-b822-6212b2f21204"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if6af8e2843d54b498ab6811a2bdb9e01_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDAzNA_fad20a4c-c820-47d4-aa79-c48e0121e027"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDYyNA_7bbe9e1b-ecfb-4c58-8944-849b9c60632e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has the following minimum aggregate future loan payments at September 30, 2020 (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve month period ending September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMS0yLTEtMS0w_1803f275-b5db-467f-a3da-8d67e3544acd"
      unitRef="usd">2631000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMi0yLTEtMS0w_7351f901-4c4f-4459-9830-36716a5c85bd"
      unitRef="usd">8912000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfMy0yLTEtMS0w_6109f59d-8f4d-4cee-b669-9357e5581f68"
      unitRef="usd">13387000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNC0yLTEtMS0w_3d29ec49-9864-447e-920b-419c2305bee5"
      unitRef="usd">13605000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
    <evlo:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNS0yLTEtMS0w_fd5ab049-e6e9-42ef-9946-4494c77b1335"
      unitRef="usd">0</evlo:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNi0yLTEtMS0w_49ab356e-7638-48cd-ab77-a774a313b35f"
      unitRef="usd">38535000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfNy0yLTEtMS0w_56ce413a-7b00-4cc5-8b48-6b511633b74c"
      unitRef="usd">8611000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i714d2fe395864b4fa7d700a7d8555b24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RhYmxlOjVkMDExYjlmNmZkMTQ2NzI5YzQ2NTE4NjdiM2ZjNmE4L3RhYmxlcmFuZ2U6NWQwMTFiOWY2ZmQxNDY3MjljNDY1MTg2N2IzZmM2YThfOC0yLTEtMS0w_2ff47e9a-7df0-4705-b921-2843e90014f8"
      unitRef="usd">29924000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="i36512fd07785419f8c346218b88c3574_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDQ3NQ_90b1c44d-a2aa-4b6b-a02d-aacacd4a33d9"
      unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i497af9117217436086fed1b12ad3d7a9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDU4Nw_27bf1ec2-c800-4875-981a-6531ce54c388"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6ec21311cae448859c4bf7db77fa683c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfNDU5NA_73905457-2a4f-4c15-a2e5-fffce5b6ecd5"
      unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1cc03be1a9fa44fa9fad574644a033f2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE1NDQ4NzIwOTYzNDM_04a81b8b-9a75-4155-9fc7-1aa1f974bb9b"
      unitRef="usd">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i52af12becc094820bd3f1230018cdaee_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN180OS9mcmFnOmEyZDM4MGNjNmJiOTRjN2E5NDQ5OGMyNjZlNjVmOWFjL3RleHRyZWdpb246YTJkMzgwY2M2YmI5NGM3YTk0NDk4YzI2NmU2NWY5YWNfMTE1NDQ4NzIwOTYzNDM_7bec8fa0-8920-4ab7-97bd-12251a28878e"
      unitRef="usd">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMzAxMw_44d66fd4-f2a1-469b-be92-dacf9ba1be80">In-License Agreements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mayo Foundation for Medical Education and Research&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 10, 2016, the Company entered into a Research and License Agreement, (the &#x201c;2016 Mayo License Agreement&#x201d;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#x201c;Mayo Clinic&#x201d;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#x2019;s public offering and warrants which were issued in 2016 and exercised in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#x201c;2017 Mayo License Agreement&#x201d;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#x2019;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $0.2 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $56.0 million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $0.2 million under the agreement of which no&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are currently due.&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;University of Chicago&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#x201c;2016 University of Chicago Agreement&#x201d;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the Licensed Patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize Licensed Products. As consideration, the Company paid a nonrefundable upfront fee of less than $0.5 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $60.9 million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $0.4 million under the agreement of which no&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are currently due.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <evlo:NonRefundableUpfrontFee
      contextRef="i9b24ece8af454852802d95c232d20b4f_D20170806-20170806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTE4NA_ca01bbdc-dd24-42e7-a7fe-e53f6072fe0a"
      unitRef="usd">200000</evlo:NonRefundableUpfrontFee>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="ib76eb2613df44ca0bf34544038de3c75_D20170806-20170806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTU2MQ_d9d8bab9-2ac2-4724-abb3-b57ee066ffc4"
      unitRef="usd">56000000.0</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="i5765428e6dc9410ba812e1aa42d7c4c2_D20170806-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTc1NQ_f97081b5-344a-4d5b-ae9a-be212ce4811e"
      unitRef="usd">200000</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <us-gaap:ContractualObligation
      contextRef="ia2705dcad5b24a6489673679a8b632af_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMTc4Nw_2d9ea167-a96e-4636-92a3-d2f69266b34f"
      unitRef="usd">0</us-gaap:ContractualObligation>
    <evlo:NonRefundableUpfrontFee
      contextRef="i04e883ac26644ef6a592b975350598ff_D20160310-20160310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjQwMA_535667fa-7165-4cde-a23e-8f9c02a06b7c"
      unitRef="usd">500000</evlo:NonRefundableUpfrontFee>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="i8f6455f87ca54808a728b425104feb45_D20160310-20160310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjczMw_f9dc5774-ad1e-4938-a278-308b6729f560"
      unitRef="usd">60900000</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts
      contextRef="ia3aacf5203e14a5cb0bcbc6335830341_D20160310-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMzAxMQ_7e3870b7-d32c-430b-b355-3628825ab053"
      unitRef="usd">400000</evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts>
    <us-gaap:ContractualObligation
      contextRef="i39a9eed2f1ed471496cc34819ec412d1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181Mi9mcmFnOjY5MGY4Y2ZmY2QzYjQ4NTk4ZDI5ZmU3N2E1YmUzZWE0L3RleHRyZWdpb246NjkwZjhjZmZjZDNiNDg1OThkMjlmZTc3YTViZTNlYTRfMjE5OTAyMzI1OTE3OA_dae2992c-492c-45aa-bb99-089d75f574db"
      unitRef="usd">0</us-gaap:ContractualObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMzI5ODUzNDg4NjIzMw_c3c9cb8e-1c3b-458d-bea6-029b1980f84c">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Collaboration Agreement with Sacco S.r.l.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#x2019;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of five years. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNjgz_88021ac0-a529-40c8-86cd-253480fcf249"&gt;six&lt;/span&gt; consecutive months. The Company has agreed to pay Sacco an aggregate of &#x20ac;3.0 million, &#x20ac;0.6 million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#x20ac;1.2 million, and no amounts are currently due as of September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Agreement with Biose Industrie&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15, 2018, the Company entered into an agreement with Biose Industrie (&#x201c;Biose&#x201d;), a French corporation, in which Biose has agreed to exclusively manufacture certain microbial biotherapeutic products for the Company and reserve agreed upon manufacturing resources to conduct manufacturing runs for such products. Under the terms of this agreement, the Company agreed to annual fees in the mid-six digits in consideration of both exclusivity for the manufacture of those microbial biotheraputics and for a set minimum number of manufacturing runs per year. Exclusivity fees paid and any minimum commitments are expensed as incurred. As of September 30, 2020, aggregate minimum payments over the remaining contract life total approximately $0.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation and Other Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the United States Patent and Trademark Office ("USPTO"), granted a third-party petition to initiate a post-grant review of a patent issued to the University of Chicago, to which the Company has an exclusive license from the University of Chicago. In April 2020, the USPTO issued its decision in the post-grant review, finding unpatentable all of the current claims in the patent. In June 2020, the University of Chicago filed a re-issue application to seek narrowed claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Importantly, the USPTO decision does not hinder the Company's ability to continue developing its oncology or other product candidates. Under the terms of our license agreement, the Company has been responsible for reimbursing the University of Chicago for patent defense costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <evlo:CollaborationArrangementTerm
      contextRef="i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNTQ0_f0d21211-c0f4-4751-b84f-c779ab68e6c3">P5Y</evlo:CollaborationArrangementTerm>
    <evlo:AggregateAmountDueUnderCollaborativeArrangement
      contextRef="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNzU4_30bdb264-212f-4a1d-a4f1-809469bd28ac"
      unitRef="eur">3000000.0</evlo:AggregateAmountDueUnderCollaborativeArrangement>
    <evlo:AnnualAmountDueUnderCollaborativeArrangement
      contextRef="ic61806bf540f4cd0a53fd6a730b06f6c_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNzYy_220ec25e-8fd9-4e62-89b6-4a224cc81dc8"
      unitRef="eur">600000</evlo:AnnualAmountDueUnderCollaborativeArrangement>
    <evlo:FeeIncurredUnderCollaborativeArrangement
      contextRef="ifc919b216958484baadfbaf3a5579160_D20190701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMTA5OTUxMTYzMDcwOA_8f9c01ac-0b89-4b6a-8b11-a78e9546f323"
      unitRef="eur">1200000</evlo:FeeIncurredUnderCollaborativeArrangement>
    <evlo:AggregateAmountDueUnderCollaborativeArrangement
      contextRef="i435a8ae096ae4da6bf33a4093a05df20_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfMTY4NQ_6ec61992-9576-4619-be2e-a85f6d61d669"
      unitRef="usd">800000</evlo:AggregateAmountDueUnderCollaborativeArrangement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMTA0Ng_55a1e722-40d1-4717-afef-5910e3bd0b27">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#x201c;Shelf&#x201d;) with the U.S. Securities and Exchange Commission (the "SEC") in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of the filing. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf. As of September 30, 2020, no securities have been issued pursuant to the sales agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company sold 13,800,000 shares of its common stock pursuant to the Shelf in an underwritten public offering at a public offering price of $3.75 per share, for gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="i5a20243cb8d84ef18f004aae73258da3_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMzI4_b7bfa0ec-ad7b-4256-b91e-8a6baed5f9ee"
      unitRef="usd">200000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <evlo:SaleOfStockConsiderationReceivedTerm
      contextRef="i2b2a5654b6754515818e140c5b08761a_D20190603-20190603"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfMzUz_b5e69f71-cdb9-4f42-9fcd-da98722f04b9">P3Y</evlo:SaleOfStockConsiderationReceivedTerm>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="i21297bf18f09435c9c8903a7a0fe13d7_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfNTc2_64ba36aa-d181-4776-92d0-1e5b07de2051"
      unitRef="usd">50000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfNzY4_16912fb4-69ae-4d0e-b7b3-1744c79f1812"
      unitRef="shares">13800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icd3ed046380c402e916b73b4e3b00f00_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfODY5_71f9dfa2-da28-4df6-848f-b06753ac1107"
      unitRef="usdPerShare">3.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfOTA1_373d7586-95a0-4574-a994-81b590987f00"
      unitRef="usd">51800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i44d0cfbc8b794b35a5748575047050f6_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181OC9mcmFnOjQ4N2Y0YTZhMDYyYTRiYWI4NzY0ZmRiMDg0YWNhMDQ1L3RleHRyZWdpb246NDg3ZjRhNmEwNjJhNGJhYjg3NjRmZGIwODRhY2EwNDVfOTM4_5967417a-5034-4a57-9c15-bc17ac052ce9"
      unitRef="usd">48400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5MQ_eddec206-a464-4432-80ed-252747950dc2">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s board of directors adopted on April&#160;18, 2018, and the Company&#x2019;s stockholders approved, the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;), which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#x2019;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to 1,344,692&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of 4% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#x2019;s board of directors. Accordingly, on January 1, 2019, the number of shares authorized for issuance under the 2018 Plan was increased by 1,273,031 shares, and on January 1, 2020 this number was further increased by 1,286,824 shares. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted under the 2018 Plan is not less than the fair market value of a share of the Company&#x2019;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control.  Awards granted to non-employee consultants generally vest monthly over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjIzOA_2e4a7638-383d-483e-b76d-0a2a2f8a433f"&gt;one&lt;/span&gt; to four years. Stock options granted under the 2018 Plan expire no more than 10 years from the date of grant. As of September 30, 2020,&#160;equity-based incentive awards covering up to 4,243,544 shares of the Company&#x2019;s common stock have been issued under the 2018 Plan, of which none have been exercised and  818,084 have been canceled. As of September 30, 2020, 1,304,183 shares of common stock are available for future grant under the 2018 Plan, which includes 825,096 shares subject to awards that were originally granted, and have, since the effective date of the 2018 Plan, been canceled or repurchased under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#x2019;s employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg1Nw_74d83430-6831-4482-96e0-5983d9562632"&gt;one&lt;/span&gt; to four years. Stock options issued under the 2015 Plan expire no more than 10 years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of 5,417,044 shares of common stock.&#160;As of September 30, 2020, an aggregate of 5,758,518 options and other equity awards had been granted under the 2015 Plan, of which 1,345,266 have been exercised, 1,261,105 have been canceled and 18,468 have been repurchased as of September 30, 2020. A total of 113,006 shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were no longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of options granted during the nine months ended September 30, 2020 and 2019 was $4.17 and $7.66, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was $16.5 million. This amount is expected to be recognized over a weighted average period of 2.61 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's board of directors adopted on April&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18, 2018, and the Company&#x2019;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on May&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8, 2018. A total of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336,356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;1%&#160;of the number of shares of the Company&#x2019;s common stock outstanding on the last day of the applicable preceding calendar year and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an amount determined by the Company&#x2019;s board of directors. The Company's board of directors determined not to increase the number of shares that may be issued under the ESPP on January 1, 2020. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The compensation expense recognized related to the ESPP for the three and nine months ended September 30, 2020 was not material. There was a total of 28,603 shares purchased under the ESPP during the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i37f994741045472492789b1f3256cad7_I20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjEz_80c57634-8c41-4964-88a0-d2c0c6c3c25c"
      unitRef="shares">1344692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <evlo:CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants
      contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTE3MQ_a015fcbf-b413-449c-a8b1-44886d444ae8"
      unitRef="number">0.04</evlo:CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i0331b53ef2c94cbdb3540b9c8689c650_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTQ1MQ_b624ff82-697a-4786-97cc-28b7d795578a"
      unitRef="shares">1273031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i7d66e58adfb6442daaf1ba85feaf140e_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMTUyMg_4f8247a3-6516-4dce-9354-46db410383de"
      unitRef="shares">1286824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9d8a41ea4f4146b0aebd206e1f94d0e0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5Mg_3810d404-654c-4c97-a3b2-ec522a6a0d4a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7436d15f4ad5490d93c800ee4ae5d465_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjI0NA_9db7b716-7040-4d1a-bbaf-0e66f2705579">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjMxMA_ebb51663-4c0e-4a58-9695-c24c6186ce73">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic17895e26c624de7b8a999fe3b1c1a02_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjM5OA_9e03eac2-9bd9-4c9f-b972-e8eaa9ed0701"
      unitRef="shares">4243544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjE5OTAyMzI2MjA3Nw_626b457b-0ba5-4bc3-94c0-c4009faa4ce7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3044b1b8e62941e0a992d3bf0900f92d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjQ4NQ_af4b4342-da0a-43dc-8cd6-e87a5e382021"
      unitRef="shares">818084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id3e85e8eb3804e36b93c6a30043a30b2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjU0NQ_b3f274dc-9914-4148-90c2-05d5c0f687a4"
      unitRef="shares">1304183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjYzOA_24ac9743-f8b6-4c14-baf5-47041df1745b"
      unitRef="shares">825096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id857f9eb771f41fa9395bb219b6db368_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5Mw_b58d1ee8-8ef7-402f-beb3-7e852d96a062">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ief4a44fb4e8b48ac915b62b55ebffe17_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg2Mw_f27f053e-535a-4c47-a1de-4116dfda19ce">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia6ffbe5b60b54ac58b8345b0c3ce8b6b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzkyOA_bcd9c6e2-a359-419d-8366-fa36bf4bc2f4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i83f3aba8c3af44db97c1de2f2eb7d95b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDE1MA_7d5fc19e-dc53-452d-9e45-f71df5f1944a"
      unitRef="shares">5417044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted
      contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDIwMw_61fbda05-5f97-4f27-be1f-4c57f5289243"
      unitRef="shares">5758518</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised
      contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDI4NQ_da8edd7f-8d16-40b9-89ec-364ddd9a7211"
      unitRef="shares">1345266</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures
      contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDMwOQ_7891e0cc-c5b3-4a27-83e3-b9ffda84e5c4"
      unitRef="shares">1261105</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased
      contextRef="i459171e04f894552a7fca4bc6f6be2cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDMzNQ_8baed25c-0654-4870-ac8b-6079c70816fa"
      unitRef="shares">18468</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease
      contextRef="iaf913522ccab41a9a9d188138fdc0c2b_D20180508-20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDM4MQ_fd6eb4e3-446a-4648-b55f-7b25300dc987"
      unitRef="shares">113006</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iea04ebdbabf44bda8de9e1db8bbf68cb_I20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDUyMQ_9a182d62-953f-4f3d-9269-3e302b94831b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5NA_0651e79d-7348-427f-be2b-57b7f4a1f64b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3445cdc78926417abcbfd87995b2d7ad_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi0yLTEtMS0w_90feafab-d5b3-4a38-a132-08b8bad22e6e"
      unitRef="usd">969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice9ffd1c5890497b8ba9733f662871de_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi00LTEtMS0w_adaef3b1-06ac-4118-a611-9a70580118ad"
      unitRef="usd">1082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17f970dc30ff49bc95066276f19569ef_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi02LTEtMS0w_be3600b1-945e-4d94-9b66-811e246eb53b"
      unitRef="usd">2868000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia237cd66629540edb0fdf167fb187799_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMi04LTEtMS0w_69b55d54-9871-487d-bc99-4961ff99c41b"
      unitRef="usd">3306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9707f9de1ed24944bcc195fb5a28ab50_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy0yLTEtMS0w_2ef429bb-54f6-4e75-bd64-942d192732c1"
      unitRef="usd">1076000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ab3a97dae834644890cbda892fe5002_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy00LTEtMS0w_a6220bc7-e9a3-4a11-a763-3077a1c6aee1"
      unitRef="usd">980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i220c4df4a97e4803892c37ccdd46a4e3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy02LTEtMS0w_8b299929-70a4-46b6-a229-5824d21c2044"
      unitRef="usd">3225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib9ae55ffcb5b4b38b1294a478dba4306_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfMy04LTEtMS0w_2344827b-b3ea-4fc6-9981-6b0c87b120f0"
      unitRef="usd">2844000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC0yLTEtMS0w_83b13756-b591-4ea4-ab8e-ab64a5458003"
      unitRef="usd">2045000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC00LTEtMS0w_dde286c7-d93c-498e-9e2e-039cffb5e6e6"
      unitRef="usd">2062000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC02LTEtMS0w_18d61d0a-065c-44cf-8604-ebec67bb3628"
      unitRef="usd">6093000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOmZhNWE2OWI4NWU2MjRhMWViZDcyZjQxNGEwMWMyMTAzL3RhYmxlcmFuZ2U6ZmE1YTY5Yjg1ZTYyNGExZWJkNzJmNDE0YTAxYzIxMDNfNC04LTEtMS0w_e2d02c37-989f-4ebd-8742-0812039a492a"
      unitRef="usd">6150000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNjM5NQ_2318608e-768c-4e97-8c5f-5ad1d568c18b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMS0yLTEtMS0w_87ad3f03-4ad0-4736-ad6a-96d921ca31f5"
      unitRef="shares">5691474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i37bfa021020a483b81d3d7f71c17fb85_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMS00LTEtMS0w_bd1f1ee8-dc25-4691-bd20-755c16708893"
      unitRef="usdPerShare">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMi0yLTEtMS0w_ce70027c-20e8-4662-a6ae-a6399696129e"
      unitRef="shares">2028718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMi00LTEtMS0w_856055ff-c487-4d57-8936-9c6a0704e60c"
      unitRef="usdPerShare">6.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMy0yLTEtMS0w_ec9ffb7e-5eaa-4db0-b5d7-4dbd2bdc0daa"
      unitRef="shares">159998</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfMy00LTEtMS0w_9726f227-5aaa-4304-af9c-44ca689bc65f"
      unitRef="usdPerShare">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNC0yLTEtMS0w_71cd3ec5-585e-403f-abe6-e8bf6cb71d2a"
      unitRef="shares">982574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNC00LTEtMS0w_f7ad6174-76f7-420c-a6b8-d2c7aa9d6ea7"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNS0yLTEtMS0w_4e44e132-7d18-4643-84b1-c0d2961afb1c"
      unitRef="shares">6577620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNS00LTEtMS0w_ba63b66b-4ffa-486f-bcb2-d23d96bea121"
      unitRef="usdPerShare">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNi0yLTEtMS0w_37e1de14-e875-4d10-8acd-b3e5ca1a5945"
      unitRef="shares">3363541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RhYmxlOjRlMTRiNWRjNWFkZjQyMjhiMzBmYTVhYzI1YWVjY2YyL3RhYmxlcmFuZ2U6NGUxNGI1ZGM1YWRmNDIyOGIzMGZhNWFjMjVhZWNjZjJfNi00LTEtMS0w_5662b121-05a8-4e35-bc86-acdd09df0b96"
      unitRef="usdPerShare">5.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDk4Ng_20231ced-c8ec-4a3f-a177-b37e1ae8f0ef"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNDk5Mw_31b08389-67d2-4522-8ab0-67f7896c6b48"
      unitRef="usdPerShare">7.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i851cd9abcdca4743b9d2ea90d5b4eeb4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTExMg_3f37ae72-cd35-49e4-b683-710fe42c3027"
      unitRef="usd">16500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iee55ced3b34d4b52a1a1f852c64d2e67_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTE5MQ_3f9036f2-7189-4a01-97b3-4a3d6bae43e2">P2Y7M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTQzMw_4a2376f1-ae94-42d8-96b7-581a6582c325"
      unitRef="shares">336356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i4888d8f783ce4a069284cb827a044c7f_D20180418-20180418"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfNTc1Ng_efd5a738-baeb-4330-b698-b059cfb63fd6"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i8463191a45964196b29df202007afc9a_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfOTg5NTYwNDY1NjQzMA_47da7656-d2dc-47b3-958d-1199f92e6391"
      unitRef="shares">28603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id704a4dd15bd403ab0cac9fc81b19ebf_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfOTg5NTYwNDY1NjQzMA_b8a4f74c-c383-488a-8ea4-2eada323b6d2"
      unitRef="shares">28603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTYxNQ_c914e079-72a2-4f6f-956a-88c5af921d17">Income Taxes&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted on March 27, 2020. The CARES Act contains several key provisions including: (i) five year carryback of net operating losses (&#x201c;NOLs&#x201d;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of September 30, 2020, the Company had deferred $0.3 million in employer payroll taxes pursuant to the CARES Act, which is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2020, the Company has recorded a tax provision of $0.1 million and $0.2 million, respectively, primarily related to the Company's wholly-owned UK subsidiary. There were no significant income tax provisions or benefits for the three and nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTYxNg_2c4456b4-910e-498d-a785-af3b08b999c1">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <evlo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i727b59e9eee84ab2b82d2423972c1f46_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTE5NA_98c55e8e-b661-4f25-9645-a25d6b6f9eeb"
      unitRef="usd">300000</evlo:SocialSecurityTaxEmployerDeferralCARESAct>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc3902db262f4181bccdf98acd1e5095_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTQzNw_27a87cdf-f3d7-4f59-8411-2153a72f7b10"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTQ0NA_cc8328ff-e2b4-445b-a633-928bee72cabc"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTUzNg_e73bd1df-5748-4c30-9c54-d5288ac418f5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b5373c9d40e4c8b87da172c6c7e1f2a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182NC9mcmFnOjM5OWRlYzM3ZjMyMTRhZTg4ODUzOWQxYTNjODY0MGFlL3RleHRyZWdpb246Mzk5ZGVjMzdmMzIxNGFlODg4NTM5ZDFhM2M4NjQwYWVfMTUzNg_fe571bed-a87f-44d9-8a08-e03f9527ffb9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RleHRyZWdpb246M2MxOTMwODExYWQyNDEyYmI2ZTY4MTQ5OWI2M2JiODdfMTA1NQ_b13ef13d-f483-4eb6-8f1e-c73d2a02d9c0">Net Loss Per Share&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested common stock from early exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock offering from ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,626,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,967,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RleHRyZWdpb246M2MxOTMwODExYWQyNDEyYmI2ZTY4MTQ5OWI2M2JiODdfMTA1Ng_8f169d4a-91f3-44e7-9138-3c5c30d0c591">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested common stock from early exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,892,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock offering from ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,626,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,967,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i102115e148ba457a9e0f7b80f0e81eae_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMi0yLTEtMS0w_8cfea0d9-cc78-452c-9d50-40d1823d46e3"
      unitRef="shares">36772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e341efe8ff445c5bfac11f2c9f50db8_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMi00LTEtMS0w_847c6571-2a7a-4ef7-a532-4388842b1fb4"
      unitRef="shares">75043</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id804b1ab406a45b386f84874e2f511e9_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMy0yLTEtMS0w_5677ad3d-17ed-4122-9e3a-1060f91a5805"
      unitRef="shares">6577620</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i40a534ca0c824a918ef5b0b5cfd144f6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfMy00LTEtMS0w_c456ede9-5941-4910-8447-1a1ffa20b3db"
      unitRef="shares">5892781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8832142a8fd34e73a080e4c3c2df3b1c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNC0yLTEtMS0w_95aff870-7648-4ffa-87be-9b5c6c49ef5b"
      unitRef="shares">12482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6f093b1b4c194114a2857f69750073f1_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNC00LTEtMS0w_95af1429-91f4-42cc-8bcd-e43a84a812ff"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNS0yLTEtMS0w_1961e3ae-5639-45dd-bf4b-979ddaaff3f0"
      unitRef="shares">6626874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibb7c6c0f8bee4b96ae12342582088e35_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182Ny9mcmFnOjNjMTkzMDgxMWFkMjQxMmJiNmU2ODE0OTliNjNiYjg3L3RhYmxlOjJiZTZiNzJkMWY0ZTQxMDE5ZTIyZjNjNGIwODAwOGFhL3RhYmxlcmFuZ2U6MmJlNmI3MmQxZjRlNDEwMTllMjJmM2M0YjA4MDA4YWFfNS00LTEtMS0w_0404e6b6-29d4-47c3-8469-faf1edd1c8e3"
      unitRef="shares">5967824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjg2Mg_77d27404-8d7a-4d9c-b7b2-c2c1880670cc">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives clinical advisory services from Weatherden Ltd. (&#x201c;Weatherden&#x201d;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#x2019;s Chief Medical Officer, is a part owner of Weatherden. During the nine months ended September 30, 2020 and 2019, the Company paid Weatherden $0.5 million and $0.7 million, respectively. As of September 30, 2020 and 2019, the amounts due to Weatherden under the supply of service agreement were approximately $30.0 thousand and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $0.9 million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the nine-months ended September 30, 2020, $0.3 million related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a consulting agreement with David Epstein (as amended, the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein will provide strategic advisory and other consulting services to the Company. As amended on October 15, 2020, the Consulting Agreement will continue until June 30, 2021 unless terminated earlier by either Mr. Epstein or the Company upon 30 days&#x2019; notice, or 24 hours&#x2019; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase 75,000 shares of the Company&#x2019;s common stock, which award vests in 36 equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#x2019;s common stock having an aggregate grant date fair market value equal to approximately $0.2 million, as determined by the Board in its discretion based on customary option pricing methodologies, which award vests in 12 equal monthly installment following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $0.3 million for his consulting services. All of the foregoing options, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase 44,743 shares of the Company&#x2019;s common stock, which award vests in nine equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i1a12b5d775194c26a646d257a891b43f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMzMx_2b009681-d77b-49d6-9e01-f60e2e878e5f"
      unitRef="usd">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ie5cef482e496443fa58c3e279239e38f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMzM4_55589550-6862-4dcd-b85f-22cdd4a4256a"
      unitRef="usd">700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i8535ad7567824b5eb8061e3eb77bcea4_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNDQ2_2f63474c-e8a6-4e4d-991e-a130887e7aa3"
      unitRef="usd">30000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i040867f309fd4a60b8b170d1d3f8cb1a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNDUz_2815575a-45ce-4989-9c99-f2e7dd12fe57"
      unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i48bd8f29cd6a448ba1d11baf833a3e94_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfNzI5_53b2f36a-74f4-4d4e-b2a2-21430e54e96d"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:SubleaseIncome
      contextRef="i9ebbc6067103474782dd50c5fad869dc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTA5OTUxMTYzMDgxOA_68a1cc21-ca97-4c7a-aedc-874047cc117d"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm
      contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTU3Nw_4987ef0a-4fa9-45ca-905c-78db72a9c15c">P30D</evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm>
    <evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm
      contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTU5Mg_1ac20aac-20e9-41c5-aba9-2afb0e38ae2c">PT24H</evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTc2MA_e2af2a00-7b2d-4575-8c47-98dddd922185"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMTgyMg_950b064b-582e-4ded-a1b3-4c477e1ae43b"
      unitRef="installment">36</evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments>
    <evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue
      contextRef="iece4b57622c64cce95e2a617bf90bcaa_I20190916"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjMwOQ_76332fc6-6986-45a0-99c9-b9fbc6582d76"
      unitRef="usd">200000</evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="ie53145ef245f461b87d7e16c0af442f5_D20190916-20190916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjE5OTAyMzI2NjY2Nw_b0352c84-59d4-4f9a-956a-5d7c21fc7a80"
      unitRef="installment">12</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments>
    <evlo:RelatedPartyTransactionAnnualCashConsultingFee
      contextRef="iece4b57622c64cce95e2a617bf90bcaa_I20190916"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjY3MQ_897b06f1-5aaf-43ec-bed6-7ee262faee63"
      unitRef="usd">300000</evlo:RelatedPartyTransactionAnnualCashConsultingFee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i810d7c9e6e614a82ad32d53275585c7d_D20201011-20201011"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN183MC9mcmFnOmMwMWUwNjQxY2JlMDQyNzI4NTRhMjRkZDBlNThlNGNjL3RleHRyZWdpb246YzAxZTA2NDFjYmUwNDI3Mjg1NGEyNGRkMGU1OGU0Y2NfMjE5OTAyMzI2NjY1OQ_d68947e9-b46e-4ef2-a2b9-6fd6bfbbf509"
      unitRef="shares">44743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358439113624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evelo Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5594527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">620 Memorial Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">577-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,$0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,189,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001694665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436968968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,580<span></span>
</td>
<td class="nump">$ 77,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="nump">3,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">84,559<span></span>
</td>
<td class="nump">81,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,586<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset - operating lease</a></td>
<td class="nump">11,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">104,837<span></span>
</td>
<td class="nump">90,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,823<span></span>
</td>
<td class="nump">8,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,548<span></span>
</td>
<td class="nump">9,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">29,924<span></span>
</td>
<td class="nump">19,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">10,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">54,407<span></span>
</td>
<td class="nump">30,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder&#8217;s equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized; 46,220,859 and 32,232,258 shares issued and 46,184,087 and 32,170,605 shares outstanding as of September 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">313,853<span></span>
</td>
<td class="nump">259,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(263,469)<span></span>
</td>
<td class="num">(198,853)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">60,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 104,837<span></span>
</td>
<td class="nump">$ 90,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435368024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">46,220,859<span></span>
</td>
<td class="nump">32,232,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">46,184,087<span></span>
</td>
<td class="nump">32,170,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358507330200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,910<span></span>
</td>
<td class="nump">$ 15,610<span></span>
</td>
<td class="nump">$ 47,503<span></span>
</td>
<td class="nump">$ 46,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">16,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,182<span></span>
</td>
<td class="nump">21,496<span></span>
</td>
<td class="nump">63,688<span></span>
</td>
<td class="nump">63,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,182)<span></span>
</td>
<td class="num">(21,496)<span></span>
</td>
<td class="num">(63,688)<span></span>
</td>
<td class="num">(63,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest (expense) income, net</a></td>
<td class="num">(713)<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(674)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(707)<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(20,856)<span></span>
</td>
<td class="num">(21,633)<span></span>
</td>
<td class="num">(64,395)<span></span>
</td>
<td class="num">(62,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,923)<span></span>
</td>
<td class="num">$ (21,633)<span></span>
</td>
<td class="num">$ (64,616)<span></span>
</td>
<td class="num">$ (62,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (1.74)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">46,168,013<span></span>
</td>
<td class="nump">32,060,747<span></span>
</td>
<td class="nump">37,050,907<span></span>
</td>
<td class="nump">32,009,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,923)<span></span>
</td>
<td class="num">$ (21,633)<span></span>
</td>
<td class="num">$ (64,616)<span></span>
</td>
<td class="num">$ (62,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments, net of tax of $0</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (20,923)<span></span>
</td>
<td class="num">$ (21,634)<span></span>
</td>
<td class="num">$ (64,616)<span></span>
</td>
<td class="num">$ (62,855)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358437958040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent', window );">Tax portion of unrealized loss on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358431661928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,825,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 136,949<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 250,316<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (113,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,299)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,030,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">118,883<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">252,533<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(133,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,825,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">136,949<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">250,316<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(113,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,072,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">80,546<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">256,768<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,030,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">118,883<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">252,533<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(133,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,045,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">100,088<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">254,676<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(154,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,633)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,072,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">80,546<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">256,768<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,170,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">60,197<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">259,018<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,041)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,321,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">261,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(221,894)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,170,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 60,197<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">259,018<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">159,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,184,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">313,853<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(263,469)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,321,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">261,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(221,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of fees</a></td>
<td class="nump">48,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">48,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,652)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,136,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">69,206<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">311,706<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(242,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Fees associated with public offering of common stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,923)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,184,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 50,430<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 313,853<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (263,469)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436709192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (64,616)<span></span>
</td>
<td class="num">$ (62,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,093<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonCashOperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">267<span></span>
</td>
<td class="num">(633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,771)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(54,110)<span></span>
</td>
<td class="num">(52,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(912)<span></span>
</td>
<td class="num">(2,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in)/provided by investing activities</a></td>
<td class="num">(906)<span></span>
</td>
<td class="nump">52,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from the issuance of long-term debt</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">19,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance cost</a></td>
<td class="nump">48,424<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">58,763<span></span>
</td>
<td class="nump">4,763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="nump">4,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8211; beginning of period</a></td>
<td class="nump">79,333<span></span>
</td>
<td class="nump">94,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8211; end of period</a></td>
<td class="nump">83,080<span></span>
</td>
<td class="nump">98,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred financing and public offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions in accounts payable and accrued expenses</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435241960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences, Inc. ("Evelo" or the "Company&#8221;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing oral biologics designed to act on cells in the small intestine with systemic therapeutic effects. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company sold 13,800,000 shares of its common stock in an underwritten public offering at a public offering price of $3.75 per share, including the underwriters' exercise of their option to purchase 1,800,000 shares to cover over-allotment, generating gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 14, 2020, the Company drew down the second tranche of $10.0 million available under the 2019 Credit Facility. Refer to Note 6 to these unaudited condensed consolidated financial statements for more information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of September 30, 2020, the Company had cash and cash equivalents of $81.6 million and an accumulated deficit of $263.5 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. The transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure. Based on the Company&#8217;s current operating plan and due to the uncertainty related to the impact of the COVID-19 pandemic and the nature of Evelo's business, the Company has substantial doubt that its cash and cash equivalents at September 30, 2020 will be sufficient to fund operations and capital expenditures for at least the twelve months following the filing of this Quarterly Report on Form 10-Q, and the Company will need to obtain additional funding. The Company intends to pursue strategic partnerships and collaborations, or obtain additional funding through its available financing sources which include, additional public offerings of common stock and private financing of debt or equity. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. There can be no assurance that the Company will be able to obtain additional funding on acceptable terms, if at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources at September 30, 2020, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434827304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of September 30, 2020, the results of its operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results for the year ending December 31, 2020, or for any future period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Event Considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the unaudited condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss. The Company's only element of other comprehensive loss is unrealized gains on available-for-sale investments, which the Company held in 2019. Comprehensive loss totaled $20.9 million and $64.6 million, respectively, for the three and nine months ended September 30, 2020. For the three and nine months ended September 30, 2019 comprehensive loss was $21.6 million and $62.9 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility. Restricted cash totaled approximately $1.5 million at September 30, 2020 and December 31, 2019, and is classified within other assets on the accompanying condensed consolidated balance sheet. The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,580&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,833&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,080&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,333&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for options granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;), which supersedes the guidance in former ASC 840, Leases. The new accounting guidance requires recognition of all long-term lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. It requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The FASB subsequently issued several ASUs amending the new standard. This guidance is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018 for most public entities. The Company adopted this new standard on January 1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2016-02 provides a number of optional practical expedients in transition. The Company elected to adopt the 'package of practical expedients', which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, and (iii) not to reassess initial direct costs for any existing leases. The Company will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#8217;s January 1, 2020 condensed consolidated balance sheet of $12.7 million and $13.9 million, respectively. There was no material impact resulting from the adoption on the Company&#8217;s unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2020. For leases with terms greater than 12 months, the Company records the related right-of-use asset and lease liability at the present value of lease payments over the term. As the Company&#8217;s leases do not provide readily determinable implicit interest rates, the Company utilized its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The application of the new standard required netting of unamortized balance of lease incentives and deferred lease obligation to the right-of-use asset at the adoption date. The Company&#8217;s operating leases include rental escalation clauses that are factored into the determination of lease payments when appropriate. The Company does not separate lease and non-lease components of contracts. Refer to Note 3, Leases within these unaudited condensed consolidated financial statements for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting (Topic 718) ("ASU 2018-07"), which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. Entities will apply the ASU by recognizing a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the annual period of adoption. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of this standard did not have a material impact on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September 30, 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434767368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately 40,765 square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $0.2 million for the nine months ended September 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, the Company recorded rent expense of $0.7 million and $2.1 million, respectively. Rent expense for the nine months ended September 30, 2020 is net of sublease rental income of $0.3 million. There was no sublease rental income for the three months ended September 30, 2020. For the three and nine months ended September 30, 2019, the Company recorded rent expense of $0.7 million and $2.0 million, respectively, which is net of sublease rental income of $0.1 million and $0.4 million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments, exclusive of any offsetting sublease rental payments, at September 30, 2020, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding payments made as of September 30, 2020)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,422</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,312)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,110</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434822664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September 30, 2020&#160;and&#160;December 31, 2019, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435393496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,050&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,341&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.5 million and $1.5 million of depreciation expense for the three and nine months ended September 30, 2020, respectively and $0.5 million and $1.3 million for the three and nine months ended September 30, 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434989368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan and Security Agreements</a></td>
<td class="text">Loan and Security Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into a credit facility (the &#8220;2016 Credit Facility&#8221;) with a bank that allowed the Company to borrow up to $15.0 million. Borrowings under the 2016 Credit Facility were secured by a lien on all Company assets, excluding intellectual property. The Company borrowed the entire $15.0 million available under the 2016 Credit Facility prior to its extinguishment in July 2019 as discussed in further detail below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Credit Facility contained negative covenants restricting the Company&#8217;s activities, including limitations on cash deposits, dispositions, mergers or acquisitions, incurring indebtedness or liens, paying dividends or making investments and certain other business transactions. There were no financial covenants associated with the agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $45.0 million available to the Company in three tranches. The initial tranche of $20.0 million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $10.0 million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The third tranche of $15.0 million is available to be funded at the Company's election on or before January 15, 2021, subject to certain customary conditions and the achievement of certain clinical development milestones. Borrowings under the 2019 Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) 8.65% and (ii) the prime rate plus 3.15%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2022. If the Company elects to draw the third tranche, the interest-only period will be extended through August 31, 2022. Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. Upon final payment or prepayment of the loans, the Company must pay a final payment equal to 4.3% of the loans borrowed, which is being accrued to interest expense over the term of the loan using the effective-interest method. The Company incurred fees associated with establishing the 2019 Credit Facility of $0.4 million. The Company has an option to prepay the loans in whole, subject to a prepayment fee of 2% of the amount prepaid or, if the prepayment occurs after the 18-month anniversary of the funding date of the loans, 1% of the amount prepaid.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2019 Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the 2019 Credit Facility and under applicable law. As of September 30, 2020, the Company was in compliance with all covenants under the 2019 Credit Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the proceeds from the initial $20.0 million tranche to prepay on July 19, 2019 the full $15.0 million loan balance outstanding under the 2016 Credit Facility.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has the following minimum aggregate future loan payments at September 30, 2020 (in thousands). </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve month period ending September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Company's 2016 Credit Facility was approximately $0.5 million for the nine months ended September 30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Company's 2019 Credit Facility was approximately $0.6 million and $1.5 million for the three and nine months ended September 30, 2020 and $0.4 million for both the three and nine months ended September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434846184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">In-License Agreements</a></td>
<td class="text">In-License Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education and Research</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 10, 2016, the Company entered into a Research and License Agreement, (the &#8220;2016 Mayo License Agreement&#8221;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#8220;Mayo Clinic&#8221;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#8217;s public offering and warrants which were issued in 2016 and exercised in 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#8220;2017 Mayo License Agreement&#8221;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#8217;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $0.2 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $56.0 million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $0.2 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Chicago</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#8220;2016 University of Chicago Agreement&#8221;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the Licensed Patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize Licensed Products. As consideration, the Company paid a nonrefundable upfront fee of less than $0.5 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $60.9 million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of September 30, 2020, the Company has incurred milestone payments to date totaling approximately $0.4 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434989368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Collaboration Agreement with Sacco S.r.l.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#8217;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of five years. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN181NS9mcmFnOmExNjkwMzJlZDgxMjQzNWQ5ZTY3NTc1Yjk0MzQ2ZjE2L3RleHRyZWdpb246YTE2OTAzMmVkODEyNDM1ZDllNjc1NzViOTQzNDZmMTZfNjgz_88021ac0-a529-40c8-86cd-253480fcf249">six</span> consecutive months. The Company has agreed to pay Sacco an aggregate of &#8364;3.0 million, &#8364;0.6 million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#8364;1.2 million, and no amounts are currently due as of September 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement with Biose Industrie</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2018, the Company entered into an agreement with Biose Industrie (&#8220;Biose&#8221;), a French corporation, in which Biose has agreed to exclusively manufacture certain microbial biotherapeutic products for the Company and reserve agreed upon manufacturing resources to conduct manufacturing runs for such products. Under the terms of this agreement, the Company agreed to annual fees in the mid-six digits in consideration of both exclusivity for the manufacture of those microbial biotheraputics and for a set minimum number of manufacturing runs per year. Exclusivity fees paid and any minimum commitments are expensed as incurred. As of September 30, 2020, aggregate minimum payments over the remaining contract life total approximately $0.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Other Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the United States Patent and Trademark Office ("USPTO"), granted a third-party petition to initiate a post-grant review of a patent issued to the University of Chicago, to which the Company has an exclusive license from the University of Chicago. In April 2020, the USPTO issued its decision in the post-grant review, finding unpatentable all of the current claims in the patent. In June 2020, the University of Chicago filed a re-issue application to seek narrowed claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Importantly, the USPTO decision does not hinder the Company's ability to continue developing its oncology or other product candidates. Under the terms of our license agreement, the Company has been responsible for reimbursing the University of Chicago for patent defense costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434661608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#8220;Shelf&#8221;) with the U.S. Securities and Exchange Commission (the "SEC") in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of the filing. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of September 30, 2020, no securities have been issued pursuant to the sales agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold 13,800,000 shares of its common stock pursuant to the Shelf in an underwritten public offering at a public offering price of $3.75 per share, for gross proceeds of $51.8 million and net proceeds of $48.4 million, after deducting underwriting discounts and commission and other offering expenses payable by the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434989368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Incentive Award Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;), which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to 1,344,692&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of 4% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#8217;s board of directors. Accordingly, on January 1, 2019, the number of shares authorized for issuance under the 2018 Plan was increased by 1,273,031 shares, and on January 1, 2020 this number was further increased by 1,286,824 shares. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the 2018 Plan is not less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control.  Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMjIzOA_2e4a7638-383d-483e-b76d-0a2a2f8a433f">one</span> to four years. Stock options granted under the 2018 Plan expire no more than 10 years from the date of grant. As of September 30, 2020,&#160;equity-based incentive awards covering up to 4,243,544 shares of the Company&#8217;s common stock have been issued under the 2018 Plan, of which none have been exercised and  818,084 have been canceled. As of September 30, 2020, 1,304,183 shares of common stock are available for future grant under the 2018 Plan, which includes 825,096 shares subject to awards that were originally granted, and have, since the effective date of the 2018 Plan, been canceled or repurchased under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants and advisors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkzMDkxNTJkYzQyNDRkZTg4YzAyNTY3MjAzMzYyNWQ3L3NlYzo5MzA5MTUyZGM0MjQ0ZGU4OGMwMjU2NzIwMzM2MjVkN182MS9mcmFnOjZiNzIxMDcxOTA1MzQ5NjlhZDJhMTQ2OWUxNjg1M2ViL3RleHRyZWdpb246NmI3MjEwNzE5MDUzNDk2OWFkMmExNDY5ZTE2ODUzZWJfMzg1Nw_74d83430-6831-4482-96e0-5983d9562632">one</span> to four years. Stock options issued under the 2015 Plan expire no more than 10 years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of 5,417,044 shares of common stock.&#160;As of September 30, 2020, an aggregate of 5,758,518 options and other equity awards had been granted under the 2015 Plan, of which 1,345,266 have been exercised, 1,261,105 have been canceled and 18,468 have been repurchased as of September 30, 2020. A total of 113,006 shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were no longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982,574)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363,541&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the nine months ended September 30, 2020 and 2019 was $4.17 and $7.66, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was $16.5 million. This amount is expected to be recognized over a weighted average period of 2.61 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's board of directors adopted on April</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18, 2018, and the Company&#8217;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on May</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8, 2018. A total of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336,356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;1%&#160;of the number of shares of the Company&#8217;s common stock outstanding on the last day of the applicable preceding calendar year and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an amount determined by the Company&#8217;s board of directors. The Company's board of directors determined not to increase the number of shares that may be issued under the ESPP on January 1, 2020. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The compensation expense recognized related to the ESPP for the three and nine months ended September 30, 2020 was not material. There was a total of 28,603 shares purchased under the ESPP during the three and nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435238952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted on March 27, 2020. The CARES Act contains several key provisions including: (i) five year carryback of net operating losses (&#8220;NOLs&#8221;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of September 30, 2020, the Company had deferred $0.3 million in employer payroll taxes pursuant to the CARES Act, which is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, the Company has recorded a tax provision of $0.1 million and $0.2 million, respectively, primarily related to the Company's wholly-owned UK subsidiary. There were no significant income tax provisions or benefits for the three and nine months ended September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434868296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,626,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434757640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives clinical advisory services from Weatherden Ltd. (&#8220;Weatherden&#8221;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#8217;s Chief Medical Officer, is a part owner of Weatherden. During the nine months ended September 30, 2020 and 2019, the Company paid Weatherden $0.5 million and $0.7 million, respectively. As of September 30, 2020 and 2019, the amounts due to Weatherden under the supply of service agreement were approximately $30.0 thousand and $0.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $0.9 million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the nine-months ended September 30, 2020, $0.3 million related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a consulting agreement with David Epstein (as amended, the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein will provide strategic advisory and other consulting services to the Company. As amended on October 15, 2020, the Consulting Agreement will continue until June 30, 2021 unless terminated earlier by either Mr. Epstein or the Company upon 30 days&#8217; notice, or 24 hours&#8217; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase 75,000 shares of the Company&#8217;s common stock, which award vests in 36 equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $0.2 million, as determined by the Board in its discretion based on customary option pricing methodologies, which award vests in 12 equal monthly installment following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $0.3 million for his consulting services. All of the foregoing options, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase 44,743 shares of the Company&#8217;s common stock, which award vests in nine equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358507425176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. The transition to profitability is dependent upon the successful development, approval, and commercialization of its products and product candidates and the achievement of a level of revenues adequate to support its cost structure. Based on the Company&#8217;s current operating plan and due to the uncertainty related to the impact of the COVID-19 pandemic and the nature of Evelo's business, the Company has substantial doubt that its cash and cash equivalents at September 30, 2020 will be sufficient to fund operations and capital expenditures for at least the twelve months following the filing of this Quarterly Report on Form 10-Q, and the Company will need to obtain additional funding. The Company intends to pursue strategic partnerships and collaborations, or obtain additional funding through its available financing sources which include, additional public offerings of common stock and private financing of debt or equity. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding sooner than would otherwise be expected. There can be no assurance that the Company will be able to obtain additional funding on acceptable terms, if at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. Because of the uncertainty in securing additional funding and the insufficient amount of cash and cash equivalent resources at September 30, 2020, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of September 30, 2020, the results of its operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results for the year ending December 31, 2020, or for any future period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Event Considerations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Event Considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the unaudited condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure in this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted CashCash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div>An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for options granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;), which supersedes the guidance in former ASC 840, Leases. The new accounting guidance requires recognition of all long-term lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. It requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The FASB subsequently issued several ASUs amending the new standard. This guidance is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018 for most public entities. The Company adopted this new standard on January 1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASU 2016-02 provides a number of optional practical expedients in transition. The Company elected to adopt the 'package of practical expedients', which permits the Company (i) not to reassess whether expired existing contracts are or contain leases, (ii) not to reassess the classification of expired or existing leases, and (iii) not to reassess initial direct costs for any existing leases. The Company will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#8217;s January 1, 2020 condensed consolidated balance sheet of $12.7 million and $13.9 million, respectively. There was no material impact resulting from the adoption on the Company&#8217;s unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2020. For leases with terms greater than 12 months, the Company records the related right-of-use asset and lease liability at the present value of lease payments over the term. As the Company&#8217;s leases do not provide readily determinable implicit interest rates, the Company utilized its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The application of the new standard required netting of unamortized balance of lease incentives and deferred lease obligation to the right-of-use asset at the adoption date. The Company&#8217;s operating leases include rental escalation clauses that are factored into the determination of lease payments when appropriate. The Company does not separate lease and non-lease components of contracts. Refer to Note 3, Leases within these unaudited condensed consolidated financial statements for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the FASB issued ASU No. 2018-07,&#160;Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting (Topic 718) ("ASU 2018-07"), which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant date. Entities will apply the ASU by recognizing a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the annual period of adoption. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of this standard did not have a material impact on its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of September 30, 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on January 1, 2021. Early adoption is permitted. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Substantial Doubt About Going Concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434658952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,580&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,833&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,080&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,333&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following reconciles cash, cash equivalents and restricted cash as of September 30, 2020 and December 31, 2019, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,580&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,833&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,080&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,333&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358433346728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Aggregate Future Lease Commitments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments, exclusive of any offsetting sublease rental payments, at September 30, 2020, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding payments made as of September 30, 2020)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,422</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,312)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,110</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358433359304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358515426824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,050&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,341&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434607320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Aggregate Future Loan Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has the following minimum aggregate future loan payments at September 30, 2020 (in thousands). </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve month period ending September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358433412536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982,574)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363,541&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435238952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,892,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,626,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435843992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,424<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from the issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 19,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember', window );">Security And Loan Agreement, Tranche Two | Line of Credit | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from the issuance of long-term debt</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember', window );">June Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436424168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 20,923<span></span>
</td>
<td class="nump">$ 21,634<span></span>
</td>
<td class="nump">$ 64,616<span></span>
</td>
<td class="nump">$ 62,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 12,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436202728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 6,830<span></span>
</td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">74,750<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">81,580<span></span>
</td>
<td class="nump">77,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 83,080<span></span>
</td>
<td class="nump">$ 79,333<span></span>
</td>
<td class="nump">$ 98,561<span></span>
</td>
<td class="nump">$ 94,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358531466712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of leased office and research development space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Minimum rental payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358505465528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding payments made as of September 30, 2020)</a></td>
<td class="nump">$ 493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">3,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">15,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(3,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">12,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 2,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436552920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 74,750<span></span>
</td>
<td class="nump">$ 76,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">74,750<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">74,750<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">74,750<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436301848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 12,695<span></span>
</td>
<td class="nump">$ 12,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,109)<span></span>
</td>
<td class="num">(3,709)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,586<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">8,606<span></span>
</td>
<td class="nump">7,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 1,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358434821784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="nump">$ 1,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358439322264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 14, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jan. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 19,481,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evlo_A2016CreditFacilityMember', window );">2016 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember', window );">2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2016 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SecurityAndLoanAgreementNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan and security agreement, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage', window );">Final payment under agreement as a percentage of loans borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees incurred to establish facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage', window );">Anniversary of funding date for determining prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne', window );">Prepayment fee percentage after specified period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentDebtDefaultPercentage', window );">Debt default interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Security And Loan Agreement, Tranche One | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Security And Loan Agreement, Tranche Two | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Security And Loan Agreement, Tranche Three | 2019 Credit Facility | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Plus | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan and security agreement, basis spread on interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentDebtDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentDebtDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage after specified period one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage on principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repayment Or Prepayment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Security And Loan Agreement, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_A2016CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_A2016CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementTranchesAxis=evlo_SecurityAndLoanAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435758216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 29,924<span></span>
</td>
<td class="nump">$ 19,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths', window );">2021</a></td>
<td class="nump">2,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">2022</a></td>
<td class="nump">8,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">2023</a></td>
<td class="nump">13,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">2024</a></td>
<td class="nump">13,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">38,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less amounts representing interest and discount</a></td>
<td class="num">(8,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 29,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Repayments of Principal in Rolling After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436334136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-License Agreements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">38 Months Ended</th>
<th class="th" colspan="1">55 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2017</div></th>
<th class="th"><div>Mar. 10, 2016</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember', window );">Mayo Clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonRefundableUpfrontFee', window );">Non-refundable upfront fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amount due under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember', window );">Mayo Clinic | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="nump">$ 56,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember', window );">University of Chicago Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amount due under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts', window );">Milestone payments for development and commercialization of licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember', window );">University of Chicago Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonRefundableUpfrontFee', window );">Non-refundable upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Development And Commercialization Of Licensed Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments of development, regulatory, and commercial event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonRefundableUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonRefundableUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358436939512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_SaccoS.r.l.Member', window );">Sacco | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborationArrangementTerm', window );">Term of collaboration arrangement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices', window );">Period of inactive manufacturing services causing termination under collaborative arrangement</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_AggregateAmountDueUnderCollaborativeArrangement', window );">Aggregate amount due under collaborative arrangement</a></td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_AnnualAmountDueUnderCollaborativeArrangement', window );">Annual amount due under collaborative arrangement</a></td>
<td class="nump">&#8364; 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_FeeIncurredUnderCollaborativeArrangement', window );">Fee incurred under collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_BioseIndustrieMember', window );">Biose Industrie | Exclusivity and Commitment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_AggregateAmountDueUnderCollaborativeArrangement', window );">Aggregate amount due under collaborative arrangement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_AggregateAmountDueUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Due Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_AggregateAmountDueUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_AnnualAmountDueUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Amount Due Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_AnnualAmountDueUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborationArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborationArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Period Of Inactive Manufacturing Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_FeeIncurredUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee Incurred Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_FeeIncurredUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_SaccoS.r.l.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_SaccoS.r.l.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_BioseIndustrieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_BioseIndustrieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=evlo_ExclusivityAndCommitmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=evlo_ExclusivityAndCommitmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435843848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,424,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember', window );">Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Registration of equity instruments, aggregate authorized amount</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockConsiderationReceivedTerm', window );">Sale of stock, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_SalesAgreementCowenAndCompanyLLCMember', window );">Sales Agreement, Cowen And Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Registration of equity instruments, aggregate authorized amount</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember', window );">June Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockConsiderationReceivedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockConsiderationReceivedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value of Shares Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_SalesAgreementCowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_SalesAgreementCowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_JuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358438781272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>May 08, 2018</div></th>
<th class="th"><div>Apr. 18, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="nump">$ 7.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,603<span></span>
</td>
<td class="nump">28,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,183<span></span>
</td>
<td class="nump">1,304,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Minimum | Non-Employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares originally authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants', window );">Common stock outstanding percentage to be declared as an increase in grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="nump">1,286,824<span></span>
</td>
<td class="nump">1,273,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,243,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Maximum | Non-Employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares originally authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,417,044<span></span>
</td>
<td class="nump">5,417,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted', window );">Number of shares, options and other equity awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,758,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised', window );">Number of shares, options and other equity awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,345,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures', window );">Number of shares, options and other equity awards canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease', window );">Number of shares no longer authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Minimum | Non-Employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Maximum | Non-Employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock outstanding percentage to be declared as an increase in grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evlo_NonEmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evlo_NonEmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358435748792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,045<span></span>
</td>
<td class="nump">$ 2,062<span></span>
</td>
<td class="nump">$ 6,093<span></span>
</td>
<td class="nump">$ 6,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">2,868<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 3,225<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358507323928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,691,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,028,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(159,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(982,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">6,577,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of period end (in shares)</a></td>
<td class="nump">3,363,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="nump">8.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">6.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of period end (in dollars per share)</a></td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358438600616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred payroll taxes related to CARES Act</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358439141432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">6,626,874<span></span>
</td>
<td class="nump">5,967,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember', window );">Unvested common stock from early exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">36,772<span></span>
</td>
<td class="nump">75,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">6,577,620<span></span>
</td>
<td class="nump">5,892,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Common stock offering from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">12,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140358439335752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2019 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Offset to operating expense from sublease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,182,000<span></span>
</td>
<td class="nump">$ 21,496,000<span></span>
</td>
<td class="nump">$ 63,688,000<span></span>
</td>
<td class="nump">$ 63,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,028,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember', window );">Weatherden Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amounts due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000.0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">30,000.0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member', window );">VL46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Rent due from sublease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Mr. Epstein | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm', window );">Termination notice period of consulting arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm', window );">Termination notice period by non-breaching party in event of a breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments', window );">Option to purchase shares, vesting period, number of equal monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue', window );">Aggregate grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments', window );">Annual equity award, vesting period, number of equal monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionAnnualCashConsultingFee', window );">Aggregate annual cash consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Mr. Epstein | Consulting Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="nump">44,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionAnnualCashConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Cash Consulting Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionAnnualCashConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Contract, Termination Notice, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evlo_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evlo_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MMYP!=BL [S=2FL.-_;[7?L]=_@M02P,$%     @ "D1>4<"0!W/I @  L@D
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MG X R9A*QH<>FI$Z-9#/?,#9F1U(=W8 2/#L0.KL0)[PD+,S09"')0C2G2
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MG"\;I[?J@CL_MV.CCX;2'PJZO<\1X>@[U2\8C38$(S-AQ#7]D]"4#%YI,3H
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M'&6BA*HGJ:D;[%$_,Y?[6HWQ@5\604I&SG,(A7'@=MVR![OT@OW H 1G_"C
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MVWU=%^8\E!;F[*,0<M^TA4+;L2E (Z_:4W7(>-_QX4"7Q-_.F5-7TX&"WOX
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M_P!V "X6]OX%9.E5'^#+$' +'_MM0!5'40$/?*KNXX2C'WYY=86/CQ[,1*F
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MXWRQF"]4.TQAH$&8QJ2#$J91&].0,'>N.P;AMHTE%W ?#0:N2I9;[UX9X6$
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M*/;E&8R>I1UJ"_(1,3?IJ;K GYZ3O(^I/"NIG+ W7];27:LU:&KY]"LU%:"
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M=VV+OI5HI7+#OH+GMBE?,RHQ8HS[+7S3Q8'UQ98-T PGG>7UL(Q!)%#>X(:
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M]5!H&*7Q$0O81@+ <26M@DAJ50RK :?1>Q;8#>>YDOV:QKRY-55/%O$7J@_
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MNI;^W !@-!X'P/?XVP?I VZ0?]GFY?\#4$L#!!0    (  I$7E'$ZSCG_ 0
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M.GP:?7@*N:>Z&QSL!\>H7/:]'Q*]1?3DTW8'L*[<W<BEP9>\Y2X18_)ZX0I
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M:3R9%0'H82X/!ZLZ/PMWRM)D]=N&GC+43H'N:Z7LX\$1C(_CYE]02P,$%
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MQ(:X,5IY4$^&H@*_XFRMMI)H#*]N5"TI%9Q"!NN,E ]C08%;OGKM(^_IH!6
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M'0]/C@?UN:Q]\:8(U]F9\;@<A\=,<$1#$_#[W!C?OI"#[O^-B[\!4$L#!!0
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M*]Q5*? $?%]XG[H7=M#??L_^!E!+ P04    "  *1%Y165C;0!D$  #Z"
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M'UJ<C%*C_KJ66G+* 2.4*&[1(E);09,'[ P9[3K]?P_$0<O[=C99XN(S1F(
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MZPUXO3"LU^/$!^C^>.;_ 5!+ P04    "  *1%Y163051?P&  !C$@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6S-6%USV[82_2L[NITVF6'U[3AI
M;,_83C-MIYYDDC1]Z/0! B$1-R#  J!E_?N>!2B*2NRD[;T/?9%($%B<W3U[
M%N39UOD/H5(JTEUM;#@?53$VWTTF05:J%F'L&F7Q9.U\+2)N_682&J]$F1;5
M9C*?3I],:J'MZ.(LC;WV%V>NC49;]=I3:.M:^-V5,FY[/IJ-]@-O]*:*/#"Y
M.&O$1KU5\9?FM<?=I+=2ZEK9H)TEK];GH\O9=U=+GI\FO-=J&P;7Q)ZLG/O
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MO/_3[C0]M^/0^.D^CMY;81NI'4NL&9I<O.9A9<=Q-B[(]&&$[ SQ0 IFRW\
MM-Z!SVMCZ+CP :9_RN9_4$L#!!0    (  I$7E$)'QNWW0(  ,T&   9
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MGVJU >V\"<T97JJ/)G)<NDNYM9I..<79^27C&NZ9J!&ND)E:(U7<&MB[8XE
MLS\-+65QOF':(BX;Q/@-Q#%<*6D+ Y]EAMF?\2&QZRC&6XK+>"?@+5:'<!0=
M0!S%T0Z\HT[RD<<[^K?D"VY2H9QJ S\7B;&:7LFO'3F&78ZASS%\BW/SQD'E
M<,DEDREG A;&()66R0R^<99PP2VGQ&W=,V 67KB]5OB=.5W[3DS%4IP%U)\&
M]1J#^5V!D"M!O<?E"JR_5/#'T@*735?[]DBH9<&2^[DJ*R:?/WTXC0>C,P-Y
M)X"]"! ] ;8@Y@5;(R2($LJ>GMSI6?M:,^.J09=IL4Q0=S?JX2XP;7<';G<P
MACTN"5C5AH[-_H0\3*IYY;F^ M+4=N+>'CY3@^@'&FAY3;&D,A4U/47J+%L0
M:LI,X9-Z Q]K3@3]H_\(H^'!Z#CJ&[X,\5G/NE.6:O$^WS[KOS7^+](G!X/Q
MN&_L(/T.W]?>?]@;,27JE1^D!E)52]M,FVZWF]6+9D2]N#>#_HKI%9<&!.84
M&AV.C@/0S?!L%E95?F ERM+X\V9!WQO4SH'.<Z7L=N$2=%^P^6]02P,$%
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MV34[.IDEX(85,BADNSBV&TN\!*+8\M9%%PSXOK:6'I008-SCJ[]02P,$%
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M\T7N?H)J0J'U%TNABR?95;:>0^)<&YE68&20\JS\9]^J1!P :' &X%< _U)
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M L(8Z/<;SM7SP"S0?.XLO@%02P,$%     @ "D1>43,.9.70 @  =P@  !D
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M(L7')]+4\W MU8,N 0QYKKC0(Z\TIK[R?9V74%%]+FL0N+.4JJ(&3;7R=:V
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M7*];W"</.JKM-PG[_]/4L*$).W7C#J)M5E:H_KZ584#;/1HT7(-37'X;U^"
M*XJIW\X5-5S1*:Z@C2LZX*)!$ W:R>*&+#Y%UFLCBUO(0J_?3D:]78_R.NF>
MUH!'U!(_A=;6X1VP>D<8][HB[684FF6FW]J.MZE[6RL[/6 /HGYPK.9=BZ%^
M]_<%2A&6B]+T5 EX1BN4P(L5ME(T I2V;3OE*C$QK=+\ VF744B/;&JZ:TOT
M7_L2/=68*F9W[]PR/PT/3*YXH4@&2\1Y5P.4+JMSN)IHL;%'V4)H/!CM<(W_
M+B!- *XOA= ?$W,Z-G]#XS]02P,$%     @ "D1>40)< NV2 P  A@T  !D
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M:AWC!:;+3J><6+7T;_^-LMA)^.$"NT/0;@-^GRME[R?.0=UOCK\#4$L#!!0
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MF[&7]&H"  !^#0  #0   'AL+W-T>6QE<RYX;6S5E]UNFS 4QU_%<J>IE:8
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M"M&LZN9?S/$\OT[8O7%%?P%02P,$%     @ "D1>49>*NQS     $P(   L
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MTT]02P$"% ,4    "  *1%Y1!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  I$7E$M]9[H[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   (  I$7E&97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ "D1>46!T"TQ2!0  ^!4  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   (  I$7E'3L=#1H 4  -L5   8              " @90-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  *1%Y1P) '<^D"  "R"0
M&               @(%J$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ "D1>4:E1-PY4!0  O!4  !@              ("!B18  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  I$7E%<D*+:@@(
M +\&   8              " @1,<  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  *1%Y1AQ.?+GT*   !1   &               @('+
M'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ "D1>4:.)
M,B3,!@  Q1L  !@              ("!?BD  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    (  I$7E&S^40I@ D  -D6   8
M  " @8 P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  *
M1%Y15(#6V<,7  #E1@  &               @($V.@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ "D1>4<3K..?\!   )@P  !D
M         ("!+U(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  *1%Y1DH1PPD<#   %"   &0              @(%B5P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  I$7E'J?&3F&@,  "@'
M   9              " @>!:  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ "D1>4;W#:2A1"0  H1<  !D              ("!,5X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  *1%Y1$E9,
M!(T%  #K$   &0              @(&Y9P  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    (  I$7E$VQ)<_8P8   D/   9
M  " @7UM  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M"D1>45E8VT 9!   ^@@  !D              ("!%W0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  *1%Y1/>-3G ,*  "-'0  &0
M            @(%G>   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    (  I$7E%5  OQ,04  $\+   9              " @:&"  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ "D1>47I,MV_I P
M_0@  !D              ("!"8@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  *1%Y163051?P&  !C$@  &0              @($I
MC   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  I$7E&:
M1]IAZ1H  -A4   9              " @5R3  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ "D1>4<%ND%L" P  )PD  !D
M     ("!?*X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  I$7E$$K^%#G@,  $((   9              "
M@2N^  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ "D1>
M433$K58. P  5P8  !D              ("! ,(  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  *1%Y1$,RJ]?@#   >#@  &0
M        @(%%Q0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   (  I$7E&7'NH!M@,  /H,   9              " @73)  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ "D1>43,.9.70 @  =P@
M !D              ("!8<T  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  *1%Y1--5*5PT#  #5"0  &0              @(%HT
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  I$7E$O9$[,
M>@,  (L*   9              " @:S3  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ "D1>4<**2U]! P  W0T  !D
M ("!7=<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  *
M1%Y10'5=3FT#  #U#0  &0              @('5V@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  I$7E%1F)72< (  )\&   9
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M970T,"YX;6Q02P$"% ,4    "  *1%Y1^FWVAV\#  #N"P  &0
M    @('Y\   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M  I$7E&<$+<IX 8  (TF   9              " @9_T  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ "D1>418>?CPI P  $@L  !D
M             ("!MOL  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  *1%Y1\J/4(4$#   >"P  &0              @($6_P  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (  I$7E$5A-L_CP(
M #D'   9              " @8X" 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ "D1>491YSE== P  $PP  !D              ("!
M5 4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  *1%Y1
M!\BB3=,$  #*$P  &0              @('H" $ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    (  I$7E&;L9?T:@(  'X-   -
M      "  ?(- 0!X;"]S='EL97,N>&UL4$L! A0#%     @ "D1>49>*NQS
M    $P(   L              ( !AQ ! %]R96QS+RYR96QS4$L! A0#%
M  @ "D1>4>CZ[%@ !   >A\   \              ( !<!$! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    (  I$7E&Y(]HWL@$  %0<   :
M  "  9T5 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M  I$7E%EX9FUMP$  &4<   3              "  8<7 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     W #< ^ X  &\9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>312</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Loan and Security Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreements</Role>
      <ShortName>Loan and Security Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - In-License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/InLicenseAgreements</Role>
      <ShortName>In-License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2139113 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Loan and Security Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsTables</Role>
      <ShortName>Loan and Security Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/LoanandSecurityAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails</Role>
      <ShortName>Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Loan and Security Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails</Role>
      <ShortName>Loan and Security Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails</Role>
      <ShortName>Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - In-License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/InLicenseAgreementsNarrativeDetails</Role>
      <ShortName>In-License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://evelobio.com/role/StockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://evelobio.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="evlo-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="evlo-20200930.htm">evlo-20200930.htm</File>
    <File>eveloq32020exhibit311.htm</File>
    <File>eveloq32020exhibit321.htm</File>
    <File>evlo-20200930.xsd</File>
    <File>evlo-20200930_cal.xml</File>
    <File>evlo-20200930_def.xml</File>
    <File>evlo-20200930_lab.xml</File>
    <File>evlo-20200930_pre.xml</File>
    <File>exhibit1022020q3.htm</File>
    <File>exhibit1032020q3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evlo-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 183,
   "dts": {
    "calculationLink": {
     "local": [
      "evlo-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evlo-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "evlo-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evlo-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evlo-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "evlo-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 406,
   "entityCount": 1,
   "hidden": {
    "http://evelobio.com/20200930": 1,
    "http://fasb.org/us-gaap/2019-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 9
   },
   "keyCustom": 36,
   "keyStandard": 276,
   "memberCustom": 21,
   "memberStandard": 28,
   "nsprefix": "evlo",
   "nsuri": "http://evelobio.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentQuarterlyReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://evelobio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentQuarterlyReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Leases",
     "role": "http://evelobio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://evelobio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Property and Equipment, Net",
     "role": "http://evelobio.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Loan and Security Agreements",
     "role": "http://evelobio.com/role/LoanandSecurityAgreements",
     "shortName": "Loan and Security Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - In-License Agreements",
     "role": "http://evelobio.com/role/InLicenseAgreements",
     "shortName": "In-License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Commitments and Contingencies",
     "role": "http://evelobio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://evelobio.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Stock-Based Compensation",
     "role": "http://evelobio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134111 - Disclosure - Income Taxes",
     "role": "http://evelobio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - Net Loss Per Share",
     "role": "http://evelobio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139113 - Disclosure - Related Party Transactions",
     "role": "http://evelobio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:SubstantialDoubtAboutGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:SubstantialDoubtAboutGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Leases (Tables)",
     "role": "http://evelobio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://evelobio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Loan and Security Agreements (Tables)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsTables",
     "shortName": "Loan and Security Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://evelobio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://evelobio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Narrative (Details)",
     "role": "http://evelobio.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "id4d98a0593604e4db29e81ca0e1ed08e_I20180131",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Leases - Narrative (Details)",
     "role": "http://evelobio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "id4d98a0593604e4db29e81ca0e1ed08e_I20180131",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)",
     "role": "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails",
     "shortName": "Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Loan and Security Agreements - Narrative (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
     "shortName": "Loan and Security Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i36512fd07785419f8c346218b88c3574_D20190101-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
     "shortName": "Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i714d2fe395864b4fa7d700a7d8555b24_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i9b24ece8af454852802d95c232d20b4f_D20170806-20170806",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:NonRefundableUpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - In-License Agreements - Narrative (Details)",
     "role": "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
     "shortName": "In-License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i9b24ece8af454852802d95c232d20b4f_D20170806-20170806",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:NonRefundableUpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:CollaborationArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i0904c02d23e4493e97bd87ba9355e65b_D20190701-20190731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:CollaborationArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Stockholders\u2019 Equity (Details)",
     "role": "http://evelobio.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i5a20243cb8d84ef18f004aae73258da3_I20190603",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i37bfa021020a483b81d3d7f71c17fb85_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i37bfa021020a483b81d3d7f71c17fb85_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i727b59e9eee84ab2b82d2423972c1f46_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:SocialSecurityTaxEmployerDeferralCARESAct",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Income Taxes (Details)",
     "role": "http://evelobio.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)",
     "role": "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
     "shortName": "Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i1a12b5d775194c26a646d257a891b43f_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "icc3902db262f4181bccdf98acd1e5095_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "if5a551ca740a46139c2913fdee05a4b8_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i84f17e602e1b46138c5d0f293fa6d709_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://evelobio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20200930.htm",
      "contextRef": "i20e66196c8ca4da1b9695a0f3b187183_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evlo_A2016CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2016 Credit Facility [Member]",
        "label": "2016 Credit Facility [Member]",
        "terseLabel": "2016 Credit Facility"
       }
      }
     },
     "localname": "A2016CreditFacilityMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_A2019CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Credit Facility [Member]",
        "label": "2019 Credit Facility [Member]",
        "terseLabel": "2019 Credit Facility"
       }
      }
     },
     "localname": "A2019CreditFacilityMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_AggregateAmountDueUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate Amount Due Under Collaborative Arrangement",
        "label": "Aggregate Amount Due Under Collaborative Arrangement",
        "terseLabel": "Aggregate amount due under collaborative arrangement"
       }
      }
     },
     "localname": "AggregateAmountDueUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_AnnualAmountDueUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual Amount Due Under Collaborative Arrangement",
        "label": "Annual Amount Due Under Collaborative Arrangement",
        "terseLabel": "Annual amount due under collaborative arrangement"
       }
      }
     },
     "localname": "AnnualAmountDueUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_BioseIndustrieMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biose Industrie.",
        "label": "Biose Industrie [Member]",
        "terseLabel": "Biose Industrie"
       }
      }
     },
     "localname": "BioseIndustrieMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_CollaborationArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement, Term",
        "label": "Collaboration Arrangement, Term",
        "terseLabel": "Term of collaboration arrangement"
       }
      }
     },
     "localname": "CollaborationArrangementTerm",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Period Of Inactive Manufacturing Services",
        "label": "Collaborative Arrangement, Period Of Inactive Manufacturing Services",
        "terseLabel": "Period of inactive manufacturing services causing termination under collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementPeriodOfInactiveManufacturingServices",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock outstanding percentage to be declared as an increase in grants.",
        "label": "Common stock outstanding percentage to be declared as an increase in grants",
        "terseLabel": "Common stock outstanding percentage to be declared as an increase in grants"
       }
      }
     },
     "localname": "CommonStockOutstandingPercentageToBeDeclaredAsAnIncreaseInGrants",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_ComputersAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computers and software.",
        "label": "Computers And Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersAndSoftwareMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Anniversary For Determining Prepayment Fee Percentage",
        "label": "Debt Instrument, Anniversary For Determining Prepayment Fee Percentage",
        "terseLabel": "Anniversary of funding date for determining prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_DebtInstrumentDebtDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Percentage",
        "label": "Debt Instrument, Debt Default, Percentage",
        "terseLabel": "Debt default interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultPercentage",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage after specified period one.",
        "label": "Debt Instrument Prepayment Fee Percentage After Specified Period One",
        "terseLabel": "Prepayment fee percentage after specified period"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage on principal.",
        "label": "Debt Instrument Prepayment Fee Percentage On Principal",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOnPrincipal",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Repayment Or Prepayment Fee Percentage",
        "label": "Debt Instrument, Repayment Or Prepayment Fee Percentage",
        "terseLabel": "Final payment under agreement as a percentage of loans borrowed"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentOrPrepaymentFeePercentage",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses",
        "label": "Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred financing and public offering costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evlo_ExclusivityAndCommitmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusivity and commitment agreement.",
        "label": "Exclusivity and Commitment Agreement [Member]",
        "terseLabel": "Exclusivity and Commitment Agreement"
       }
      }
     },
     "localname": "ExclusivityAndCommitmentAgreementMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_FeeIncurredUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fee Incurred Under Collaborative Arrangement",
        "label": "Fee Incurred Under Collaborative Arrangement",
        "terseLabel": "Fee incurred under collaborative arrangement"
       }
      }
     },
     "localname": "FeeIncurredUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liability",
        "label": "Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_JuneOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "June Offering",
        "label": "June Offering [Member]",
        "terseLabel": "June Offering"
       }
      }
     },
     "localname": "JuneOfferingMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Debt, Maturities, Repayments of Principal in Rolling After Year Four",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFour",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_MayoClinicMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mayo Clinic",
        "label": "Mayo Clinic [Member]",
        "terseLabel": "Mayo Clinic"
       }
      }
     },
     "localname": "MayoClinicMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments For Development And Commercialization Of Licensed Products",
        "label": "Milestone Payments For Development And Commercialization Of Licensed Products",
        "terseLabel": "Milestone payments for development and commercialization of licensed products"
       }
      }
     },
     "localname": "MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments of development, regulatory, and commercial event.",
        "label": "Milestone Payments of Development, Regulatory, and Commercial Event",
        "terseLabel": "Milestone payments upon achievement of certain development, regulatory, and commercial events"
       }
      }
     },
     "localname": "MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Cash Operating Lease Expense",
        "label": "Non-Cash Operating Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpense",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonEmployeeOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Employee Options [Member]",
        "label": "Non Employee Options [Member]",
        "terseLabel": "Non-Employee Options"
       }
      }
     },
     "localname": "NonEmployeeOptionsMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_NonRefundableUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non refundable upfront fee.",
        "label": "Non Refundable Upfront Fee",
        "terseLabel": "Non-refundable upfront fee"
       }
      }
     },
     "localname": "NonRefundableUpfrontFee",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_RegistrationStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Registration Statement [Member]",
        "label": "Registration Statement [Member]",
        "terseLabel": "Registration Statement"
       }
      }
     },
     "localname": "RegistrationStatementMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_RelatedPartyTransactionAnnualCashConsultingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Annual Cash Consulting Fee",
        "label": "Related Party Transaction, Annual Cash Consulting Fee",
        "terseLabel": "Aggregate annual cash consulting fee"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualCashConsultingFee",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value",
        "label": "Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value",
        "terseLabel": "Aggregate grant date fair value"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Contract, Termination Notice, Term",
        "label": "Related Party Transaction, Consulting Contract, Termination Notice, Term",
        "terseLabel": "Termination notice period of consulting arrangement"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingContractTerminationNoticeTerm",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term",
        "label": "Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term",
        "terseLabel": "Termination notice period by non-breaching party in event of a breach"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_SaccoS.r.l.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sacco S.r.l. [Member]",
        "label": "Sacco S.r.l. [Member]",
        "terseLabel": "Sacco"
       }
      }
     },
     "localname": "SaccoS.r.l.Member",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SaleOfStockConsiderationReceivedTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Received, Term",
        "label": "Sale Of Stock, Consideration Received, Term",
        "terseLabel": "Sale of stock, term"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedTerm",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Value of Shares Issued In Transaction",
        "label": "Sale Of Stock, Maximum Value of Shares Issued In Transaction",
        "terseLabel": "Registration of equity instruments, aggregate authorized amount"
       }
      }
     },
     "localname": "SaleOfStockMaximumValueOfSharesIssuedInTransaction",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_SalesAgreementCowenAndCompanyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Agreement, Cowen And Company, LLC [Member]",
        "label": "Sales Agreement, Cowen And Company, LLC [Member]",
        "terseLabel": "Sales Agreement, Cowen And Company, LLC"
       }
      }
     },
     "localname": "SalesAgreementCowenAndCompanyLLCMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security And Loan Agreement, Number Of Tranches",
        "label": "Security And Loan Agreement, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementNumberOfTranches",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche One [Member]",
        "label": "Security And Loan Agreement, Tranche One [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche One"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheOneMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche Three [Member]",
        "label": "Security And Loan Agreement, Tranche Three [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche Three"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheThreeMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche Two [Member]",
        "label": "Security And Loan Agreement, Tranche Two [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche Two"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheTwoMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTranchesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranches [Axis]",
        "label": "Security And Loan Agreement, Tranches [Axis]",
        "terseLabel": "Security And Loan Agreement, Tranches [Axis]"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTranchesAxis",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_SecurityAndLoanAgreementTranchesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Security And Loan Agreement, Tranches [Axis]",
        "label": "Security And Loan Agreement, Tranches [Domain]",
        "terseLabel": "Security And Loan Agreement, Tranches [Domain]"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTranchesDomain",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments",
        "terseLabel": "Annual equity award, vesting period, number of equal monthly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease",
        "terseLabel": "Number of shares no longer authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased",
        "terseLabel": "Number of shares repurchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised",
        "terseLabel": "Number of shares, options and other equity awards exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures",
        "terseLabel": "Number of shares, options and other equity awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted",
        "terseLabel": "Number of shares, options and other equity awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments",
        "terseLabel": "Option to purchase shares, vesting period, number of equal monthly installments"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_SocialSecurityTaxEmployerDeferralCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Social Security Tax, Employer, Deferral, CARES Act",
        "label": "Social Security Tax, Employer, Deferral, CARES Act",
        "terseLabel": "Deferred payroll taxes related to CARES Act"
       }
      }
     },
     "localname": "SocialSecurityTaxEmployerDeferralCARESAct",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_SubstantialDoubtAboutGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Substantial Doubt About Going Concern",
        "label": "Substantial Doubt About Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernPolicyTextBlock",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evlo_TwoThousandAndEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 stock incentive plan.",
        "label": "Two Thousand And Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndEighteenStockIncentivePlanMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_TwoThousandAndFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand and fifteen stock incentive plan.",
        "label": "Two Thousand And Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndFifteenStockIncentivePlanMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_UniversityOfChicagoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "University of Chicago.",
        "label": "University of Chicago [Member]",
        "terseLabel": "University of Chicago Agreement"
       }
      }
     },
     "localname": "UniversityOfChicagoMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_UnvestedCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unvested common stock.",
        "label": "Unvested Common Stock [Member]",
        "terseLabel": "Unvested common stock from early exercise of options"
       }
      }
     },
     "localname": "UnvestedCommonStockMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_VL46Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VL46.",
        "label": "V- L- 46 [Member]",
        "terseLabel": "VL46"
       }
      }
     },
     "localname": "VL46Member",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_WeatherdenLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weatherden Ltd.",
        "label": "Weatherden Ltd [Member]",
        "terseLabel": "Weatherden Ltd"
       }
      }
     },
     "localname": "WeatherdenLtdMember",
     "nsuri": "http://evelobio.com/20200930",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Mr. Epstein"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r123",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net accretion of discount marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r22",
      "r117"
     ],
     "calculation": {
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r146",
      "r148",
      "r171",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r133",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Fees associated with public offering of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r148",
      "r166",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of leased office and research development space (in square feet)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r251",
      "r259"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r36"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r149",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment additions in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r20",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r20",
      "r68"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r5",
      "r69",
      "r75",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r68",
      "r74"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2013 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2013 beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r205"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "In-License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r122",
      "r256",
      "r264"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized; 46,220,859 and 32,232,258 shares issued and 46,184,087 and 32,170,605 shares outstanding as of September 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r191",
      "r194",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Amount due under license agreement"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loan and Security Agreements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r252",
      "r253",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Loan and security agreement, basis spread on interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r10",
      "r126",
      "r253",
      "r258"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Loan and security agreement, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r127",
      "r206"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less amounts representing interest and discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Fees incurred to establish facility"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r33",
      "r207"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r115"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r82",
      "r224",
      "r255",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amounts due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Common stock offering from ESPP",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r201",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r198",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r198",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r198",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r198",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r75",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on sale of fixed assets, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r101",
      "r182"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r75",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r52",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r61",
      "r63",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r50",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Minimum Aggregate Future Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding payments made as of September 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "verboseLabel": "Rent due from sublease agreement"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r254",
      "r262"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r25",
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in)/provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r43",
      "r47",
      "r67",
      "r90",
      "r257",
      "r266"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Offset to operating expense from sublease agreement",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r92",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "verboseLabel": "Minimum rental payments received"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset - operating lease",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of revenue recognized for the period under subleasing arrangements.",
        "label": "Operating Leases, Income Statement, Sublease Revenue",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "OperatingLeasesIncomeStatementSubleaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r87",
      "r100",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r189",
      "r190",
      "r192"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on investments, net of tax of $0",
        "verboseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent": {
     "auth_ref": [
      "r189",
      "r190",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent",
        "terseLabel": "Tax portion of unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r27"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r149",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r18",
      "r19"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Plus"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Net proceeds from the issuance of long-term debt",
        "verboseLabel": "Proceeds from Issuance of Long-term Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r58",
      "r169"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r54",
      "r55",
      "r105"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r22",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r21",
      "r116"
     ],
     "calculation": {
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Property and equipment:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r118",
      "r263"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r6",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r6",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r223",
      "r226",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Payment to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r144",
      "r225",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r144",
      "r225",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r174",
      "r270"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r75",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r74",
      "r250",
      "r260"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r140",
      "r261"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold in public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold in public offering (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r148",
      "r165",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r148",
      "r165",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Minimum Aggregate Future Loan Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r22",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r77",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r5",
      "r74",
      "r250",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r149",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r155",
      "r161",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r79",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares originally authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable as of period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)",
        "terseLabel": "Number of shares canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of stock options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r157",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued for purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r147",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r75",
      "r149",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options granted, maximum expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under the Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of fees (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r133",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "netLabel": "Number of shares exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of fees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r11",
      "r12",
      "r133",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r133",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r15",
      "r16",
      "r104"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholder\u2019s equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails",
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Event Considerations"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77891322&loc=d3e41620-112719"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919396-209981"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919372-209981"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r271": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r272": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r273": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r274": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r275": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r276": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r277": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=SL77927221-108306"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001694665-20-000090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001694665-20-000090-xbrl.zip
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M'O[I@Y)E$'=]M!D+]K$PX$FISW#^9JWJ[=53<S#BD>DW_4KEOP4K>G08R\3
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M2"[Z7MLKDI IP^,Q,7UJ/FS5]P_F#%E9X2X?,$W.V(A<R@%-EJB^NY+F'[8
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M26CK?3N;;/==9KLM 0P:XH^#EV-Q \LD]IDTS\G6?=8Y8O06V9-CU)8_V5S
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M&L_:6>Y-IV.^*+HW*B3 =F>F'E9YZ%3NP8/AY34[IC8'YOO_ E!+ P04
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M"Z;S%G[I+K&]#]N+46P%,TX19S).G<J8<"2S@L;,&X4IL+<E'-@XS?_4H/T
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M+APP_WF8$XMU/[*BP9BV>("$49@1X@10LP;_)$9+TS*;#C31\N(!.I58]Y3
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M.8H\4,:"-\ZBH(VP0AFLV!R$[!X%S_M@NN&PW?#;S9-.^[3,<)@33B($@6=
M@_'",18]8,*C5 H9ZPP:;@5?&$Z:.%1CY"H9# :%!.*-I[-1N%8 '6 CE#<D
MFCE8MG@45&_[G5;>ZW<"-'R;GZ=/\\)4,7)+ "<*=@.CB"JK?,2(D>B4('(.
MHC(SC=08>2IPH["@S BE&%)$:RFCX9:E7SR;@S,*'X14D9:8MJ#T>Z'3A5:?
MVK%W9CKS<BZA=2IR%7UP"J>:M$99AZ+0 AF!P:Q8$(::"DSCU%#1&RRCD%X$
M%L$H#XRGFD!2$6^HG(/\BT?)O9T8<Q?FS7=RV",DL/&,<F8"T=$+$H@5"%/)
MA[7LYYZ7I@#2&#G)"FVM%-HX1QB8X9I%!<8?==%R1?$<'''\*)#>M(M NDO[
M7K9;<.L!F!#S8NTQ#G). %=1AI@,&)PGC:4)F@8)7+5H##5YK,;(5X10B1GA
MH*<0P^ ZN4@999I$A!V+<Y )_M-]1^)1^XYFA8&D8\: D\2]MLQ:L,&QI)0I
M$KAF9'"JL4;@Z\XE*&/>##;]K5<W]U/+#.NG$<'5CH]>N2_M[MU4@XO#/AZ\
MZ2,5C3?2.<,Q8P3$,1&8@M? )6C6J*^*4L$[+,GKQ?8:[K3N<U[F@."_+]%T
M3?+WE&@:;?J<T_V44C(E5&*CF+%!.Z\%Q]QPIBCRK-PXBU&Y&QHCC/FL$7.W
MT[LNBO')A9:!MR]1+"X-?GG;[@1GNO>A.).\,V9*G32OU@_A^\MR#U@-&#UP
MVWG:EIEA/@;N<9JP$$VT2 @67:I@1QQ8@"H8%<$?GB-5\ 5XQ-A&V(6IN%W<
M#%JGGY><,Y\R/H#3Z*3"W"K'."7:&6IPY"QPIH6<)RI=DLYD22<*$U4@BE'/
MF65:&2L4QH:D>ED!S<$RQJ14YB*[T9AY$@/57 D@@FBDEPC!7\4YMV0.LBYF
MP:4=(R 4+'02/9)2<89U5(XR0;"R"CYQR6Z?U#S#R$R776X+V$<<SSRF$KE,
M2Q,UQI)@R:A 2L3@L<7$>.JET</"1<-J5/,*Y>-T\_.=@8=6.[[-E<^I=AP<
MP11C9P)C2G'MF(W2V[3P+Q1U RCQ$LI'0OE KAPCE-@Y1&W 1D?#0.&E[7$@
M5P5C!E$:Y^E0@=F!<CHUR#DQ$1,; %'-%$'64_A.8:Z5\R:$1=&5$X=R\KI2
M@ZT97% F,LX4)PH1K[DCE'C E96!=XD4$MGPPZQ!F0*2;U))LM Y@2F[J)GF
M:(I.U5RTWS3R5NY>&#_@0Y4A\1#\;C5]!GY6BF#38HF/C#F#;*0L99Q2Y0-U
MDL\)?KNF=1"NX\M5<YXW^\WG^H^_-&5P*3@C*@CO-,/(&H4):%_#B)>..7*#
M,F;3=)H__,9H+QDB$?<.C"00T48PI86D0FJCK*"@@&<W0C!%V%XD-(!84(H:
M1P08JR$*PS6Q6G+*$==J<-"Y0!2C;/AA%B&9BHS]W,I/0Z<+<[ 3WQSFSAS<
M5\[VN<PJ,D0SC!XB;&\U?0:SJB@8YU')=%::0LI(HBPC'",6@V5\3DAD":2A
MQKC(":(!,\.=1=99)RCEBB+*\ T@YU+\SC*08U2?5!L=@B<1!\\D9EJX5'L%
MZ^ 8)GZ&5UEF ;^7T:,:,0?^):&!,4V#EM8K:8VFG ?!OSLG5,YN$F[*M-V)
M&YU.TJG7D8/KM-M&P]AVQ_0 JY%6+ZQL/QGGVI_6.FN-M9D*.\F1?. GUG /
M_>^+3.?=-B-8KF]]WAW>_N"$0R<P>#XV<H8B<QX93J,71E)DTVEZPX.PER0X
M2R1X.Y=U+%GFT6FL+0&$N&**66-\M"92P[G4H.IO2*79U!B_,$D\42J-T=!@
ME!ME M+"!.8-R!1*#0,R,>"^1X)FU]"XAVP*\+;.7:/?S4_+1,1TZF->'!EQ
ME8[XPL3S=][NANV6[W=[G7Q>=L!R ]TQZJSRBH6(542(&1,D)5QY,SS#$-R(
M626)^\ZHV@T'.2!BTKZBJSSAEQ;XR8\8 SK$$L,%9U9(SCCF*IT!RI#C-IT.
MBLU X ,ZV1*F)PGA4:#N,0U'FSY#"!-,P)LH.$V#0';:*8VHD0;%@*F7\\]Q
MZ=?NE=1]TSX+K5(@GYC6Q?OW;^:$^:B,6C/),&*<2<(TD4I;'$$R"F<&0"G$
MD9I5H-*^RUM*JG[6KA^V^UW3\FE#9GYPV NA/!QYN^72(T]#NFT<NO))4=SG
MH:\RQ#.DQH"^PX V#T0X09@/TBJCM8Z!6NRP062.TGE^$3*8?MX0HA1;3D,D
M3C-GO:7@LUL0\$)I)SBZG6PRPR>N_8(T\\BLEM&FSZ 9Z84(7"5/7C!&O#$1
M6Z-X#/"!H7!;SBQI9I9HYI%R9DPTH[TR# ?#(L.I4KL)UA,D HZ:>1304C<]
M9LO&QIGI^#N*8S9/&NV+$(H'3^KHW,GK+"$415K)=.9X6FW2+AI*6"I=H<'O
M-$M:>JK\R5OC2%KX 946;U=KMX946A+H"Y1+F3Z%IHT1Z>@?9CQG&GE-77&P
M,S.!>R;XDD)?5$,N*?3^2 %BS&*K@B :]#("3Y%X:B/2"$7XN*30>476TZ!X
M4,%2A5B@PH+P$88BQ"C\M63V5TQF"M 7JI.FL02N8U%IQCDQ,CK#K!-1V$#<
M/&V\NA>LMWG\A9A/<1EUL%)B<'2BT51S:PG6Z8A&*M02V*67\V ;DBD9'(N"
M$R:YL<10<'<<T=X+K.*2E)9.SE0)-(![PUBT+"C+E'$:<RN(Y3S8& .6<T"@
M+^]AS)P4_84(U(@8;0"B1)8SX[BRBC*>3HET0++"+@ET:;_=WFE"(S76*$=-
M9,Q;+1WV@40")IT'4VX!G*<)XODBOE,J/D(Y 2_)6(:--MICI3!5T3OD2)GG
M7N0X9'.?[# EWKN=D_"S9<5;39]C3QC$@O766& ]ZXWR00?LK;(V"N7L B2O
M3(7WQIAA0AGCSCNI-!$,2V.=C5Y)#9*1>&G\'-7^@>EO-\-5VM[[MBOR^&ZZ
MFN]"*W1, Y#;\$WP&\ILO].P=7X"_;U\@= I)%R[H&/T&*PEC9B6P'U&2TJC
M$$1)T(5S5$AF]B&>3H$9+*.6R#N*8F3:.LV12&=Q1:RYT&&>(@NS#_&47!]"
MI?,"8-6<H> MBCYB(:/%2H*\GJ,:0K,/\91J"TD$?.P##IXP#1:3<\"_T7)#
ME+$<+9HNW@W=D,Y7!HPWT_G)[>)8E@76Q,)8"KK7FZ!H*N0&"MDELUB3&#A"
M\U32;=8!GHX>)@0YYB,#D -3B *R#L2V\YX)PP)=-#T\90Z>O!:VV@3.8W26
M6V:ILIAH9IA4X.0RBL2B:>$I<_#D=;#BV'D-;K!W "NC5GL2C$8>\ [!SD&=
MZ6FNL;Y(>#  Q[G@J:7,,\N)P09'Q8D3#+ 1\[ J-0O83%]X,J645U$JZ@(S
M2&BBF+.*2(,8<S(.XKP,#^*\\&&>@7SYB"[+\$,CNJ--GR,>F:!88\.X%@QK
M88E.>_:35V*BTV:.7)3I0S@=)\1+!!:+]YA;SQ U%CGC='0*6ZR#G:=8T6Q
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M/_VQP3<SH8F)DN\;^+C3J;?/6DOBG13QTF]$<^4\QQF6PF6,V)AI3\!H2A7
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MN^4"*[QA>1S?'<?GM#O%LQH7Z>%G.3P:'EMIA;.T>ML)IWFWB .T3,NELFZ
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MS.PH+>6MTW8#X#ANM<]:Q:/ZK?)S)^\>0X_]E@N=1+0%PQ3#+\@=* ;(-1G
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MW/XQ;%,%Z6'R91H@P8-O@437U!"DH8<!4SZT$TK$#MKEEMVD*5JKH_Z@,R?
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M4>@HH@7JB2L>)@<N$ XL$N.U((R7=GP9Y*C&+M%7BU/7!>3J:5OU:?OP^:#
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M@"2BUTZK8*EB7GH5:6*VH! U9RB4'U04:@D*D0L4XE8FKJ@#Z2P#9"*"98A
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M$T 0,"'DPYOU'YD)8*C)1C/M\H6FPE?6;9M(?<C$G<JP"S/LQ,L5F,_ZKQ;
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M2]](ZM/7F'F2V>C&E\D3>N-KMUU6/J'BYD_>=M7;7V.<+7VMXHD@;5KKP^^
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MMA'O>1N.[,=1?'K^X,?0&WT\LE^>]OK-330?^E:0YZ\Y R5CGF3=LN#265W
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M*UQ&^JQY95W+2V(I8]%G_J".S@!7505[."3;G:A@46&RW%!03/",9.A <R9
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MI7W[]Z^#85GWL_%XV',GS8CL_<&OV9[ICZMI,H]I\DUW.">)8-Q#\EP!1LG
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M> 28.(KCGCI]DF?&;_:/=K\>;)_0O*#,:T[R0CD"JP36JM IH8)S(PJ/-;&
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MPXR&CM-A"N>'NCGU<E=&[NR>5U=Z'555&8.+%ILT&C.<A/ZNWU&/1V/''@R
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M":@BG9)&)(YHFPK"T]P0[9D@+N$6U\<G0B.J+'<NJB6LF7[T<'O+#4^X7B$
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MTT*#WF>8AEMH150A'$G!A. ZL;G(%7HD>+&<H_(<V,318%K]=1KZ^=GLXLI
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M]5()HX3F:4:X$XPH+3S(%-=:)<J+E&Z\$'Q39,M9N]\,MGTWIO9MF6]!XBF
M! A4D3$A$I$JSI0N6"%3*KUV.F$Z+UJ06%^02*8@0=-$B1R[Z11*$2X*2K3@
MAA3,>Z8S;EW&6Y!H0>*6(*&,S+UQB6=4<^J*(C>Y227CGC/8EL3U0.*K&PXL
M@$"+#P^$#VR*#[K('"RB)BG+*.%IHHGVN2.L2!V3A1# "C=>A  .^T\+$"U
MW! @"I4#B4@-\T9PD0F !EFDU!;:*6?I-5E$"Q /#!!\"A!%4?@D\1R;?1H
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MBVW^;0L2WP8)0( ")"S-<TVY,TPY+;0KO+)29TFB6I!87Y"8Y2)DQHH\89+
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M+:6(@/Z!6"KI;*B0"!LB88L*4QAVET^@?2/QF>&T8O1_!HV0U?1>)BPP)&V
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M8 F4ETAH-=P+1!HG%>%6.<8+JAU8CR1R%CC30JZ@QBP!P!M0[[#[3RTZGC,
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M@0WA7Y7B'Y0]0J7H:4ULHJ&-,WU 5QO'M@^ZK30RD(FPOB4B-G/EJ;4IO_I
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M$J5L=E43^85)+)4;..3N%#N-UDV4,RB!N/+N5ZW=.[F=2G]:MDZW9JM# 25
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MNT]+W_]HNFH@+P,Y4PM;+FG*S+G()SC+)V[E:]-O6[^6[K[Q*ZM,H93V9M)
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M30ZZ?^:E' ,&HL\,,9I'^P7HLP9X,#H;D66D 'U6.V24!?1@H"=ZQI@)"HS
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M?$U&=A!GI<"">Z<E<7G-(/&X <P9YBQ:8/=NF4_;S6?^LV/-FDX6(H.S4 J
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M"[\)QF(O14@RS]8ITX.45#K-?#E\-$7$%;64CNYAE9]6T<R@S/ K>6$!99?
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M)X/)R;"+@)FGJCL,CX/)R4EOHN.YY]WAD?YC&2(39- X6%10SE?X%NPN8%0
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MP/IO@'0C[.B>2=H&3*#;77[QVCMC7O?QU[^:]WDOSW PK![DB!129Q\_0O0
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M3!TR"M<8O2 E@Y3##@-9HG2;@%Z9ZN0P2@IT.1 70+MI:!-I/.54BF/*54+
MGUD0$2AM&-BL1\9.P$^O5:(R^=2-)]Q88 5A<W@S=[(KV%W,G;(C*CM(2>4,
MKINPEDKGCXR"]X/]].BUOU%PWTT/UU7 -=PWJL;2TVJIN3.!)?PD_58SN+P8
MSL"B0:9:%6; TD+_WL5$T.);8O5.3EZ=@BB?G_H9(Q92AI=<XV[@0C$1/&-
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M2HB]3B6V81&"[,5% F:)@G=TG06S1F<MYR4Z[EK;:,Y5VJR3;2724U7C,ZC
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M6*?#WDR9F&W[X=[<VEDX!;DX(ZR)4W:D46$ Z0_L0E^1G'ZS1!Y[=)NO)#Z
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M,]:2UD>JJHN!ZU$U))=YE#-DKG^BBL2U>L#!2%UR^(2FEV2;G;JS*.5Q*DW
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MBA)0!B31ZDR M[:81IE]AC3ND7*V%,ZOS#V!V5"Q"BOZW=^#I$1/.6);P"1
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MJ.@2JY$1)<FE(]B3,));\ALK':]A:LC$]X:LL%9R%B0!LP+$Y>N>_I"[=,9
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MR_:IM]ELIL81$D[W^"\R!9R!K*;6/8WQA(SSSL$4T@T3Q:P((HWV9!7N]6?
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M<H/0YGXK"F$5@T1AY8GI&(# ]$XFY"3*L+T:8LU/%8?[-^E[YW,TEYI0<8.
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M<$]?"<+7PO=>U:+9[VVT]4+C>&$+$KB4[R1N>6GBRH=F*2!UX;8(CKO@QS1
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M1V &#IV.24:A!)1%K9/@7&7VI>)E@7/$U!.=$E)?0J6GV[4JW/GK]F64TLL
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M\KEK1&+MP.Y+I&=B2Q^<G7V9PGP%=3*%SA]G0#FOW71>A!6..(&>&Y0&C5=
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M:'C!4\*<L;N^9:)+*XNPI8EMH)0Z&6V;IQ++)MUED^8K-T9A:%^CV3-:]F'
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MO;/Z<#>,*3]D7B)HV2\_;;^D=T:8_G?%4'QB1<'Z#;SZF#^86&?1T.7J#GI
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MM@9^ .-G:(%(P/.<8_W,LI'P^TS=V5KU!K>JJ*?R]2.E'&T"336]!Q&C?\*
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MC(U'Z4D1O\%X'L4%OI?AF>I$B,@-[:%]+*^#VS[>R\-(X%&Z<H-VZ9EE4VZ
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M\0\V\=*#X8BU8J"S:83EDG$OXL>W17E8]VW'E#KSB=EED1YLD:@8'*YUO6L
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MTK'K#_I5#PGW1Z3*P[[;*ZF>/U3\%U;C&LML)4=+ACD8%C*==I+B!"26&F*
MW*X!2CQI%V$*=SW/1$<AJJ).!?I(C*VT([BGK*^UJ%T"8H4+:"MIN GL,V-
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M^HR[34 1FJ_0/"7+8AVX+"&H!TI2!,NX+090\C%C/LBP%UJ0AUM.<X?EMN1
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M Y, ",PBF?1_IA=;T&Z2*=G1ZM!R,\9-*I+ T0C#B;#(NK5P>RO\(4&GC%!
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MN7YX^[(AY'GSF"FH2>^EB0Y(0-J>G;P&J!6%H0-%8?6ZP>.H!X5B=;W(&D&
M\<$1A\&[##+&+%X^3]V3,<U3A QU(<7!6O(+LV<1UFD12J>6Y ,<,MSI)-"#
MB4)]:&J</LO$\)4&>G.0Z0UG"G#CM5\Z<F6'$#A?U@@I8"K[%B8.B-A1PZE>
MUHV9 R43XOF)*H48IBA$D*Q'CH1.N8,(,V6]QF@#>U#P*AB 9@ ZQ^S:U<J.
MZ,23%A(1\-BC$GH129(IB&Z(O]N^(":^:E+)2-V&&" AKCA^!20'4\6VA?R'
M-@-Z,K00%'!:%"N.!P'Y3Q!G3LD)-W<(:!D0C&("!B7(0 *(7ONV*'W&2PH_
M9"E*X>O&,BGE<(F<HRTP'QM3:K>M*5.:-!V>6@T'9PR0:@7%I,0F;^N7 ZS[
M:[SH*M-\DZ?F]ODBBF9;:>[ FG$,C$.<V$K[CFGM&"$_$4%QL5&!8%B/W6AW
M4AFOF*222/KYF$![%U( .E(R6E$BC@R4?R:YR' -\GJ,RA5%D$[_B--!^H ;
M6#J1C+.0@1*AZ3R0U+\\)9Z-^\^C/B4?,>0Q7QYRW>')6=/$(F,.M4;%0WU1
M60'?PDWF>,HZ)E*:L0RJZ-G;976NVS]F!&!S8#M*ZCBN2.&(ISX@Z^,@E87C
MT5RI=-L3.T%,![6+B< ]MHS5SH,,Q1#LP!?1)[.P!Q.H0QV=QM'QX=$19;1^
M-<GY<O_3'-;#JSG0U"7VK2]P/J#<0V6>X%M0Z,%B*O@?@AFU.X[239VO2@T$
MRD)>GDJ!Q*%A%K>PO4AG"TM]1LHHV)1;>U4B!9F[3);#XU7U=,Z<.\ _E_LI
MALG/CA@;DNGX96]Y=<7586?2MJ)7H,2=735H=IHJP&MVQD;D;IRW%4A^J7%1
M5LUZ?>64G .'Q.U=EIULVH%#?#AN(&,2$(/>J[GQK!ZPM7]#54Y>+2<'T:N@
M;(,3 !>K/76Y&GF7 <!1),$0HG8!_VWB=3U;04+Z70J.'W?\N4L[-LZDT,XP
M+O=:]T6>)RFG.W0A2*F(PL+%+W#B7KT4YQ,0FAIFL[&SRR[9_X8%>U;"@]CK
MP4/*S*' #GH(_J8TW(PN'1HEN"$PY4I'A5[_P3*&J$-,9T<PE <WG*V@E^T,
MB8FK0?Y:F2>UZ7;E1/..I 3/ZD6Z0CB!.I(#'ZNZAU)G4 DJ8,#I&C3<A44:
M5NTNL1PGVEA,('PSSS!X/S!+<U.D'F+=>4Q>RQDH9X)<0ZW;Y-TA22)$#!_0
M1Q ;)FD$[NI+[<PBZ55P>K,):4%I:Y4]:HR7'//"#(R,Q &!9F:Q_D 440]H
MP_6E+H0:HJ]8%-A+.??4>0=K"9U0EF?H6 OI#:<0AJ_,-J]KQU_[/MLDRDL;
M>]C?<L*A6CI"972IT7H'2B3@'E9>GV+E+^'9I+Z-8658(?=:(<K&@SF+._
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M;))"5]=U$! F.EM0DYYJDB2CYH8/(#G]D0O(L!U;M QTN<[:!99-TC9\U=I
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ME'N@"-7W5?L+^%<7B!>PN@PT%6%[V4 +TOTZ%/\TGH45F^D[MG"M'Y-1T2N
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M05#.KI]FB-ZV3CQ<W%5_]Q"+JEUTM8)ZL3>&V,&>\J3>Z'-P-YP?2#V"?0R
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MK5H,JX((0/KFK:\%)$+P3@VHA-HAS5#2UJ'SY,!#NK\A:WIL_,H+]"M,ENE
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M&+V;>R/$HN.<T+;1[C_U*4$C W)_0E'!RUYK58I>G]+.1'3"29KH^)>5C4
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M+^5T-]V_17^DI6/=4=-0_\O2,WJS<*H=2%,+_2LUOA)W G3@>""-70"&N+F
MW1&!4K[;!D1\[09C[B+Z.[?1".S*#M;2B=W"#=E7Q;HR@*Q<-^XE(P'<0#J1
M>M6]B'V:>;)$E;44);D84,>ZX.0],[$Z,C/QK 0J0XXPU0"?F^FO(9R"J%Q
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MLK*:@K"<!&4%D=90$AAX8IWQ2>1$M6NRYO3D+DD^' /WNU1Y%T-6K+^X+O#
M@Q &6"#4\HP8T+-XD$!49L9KHW-@34Y^N@FC;\/UX["F@VF:3?PM:SWWRCXN
MOMDU15@'H%NNMFIQ_SF#&]^O(U[]G'_5;HV<?D-+=01OF9.O>O@43R M1C#)
M[X;CX>GB],7Q\12._1Q>+^:+*2P_5:I4AJN=RITUM6^'=11:1=Q*>?);F,T
M-I2-7ZZDO4)'B)$O6"LM"2 \D308XJDR.'R"T$ %"ZG)8?3; NSJ<^_MY_=Q
MNM@[7W:<1?SHB]/RW\!R;45930K&EQ->2OPNDR:0@*6HM77Z\%K9A+9/<5\3
MWMUVUNUM6O^2BUL;-X+@42LE2*19$AFM(EY#)I0F;IQ)TK8I^^FPQ>900>!!
M*%3#+HT#OSW=R8 =W']BEX_J06^+?&@?FGG64H1(O.(:LP5NB'/.$ H*>-!>
M4]ED,K87/O1:/_\-?OH: \J!8(HR*1WA&<=;?#(E\:'<K.ZXH11'80=-,MM=
M@3Y)S[D+VW;RG%TM6<UI[H+R,_('T+<G'T5PA!FNB&3>EMN/#<+,";V]HI(^
M:A1[A?1).MI#,6YW6QZ6<A_AU ]+1?K[_!IC3#\JH <N9RL91B#,E-4#76K0
M%!?$8G"2%4V>ZB:WENT/N4_%?OTA87?K'GP ?)'G,+T:J[TO!T<+3B"4:D6?
M@#A**0$!0+,2WILFQY#LA;9/&UWZP\%.-GT4__MZLI@.0DZ,92\)2QSP(8F*
M.)8"X<E*#E(FX$V6Q78%VJ<3 GM%NKTL^3CQWM?)H!RDFX4H2W;E@+MD$O$2
M'XH<LV<^1Q53DP7J'7'VZ5#"WK%M5SLVFVQY[8?3Y9KP.X2[F*[N&-IG"F5]
M0UTG1K: UVVI9FT'^Z_0W==<$UW47[];V\U5N>3%]E<_6NT1\>/KISI=?"/Y
M^54C'1:UV@!I8H6ZZJDT@;>"\+TKC.I'DP)@D%)TVOE ?$R12*> !"L#,3HI
MD373JDW.MA%1F_*E=:)[:[3D5A":'4:4D',YF)ZA)B(-T4?J0Y.#Y+9&V*=)
MN3H,VJY$J:NQFGG(RWV6_MH6RW(I[AXCVJ:FNHY)6T'LYA4V=+&_I[R_P48:
MJ>\M-W1TY1#6O=_!)W;IKI%.=Q>UDG_;N &ZW-X<J+(LEV/;=+)$AC) )9N(
M44YEFFQDJ<DX?Q^H"ENLU[?]CVFYET>Y'(/DD60?R@WPY0!-<)JXH(.RQF9[
M^VC*QB(O8?7)GU5CS)K-U+4L4_,>E,5IT36DZY>RX-^CU2T:XW3](HW-QPED
M)04UCA.A4\E3O2B*"<09T-(&CNEJDXG56@+TZK2(9A1\%',?.NBJ456Z;=.-
MW&73NM.)Q_0S79PU<_[B> K[3^AL;JQSM<MV,!OIHD/Y]0---M-+@R+M35U5
MJ=O>NO%F&GN4I^S!^BW\XM4\< /U[M-_,PMT5D:M,K9KAXG^-ADCS&GQ<LIK
MS0TZ6"UU(E)K0USDC@CJE7%2^>3:E,RLA=/]YL,P?S.>S:>+HL_?QW[EZ3$4
MN"@&OK@8#1W]\J,7YPR^G,SP4<' 0S+G ((G-F&4*H.)Q"H=EV6@2>5(6:O+
M$COAWC&W:!O952#:W<L4#V?6BK=P7@=]N>_PH@J=.Y<PNE0DB'(T6:06DR K
MB)6.,96<\;K)+8OW@>I545IK$G6PQV$8PD3F2B=.K!#E:'"/HF8MRUD#(@8H
ME[L],D.Z^:"+(R*7AXM\/_+ZPW0XCL,S/WHS_@T=W\?)"-LZ_OP51E_@W60\
M/YD-O#2<9YU)*.J0ONS>E6"(X-0I[AGUK,F>B1K@^S0)5(U]=];_#VWE>A4H
MNR"_0'U9Q: 9Z"@X(A1E&TJ4G'BK/$D1G-5,9DV;G%/; 7.?!OQ^L+&#31^?
MA,NR:4^5% G=%Z/"H(=$YVA=!.*%"M'QS(UM4Q35!76?*I'[1\2=[?KH5%S6
M$,8@/(95C@1;RKJX8&4L=R1[Z;)/7#+Q^'[Z%N@^E2/WCH@[6[7.G73[P/U>
M/5TP\\A8SK0<N>0$D8)B5($A!&$I4D55PF3BEFO><%==9RA]JCRNSJ]'L%:S
M=9<W^,VXO'JVT]K!NF:ZSC0^"*W;K.Z:YFO,A6_3; /-M)S_OK8#V8_3R\GR
MQ$P8[WNB\'W-==7,UE";::0&AW9IOJ'&FIYB6RZM.9F,T!/,RFKI_'P?1:UI
MI?,YL0\ JRUVET-W-S967PFM*'#G;J.]%7&WI2I:> !@"Q5T.&/\OO;:J*/!
M&>)K^ZER9OAV+;=15//1]$Z/WX^\+F^'VV__^JW\65^?NW7;1MD=1&]OB=5=
M;1?7NG1V 'MU=@BM;R%FUP@>_X3/_MM^@^7UKW>/R#= J29AIY3D3BL5Y6U@
MV-]@_G8RFWV Z?+^PWUDOMU$5X'OA515VOV]__J&*DM>W]_?ZN#[]H()MCH?
M^M'H_-5PM"BN\_NE>K]^*[=?0BK3/64(6LS]ZL:&Y4<A_7,YLP3IQ1>8^F-8
M7:_Y?C&?S3'+P0RGP^/TJ'@K6_,1E=V--!]A6?G\P4_GYY^G'AU0+)#V,NC&
MMKHJ>SN0;111(U[>NNU6BMH^9KZ8$2T_2K3W\U_^#U!+ P04    "  *1%Y1
MA2%Y?PL_   ?DP( %0   &5V;&\M,C R,# Y,S!?9&5F+GAM;.U]67,;29+F
M^_R*VIK7C:ZXC[;I66-)I5ZMJ8HR2=6S\P2+PX/$-HC4X- QOWX] /#"02:0
M&0"+K#9K%D6"&5^X?QGA[N'A_F__Z]O5Z(<O,)D.F_'??F1_H3_^ ./8I.'X
MXF\__O[I#;$__J]__Y=_^;?_0<C__?G#NQ]>-W%^!>/9#Z\FX&>0?O@ZG%W^
M\!\)IO_\(4^:JQ_^HYG\<_C%$_+OBS]ZU7S^/AE>7,Y^X)33]=]._IH$SUYP
M1HSAE$AF' G99!)]"D)0Y80R__/BK\P([QA51.<8B#3*$AN4)$%H[H1S5DNU
M>.AH./[G7\N7X*?P TYN/%W\\V\_7LYFG__ZTT]?OW[]R[<P&?VEF5S\Q"D5
M/UU_^L?5Q[]M?/ZK6'R:.>=^6OSVYJ/3X;8/XF/93__WUW<?XR5<>3(<3V=^
M'&\'P.'3[.8/[Z)1/RU_B1^=#O\Z7?S]NR;ZV4(]CT[AAYV?*/\BUQ\CY4>$
M<2+87[Y-TX___B\__+"4G)_$23."#Y!_6'W[^X>WFTB'X]E/:7CUT^HS/_G1
M"!$OGC#[_AG^]N-T>/5Y!-<_NYQ WHG^>LH%E"IP_K4\[:?.F"X1R"3. Q#\
M*8P+P7O$N.WIW3'?/(LDR'X^FO6(>//9O>)MKORP3P%O/+H'M(L'D2NX"C#I
M$^J]Y][!>0UR'2%\@5$3ALU?8G/UTP+:JP;7X/?^ AZ'!5]&#2F+*76"+L:_
M_>,[8Z.2A^-A63?>X3]73RAC[8\"OLU@G"#]^,,P_>W'H>1! J[&,N<L:;8N
M1NN5ITQS\,JRP58\^\@"!QM/(>$WTV8T3&6?^=F/RA+Z\1)@-CU,2(\^M;/T
M]L.])E8>K62"94>%E=8;&VQTA@6->Z+.E@[VFT&?\G[O)[CE7\)L&'V+A?X0
MX=\?HKHF'IC1FEI4=)J+X,$X*A=6B)"&,C19LK:\E5IVSJVCCC[.\&LQQJ9-
M/L?M:&$E3/T8/W3U>0*79?W\ N^::7\OS!Y#UM#AH3->TVE05G,>68Q)20O@
MA;!,.,LBIU:)N%VGA\W]:#JN\Y(>.OYIM=_^]?:6996S,Q%?[^BCRTQ2;D!P
M(8..K"L5CO'N?YPU\9^7S2BA&_?+?\V'L^]5U+]EF-I:?FQF:\K$J20)1B>1
M0')A;/+H1 KO@3L9LWY<F5L&+%.\GN2HB??&'Q77K+FQ)4<^P&CQT\%\2BZ\
M_SRX>3A*!=[BM]-!L$DHEC-!CU<0&:@CSCM%(+F04_*9&;G5$EU8H=E/P\(4
M78V )BES/\%H-KW^"2D_(92MO+M_W0UEJ;_#)_=V'"> _N1K6/[W[7A3?A^:
MT>A-,_GJ)VE@HA:0742$/A)I<R)6173EK<A)1J5UYC5FOB?.^V*Y)?;9Y%I
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M7B2-.BAHDT6RZG+T ::SR3 NO G\V%D1R=\GZ/\-*,V<*DI1)$H222TC@:5
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M7!,F@D'K!R<>C$-C*/@0&<69BW:U!8^/_3D1^8EK?I/HKMZ*^\I/+V\-^C<
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M,IP.BWL0D 9>C\_A<SW&WP<HCZ4N"& CK4[]@/-;1:[BT4G\E]\>CZNO:G!
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M1#62*I(\9K,G5?!5GZQY9_OT^9;W>Q[4U;^7HFW>"%U7T=EE_+X#R]K!M7U
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MJ=>I.3_?7(A=L/;^T49L&V&BE6_22[<!<:3OT# /3<G7"\C;.-E:[G&JQ9_
M-%9U^%W'DZD&?X*%3_7WTY?[)MA=VE"*PWPN[-O\8?/PRZHH5K];#Q@S'YB]
M&Z-Y3AFV;(516@=B$2K,?S),%>4RYM@KYXI/YU.CKUWN^T<S-&+^R!: /5C7
MH&]67H\!<..IH6 =F*ZLV%4 UF'"ICO0R ZVPH-6^I")?OTQ"YL"V*/_D9,#
M^R-SFC:X1QO]",W6#-XE[/NK^>#L7=E_& J=EY7G_D.A'N:;A_NEK![=]Q:]
M4^L9%9%B)#'T)E!B;#.$((UC!!'.*2$*942)UH7NQG(W2M3#@3XP];U59=EP
M70D*]6C:5O4]F_G24*\JZZ0@LE'/CP]O'3\WBAQC3,8ZB.;KO32I=V!/&=!J
M WYL]/FI&IGZG0/G>96E(!R=!L(W),/>*M*HI!L(OV,>#M5LX(15=MXR27"*
M<@DE,18E)@)!$DD!D:(98U$6B\0I2;M+9U.S)5M9J\FI=KF4EAU3TA]A$:=(
M"<RA%JF"F MAT^ KF&D>F07/)G(@/H4S@B$\0@F-<1!V6WM"X3;PPG(ESU?0
MY<(%DE$2>XU.]"Z:.Z?RNIVB[X78/&RJ(D"7\M T>3PCC7.91QF,<AO>&6<:
M$L$$C&EB,[,*JMR*:GCW/#7RWA,<G$L&9?/V>$:.. ^"8YC($- .'1/R_L6;
MBTFR@F5P[HU0T.@.Y\['#>7PQ>0D;L.[@1 [_E]8.2\_F8Z8?+_\&ROF]N/Y
M:(2(9YC%/$[- $38[N\39DS,F"*H(\+R*)(<Q]*'LEP[GAICO5VQ9;6<E^V5
M=?:E4,T5$F[5 &6E!U@M=UOZPJARRU:^8V#Z[-G#P#WVYKR2&GS:HML*#CYV
MH7OC]OLZ5,/MLSOZ?L8-]75$NG?.#N_WM+_*4JW+69[(K(H-T]0RE<3VC 4E
M,(]3GF42Q0PKGZU:W>S4-F5U74-6R>9I(=4P.9H_WLH/;=MT:^QOO1PH&-0T
MJ5L>U^XXT.;$J#C\[4!AG>65L)&V#%#Y9EF?R?ZGFG_Y:@R=^R=5L"^J_?V'
M8B[4#*LD3>*<P%SE#.),:$@YSB&-4LI3(;"DL5>XQZCB3\UZ>7506%#:6Y)%
M"<R&N(X%#!T*&/93<&.LZ0[PP,SH$D18ND81;D&P$45MW$L+!&B0V#X%*BQ&
M##,<9 Q'C4$,J\&T A0'&1WOZ,5AI/!/>_=JN3;;Q'LIS60O/ZV-H?N^^%"L
MGN8&[%EJEK=(X@22*%-F6QU'D"1<FW_R#!M#EE#IG/ZNJZ/)+425K* 1UMY-
MLM% JP*T KMGQ.O$MWO-"(G:P.S>'S"O9'DN:-R0-*^S^=&2Y[DHN9]$S^GY
MGG4_+N6&YT@G.E(V+:;-#8\IY+F@4&99%.5$9*G6?BGT J37'B=QWJ6$\(XI
MRZ\A*Y1"F4 *DC23-D8I@E3:4_-8I3DBN:*)$^,&Q'4,PJW\!6$0=+/#IY\R
M_RA?^UW(A.V.* 2M!_*<Z=L=]3VIUS%(@O9/&UZJ_]D8>^_5D_E/<]Z7,891
MHB6D+#73/:.& KBA@"QC44[3F"2QUZ'KV5ZF-NUW0H)*2L\-_ED@'??AM\(S
M]';Y")D!3D8[(0BZVSS;T;B;PBY=3_9NG0_WF_3[)PEU#= 9RY5&E!JK";/<
M9M'2D&'%8<)PCK*<4RTBGQE_VL74IOO!D5C/HK1G@'2;\;?!,_!T]T3&>ZY?
M5C[D1#_3RZBS_+*6QU.\X\E^\_NC>JQ]..5[_7:U_/)9%0_V8'&F=9KP+#58
M*6)FN: ,4LP$S @E*DT8,U9]C[P]E_IS^J;'S\FS%=?> EH8>:'-" NDD=AO
M^E_$V8T$;H)M'"K8B6BQ>KO%ZF475MZ$< V(D+1PL:]1R>&:QL<4<?5Y/Z(H
MB_7LDU!+0SRKOR[+1R7F>JYDLX11K07*.(922P(QC@0DF''(TUA@372:(>5B
M"W3V,C5SH!74TQ+H1K*;!X+A,[3Y[PR-\\QW4KUCVIOW]Z:\^=?Q=._N8)2Y
M[J1C.]'='NYG#KQ850%%54GX-\L/Q>J+=<XV.]0\BXU]3S.89UQ G*H<$B$S
M& N.4$01BRGS,?R[.IO:G-^7%<Z7L"IZX1M%W8FNFR$0"K.!>6!?S.JLNQ%T
M '> "R(AK8+._D:U#%PT/[8.G-[I&?0\+\5B56Z*NA#&]O#XHZH"KJL;>]71
M,=\[.BZWU;IICB*-$P*C1%0G"!@2K;$][T(BSA*F8Z?DW&'$F1K_[+1I"L+L
M E$:A=I+LV?B4$J7(MY#C*D;IXTW4D-;/^="@/9RC0U12CT,>$&CK6^3:-P8
M["#HG41FAVFU'PW_12U5P18V"[1\F"_GME%;E*%)!MU8&TQ1E62&:#.:I89M
M)8*$2PUYDG&:L"C+L1?;.O4Z-5)MA*YK%AR([<>2;I"[D6%P( ?FO'T,#R5N
M4] /8/-Y@122V]PZ'I7"O+ X9BJ_E_NZF"O6^\"*]??/9C$L665]WM?96M[K
MO9_-$D,\DB,%591F$$N1&5KB<57=.Y*2*ZPS'UKRZ'MJY-0:$.L5*!H+[]&J
MX>MW=@??U14]"*2#>Z=K""NQP9Z,=Z"1W-K5>S\/Z;+V!BRL%]N]^Y$=V]ZX
MG/JZ_9OHF930[)*5NA!8TUIP+S?JOQ0K7INO=B:8C(R%E4"<,L-DFL60,<1M
MPFU&$*9)JKP2JOH*,#4ZL]MXSS2$OI"[\=>00 Y,8K7H]C[)I1"[N^V6_PX8
M'8!5 E@M J8E[(E?T-2$OC*,FYZP)T(G*0K[MM,W[VK=]%R5+S:%36NQ]>,D
M3'.*B(!42VS,,DT@%XQ LTE$'&4BDXF7Y_]R5U.CK4:\;;BTD?C/OME4+\+J
M2%A!P!J:FG9"WH$6M"'\7=?1")L#]6)O(V<\O:;U:7[3JV_T*,3YJ4G/83:,
M-F7'?9NDPQI:XJLJ[[_-RQD3"'$N$<PHD1 GN2VS&3.H8YRA)(N$D$Y)39Q[
MG!IIM#)7!?FJU";WNVPFK>!F=AC1'?WQ[N!W<\H@D [M57]&-#TJ4H9&=:1Z
MDT'0]:LEZ8-49Z5(IX;&JP/IH]=!E4>O%WL&=APDNJZ^[3PCFE*<04(1@CB.
M;!)]RF&>TCA-A%9IXN5K.^UB:KQ\E,;=BS,Z@'0SXVZ#9V".]43&/TCCHO)!
M0S-.>QDW(..BEB=A&)>?#)S(^+-IKPDQ)"3&0F(!)8[,A,_-!HY)G=O<<YJJ
M)$>YP$'R&>_ZG!H#7,D@:P7O>;_#90#<B"(PK ,S1Q!$PV7G/<5HE"2]>]U.
M(U?O*0[.*7O/O-J/DU[/E\9^F;/%+DM=M5[&4L:Q5!P*21.(M4XA2_(<Q@GA
M"">4".IU9?1"/U/CGJV8>^D7>YD@EW!UHY< : U,*7V \F:0*S"$9(U+78W*
M%%?T/6:':X_WM5*:>O95';$VK)S%A&B;K$?8"O%*:\AQ1B!)4I1J+#2.G>Z0
M='4R-2[8REB7#_<U-<Z@Z&I;W(;-X,;$ 2P#1 YU 1#64CC3S\BFP65-3VV!
MCF?[375K3IB=C=]1Q^%+$_HP:\$&.= XKW/(;_&HAU&_PO/:'7]_%Y[J<T#!
M%NJ]KCYC>]5A+JO#4QMZ*]3\J;HT_#!C$=591 2,M;(&J,PASSB'&*5",)TD
MD7):<9Q[G-KR8V6V\4Y5==L[8._I^GC.73!V.8<(C-S0YQ 6M/>Z7IKNP('(
MH)79['@' -/G&"(PJ&,=0P0 U_,4P@.H[E,(EX9&/(7PT.OP%,+GQ1#V?W4%
M8K_>^4QJCCF-)$3(5KJD40X)4A',D< 9XRG+8Z]JOE?ZFQHM[\S?AIA7.UFK
MU-)5.NG2,Y_T-=#[[!QN@G+<341S(ZX$>](.M9^X",MP6XO3+I]QEW%1_^X-
MQ^77^MYB?WB8K^M+54MIR,R&SZFEF*MR%LDT,DS"(:(VE$TG"')B<*8HIQG#
M44(RKT25'7U-C5[V1*W<]&)?6-^;[)<1=CP.#8/;T.>B1Y"]<(*LQQWVJV"$
MO<)^N;N1;[!?U?OT OOU5_JQQCLC,RN_OED^J=(V:IIOO*#++V_6ZF%WK1GG
M(J,LX9#3#-O("0F)U )FJ4QBAK.,9%YFBG//4V.41G P;R6O)HEN90?VZL53
M%8/H1R_N0^%&-H, /##UM-B^.<!V*S:HY![$(^6-5DAN<N]\5*;RQN28M_P;
MZ&G[F$[L_ZQ+[<GLZ Q/?C0]%G-A;YZ;7YB.#W^P]^1,RDS:\%R8Q5A"G II
M#".%H19$VN()FC$\>ZSJ.GQ:LV+M:"/=(I//E#R6;$##P AY!ZH)JG:R5E.T
MV&I2__Y?_IDD<?RO@*LO\^723MV5!K6DGD;734.K,4T3A 1DB!.SMY;&\,4:
M0Y)&.H\133G+FJ%]M923'-A6KDD-JS*_>Y8!%2I.DX@E4&@90RPS!GFBC"EB
M=C LB?(XRKV*IX\VF&,4\G,?R#&'S'%K--9 #+UYJL; _A?L"7@'=K+7O[2#
M<ORSO1<";K-" !MT(W:30.-NU4)@=[*9"])H/T/IJ"[5NXT]]'ZO*U_4GBO*
MUE451HR7\\7&/#UC*5>4T1R*RG^4IAPR92RD+%-)3B/)5$Q]]G[]Q)C:1K#5
M K*FAMVRTL,NC,)LV%>MZWK?HUT7=A;5])>U6OV=W#U'TXV0AQ^C@9GXI,3@
MN^WPG#K'ZY+0];@TJH2CX-N@#,F]/249E71O0^N8;6]L;:#"MF[U!&W2^UK@
MF>9:<B1RJ-(\AQCG*>0<89A'F&>Q%DQAOXHSH26<&CGO"0A8N=NL5%N7WHP;
M?F#=R/A9AVOH$!.'8K.>M6:MGG<-WX]82K;O((Q:+=9;R&D5A.V+L7?-U]X=
M]5LR?ETMU?=?6?%WM7Z]6<HV039)):.$1Y!H93/"H=06=14PS5'$4DPI$UYU
MA\YW,S7RKJ0$M9B@DM./IB^ Z<:UMT,T,&&>HC- S'@W"B$9ZT)/H]).M[;'
MW''EZ9XVHPT*>5.6&R5?;@ICDM:5I.NMRLX?4#U6$=%?BE59SJB2S%A_".HD
M5A#'.35+I%!0,D*4,1H9S;P(HI\84R.0OS6GA\;LV_=\-KORZII%?QNPWT Y
M&GJ#PS^T-5>!6VL :A5 K4,;DW;@"ZT?;\RX2I> ]MI-6 8UROI),J[E=1-:
M)^;5;:WUI-!=,.\'T[XR?58=SG*1LB1C&90$9V;W+&)(XB2"2F BL.*)SK47
M25[H:&HT6 E7W7FH'5[E:B%M99+'#5_,A?F%5D4;9BM7BP4K2KM-KA_WI<5+
MX#L27P!(AZ:VY@))$V%;@VODK'DM(&]=@2(H,UWJ:USNN:+Q";M<>WYDMUWU
MG\;FJ(DNGG'.")5<0DE3#C&7EG,T@HB+2&@5$9YZI8\,*=S4>*HUU_K$$P0=
MM(&]<3<.Q?0=<=4?H!W.#]W#.9X#K@/W2?C>SLGWQW"[=2 ;S./6U4>/V[*?
M?U]]_KK:E&PIJWA$O59J6=NK!JNEK01AT\,T/B-%$X*C3, 4I?;:+$:V_E\$
M(TDB)46J4>9T].W?]=1(VGST:;-?VTI;Y3_RN/CIAWTW&P^+Z,!<:^0&K>!5
M%LI&]+, 7W?OW8JTQUW;P1 ?Z=*M17[=(E]'[M?(UVZA^1;Y1_/:GP+=N^T%
M6N<%7+\6Q[N)VTO3@RNY_5KHL1#<+Y<;MJCK9KS<J+\NS7LO["Z8K^J"0'MK
MTTQF6F:81_;LW9CS"<DA29F" E,JTP0K,T+.ZX!/SU-;!FK9 :N$!W*CP,:*
M#\2^_(#M%/ @+:\1<5@=AL)YX,6A@;B6NRII44D.#D3?M\J'@MAC61@*ZI%6
MA7"0^RT,?6#K7!>\&AQO6>BCY\&JT*N!YXG>>KTJM)JO-^;[?+.L-RRSE,04
M2X8A(I1!C"B%' L"XSQ2+,IEFNMXS/BM,S).;:'9A6LVWFO!S'>VN"5@=HB1
MS7*5Z2R*H<BIA)B:K2)/\PA*'F4()[$0/)HMU1=;LVO:8TOKL=V7=;C1?3')
MP1S8_Q=F\DW?#;B-Q]O3U)X[3<8A>'T@)N$7[!#SC^$>O(YSZ+B\KJ[ZF0-5
M/45M%CRS&_VDBJ>YO;W\7I])%EO:+-+E^5\UV=!3FF&"=0))E"B(6<8@B["&
M$2$H(CFA"B<^=D!(X:9F )Q+B5SVS%0?=!#=5HGG&IJ!EX>>H^+-[4/ %Y+4
M@\HW*IL/@>PQC0_21P\?WW\JMOZJS-/+MVO9YM[FAFJ58K; =@ZQC!4D1&*H
MM"0,YYKDU(F#+W4P-1[=B0B,C!Z^HG/@.7C=;H1D8/XZ1*//T<HY6#P\93?"
M,Y)#[!"F4.<@';IW>K7.O3>>\ZI#Z@,?5==S/5U1XJN2FRK8Z9I=7%XRC#_;
M.RHSI#%*5*HA839.7-CZE'F<02H102)/L"$_+P=4*,FFQI:M8MM[PE>VPF7G
M7AC\5BGI::V&&W9'A\9S#.;0;HQQQ]'?=Q$:\Z >BV#"C>NG"(WIB7<B> ?]
MUH5M??0W2[%Z4&_M!1.4<I%CFD*9VJN".$TAR0F"FJ9<Y5SF$?8J;7FFCZEQ
MM94)V,\ K!Z;Q-V>-P7/ >G&F3?",S#[;:4#M7C@1RO@90^[-WUUJ!^2B,YU
M,RJE=.AY3 Y=C_I-<ZGFLU?+]7S]_=,#6RQ^V93SI3)?IB(ZPRKB$*>QA)@3
M 8G&#.I<QAF5F'#A%(QXH?VI3>]:1%#)"%HAW>;W)02[YW8 7 :>UWZ0.,_J
M*XKO9G393NE2B3]]63W];-[\V>[7[%^JC=O>)+[4ZB@3^(I*[>2]]E@/G]-K
MI0P#;&RF]^[P&DX4D^;_S)[,X(83LQTC2,>01@K'9E,FS)KM[(AR[75JD]S(
M;8,N*\$#AI(Y#X*#0VL(:(?VTAM46YD#1H\YH^KA#QL"W9&<9$%0]O.@^:+5
MZ59S;FP\7YNO?@<...^7>[#[_[U9FNU??7&V3=*BL<(\1I"FL8;8UE=CN4@A
M0H1I0CBE;F;9A?:GQMA60M"*Z$$>9Y!S(-_;\!B89@^@Z'.6< 83#^J\#9N1
M2-+M<_%CP<N*=_+=F=?&8[;+,A]P6,=C_7Q%]_*_-V5=/.3UJGBG?K\7PD;1
MVMMTQ6II_BIJAU553YOF).6*,*CL966<<6UL4LZAB(@@.24ITM+'B^35^]28
M;D]XH%<%,.*#G?S@4(%>9<W]!L?-,S48Y .3:5"TO1U:O5 +Z>KR$V!4)U@O
M;([=8_T:Z9M,BZVKQMZ:W7Q5:60FDY23B&*[+!AB8UQ IBVQ82X2PW \3;TJ
MKI]V,37VVDH(?K,RUL5S?$\B3X%T(Z';X!F8:3R1Z9%YZI+R8;-*G?0R<L:H
M2UJ>9H.Z^&2?<M<K&R;V29F-WGS]_3/[]NKA<;'ZKHJ757U%MGAQ__'5IWNQ
MGNF$*)7)&+((596N$\@MEC'.$YDF"5+"H^:U:[=3XX&7;6G01_;==+H :_9-
ME:!0"WO/ ZQ7H)+<K+4^KB#W47#8Y V"[= D4LD,6J&!D?H.M'+?@5;RNX'1
M]2F3/03*8]7*#H>V9\EL7]"ZZV8[MS9B\6Q?#0\K:'N_W<^D>\WFQ=_88J->
MSDNQ6)7VAL>V(F)*F<8TRV&JJ0WI10)2A1B,>,HDRE3.N%?L0U=G4Z-W*RNH
MA 5[TKH42?3'V<WV"X7>T&<DO8'S-@A=$ EI&G;V-ZJ1Z*+YL;GH](Y_1,6]
M6::D7:I>+]B76<X8DSPB$!E;$&*:(LA4KF'&$*.QDC233K;A2<M3XX>M<,!*
MYQX^<0A7]\R_"82AW4IN^GO%2IS5]88HB</V1HN/.*O&?F3$^0>>)ZW"7K6>
MHZ(^32T&5>4"G:5(<6-Z8)BJ+(:8I!32/!:0)83$+,JS!#'_<JXC2>\S;\8K
M_-KH<%3(;%O:E;.%O<T?)HWP2%^),M\$$RF!&@D.<2XE9'&N8*82&:-8&HL1
M^5:&G>PW,GP-V;-?B*K^_$-^'HY.SND-^-!.CX#)(0[*[YU4ZVL1J/-L3R=G
MA.>832F/A*OH?ZC<$I[C$3K?A&_W/?S=+Q5?[RY%VW^]5)IM%NL/I@/K>?NB
M9F81RQ.4$$A01NWE#[N<)10JFB214CA)E7L(DD.'4]OD6"&!K*4$\Z7I4I5K
M4+"UJI8:MEQN'CS<KRZ0.[BU P,Y,+=7&.[$M4Y5\X-&XCNPDSDPD!X>[,"
MCN2[OAU8/Y>U!TJ=SFJ7=L9S4WMH=>"@]GFOSVGDC0O(_5*^6RWK?]A"W^OO
M>PDP]K(9S522&1Y/(ICI-((XRR/(TE1 KF2D,D%3$3M%9HTJ]=36B>.D@G=@
MU>Q<;"KHE;V^#U2E#V!6W5NR#H[[>;B<LDYPT*>P7_FEZ^)WN[.U2=J-]LV_
M0:W_00ZD/02F^('X'!1/\$,9ZYQY8A^,YV'UR /7?=8]EC C'I6/C._A2?O8
MG??S\UOA"O75R#=_4O55Z'=J_5Y_9M]F!G"<<YV:B:.QL6%8 JFMIL)BD1"F
ML-9I,ENOUFSAYG'MZ,O+\MCV.!RQ'(@*%EV5+KUA592D<9QI:.S!'&(F<\AQ
MK&!*E"0J0:EFRB\'\:W CIM+>$!HW1S!@;[#@8VA0YP.$D/< 2.O-8NKN*K[
M];J8\\W:9BJQ\8$?#*N$N,'H 5=(OVE7=Z/Z.AWT/O9/NKS2CZ=M$95WYFNI
M;I8D&<D4T0@F"4DAQEC8,M*&IY-$$10G%//<)X!JO_&I[0&KDDI6N%XW=@Y@
M<V.'OF ,3 ?..'C/[W,*AYS0!^V/.H//:78\9<\^TS-F8L-+]3\;0[ZOGLQ_
M;*K4ZKO+(RYQ) 5,XAQ!'"4II"1/H5*:IDF$S;1-O2ZSG.]G:C-W)R:HY 16
MT%ZS^!*PCN>^M\,UM-^C#U+^9ZG=. 0]^[S0U;AGE=WZGIPM7GG\UIR@]\OU
M7,X7&YO=H G GJORU3>QV$@E7QOQK?6PJ5TF[_4K5MAPG;*MEEQGB.0\3G*5
MQC!1S.P=M V$,7LRF&D5)UK27$9.)X?#B#<Y!MK+*KFO']@I"%H-Z\QT>SK:
MEUHM=X7#;TT1&N0K<.2]9QO;H>GR&8;UAHRA(=$?)FUH$ F?*7=H2'0O)Q -
MVDN?<\OFQL[]4KY=L>7]ET)53D2;N=\(^7ZIFGPD48P0UBB")+87IU&40YJR
M%&H=2Z4DL9X[]W-'QUXGQ_OMO3/KU;>2@ZWH=Z 1'ACI?0Y^7 ? Y61O %B'
MIEQ'1/MDU7&&UN=,; "(QSK3"@:UYVF4)V3=ITFNC8UX&N2IW^%ICN_+-V;"
M>*^K&LI?5POS<EF?_VSO]<5<1$JI"*(TPA#31$,>XQRFF2(LC3%6J%]RC*Y>
M)\?QVZP0-F7\GMC_JSV\[7NGTFT0'&WPT- .S?,A4.V?@<,%I4&2<G1V_#QY
M.ERPN)BZP^GE2=\,^[A:+/2JL"_.5"1U$A$*<ZDCB)5-WI@G#,899C%%6I#(
MSX$ZN@I38\]6;.A[@V,JGX0C_4YZH(?F\F>Z_3/,$O%L(_D'O!.TK\7_'Z\'
MG1FE9[HI=$Z2,</2ZPCIIL!-^5$]&O+X:A^:,9;DJ48(*I;$$*.<0L(HA51Q
MFIGU4F6)AR,HN'Q36Q!/ZM<7.UG'#B:_/*@NSJ5G':HQEC3PBUN\;_/<T9+6
M#/3[ILY8"?8T?=[!'2/D.\@@CQG<_0R#/5(0]]6A&"9<^W*W?X# [*N8A0G!
MOMY-OZWSFZ4HE&GGI:K_?+/<5J%ZP1[G:[;8NI=H3#7-F8"*9AKBR*S<7#"S
M \Y%'+$\PPF*?;:\[EU/;65^\=4.5PG,&LS*4JWKRU^+.>/S174*]V>_S:K'
M(+AM,H>!=N"5M!4:_-B*_9-%>%>)KA%]D,V</V(A-V$>O8^Z>?)'Y7C3TZ.%
MWD36U,RKC[YM7O"-K1F_+>SXBS+;HB8$^K/-8/OK?+DJJELL]77_^Z4\;*5V
M4OZJUE]7YC=/JLD^/L,IU5'"$=18&R:TE5MXAB7DN8H1$H@2XG4+9439O:AT
MA%LM505.7FEGJWC9"P55=F%O AUM\)T9>(I#.CR%[ZZ$M'%.K>I@IWL[XLT!
M3JT2V-/IKKU=4B%S9^]!&LI:V^S3=4W2&J*@_#_V> 5>0$83?^P5:.QQ.;.$
MC2Y"[YN3#ZME=<Q6[Q/V7(8SP9*4TP3!+.4$XDPP2"C',,EPFDHE4!XA'_.]
MJ[/)&>R5K*"TPMZU[K2]5'/^[C0GR-V6BE! #LSM#8:?:@P_-=DO]F0->KWO
M*B*![_==[F_L"WY7-3]SP^_Z._T(Y:,JE7GIJ^&OE^I)+5:/E4-BYZZP;&B-
M]\^K#ZHP)/CP>E6\MTE0RK?;>B]I)F),"8<HM;G5&3;6,J,<YI%$6%'%HIC[
M$$\(H:9&4*U.E2-A3ZM]Q^(=:!6KKM36JE6%KFKE;JC2$V2<W=AN[-$;F!7'
M&SAO%@V)=$BV#2+7J*P<$LEC]@[:=C^6WWIDWEH/35E;JMNXK4\;OK __VBD
M6V[43,=*QA%*($WB%&*I;'ILQ""BG'+"LI3%B0^=>_4^-=YNQ0,VOP%;-"X,
M/_+U@]^-90<#=6 ZW3E[:\&W?H"M[,;T;#%OQ _'F+U0"TF-?@*,RH&]L#DF
MNWZ-W%COY\WRT1C$;RVYQLVU#<0ER1F*(%>4F;TPL6Q&4IAQ)0A#*L:)ETG:
MT=?4&.O'2C@0>^YSN]!THZ1 & U,0+N:/I9ZK*!WH$$LX.T6#TP&J>ISIKOG
M*>IS6>^+-7TZ7O$OZ?-JN9ZOO[]0UL1:O%E*]>W_4=]G.F%4Z$3#.-7&Q&&I
M@DSG,229BF.1Q"++G4ZZ+_8P-5*HA02-E* 2$Q@YW8O]G >RFQF"P#,P'W@C
MXU4&J%/[&\H!G6]WM+) G6KMEP?J?K#?NM^4#U2?5/$T%^I\Q,V[5>5T5[(*
MKBD_VY/._=^_6)7K=ZOU?ZGU1R567Y;S?RA9>=B:6-Q9K%/)XAC#/,ZXV05A
M6QF6)E!(S;.<*"P)\;$@1I%Z:K3SUV6QE1.(_7@Z]<W^W7,C-<[(NUD[DQO/
M@7GR[(V-?1?85M?#BQS6-U:NS6_7X+M:@YV>=^#^P59W#V=LC3HD(<VV<00?
MU0 <=2R.3<EQ.[\MN>++U0.;+V<XXGE&602)0&;#FJ8$4L883'(<Q2+*6)PX
MY>X_W_S4UH6]Q(*U@#U3+#;@N3%V?T@&IE8/-'HG6CQ4>HA4BTT/SY)L\5"[
M2^D6CY[JFR[A^(ZS(8F].K2?U;?U+T;&O\\(XQHQ$L&$,F5362M(4YI!0IC6
MD9 R]LN8ZMSSU&;[ON#_\L\DB?-_;0+#?),DN$+O1@B# #JT&78N/X(5>Z]"
M-?C-2@XJT8-F3/"$*VS6!-?.1\Z<X(G):?8$WP;ZT=9?2_5>ORK7\P>V5N5,
MIXQ%F38&O>8IQ"+GD"J95Y6#%".$),)K=WO8_-0(R$A7I>!KY?.CG2/HW+BE
M/R #$\@Q%G?@PVHQ%]_!;\V?@W#'>3A"$L11#Z.RP'GMCJ?ZA:=Z;A^*U:,J
MUM^M;6.C3RUW5($%;W=A6;E*<*PT3+ M8"P8@3Q+(Z@B'*$H1P()KPPFU[N<
MVKQO)3;?N)6Y"N'92GU#-)4#^(Y;DJ"0#KU-N1U-_^V+,T!!MS37>QUWF^.,
MPLG6Q_W-?CST5I6E4H?'_F^;>Y+?&S]A^7*C9FG,<1;'$20ITG8W9-@(*019
M+IGFFE!A$\BY7ZER[=B+DT:X#U7YF4 =W_+8B.G'/LZ0NW'0$$ .S$2UR'?@
M*)CH#FSEOFM]U,:^>1DR@L@7K9"TY-SWJ.3DB\@Q17F_']A@VGD-D$@XQ:FP
M 0$VC[$2%3M!)I5@""&B$K\2-U>[G)K!]&GS\,"*[W:#T I_N,P'LI-\/35A
MD7Q>.ZG*RSW,+LL=IE&LI6?RR;BCX&PMA?+"O&#EUYG(.<TS8K9D.#&6D U#
MXI&6$#&-X@3%:8:\]F6VT:D1B97)\YZ=A<:-#7P5'GB^=^KJ?S5N3[F@5^!L
MN^->==O3Y.1*V_[O M8F:+/H-#FRRQDR:WD<(7L?U@8"ITD$.4T(U(AS)B(D
M9.24M]JKUZG-QEVBN74C88!4^2=0=T_>P0 <^L"E*S7^+M?7YP&!#5"#X!:
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M^+?SI7JS5@^&#T22<8EBF!.)(8ZQ@A1'ME9G)A-NZ$#';)3;TUN1IL8?-T>
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M#+'G#<E;AL+-(AX+X(&YW*H!S2 ^ *O('=BI8F_3M\I8"WFKCDVST"@$K$;
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M2EZ%(5O9P5;X.]"(#RKY/::KQS XL-DPX [,=NZX]N%##X ]^'(8H$?BTY"
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M2M!BGS4_+*Q!T5QB]&0EYW%RXZ<AT!^8J1J1P;[,H!4:\,T:&+'!=[4&5O"
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MK2!3#$&<IO:$/;8AY3(62+%,YUZ!Y-<ZG-R$WY,7[ 2^ U;DGE[(JZ [SO.
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MWH GM@8_RHB[$,4('.?#C3+"8SPPC^S _5J!:V0VKS.HI*X#&[<I$"$+__H
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ME*0(R]BWEGG'>%,CJ/=-C>Z6S#=5QK%-/:XE!U9T__+F7;AW<\T : [--0&
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M. 7>]!Q_:DS8B ]^:13XU=HC;1W^5U._X$^K!Z@5\=R>]9TF-R(<$/R!F7
MW+VYL"=Z(<G05X11V; G/H=TV/<QO?EP]:C*0"/K_'RR;X&Q<=ZM;'WC&<N,
MT6?MOCB3Q@Q,)()4D!@*1FC*I<8DQI[L=WZT"7*=$19LI06-N.#/2F!_3NN
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MC#C3*N4Z95X%$RZ..#4V:L2SA9VL?-<&[1\"[,9!06$;F'[.!.9O@;R_ &2
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M<IQ%7&J99Y[NT)F1IL8AM<%O0RSWQ065O+Z.T3F 7;VC +"-XR+Y(];#3[J
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M_\Z^Y)E!IL861DRXWLH)GBM!;>J+ASMT#E 'US$ 3 ,S@Y$0[$0$M8PV.2L
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MNI(8BBS+(&8*0Y9P#!5%#$>21IAZ'6RX#STY:C!2WU3[86HG?%4+S8H/-[8
M0._V:AYSXF:'#(/TT-Q2@ESNAK7DOBE1_KI#^:,#RM[6B3]@(>T4C]%'M5C\
M43FT77H\H1^M_5TMU9HMS,-OY>-\.;=A<K;E0ATX-Y,)YQ(I 5E$C$$C&(>4
M"P65PEHKD<615#Y<=F&\J1%8+6[Y+;$]@?V8ZA+,;O04$+R!.:F-V[ZL3<1L
M. YR1"4D\5P:<E2V<=3_D&)<;^O9'EN(U;.AIWOV8O=V:J-LEJ$T2K T@$;&
M-<(4(4BSB, (BXBGFA#&O%JFG!YF:BS22 F>*C$]VV"?AM*-,JX':&"FV&)3
M2V@LF4K&@.VN.S$(VN?Z]$CC-KCNU/:HLW7WU3UCQ.8/R[)VVG)3/]\&IMG^
M3;8MZK9 #!8)5B2-(*+(V!:J/#S3!*9(")$D6J9^&[)NPTZ-'+X^/SZ6O7 T
M:"D =AJ 1@7/Z"ZW27"CD?#0#DPK%Z <J"R/'TQ!@ZG<1AXW4LH+C:,P*+^[
M>YLIZV?5/K%JEE=*<1YSCF&,;<8X(0B2F,=0)C$E+&&4)%[-+\^.-#4^J@4%
M=5J@)^N<!]397KD>IN%-EA*AEI##6"W=2 0V7,X,-K;MTJWS"?/EP@W^ASOO
MZA24:@>Y"J7\8/ZNF$7&7S'_$(BX1A#CA$ :12F,I20T4BB*(N)ZNG-VE*GQ
M02-H<W91B0I*6=V/=\Z#>OE\)PA4 W-"+Y2\#G@NHG#%"<_Y9X]VQ'-1O?89
MS^6+>Q[RK!X?5\NRFV 98EU\+ I#+S-%N#$%8@PC)87Y\&D$B7D/(%(\,7\C
M<HW([(=:\Y7SF<[ID7S>Z/9X YXNE(*"PDIZ4Z?1@GDI+/AEOJS_YE?/@YLS
M.#N>TER/W=!',A5H7RO0OM:YQY68 0]?NG$(>M)R9JAQCU6Z]3TZ0[EP^=44
M<<_6=^NJ(TT9 &=XJ!QHAK3.6488Q)G0$ MA#TTXA5(IF>58*Z*]=CD=QIR:
MU;!/&T]L#7Z4P;^6,J0M$;TN;,Y:11_]V>/L%'@S20A@1V45([#MGURWMZI"
MJXW0%=L,0C*7(!J(<,X.^UKD<PF'#B*Z>&O/;8SE9B[GBV=[?O.U:C)G7*'W
M/\7B62KYP2AC4\F>JZSZ._V>K9?SY4/1C/YI&ZZ9I#J/4V6[=28)Q HK2)2.
MH%(QQBIBE&=^YS.!!)L:O;7U CO%0*,9L"\0:.EFMW<;[7:?Z161M\&FW'%?
MYA4F<NAMG#'GT'_[)S#@07>+0LDV[N928$2/]J)"/[]O1?FJ76)]CF][*<Y(
MQ+BF*H>8)A1BHA%D)+<UHA7)<(+S/',J"MTQQM08>ML%5%V(-W$&T8THKX1F
M8,[;HE*+=P.L@"'KPI_5/FP]^.-A1JX#?U;/X_KOYR_M487NS7Q5J(]+^5QL
MUG-5=7"?4:0(H4D,,ZP%-)\S@91E%,:2Z$PP(G3F7C/NU A3^[I+&<%62(\B
M7"?QZ_ZT@Z R\(=]  CXLY+0T:@\CXQ',;%K$1JI]-<!4J&JN7=IWUE!Z^2-
MX]6[ZI)[KSI5YX4]B&R_R?/M<FG,IG7!UB\?5NMWRH:LSZU]=+]63U6-DP]*
MM3J:<Y9$2B$"&4(8XAAI2&/%H!:19 IG>:*= I,#R#(U<FS);UT66WC?QKY(
M6_-=K]9 [C0"3UN5;-UWNR5WJ4MZ\)ET(-_QYF?H8\+#9O7MN3+*@)8V8*>.
MK5;NTL$^^-QXT/]X<S320C'P7/DM+V'0[5R(KAQBO"4K#!9[BUN@1_;SV ]W
M G;!F5',$Y2D*52)9A!++"')(@P)SG!&\BA)D5<FX=F1IK:$V?I.GU9%X7"B
MX0FIFQ<?!*B!UY)36Y&#1+5>!".D:W]^L%$=_(LZ'[KYEV_PCT1[7W8C_S!?
MJ/5;8[P]K-8OLT0;>Y<S"26C&<2VV!0E,;.MPP453 BDG+;RSCQ_:D10B0A*
M&4$CI'O8V2D$NQD@ "Y#?_=>D'C%F'4H?D5TV:FGCA97UJ%2.Z*LZ[(K"B6_
MN5S&\\UA&<^F=G,5M'+[@\T7-C7'6")_MP6 9PG&$L61A").%32>;@0Y0@)B
M3;5($4$Y=ZHQ,K2@4Z.2S]M6#Z(5G )8(W?I&^OGC>W:7)9:[A_?-MC<NUDO
M4YC1@4DP0-WEW?M0J0MN]]Z$4N/ I9@'G)/@E9F'D'7\0LT#(GZR;O.0X_5.
M<7I^?"Y+8;U33VLEYJ5<YN>%JAJOR=O'U7HS_Y^J=/2YWN<SSCGCJ48PUW$.
M<8099!1KF H:$ZU$KC6;+<O6DM)MY0DEFA,OT8J7V@(.1T^?5%'\!V [_8!L
M*>B=4A5F MT6CU$G9;2$K>T\M'6RI]^U5E6EBI9>-Z#1S/QD=:L*ZFS5"YKH
M%13PP'EA860;.XTL**(GLL["/G\@#Z,XM^*4__IF1C726*D^FX_GW>J1S9<S
MK2*5"I%"JJB-7<<44L9SF.:<JBQG(A,LJ'?10\BI>19V0HU'7G6$^K.2T3.<
M<Y"Y#.0M##Q#0Y-_.2M6RLM3$]ZJOP*[42WZ/G).RYJ_ FEO2_Z:L?JG'<VK
MBF_FT6]7934$M;2U$-[-"[%8V3+;NU,.HK502!/;D,7666(($AY3J%,213%%
M2>;7E\!O^*GQ<TOZTHC;D]\_]\AC'MP8>#AT!^;63F#!3O:!#J;ZX18Z3<E#
M@M$SEOS1.96\U.,I8UNT=8^\<L.D^%@WP/H_:O[PW1CIMS_4FCVH]S_56LP+
M=;^>"S6+$"."$ %CI3'$&8X@P1$S9*F31&98QSP=Q]#UEGUJ_/KWJC%AD.3.
M,5^!H>WC02=V AOLQ84=]EK_FVHOO0#SY;9/;H,"J&$ #0Z@!&(*%GKOV9N&
MX>XO_C^)/=][7L*9^?U%Z+<N?E)&@N^KA?SX:+L)5L+5$?JYR)1.J8()4V;U
M4B2#E!O+7ZB4XSP6-/,K5-8QUM36G:VH8-Z2U6^]Z8+6;7T(!-C ?+[#JBWF
MY3P1;\)U@",D078--RJA.>A]2$ NM_0TI&UH0U7OY-WS>ML6O*PY\/[Q:;%Z
M4:HJ2&#>K^]&"KM9,6.QCGB49###,3$F<8(@1YC '!/&2<RUTEZ[!KVDF!K)
M6/F9>0-LH$ 5,?*\-!,!-M^-T5(K4=7D (T:Y8&1I]G;:\(<#=BAIV%H4[0$
MMU( 5!IL[<BZ2V&OB?"W):\!,JA5V$N0<>V[:[ ZLM2N>EA0"JV"-#ZKO\I?
M%3/$499$PLP2-U.%8Q5!GE $XXQC1")*M10!./-@V"F3Y%YTG7'YGI[Y8B[,
M;[2R^MR I=J4>6E*%5>$V+E-SU4,>07HKTB)3;DY(W=U1<!^/WY C4!YAR-/
M@>/.H.%(:N?NOJH/AWGZUPU;2N.[%G\\V4Q0 W,6Q;6C0U1*8B8E3)4TAI_.
M;<>RG,&8",)CXT2JQ*O+C].H4^.P5IGXK=2@$AM8N6$4]VK<<0%[YZBLL(@.
M'W)U"<P!?$\OE 9H_'%AX-?H ^*&Q9FV((XW]\C^_\K,"%]_6_^V^*W^#KA*
M&&(DA2K&"<2Y2"&3.H<$JS2B/!)$.177/OWXJ9%-*:!''O<Q7MV\<3T*0ULP
M5C90"=>G6LDQ(!ZYZE<!,U+ZN1] ?MGD9_7O3! _OFN\G.^S$N^E<9^_JF]/
M^4*9F[[?+N4[]4,M5F789EW)J:F]1!"A"<]AEAG*PHG*C0-(#&\Q9B@+4T52
M+]O)8<RID5DC<AD#(G="^_:2OPRVF[$4&,*!F7 /O9:\38VV >PD#X#"]I6_
M/.S(K>6=<3CN+N]^:S_R^<#FZW*'Z[8H5!E]TVIS\KMB-O!&WBV_V%*3UGTT
M%WQ>+=?-']^P8EY\VI9YQ4SK+$HQC!-N:,J>$#)IX[J3S#!50C A3B7B!I%N
M:H1FE6NVEBO]RH^SI2%H5 2K)=@J65[55A.4>EY1YC?L2^!&GZ\VM0,3[:O,
MJC<W#X)^2!8/*^"H?#\(MH<KPS"#] P<V8T\B[#6G&$!=<R8K9C'(5,RABE.
M,>%F&8@(G6U6&[9P6P%:S_;B[^T(PWWIW^P88+$3T#,FI(6:&V7VQ&)@POOD
M (!_?,>QJD'C.5J/'S=^XUBOHWB-$Y=<W46FI(I9Q$@FJ##F68HS8YYQ"0F-
M$YA%4J:YXBK32<^6,>4 4[.P]OO#_&OT6Q2A79N8OP$CS4U4_=,TG6+/F^^K
M]?Q_E/P;P-E-'$<W)*7EXIS$-['])R4'':KL+\VUB.";B.3-M2B/;HPMW%R[
M>MX4=I>S7.J+LB"$>5]*$QXDT0VP.R&U<R;*O_VW?T%9]+<$V5\A>@/,0YZ4
ML'7?%XZUB<Z^!VYT<\WL#LPY^TUJ:FMKP,Y7>_H/U(&F&N.UVLWL:=C16V;_
MNIZ\Q(KO]A^;T6J^1!N/9AS=S7HN-DK:7QAC9?\O6E?><O,+)C:S*!.:132'
M29H(B FR[0:R&.J(95@R+;$GF860:G(,:,0L6478']1.X/_PI) @4^;(.V-/
MQ-!D922\ >5,M 2] 3L=P'::#O^N=0/XL]$M9');2*R#$F,0P<9ETY!8'E%P
MT(?W]?.6ZDZ_-8[E?/.!"6NDONRV?5"*%24LA@QS!&U?<T@)D3"-L.'C)$\-
M0WNE"'2--C6>+3=IC$U7B0L:>:_8D^L&V]5A# 3AX"[D%>CU\"T=4 GK;78-
M.++_Z:#[L4?J<M, AY\S$DO*=4J@TKDV-E[9XY1FD'$>Q80;>\^OI53G:%/C
ME!$./$,<=4Z(1RX=<HYTMCGZJ>:$SC-[G63VY)!BO3'/?:JC\6\?UJI,;GIK
M@\K4^HFM-R^M.D4XEYARA6&&&+5=1XVE(A);\#Z+(FD+W2.GFE->HTZ-4]I2
M BNF9R4I/\B[V64P( ???/+&T)E?>F'2P3/F>2V.,7\ZY!>_ 4?AF5X8-'S3
M[^9^MLO]>B64DH7MNMGDIC0%5O^PZ7L?E[9WQ_R'+=1T.@_<IA 5YK+%LRS#
M8%?BO^JT[YG*"&5$<9AI0HSMDR#(LB2#.>8L27&2B<C+GQI4VJGQ7*-LU5YW
M?BYQJ$JR5$U>7_67S<L#GLPC2U-"-64CMMF9JTIM/U-LV/?%S92;S%LP,$DW
M>E;' LWD-UE+)\N)[$HRF)L:]>KR(MO*(0'/%T:9BI VZ+ "CVK#CH+]H0T\
MSJ#]SV1LZ:T+6XP'O[]?+>;B9:9BDC*9<YB0W!C46!L/G<8*QDQ13AA-H]PK
M/?4:8::V$IW>_3^UV>]_(M-[PMP/8L:8AA'.7ZK"@4Y',,=751J!/^O_#E-E
M, #6H<]?>LLS^K'+M<B=.FVY^IDAB?AV\Y:MUR^&\ZL(#D0)2DDD8$9X C$W
M;@*-HAPB0[?(_!$1%H!Q#T:=(K6>/-P.P:2'B+,L1REB*23$+&\XD@*2"$F8
M4)F37. \3YA/8&-XQ$<+>11CXG[-4G4%FJ^W)K$-:*2N(IN&7F3.H#3\:G(X
M\ 26C3-8N*T/YV[N&[VY,']<K5GI$.R<TU,5H&7,LUAF"BK"L#' 8P:9SFU'
M5X:C+.91G,=^@9W.8T]M4?BXA)_FHDQIV^[^>9??=D?>D9Z&P7/PC>Z6U'L]
MST8HNNT-6-BP3/?A1X[8],;E.)C3_Q']&.SN2=E1E@]E"<(OMG#IG?ZCJ%)6
M9H+D!!MC%6J;UXR3+((4YQA*D=,XR_(L<>LQZS3:U%BJ%,_N2#X;GF)60@#!
MJM$ +*P*?J35#38F44+R1$.:V> L)1!D+&&0Y%@QFF*.C;_P0ZWY:G2XVZ,.
M!_C=/K9@;06&*PVW$^"Y2'3C[;8L!,-PX(5@!UXIZ WXTJ#WAUUFK;3AJ-\)
ME)!DWSW@J/3NI/LAH;O=U#/D<[5\^*;6C^\4W_S.-L_K,B_IBWJJ#DV*.WV_
MGB_%_(DM/BZ_F)7%B/&?BJV__;6:$941H3B%7-ID<$4-P0MCHPIA^)W%2FCE
M5;/B"EFF1O]Q%'N6^;IF(MS(:"1X!Z8JJP4T4_@(K!XW8*>)W>UM=+$K[U8;
M6SZRU@=8A8#1*&"TZ?6P!HU%O4*<<2-5K\?M*(XUP"/[EGEEF]+(KIKXV1.]
MU;+<,O@Y+V94YDJAU#KNBD)LK&#(2(P@BE@NA;'3!/.JFM$YVM2HL&YKN!,2
M_&G%].ULV FP&P$&@VU@BO-&K$<!5@<DPM9=[1IPY'*K#KH?5UEUN:D?=WQ6
M?^T*)=ZO5TOSHZBVM>[6;[];]_WCLGU%26$+]6F;+!)CA1&1#,:)T!"GF8"$
M1<3N#@H2\5A+XN5I7RW1U#C(%C%NU1+=5\E,%JB4LH;"WF6U7E=D^5P_N6[<
M-NJ4#<Q_H\R6-V<&0S@DKUXOU*C<&PS#0WX.]^ >56B-^?CM^^JY8$MI^W*7
M_9M4E4V_#?BR<5UU]4'C-&N%(EN?P];Z1U1 GE$-)4UHKA(M%74ZR^DQ]M1X
MV;S5I&ZVL976H^U)'_2[Z71@3 <F3B,X:"0'1G30R'X2XS[U<CW!]BBF.QSH
M(U7:+=_EIEU%@[.-,/\M4+G=?@AUUN+U?.1XA7K[Z;I7Q;?G(ZYH\V)[<!G2
MK%R$F<*82LD(E(D6$$>1@@RA'$9*YTHF<1QKXA-/=#S$-(.'BI:<__8O)$;Y
MW\H0HHUG4:.3D,J8$,PAT=A :G>="1=F^8P)$B*)8L;Y[*GJ?[%AZ\T8P!X.
M-QR\;]3#?+FTIBYG"QM:?C6>7%"&,HXA23)B_$;&((ER!IG@<4H$R76J:SS?
M+^5X:#:##;C%4M7I"@6DZ_[3-= ,;#NTA?M?H-Z"NMULUG/^O&'<N%6;%;AG
MZZ[\]'Z-@$XB$KSIS_XHXS?X.:GER68^IZ_LMRZ9E6YM#PW?J>J_'Y=WF^]J
MO3M1;-6HU#15C*?$]BXWSHE(%*0RCZ$]Y<LQEA)%7L=Y'F-/S2\I!>U?^=,'
M=3?J& C+@3FED1K\TLC]J]VTJ=!MQ1P,46"T!V(A.<=G^%')J <NARS5YQ']
MZ.N=TFJ]5O*+S? NR]-\-EH^K^TJ-,M4SI)$IS"7*K+MQBBDB6&N/)>)H@*E
MQ"^^K&NPJ1%4(RM8E]FL=2_$6ECPM%I;7]>/M#JQ=F.I4 @.3$M;\*R<=4VJ
M&[ 3-1P)N0 2DG4ZQQN59EPT/^05IWO\B$2J^>R3F:;%_??54GU^+G>EXBQB
M.HN-/TX3#G%&<VANDC##)#*>I3(&CY.A<^KA4R.*4CY0"@@J"=U8X21PW2QP
M+1P#?_4>2#A_YUTJ[[[KHOFP"R5^>UC]^'=SV[_;S3C[0[DKU_J43SYRE$^W
M2YGF4^V\ID\#OY-)\*V@]3<ONTOJ0@ZW?[&UK(9NDNMOMT6]#VV361['.)9:
MP!@K>^0B$.2<89BB6/,<Z91SIRK"XX@[-?JHY"[+HE15SI<KL%@99=>M0NK^
M[9='FGN'LYY)S>C06SQ65%!J MK:[F7^O'D![>NVQ5.LSC5O@KNFT K8Z0VV
MSEZC^:1>!9^VCE-Z)<9J$SF15\.S >58,]7=T')P*49LD#D6HOL--T<;M7?[
M\[4J17JTGO7_E.+=:9M09P-*;'.F^[5ZG#\_%A^7/U2Q*0-/9E*F O$X@U&J
M;-6<1$+*40Y5E%);J))1A&9+]< V2G[S:HO>0QHGTJ$5Z1S)-&2LUP:P1B%K
M9\A:#?#(UO^EJI.'PG:UZK$/VW/>W#8[!IR&T9JKU[#_TE;A5SL+6RW*&@:-
M'K9LVE:3H/W6KT R< /V/I*,W9']"K1.M&B_YFD]HR7$=R6?%^I.?U$+RS3W
MMFSG-T/W!1-EL;,W+WN_L2PP8U&$"9(95)3%$,<Q@40+!4G*1&:09)I$7ED4
M?:28FH/6*&$_VEI84$H+VHK< /YR\.L_2W5\LS!Z39SCZ?C0TS&T=S743/B?
MJE^#9-"#]UZ"C'LV?PU61\?W5SWLRO[.N_(.Q:YZ"8OR6,<I@PFV*;HHDK:,
M6 :1T#0G,H^I\NJAU3G:U+AQUZFWZ<C;HU9,-[YNU!8,M8$IK 582]*!*L X
M@3)(Q^&3 [Y.!^$NW<]V!.Z\R?]\[/UR,]^\W$IIGE?4__DT7RHTRZ5.HBS3
M,)6:0N._YI @S2'77,4TC9(\<NJHT#G*U%BC$A34(MXT/P K++A;.FYK=@-[
M^2 M"%P#TT5OI+S.URXB<<5!V_EGCW;B=E&]]M';Y8M[G,%]40]SVS[.&BC;
M/-<Z@4-D29S$"$-&4@YQ3B/(I-3&^S(&!4&IBA5V/CWK&&AJ)- 6%6QE]3C1
MZ +5X5@J$%0#$\!IE/KD%77!Y7%T$PBVD0Y=^L+G=TCB@$GG\4;7_>,=3#AH
ML7>DX')]7U/I_:-:/\R7#W]?K_[:?+='%FSY,J.:2FPC"YBM[X%3$D.BS$]$
M1%&*E:0\=FKG<F&<J3%E;00TLH)*6%!+ZVLLG8;6U5RZ&K!Q#"9?K'J82YU(
M7&TPG7[ZR"93IXK'1E/WY?WV7KZ9V^YTZYRR+$:3&)\I)T+".(MM(7&AC<,D
M*50((Y['&<_=^M!UCC(U&CA?2K;,16[]N8K^WWQG2[!_4Y^R0*=GP&U7YFI<
M!V:+X2'UWK/IA"SD7LWI@4;=H^G4]7!OIOOBOKE;YL-5Q>:>S>5GM9DIQ),D
MPQ$TAH;A%94)PRMI#",A"#>>&)(Q]\O/VGO^Y!C%%LY_,K(!O5J#>2VL;R+6
M/H1NQ' %, -30B,9L*+=@/<_FR9F;]G3?,,6=;15==%-*\7J5A@^")YA=1*F
ML%E4^T.,G"EU4K_C;*C3E_FWNOTJU)*MYZL/J[42K&C\7ZY1AE#*;?D !'&&
M&>2Y)) KE.4I%8G.G-(5S@\QM4^_D<Z]9>T9Z+J_]S" #'TF4PL6<%O@LM[7
M-IP]\_31NLMV:]=N)7OARKY]8^M,IC*?NVIS(U6:$D[,MXMR8;YB@2 E9O4V
MJF4ZH227L5=#IQ-C3.TSWHI8U02Y ?\:_19%R"SJ:_##"OPW@**;*"K_:1(,
M=FD%?[/)!O7?V@:OYCG&$%@];XH-J\HWL++.[U?S,I2S!I+H!EBGM6X/+\J_
M_;=_05GTMP397R%Z \SCGI1=#M7"LR+)J6EULRBNG*R!*68W3U^K>2H%K!JK
MANV'>A:%L%U,CX<9N??H63V/.X:>O[0?]_S#L)D-*_G"-JITAA6.A<B%A!A+
M;MP&)B&5B,"8:9YE1)E?>1'/X0!38YU&/F %[+6I< 2AVT=^#3 #?^%>F'A_
MU^<4#_E1'XTQZA=]3L/#S_GL=2%;19Z( YE1GG'*I(;(_ 0QS3-(E,UW5(AG
M)-*(BNSZ=I$G1I[:U__[:JE>ZMP!H)^7LK#5^(R7;%:WO^:;[_/EL-T-3TV.
M&WT, OG06Y3GNQR>C"4;NM-A!UK#=SL\-?@$.AYV8.+6];#K 3WSJ9:;N9PO
MGJT1_G6;VU/M9BEINZ?;\YGG39V,\)ZM;=F[XEZMRT2OVT>;FC"C.)-4<0&Y
MP IBHBDD5$0PPC31BN XCJA?RZL@<OE\GN.TQJKJ,BYWJ=Q;U8"J=0/V;0)B
MIUV5BF6@L+RIRN*9$C(C+WM0C5/6=L6\4\##O@MN%#OZ_ Y,OVU]P$XA\'YO
M5M_NSVJC%3!J5;FZ-Z#2+&!&5TB@@R9X!1%LW'ROD%@>I7\%?7B_U>!,KD3I
M><5)0K'B!%*FD>%XVVQ,:0X3@E(D94R4< JJ<1AK:I;LV1RB7CYM%\ANY!D(
MNH$IL3=JWASG@$=(YNH:;E0^<M#[D&5<;NE;(/!IK<2\"@W-J8Y2*0DTOG!N
MJYABR%2$82[2.$=*Q8AH/X.P_?CIV75MZ8PE9PLG>)8RWH-/$ZYHA!BDU+8J
MDRHW/PD,::2$1BI/4K\>XWW!&Z=^XDZV*R!S8\Z^0 Q,E4X8]"AY>*QLV!*'
MK>>/7-+P6+/C$H8GKNGI)$LYMX]A"QM9\'%9AW@8>^QQ5;4QF.E$I2D7$DH6
M28AC'D&NHQ@J2B1.LC3AL5-VAON04_N.=Q*7H4*PW-XKA?;T0B^#[>AB!H5P
M:/]QAYZ5UM9FKN6] 97$U8E@0,?0&9Z@7M_E4<=UZ9Q1./+7W._LVXQP8[?_
M[M>K'W/C ;YY^:.PY92VD62[0+(9QR)3-!<P3FV]>$IL]PB908XR%A/S=Y%.
M?!J<N _MQ4(C-#ZQ18S*PX1G6Q?-?$6K;> =NQQX=^T\N!'3,.@.3% 6V/)H
MH1';5L_XY8\*Y5\'CF_T1RQL9S_GT4=NX>>+RG&O/N\G]..R@UZM[U:/;+Z<
M9<R6Q! :1FFJ(69*08(3"C.18A4)*5A$?(RFDZ-,S4XZ;"D,_JSD]-Q%.HVH
M&P%=C=/ 7.,/D3>C=$(0DCQ.#S0J3W3J>D@)W1?WW58NE+G)'FB^4S_48O54
MYF5PFQ4J-K.4)BJB-@Z*)PQBH3)(4F.]R%P(0F*2,>*53=$]W-3XH)&VCI3<
MR@O^;"3VWE_N1-MUBSD4AH/O,O>'K\=&LPLJ8?>:.T<<>;O91?OC'6>GN_HQ
MRYW6<Z$L9SVURA0PB9%0*H&49Q1B;.P*)BF%J5(H85)HDGBUHSDYRM1XI!*R
M#*)Z<J^0T0VD&U=<#<_ %%$CLQ4P8/Z&$P0A^>#T0*/20*>NAU]_]\4]G8G'
MI\7J1:ERD^7NR6["U.\K%8Q$*,IASB,"<:P0)+FQ)!C'/$L04SC._8Z=SHXU
MO3.HJK%T):/G%L=Y1$F6)1AG",I8<(MH#)G(,41YDD5$"9Y@ZN6BA<!SE&JN
M)9JK"DW;<//)//F[K9POJNW8HG,[UA-F1[\M!'@#DVT9C +Y?EN"73+V3?V"
M#L#!%]$)ZM:='6Q<U^Z2SD?NW<4;_$OQ?%LS&WCX]>61KQ8SFK LH3PQCAPU
MC($2;3@X(9!AEJN4<\69D_%U].2I,40M'*BD<R^OLP]7]Y=_%0@#?^F.^GN5
MS#FIZQ5%<O:?-UI9G)-JM OAG+Z@_][JGO>CTB0C<69PB)7Y $4"22ILR>$8
M2VQK!3*OHC<3]WO,X_LZ/?W<G>DZ.D-Z."/X-J_JU3CZ,V$\F;(NWCO%-Q^7
MQ69=%CB\7ZNGRESZH-2],F_$<L,>U*TVW]#7)R7F>JZD^?OY2MXMU2SC)%69
M,<1C+7+S:5,)>8:T3< PRI-8Q-AIS_1J2:9&!SOI@58*/&WE!\PJ (I& _LK
MHX)'9<RK)JR;6T:=AH%9R*H!=GJ UHP83<!.%5#J K;*@$H;]\K.U\^*1T'3
ML69GI(JGY2S-=[/TY/G=@-52_1:H+FH(:#L+IUXUP'B554/@L%=Z-<@#K^L7
M_V&^9$;SMZMB4_Q]O2J*688B@N-40JH%@3@U/Q%I[%,1<QXSLZZ1M%>S^*.1
MIK8T&=3+%.CGLL#'9@5489NJS8OO0#,Q7\PWGE50SF/L9LD&06Z4U:0HGJV$
MH!3Q!I1"AN\-?Q:'(1K#'P_V*EWAS^I\KB7\^1OZ$<6G^5+=Z:K)?%/JGB-)
M$LHAS8U'C['2D&3:!@=)%<>4QY'T\F"/AY@:-5@);49H):,?"YP T.WSOPZ6
M@;_[?40&<&C/:Q_R:S\QRJB?^7DM#[_OCBM[.+=_E!T*RRZR33AT_6[&%)$\
M9PQJ\R%#+"2"G&D-4QT+QCG"F*7.GNO98:;V@3>"[IT>54GABJT7+T#]- ;9
MO"C?^97/&=X%N!W\SB @#DP'6_S:R1!]VEN<1\K#%PR"V$B.WLDW+Y3G=A&(
M3K?L_-WC^5P7-=ASJ"Y?'2"DH7X?%9:YB'/;Q2+6$.>80TYR!K%$29Y(;8PD
M?D4PPU3#&!HAZT_\OCEVOS=777'<WJP^F,6Q1BF,26Y,2YTR:V2FD&G%C'7)
M1,Z]NC!>">DX_0!:*\Y*&RO>GMJ52\_[K_?WUV/J>&QR'5)#'YWLOW4#1R>,
M%)?PZA$)'K$(06CT[6I91I4^L\4=7\P?JJ6<,XP2117,"$:&2)5M!Y3F$&>Y
MR+C&$<V\LNE/CC*UK[ZJ!P/DLP+/2X,@6,R%K4H V,-:>;10ZX;6[=._&K"!
M/_Z6?& G8, *>5WZ!ZV&=W*@<2O?=>EZ5.6N\^*^3<&^?E>+1=.P*E-*<YEQ
MJ%B6F8\_R2'[_YN[8AT'81BZ]ROX@(M$@!"R5.K>GXA)HB[7#C?=WU_2 @(!
MJ9,&C@4A!+']4&QC8;_:4"(*"90U2G&%ZC%;7OYHN[ZCM7JJ&$O\-8'/O\$_
M!V7KL!Z"1P2YUY+9'W-Z31;=F<IKR: Y@]?B7;$A>\22-/I1M,LM[5>.9K3)
M">?@(K:PV[>D0/*B*8 ;Q6O@8;';)^YHVWF5=RHT=GLQQ@;Q5,AM'LW7R+K2
M9_4X4-*&>*_$G6,]QOIYT$<]%5%T[L8F_E[NZOJ0]TN?Z;I!9^U-_W1-TDQQ
M"= 8(BKAIF6 L2D!,X2RDEI_4[*JRM$5:)S,HSF67NO,JITYO;-!\:^L5SVP
M,SWD%2"JTNF!W=CO_#>F ?7K]-CN5,SNT7L2T2$!3S1L,@(X;_$;N=1^E? P
MVR9E\<!'8TD8V\>W'ABDAX9V84"ZKS@BJP8<R6M+P%XANA2%+JB658URYV_D
M',V%O]0<DY5'S@M8PQ67%B9 :V._' -4! .C%X:T3(S+HG9F9/3:.V=F]-^^
MYA'&+^AJS\ZG_HH]N";#\^D/4$L#!!0    (  I$7E'X!?&<"6D  &*Z!  5
M    979L;RTR,#(P,#DS,%]P<F4N>&ULW+UI=YM)<B[XW;^BIN_7B:[<ESZV
M[V%)I1[-J"2-I+*OYPM.+I$2KDE !D!5R;]^(L&=!"@L;_)-MOM819$4,I8G
M(R,B(R/^^7_^>7;ZTS=<+*?SV;_\A?^5_>4GG*5YGLX^_\M??O_T"MQ?_N>_
M_M,__?/_ ?"_?OGPYJ>7\W1^AK/53R\6&%:8?_ICNOKRT[]G7/[G3V4Q/_OI
MW^>+_YQ^"P#_NOY'+^9?OR^FG[^L?A),L/L_7?PM2U&"%!RL%0P4MQYBL052
MR%%*IKW4]O_\_#=N9?"<:3 E15!6.W!1*XC2""^]=T;I]8>>3F?_^;?Z1PQ+
M_(F8FRW7?_V7OWQ9K;[^[>>?__CCC[_^&1>G?YTO/O\L&),_7_WV7RY__<\'
MO_^'7/\V]][_O/[I]:\NIYM^D3Z6__R_?GOS,7W!LP#3V7(59JDNL)S^;;G^
MYIMY"JNUS'](UT];?Z/^#:Y^#>JW@ N0_*]_+O-?_O6??OKI0AR+^2E^P/)3
M_>_O'UY?+XG?\'0>I_._IOG9S_6'/[^8$Q3>A\^5U/4_77W_BO_RE^7T[.OI
M]?>^++#\RU_PV^D<JDZ9EZPN^#]N_O'/-VM_7>"2X++F]0U]X_(SZFK[TX%_
MKG"6\8*WJQ5.Y^G.+YU6R<X75__R-$0\77]WDG$Z67_R25RN%B&M)B4K&9.P
M8!AJ4"PH\#IG"+Z$S*R/)=J[;%>2ET3S6A%+3'_]//_V,WWPSU44]8NU3(#Q
M2S7\CP>+7DCG,.JO=M\G^MU)B)J0SS)@, *49PB.-@U$AR+2IG)<FP&(O[WF
M7=IOZ_9DD7Z:+S(NR(A<+1H6Z8Z>'P+X\C=^_AH6]$&0ODQ/\]6_KM9D"+VM
MY@/([T(Y1.Y??B*N"RX6F-]<Z&8K<VO.5F1:<?V;0^C]_ST/"_K$T^\?\.M\
ML9K$[ QS,4$,Z(@%YR JE< KG;F4@7$K!H3 O>5W0H/H'PW'2+438+S'Q72>
M?YWEEW0H3[R/C#&1012503DMP5F?P=OH;+(LV.@'A,6=Q7<"A>P?%(=+M!-(
M?%J$V7):!7\):R:2L4(64*7".I(^O0@(07B5HLE9<#7D>7%O_9V H?H'QE%R
M'1D;O\Y6T]7W5]-3?'M^%G$Q,4JPD+,%:T(B7 ?"=:*ON+92A>1Y<D/X$/?7
MW0D+NE\L'"7'+C#P 3]/JQ!FJ[?A#"<YB<A3$&"=(R GKB%:&4$'GICG(3OK
M!L/!W;5WPH+I'0M'R+,+/+RFH']!YFPM^(\D?WPQ/Y^M%M]?S#-.1/96Z,3!
MU)./Y,3H^#,&4E+D+",/0>3!X/$H*3NAQ?:.EN&DW05X/H4_7V<2W[1,+[(:
MEU;1<T1-E@\\UN2.$0JB)M.H; DQH=<6]6"PV4+$3H!QO0-F" EW 963G$D%
MR\O_O)G.D!,3 3$H![QH,I:"/&PB/ !&+5!+GLG''@PF&PC8"2*^=X@<*]F>
MX/&"OGRW^#3_8S:Q/@B9A82@-'G7B1SKR$J"S"@D%TE(C4-$+5N6WRWAQ9X)
M-@X4:T_(6!^6[Q;O%_-OTUG""68KF14>9#0<%%><8G)BBR6C,B? AS X/.[1
ML!M&.LZ*#B;@GH#R?KY<A=/_;_IU[5+I8CP)) !79/X416LUUTNLQ(B6,QYY
M&"(CMIV"W4#2<;)T(.&.#)%J 4\6&-9T6YNTJ.F:[ -!V^4$3F4')3F1@L0<
M-1L %+?7W T&':='#Q;@R(JO]ZVG[[_,9U<9&Z?)BA'QD&6-T!E:\)D\9R&]
M,)DP[%(:0/GWU]T- !VG08\2Y,@@^(CI?$$ YB)^FJY.<1)-*F2@$-#4*\"$
M$:+P$AS/01<ZX826 X#@_KJ[@:#C_.=1@AP9!)\6H5:W?/Q^%N>G$V,I9@Y2
MU ":3)@* F)4'L@U)N8R63,Q1.QY9]'=U-]QRO-P$79B '[],WT)L\^XSM5&
MKH5R5D(.F$%5Y]8)CR"BYU)XG2AX'M (W%Y[-R1TG,X\6J!=A POSA=57!?W
M>178I(/SY01=5-I(8D$CDE"\ V\D N=.E9)4\G*X2Y'--.P&D.[3EP,(N N@
MO)[1IY$XIM_P95B%2[8F1=B48R"3%VH Y,@9<MXHB*HD[9D(0@T12#Q&PVY
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MXN$F@=?,DI-GM"\^)<DWW$4- *!-U(S3N*H%<(Z6=0> N:!_8FR(!K$ QUA
M.2+86T;.?V*\$,58RH;&54,Y-N/TKVH6O.\ES0Y\F#?3$*>GT]44EW2.KLLQ
MOLQ/2>C+>J:NOE^+IO9:PE01'25Y9#9XB(I+L-DX;Q69Q-0D5;@K@>/Z-LV3
MB$WTU($-NL77_;C"!LEDPGK37\7%G0.?50(N#!E2BC6$Q,:(ZRK1V 8"VW%V
MC#XZ0-9)2K41V/)]^![B*5[%F$YZC=%Y",@4*.4DA&3)V,<@@^","[NAQ'.
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MS* Y7Z0O)/+WIV&VG&AO4ZII!<^= "4<N=8F6J (S7ECLM6AW2CC_>D=O1G
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MJ__ M0,QT8KXD2C!A5I-H!)6XY\A8T)I492@FC1OVY7 D6_EF^*SJ;(& ^&
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MHR%(;>M(P1)="(';)F_<]B5TW(1-GPC=6X'/#:#3;SA1VECK')T*7M?QNC&
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M5%\T"(IWO"P,7$ID#(0K#MN8S\-I[L^XC@#=(]3XG!%;FTE,DF*FR&1!*VM
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MT&F7V\%*1)VE4?[N^+"GL;3S;>/ZH'KH&4:\#:QC-U?YB[(0/V8++GAJ2(K
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MEUO\*E*[S1+ES%%C(WBM,6@Q@8"ES$*B#.,90H6LTQNE!VWC-HJHA[6AU=(
MTH8)0;:;*=&)**-$>;)R38B&TIG%:M#2ZZ!,HI6JU@?FHY5F_ZU$B&/"I $K
MV7"6XL.,;SS Q*:<%:4!?"A<L9!+O,0@)$YXL$'*6*4Y:C_RQHT 1D70W4;4
MPZOS5/=?U^>B5R-)*^^Z/ORR9]EK[<%G&SNL*<OH1;9E-H=%+^T(F.#+SG\F
MB$8NO:^R@(Z\PWKDY9H;1RA?YN?G[^:+\L.)<3H:@EZ!*%EFZAJ4HZ04%%5)
MY)B=J;3%6H6=D]YCW0?70U^]&@ =#00A TIA??%S$ISS/)$ R:>2"V4#1FD&
M5@NJI-8J-M9@=A<G)]I><T!XUK.8 [!RL+'\6G>/6+E%&^T;;M_9_&,Q7RXG
M.DM/)77@O.NVDA18C#;!!<RC9*)6I";7E =X.=&&GNV:S;%X::-S^?X]7:S1
M(067@48E0$AFP"M1YLM)IIT2ULLZ3=KJ=.MIKU:J(N3K:ON(#C[?2UC9Q#+P
M4*<6)-3R%#Q$HA4(6H3@A "5*<6%41-)7U07G_8JI]I=!H[%RXLPFOLAI#>.
MX6JH(>;2^:O<L?0F,\B"28'?<Y*U=?WUJ'2CO3JH=@WF.*P<F6Z\G;5A,)L%
MMIS5;(3 6&;<2P^.112"M!9,&:>C>(PB$LY4JE*.,3@GXR8:)[QS=1PF7M:F
MU9V2R:MX]/-B&E)Q9/G*D0E%5)E-%GEIB6JE!4]B*%,7O"+=>) ^T^''7&9Z
MLCIN,G/"9E495?\^=C?1T2>CI2F77'AI,B; 9IH@LB2XR1A0V#[#U5LUMA>S
ML5P%YN-8Y5Z8.YVMZ)VCZ/KT#[@M(($10L9  +B@$EUK(!@\*P;)>^]H5IR9
M.LVSGX_'%[-UW81ACH2]4U@GGQ+-%??]I).]UR1H!R+HC+I3$8RG!J)+)#$2
M3 ZT2<O<B\T7L\E^$L99#X$OP3X?V(M]7#[1,Q^ZWE8"TQ(N&/BL+&B,.0CC
M5!DUSLC1@1E],9O^)V&C-5%X"E8Z4.0O;:#)^0P^A=+P'2W)LA3 \TBSC]ZZ
M-D=G#)EMGL*Y0A,V.0+F7MY)Q*.BB3)+I;4&2QRJ3U$*AJ"_,CPZ8D,0N4US
M[,G?N$OD"6^OUL!/BP46ZTK#;^ZO=%#)Q,T_/[H(8B<M Y4U7#]_B\MKK$6,
M2;0D' .5A!^D5#^J8( EPIV42@I7):M]A*9A^@C<>O0WE.0K_)U_3$)D45(C
M0#.-_$J,SBR:&W@KC0N:>6:J7&1XC*@6ZKN/1\?#700&4$/C[N.(PJL'GC*D
M,ZE9*O48:HQVF9G@2D\>7!MT+J$A)\")=#QSEIRK<K!4P:>LFW3/P]2=?TWA
M8C%=7>+S-P61BS<=&MWYZ[,O;[^>E97;Q$RIYV!M$B#*N 441L(8.6K, 9UQ
M=R^8[^JYWO>5[?J.?5!PNR=Z%7$WD&I?2VM3I?HJS5*>KB8H"!,"XV"\)N6:
M>09+@X2@2R05B<R^REVA'?2TT )B.$@-*?P65Z*/:?5AOEQ^3HLNKC]D&;K[
MB*/7H$=I&F@!>NL6,\S_KU]R#1)&DHB"!-"<L3)6F8&73$"T7%*AE4ZD2H2W
MBZ"CVWS<>>XVB/+"6NZY!**3 Q&M+!-^ @2!B:/C0GA?Y:QX)T4CMRD8 A'W
MNF<,(OT3<!Q=HY&#HMB''S2T$WF(OMJNQ!N=I706*(D87VBMP'GE066IC-2.
M!9=.R95LF].<S5;3.#V_*.VV-I'6-"W?_A7.+U">[]"VRO;1Q6K3T&.W%5@;
M-<99$01:&6:(W&$(ICUXSJU!>XC<5VF<-CPKC3JO?3"XN\'I*/H^ :]WW6GD
M\QQ=R0KSCO/+-SOEE&_+:9Z[7TUWSP/7!7@W#BF.V"(8E=ZA??B(TJZ]5!#.
M.;4$[8+J6/;L/1A>H@'FF"XA1V95_&#[2T77P(Q%0P7F4T L+?<^ V9NGB;@
MZ-X"2\H86Z=^;% V&ETB]L%>O25B;STWL"-S),^O+A]^0->!US%%@Z4$7,H*
M1*8*?% 2A:(X32H0'JJ<L%;DJ97FV\\/U;M=Z!K!3;,F]-']3)NNK49F4BJH
MP>$7@$DS T,(1HR*V1"95B16:;KR%&'C@KD9!/5"]H'J''O([O]N)F&A*'_.
M9^L!/>M6O\$(3;WQ@&9?KECP#,ZRA*R4+NF2XGIJGPK-'W]%B_ Z5(WSP67:
M@..Z[FJZ;92R881[QI7P&A0IW7:I2V )+@]4&)135IS$*G<B=E(T[HE,%2P-
MJX76X+1AP5+GG"8"N$T>A#,9C/8H)VM"LL1CV%YG@_X^+>/6=3P?A Z0? /@
M.3(:^+!MK:PU2TP)2(Z@''EI59.S!&:R#%Y;1^L<?@W%0"O-VT\]PS@,$:=O
M"6<_YQ>SU80ZST)T 91P&(HHJ<H5$0)9*,:=,UZF*BOX(-2W&#G6!MZPZ#\
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M*@SC,*H#FX0#KK1P ;V =/%X-W[OO?W0>5K'5[7%WT(*>>'/RZ[T>D+)Q,;
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MH9B>'UI\4L,J7MIK ;8LW%UFPB'KPU_[H.*C7;MV&K.VK?I$2=,U'^3-+@$
M$UA!@-0 (3P99)#G$W*]8UMSFE['OY IFSZU@F?7JV1-63T(L-(2H+JF"4 ^
MUP\-Z]+O)GAP+_[-CUQ7K2-YK?AY=^>N T9--<,\!4[]>#W):]&,O ZZM: A
M>O5:]@]OP5X'72CT[CT5RFP:SW^\QO,LSGV8$*98>T/FRM[H*:*:36OZD[2F
M(PN'(L00L=EZ>/;=T&,\CWV;#OE-A_P/VR%_%]1>)1"W $&NL1L6%4Q<)UA_
M!/E$*I ]F?MRH&=<X*G.3]'SS!.#-%!RGT3HTO1<_J"<F=Z)7@\-&5NY?5]I
M%Q50.R?F B2?>_VT@*Y0'_&^> G17("Z&?9)#-D7R&'B14)JW2*D]C;>5#W,
M5<G#_/3AX:ZGU_^'"JYLT,NC7=%7A"@(5P[&C""OJ$%SIQK-JY"V4".ZKU*\
MV,3R[50W=@9B)N&^R"-:5]J=5?Q;N'"G^N;W=B3/$>RC=,>UO;V]QJ8[;M./
MO.E'WO0C/SH+SB':D8'( K^'ZDXN8^7AZH#[8=#^\5J?=QH[&W!?YCHUZW3&
MNBW]5DW,^U-=&YS?=#AO.IR?L,/Y7K"[R567S%7K[H\RTY^'?OM_4$L#!!0
M   (  I$7E' G1_]S"T  )@' 0 4    97AH:6)I=#$P,S(P,C!Q,RYH=&WM
M7>ES&S>6_[Y_!=:93:14BQ))68>=295B*Q-O36R7Y:QK/VV!W2")N ].'Z0Y
M?_V^ T"C#^JP+8E2G*I8)+L;C>/AW>^'G_[SY9L7[__W[;F8ETDLWO[QRS]?
MO1!/]O;W/XQ?[.^_?/]2_/;^]W^*P\'!4+S/95KH4F>IC/?WSU\_$4_F9;EX
MMK^_6JT&J_$@RV?[[]_M8U.'^W&6%6H0E=&3GW_"7^!?):.?_^.G_]S;$R^S
ML$I46HHP5[)4D:@*G<[$AT@5'\7>GKGK1;98YWHV+\7H8'0@/F3Y1[V4?+W4
M9:Q^MNW\M,_??]JGE_PTR:+USS]%>BET]/<G^O#H9/)4'9X<AJ/1X3 <3D;'
M!^/QT>%01:/#4W7\?X=CZ.4^W,\/%>4Z5G]_DNAT;ZZP \\.1X/CIXOR^4I'
MY?S9\.#@OYXT;BW5IW)/QGJ6/J,>P]5IEI;0DQP:YH^=]F_YH>L^:B^'69SE
MS[X[H/^>XY6]J4QTO'[VPUFN9?Q#4  ![!4JUU.^7.A_*Y@,F!?ZNC)S!4_'
M.E5V[H8CG*WS3W,]T:48'@S&UQE<",NJ\IM.2>.I.QK84L69^$5G1:A5&JHB
M$*_2</! QWC<.\8765I4<8E[]&R6*\5[KM75:P]#IQ$\_VQ\M+A;$GP_UX7H
M&XK8*>=*?/_=^/"Y^XV^[08BD9$2LA#95%RH1:F2B<K%\"@ GC0\#02T2,L!
M/$RG928F:V$'?W?+<P4)WMT,!T**ERJ6*YDK$6;Y(LLE"@RQTN4<IG"JH7-"
MEN((^/GO*LGPE>)EKI<J$"]D,LEU-(./O\NBD.&\*E19%N)@-!R?>FOT(DL6
M,EW;%9)I= ]S_E(N=23>#<3YHBB53N]ELE,@.MA=.JI@&G-5Z CI&N;W^^].
MA\]__/%'^#M^WI@ZHGYIZ;O+IK9^%W_X[?S=^=E%('!0AA2(!OB['9\ 74(#
M%<*>5$4I)[$NYG0+;-:DH ?"#"8/R;,0%0PF%ZNY#N?M=E8ZCL4BSV"6E8 ^
M+XF&H5G__=,L][]__]W):'C\O! 35&Q4 1N2VU[ (L&LQ6M8N#"N(FP)'L-?
M91[. ^@U[N4%<27HX_??'1X_A[;#+$E4'L+DZ7_SC@)^!$_F<J&J4H>%?W.D
MY2S-"OHYA]U(S XZG.@PST!)DZDN8 IVN MXD:Y,=%;*7>!U108O0JV,=FVD
MH6^@RHE?S1@+^5'AZ\-8YKI<!Y<.7!0+%6K8]S)N#QIV-S:3I? G%\ +5*N'
M 4[[3,'TXJ" 6I8PE"4_G2N<@ PG= ES!9U 35+4HU>NXP^/Q%^_^1"(]TCG
MO[YY=PY")D5:A=VM<G_Q15*5N/'##*8 2)6I&N8L@9$7^$@IH>U(X'1!&W@U
MP[D3LRR+Z.M2QA7L#=5L/S!$&2J](#(4186\&X7+&E_.Q RR#UL&D2?#CVFV
MBA4P[PA%(#Z^D'FI%=]29D'C-XE2%J7J-(OC;%5\_]W3D^<W78O^!;S+=1H.
M!/QWUYS_.<U'I$(C7)\1\\*[GOQ\8?C3 R3ZX6"(L_F^R7V)4HC=+E0.7#8!
M4@32"YT6!U(P6NHBRUD($+\#(O09-?[>8M!(>XE<BPF2N2S I)T >\K5ORH0
M%O#X%#:1*'5"\H/^&JHVSP?",<\ >%TITJP4L4XT/FRIW?7!\$"X!'OW(IRK
MJ((M=\9"!'91GR)J5]+(:?&JQ/U&2UV4=OO2[*#D ]:WSJI>T16I"+AO"=MM
M :SADT[@,XSUZ8%8H4$-W#^2ZP*G5ZQ!"+4DVT"\K'*2'U[3Q(/>PC)#-W9@
M)B,U)3XS =&UVG7S+;%1O,=P>6X>^8&<@A0.VMTMYB D:"95.I,S)8AG(7<!
MM@^2AL<YAQ=*)(!IK,,2V]:D@!<ERZO^5:)K6646B4> ;8-@7:A2HUP1*EG$
MV3HA<>+D%XR#>:;M!2N<=5]!7NJBI,;X1AAT@3P:'B1)9@0V=9Y?APHZ7,9^
MIQ&1J/D]Z SA"CORNEQQ2W;XJ&>'Y\HH12R^P'3(29;1?/52B%/&D!/8?4+$
M0EL5B#N1::IP@F%@.5*)#(%;1A)LHWJ&61$D4=K8@[2Q%@N@+I*,CA)07:Q"
MH(U<S2K@,I;ES)6,H4FB"CE50*>S"KJ'XX=U!F,(_@4-M*QHW7/8^H5K Y5/
MI 4@4<F&FQ'A4W@C>=KH!UBQ"D:"Y(K:$RI?W!DCB='<\KILMK";FJYV_ ,1
M]J6*&_RXPKV*LX@W K>(HP;?ZVXIDN.@6.[2L U#=@,%M6.I\M1RDT4%&B\H
M:&;F8M(&"Q4"OR$E 886T]L765'P=. =R+^0%@/8?>FB L4^A)M0--@NG&(7
MH _XDJE"I09GL=1['W7X<0*ZBET.L7,X$G\,+@8O!L!T1Z/Q\^%X="#WCB<[
MDUWF8WBG:CV-8W.OT;O,H^K93R7[2 /[\L!K:8%:;,B$$\E2XEJ7*N3Y85JI
M>18.X#>FKE>P<CG1[]LL!W-&Q\@0L94S(.TJ=3^=,4\<GIX>!2CE)- TB "Q
M0X+DMU=OS\Y8I-@1+'FB<!I Q<]@B5_FU8R:?I$5"3#'$!MM--81CZ:Q)4\&
M+3[05[WV)%HU"1)0R\,X@]'0>N/M"TE,MV!?"](<B3EN$_NQL]1>PVVJ\DT<
M6BC8ZGFU8$66?ICD>J)@]W@63U=F\RRD].T"UZI BP?X5PKS0 V*MSD* =Q1
M,"$]MO-#9LWCF[)FN!5%,4XB;OB)4JE0G\B^B]".G<#=^*FH0/TAJK&B= 7F
M":\U]"/6,VUXEOJ$)BY<@YMT[G%!9LDL?Y$SL+6.Z^5MNR[1%9; :(/D:Q*Z
MQ!E8OX@\!8/'M,JJ&-48,<OAD:@@-8;$#(VL()*BH9&DH(LX.KPP$'\LH*LQ
M*#G$XE !"BW1._/(=FD*[Z3NACH/JP280TK:*O8"%5-HAHA2AETB9^/,+(T9
MJ9P ;_4(O(\[!R+,X0L)%6YVMZ.#D<JHDP241M83S78UTG93M[/'JK.,ML[$
M>P]JR]T[&P?B?5-+8E6,_%(HE3)6$B*4<<8[4ZO)Z(G0::5@XY8Z9KFL<U*:
M4U"\\T+F:^O34-,IBL.E::NCG@702$R.I2Q#'0^U."#ITNSF'CV/U,7"\H,+
M%K;BT'I%=HBPV5(A(:=+:QK"(A#G G- X=[+U50A4Z.-R4ZLAE?5LXLVN5<?
M[DX8;]U.0'8#O)=^OX<=\?!<+&-VL6S7&KIPW*]*%??#V&JWD#$P8?L[D5:[
MHE!92-GAZCH]5<2C_C8^. B@>]P:_L@M(1,!?8 ]/U+\JY(Y,"P0JQ-9 %>#
M?^VE$ R@-)*YO<=CGQ-TG&KB;Z$LYBU7%+$]X$HR9V4,_5^H',G4,-II":H9
M.O+EVOA;K6VA4O+-*(D>M=;[!V!R\$WH7^\$5S*0^AN)O)4T ?8;A5F>L1*S
M5!O3*"9966;)LX/Z$3DILAA,M<XC5Z0]\+_SW+:\ 'T/[  E/^Z1\^F9C%=R
M73QYE D?=[E_D.30T4GN?&FW!M)(*T0&YGY1N=\;N@0Y"U,,I&/$KDV)@3'D
MS2ZH]T2._$35OMT%6,;&2<!.XO:6BMB5V1OF \6VHA@5#2:Z8C1&'9()6A:L
M-$]019[\J<+2>*M!"P#3.5=+K59LP41_5D7)/J92]#E?4-G.%0[B 4J7BWKT
MY&I> J<TK.J73.;$:E[" H=EEA=6W7.>VK+#A3&+(.KAPVAM2H$)8S$::O@3
M.I@7; CAW%O'TO%3Y,G87*[:;W1SCBILAH["+/SH^=]?I<" 8 3_R&6=#$+.
M".-:,EYLJ_E^ABIKQ<F,K>H-@[A![^=R2?%_$ @S>,D,W\H31!V82K"J$YE_
M5"4%_J"'_\+WVP5SL8&_C48T<Z0.1XI5[#JRQZL)8D>7/LG6TBP$,L\2F@D:
M$'J]0HHS*[!)(Z#"&9KQ[)(ZXTF@>7;1#I2BC15@5Y=_:\T(:(B81$AN@8;<
M]'9D,_;?- KZ9G9T,#S!-!KD2K"$9T2-;V-)GOW:V^]Y("SYHJNK!(87LPA.
M8<ZU#<6V9'=-;^?\$+Z )Z$Y$#M&;T"\/Z2EIH;G4):EQ#@3F#"4=D<7\6&T
MV'%68^X'1=0PAJZSJHC79N.VEKH._<MEIMFZ@DF+LFI2FD@7TJA(*TR.*GIG
MW^=]A?7@1]:W[ V>UQZC4=RH<PHA#2F[6%W:("7&)Q!/ [-4CD_^BIO@=]X$
M_T.;P(]@=?NS:Z-7W)WK;$/?%L8/9A/ UC>KV$??W-NE*G@X$]"6$S=Z(B_H
MV_BHM88\-'AU.:?T"K@4Q^Q,;:IZE@-1#P*6CR["TM<3F+=IA:]8<D34# HX
M&!)=E]EU7M#8>![[-LX X\NRL1P3J[B!TE#.\ZR:S7GA:3S84XYGEFH@SC<0
MQ&53G%F=>8-SXNL,LI,]] 6C_(.=(9Z0=1Y6Q[@IJK3VU:/NHK,&UI@NE^11
MI98&<OCLSY>A'XH$F&:M/\:]J<=K!+3ENQB!"4T5^=TK]* R;7K--..MGN@U
M*UCWSNO;)AF"S?3)$2(+V&)(](W> =_)7%0\"\,*;"W# :5X 686!ZIA\<L\
MBZ_B)H%MB7Q+,.]5B=O9YNWQV&$ZN?M>B/*&/ \:%SO#@UT*NA<F8',Y4WIX
M&N>8 \K;Y,\X_X0NJ6UQ9.1*)Q-@+JK-G\CBHAM,\@M'85,%W(D87F0J*W!?
M5:1@+T"T@<Q49H"H;%3D#(6FR#!SJHU["^>MI<;CB@[9@",TG*/CLL(XL\?J
M%7[H>M .2?&X@/$FNF-A @M)8,),J-7I1+!-.7$(%JO   8&[IN/!LYF[ SO
M^OZA*D6NS[R(#4/D+=DJ1;%2\V_7.9H08A$Z!_:P,X;=2JDXS-QL^IU)=GQ<
MKN3QMNW;7U0*3+N\QWW;DP:%NFM*E4T<<D@Q*L']#"CK,Y<S1>$X3"O0L9JI
MXHH,C<"FJVB;4 !J#.;[QC;U8HT1%C\5*J$$LIA>PZ%.%[&WY1%+J6.;><*/
MJH[)^I@(^'#K8B'O:WUI"X*#)G[6C,VQO6F-$D[1,@E#<A>E!^B <]5,TW1)
M2C671161_-RL]\H>!LHJVPJ(&=4@N-FS+$R.GH0G3-+*9->*KC1+R4<<SK&'
M=$_ +RQ7,*SUWC2K<K$S.MP5L*WRRU_4:DAH-B/YRYSR3SF1":,!="]E<OKS
MR!W$I(5P%[5#G!'2M;E/=0:X[0'Z*Q7[P\I."G;+HX_WU$2S(1FSQ8',OG<>
M5V?0&!&N."UUIV48>3F70 <V @O:VRZUY&0NJ1&4&&E4BX;NW>-.\XP$DQNZ
M5(9SJM3W:V#+ W%!D5XS!A>:!G.*DL%(\\>*HYB)V&1J6*,AC*5./*;F9@HC
M*$M,+XI4$>::]6HYDVB--XAYVJ%FYS]PJ<(VM<4G@X%XG97(RIVE8%PW:I81
MF_=?@EO/[;NV^55/H6_A /7/-'D.^RG9U^@ZHS>D:_()J9R7'9A\@2U/ZVSS
M _!#>.#H,0F%IULG%%YDV<*4=&R-7H-5/ST;8(+F-Y!GEI>%%18MNZ#GJ6P2
MZYGT2[C:.Z='>?>SAV48DAC)R)?MI9%:)S'TH;RD6D!SX2=F\*K<Q'W(,FD.
MW2M?V,  _)&X#,@-4QB:956=;''7'.>@IRH./'62\N2GF-+KGK-IQ!O<FEXR
ML'7!9!,3[4/KL9/+S#<:1=+.$/LCFZ_ -X=>,K#)G$8[D[I>-!;@,;&)HZUC
M$V]AEG.M2K3[7[6VP*L4E05<VF\9-M=:W*W+L-FPNMNPG-_R1;8C7Z0>=(3J
MY5ZLIO>P=] *;,D[KZ[4Y$;WB$ZF$OA]KA<=B8@.;JHPGHHYO$N4>67"/UA!
M!GH *A=<'R-+JWB$&?E,^W6.HC=2%722J,D6J?4+\\H2<\VIDYNX;K>@KJ,&
M4/LHT5UR-HYT4X/&<U27I9%%9^/79$%[/ALLH.[/T:#PCW$E%S)1)FV'PE>P
M_S"@[S79K\,UC$9\'+-L$@;5,)<G-E=D4S]VG5O+FBM^N@G&YPEG(F\]%EC_
M@LD"PK=/2]4TR;P,7I=HC"O'B<ND,FZ:9C3I34#*5"752?^VPU,)+^DZRF\F
MZ*[#!.YY)T]V.6? 449/&C=E.6R83+IF%,Y$R33 .0/^2]6><8RU<+6*XLIX
MC",#'_(T>81>4+3PT"%6@XEPV$':O+1 Z[5TX9#6U=#B4>$- 0< J9X+"S=!
MZ<T5Q5$M8Z%@'5CA58XWKU+,(S>E;":66G020H*V7FQ^_\&'DG!:N<_Y:#M-
MJ8P0WRNGF.USM3<8]Z_3\0(*E( N'PCX)2)/C#>/G-:C6K_"YI.P&A6\"]7]
M16+@&"3!9>"D$(Y#2%VO@2YRA?%HN%&%\]3ZE^UE*HV#%P)IT27^BOMI;YZM
M BJ7K7#O(D!$+A/T84]+1)VI/[D0EO5[ UOAWU4!PM&\&7.1UM1!KNTT/46S
MAI.5"MM%+ UW$U1P'ZA(B!Y"=U?1@.\@YSBFF1AFXU8-\X*H(17*@NH9B%\4
MZ/^K%]"%B7"]@8? 7^ IZ"<+.!4&>X"/VU7!= 3,16)Z=09@PZA%YF]8/;16
MF*HGS?DK54IUXAR7BVW:\M0-JEW!Q=5-:D/@[]IR](I$RQNSN*UFC.%NM\SN
M*F^&=9BA;>&5G<-:KZUL]]>8EA1S)#6Q!!9)!6V>U$[N3*54%6L$%;^L6=*E
MTV46DU,P=;Z\[D);@G RNEE4[74]X,1)S#?@EWNU92;+$S.+K,NZE2=G61>6
M^6-!-Q&S317Q'[0U?OPJE\XVY; SXL&0*+&*0P7-YAZDSD;MX9'18=1#APYK
M PD(R6RJR;UC^2@6LRN8MIQX8P*F9AI)R\B)MV/M%3Z =<T%<#[T"\/77&+$
M!Y_*(A533?P$#56,PP,IJTF6?31@/\#+B3'Q_8[-.\'"2$"D/G:E@ ?68!88
M&IUG)5Y<S'48U-=AO%QV:H,P%BT'"7Z#4E)K"Q:U\I+]8 &?7)F<8GRX#>X_
M8N(1J=AUM7M0!V$H")$KDSE$I:A+5?LG6XHZ>M]52[VHNYA2IN U/:Q11=NQ
M Y_22,F:(*M?:!80.9#&TM6(^UEN<(6 B6  :N&$!"6_:>>"K($WFOM/G,5&
M ;=+QG6H^-X:$<H&:]SZ;IHB*Z'ZYKTGQN,6 G$=EBI74<?^<S$YD)PLA:<F
M5=W RK1YFBU&OC)K#L9.A@J-WG1@?0EZ"JA<TE0V7SEAQH1C1MJ>M$?&]-15
M3.]*WSPG(&:UW<W12;2*V[$#;]*-9%PO$ I(4?24$C!09DGB305%H2ET"IR9
M:KF#'M2.OA[!ZV&]JSSUWDA/=G9 _ZOK-YIR5_)6,#U0CPE@QV."5[T&P4F,
M2MKG0;!*:B<)MN;-#45@-<\H]D+NE%IA8#<&.G-45'LDNDUV6.XCH^EI+TUW
MW&:-,'0'V\K-;UU,8! [RQK0B+B'<Z\U@3+^0< N;*T@1P$5+_2X3&#LC&1!
M>\93<]GFLRI=81.P;5>QAB6GB+=V<0A..8IJ5*K:RD! *Z/,<G2O'@X#0YC&
M3.2K;:6[)$!LI^-TJY'()NBDJE(2KM)*)7]4C%#B#8M5*GA#0PMOU):R0$%H
M1:I]8A6WSL<T3 >,V)G)W_5GL;G+>F?@\X(I]TO=1]N7W_OPXF'W[]0_(X><
MG;= P+8C!PIJT?P+DC:R$-VKU@>T(1G-A0PV]'<%QBG4]+CX/AWV\Y ++,V6
MWM8$/H16(3.&G<]W >YZZ%O(E(SS#M2S"*VAJ I-UI2!#0JLX1#4]@EWD@5:
M[6?I:.WHUHHQ5P=N^S/3A"!;<^B"*S,BM3&_B'WI5C>Q@S),-$7A'M>:-^>V
M^;Z>@#39Z'(D0#WU,KL[NORWX-^WX-\E?*+/,+HT/,/D9F$87-@*O4J(%&P-
MT(U1-AA.S+EPL96882PK"F/I75?I&]AJ8,N^;"EP76F#RF>VV=3L*!(6,[<@
M]M366;'5^FULT'I9B':',9LB;FDX4F&<[NATMI]!L4DLJ"#K<@9)4#M@P5+1
M/& 6J1L M^<#(5HU!KH.<QA8\[FI!5))4EPHA@TT3R.S*KA>MM>Q9H%T>GT/
M6)%J7'286@K[/4_5VF"%A17&7=!)1;ZC@GZP:4,EI9]:NV""O>8HZ<RIJJRF
M4LBERKD"CM\%AJ_X+5MA4F? IGAM+?4X8+W58GD09<8,CRD%L\T+O3 'H0!Z
MB-\F'<L4U<28(AT9C;.^U'(C^#5XI/.Y_I!CWTJ<EH#B;G1$E!$/OE2SD6OS
M7->A1('HAB2QP+(D2 *ZH:G8UWEJUB=D WE\$$S?K666Q1QA8>]?PR>X89MW
M]MX45IK!7-L6$CFX8?%GA(]&ED1#WZC+(6E2NM.P<ZF$WJVK?6"98-.Z<'@3
M>-2]Q= P0Y"NZVU.;FUF2M1)Z@VZY\!J5@$'3J6U^E2>X/VM>L3FKJU/V3D+
M;QB)W@[1@:X3^.\/ZW^S[K8VGT%^U ^[81+0-[C4#*LQ 'B6@(A[&ZW3><@;
MC!;8K/W5I8_6!AWI>X7.;=D,%UOS7DL6L:+,;'Y+6R:T)49J ,D*W4HXURES
M*0(J0K:=3:R/FW@U;I20*Q1*:R77\J3VR)CO&YF^<39.#5RF@5MD\@=>M[ 8
M 'ZLN6M?QT5F9>-*$LZ_EW:/QQ=D&+*J^])H[D':MSMA-[?')2DGB]*'7[Q:
M3:"L( LU(8 M_*N21B!RT7*=,&-"-8@7:6L)$MPO&(U!M.).[(9WCR/C&M"\
M*8QVR4]A#_<R;A9T]AO+PYY080KL6>T@,61]F4X0F>H+CUZH>J,]@CI"XM>@
ML0,&Y^)*]4R88!?*SQXB>LC.P6/*-*:C8 AJG&&)8P07G99B NK%1SH?YE$-
M^F3KTJO?$ ]U8MY 1W]@,-WU-KB1'O9Z]QT;8>2(!V","E%@0X\=FX.R]^KH
M0ITBU@GSM3-=&'3/^8,;.1#$7IQZ1^*0PK,NP+'F\,TT1TY%]BKKOV3.4F=8
M5J\;^52=)#,J *X58#\4U<G$V12 MC^%ZYYC%-J]-*<F8%*9,[LI6\Q^\PXR
M\)U K7P-&Z%IM W,6H<\]RXM-?!#2GX,J:?-C3I_BQ@VS40K)DZRH9/8TE3:
M>T+II9_HVDYQ:DD@8R\Z&4X$55?/74U!O8!V9"?P+5?!0F.3*1Z&52.SYU0,
MZT['H(I&TXU=&YKLGL_034SN1N30 Q&JQJ\FA&K*@JY%UWABE$W=P"SI=.80
MX-=.W:'GN0;4TE)>IV@\-C[8=[A&AP\&-8H[VQKVZ*B^Y9P;/EE\A'4U_IU/
MB&Q(6?.-X)1?WF;I/MA,(^XP'ZSX;1[AX1]^$=B#4>Q&\X_WZ&_>]GF1K;@B
M#T%,<IM\T[-UK\<)7$U>3>- CNCT,-780%9 :+&%U[$FU+2S7[T;R6BR9T3P
M^1!(UYB(J1= V AI_[BH]'3KM+-7\)'.)TA+QG B@!BR;JNMB/$][.7N4\Z,
MB6M8 'Z^N*S\G<1GRBXO[:U6Z%;+>+V,"Y%O=WG.)A^A+74[:H+1Y#Q_,SM5
MJH3:8$<J.[+K[!MVYL+^+S2?OX(J)O):TE-T@FI*%*#W<Z)@U%/*IR8A2'U!
M][S@_(AVULI$N_2?VIF36M[WV,BD3W8QF5!>BN.H?%86(ZVQ\]Q@W#D?>(!^
M<XRUNO1]<Q@4)64IR>D2AOBLK[F&FWJ5;KK&BV00?Y&6T.$>J66V(1.4EVNF
M0< 2]+8%"6:48^,=UFGKN1\*.SX_ <PF07, :%U[TQL5YI7+J6SULB&IIU4\
MU4:I[19H=ZOGOP5NOP5N+]F['<W.P"N0Y]R%:/@,4;+:BAHX88/>N(DU^\])
M] +:<Z! 9U)DCA8M#[\7QR,ES8.[8XB3#2Y_;,ZZK^MS=I8=3"MR'HHX"UTN
MYL36%_D)XC:7L:."/D2G]2F#M[VZLKZS,[=6-7=AU@XW)^_!IG8C3&NN\VG;
MK^$%X8-:[(F0A%M;I[MSOD!APB"([>>%>3U[G7#\0';[:^B!6V$%,5&(]V+@
MVX3.(]$I;4+?7)-Z&1YU_;"MR&$I1SFW%#=Q^*?5 GM7&#(CB U[4%8#V-!$
MCWHAY!^VCG"X44?@P+%J36DC \)/C;"59W2)_$GF![KN/"1$A@1 Y=;R,=<$
MG0Z>;IS@B;+Y9T[;C94#$;5G)$;NM$6=4L5+*3_AW/MP@C7N()-U$WJ0G^C!
M#>TSW:?D ]*N;,=%O# NKO+B!W8>F ."O!=;Y,3'M7[#@ZVSK=\I!!F[3S#<
M2U+B25JPE]7"Y?4=%%:((;*(HXU@UBQ4"%X?$],J$Q+/07.0N0%N_[/J0,X2
M^?J.6P.+!,8*5U19<H[7-1VS.$JRE!VBD4P( %3&\,N&A/7 96VIP 1!*#H<
M:1\<PL3Y<;TZEHRM#N@[HZ.%#\@9!28GCF/$85>4-R:Q:SF9?(9"J8\"3 7$
M D\60%WFN%U$V)(ILY(_JY3A[,#FT&HJ=IK@V@S&968MEJO=!F]GJT@;U"E<
M>V0B').V,\MU812,D-"9]#-1LN^9,PS_BH'@X>@O.>KM.Z;O-5E:]R($SE@Y
M)*7>68^,CF 80Z_#L3ZEH(X#-]3X"&^,/#A-LBZY3@JYAZG1I+1\O!(I<G7T
M9U"]!08CWE!R+.&<@$VKBU*9KH8*;$=*M0%=)R8$D1)8$P:V$-0T0%:>,Z1(
M%^'6FL/F'@-';NH+47LS)PZ8HVS,79G[R+%+@YO#+?(<.!NW^=+>$S@]' "@
MSL>UV[8/"/IMGJ59=2_E2>+#'*S8I<G9)R/Z$ZL/9N\%%@V6>L@%Z@R W]U]
M'+)6IJF<[8Z(D:.+L,+7XP'K">K^'*]65#2$JD91^TXQ@8(\1/0[Y[A5-;HD
M?^F^<1%7[N!V,@WI()A;)=[#@\'3NR9?@JS=)NH5YWP&H*.&+0 S]R"B2;?D
M'M99&1-5KA!NVO?T.9<-D+A)9#6NA+HDE7'%8.@6UKFH$29LFB,F*Q AML__
MMHZD!!VA>8_O_C.(;JLY[='6D>H9S',$_]\]B9:; /=E0N=54Q9!%K':0 Y0
MK#=R1%6GIMO<=C*0V-9J)Y8W;+-')KV/MTYZO\[2O3-*^I<<3S:P+!CHW@8Z
MTT6MY6ZH8M_DH.T&<FUU0[J^)#&QKD4 K9J/M+S\ 8-8XUOZ-B2_X9B$&F*&
M\^#VS'45[;E>UN!#U(D&'% WXD_ 6WCZI4%?QS?%<N55#>)!BIY-X<D86>?^
MP1U8NW-=T,@'O1>W+V^;02U0YOY3KK9 #ZG/ J6.,=,VQ7G(T%F9[MI?BO+(
M/&)/LG3%AP#!;[\#?0.U57CP1;UKS'D0;."ZM,IY1I49G'T<:\:-A\;] QYR
M0H5G%^LJJV+HGK2Q&:^8U#SI,N38?ORSRG41,6K&(Z/O[<M\NZ@(G!@!=NEP
M7:Y'WB9"QQPH)$/TH02FTHS"GJ:DEL_"H@0J4EY\[9M#HZ;Z#%TT17.XIORZ
M<6@NY1_G"S-7O'_(16]RMFRJ=??$%>ALHO(9<W[VZN//]$[VS&BJ X1=5OA@
MH($["C<0\SH6;=PVO1@OM;3-52V,.X!L/+Z^U*1O..S?,GHNVX^C[0LDOL)\
MC@7BVMW763:O6$SY^*,-/#7GX>1@H4;(1 L116R%( :F7CZ[+^LL8F-J FA<
M]:U8<NK2(;,1#&.6":QWP%1Y1L*P:7[H+"#O&]PQPW15Q!ZD\VE1R"(7U,0>
M3?YIAKBNF40E<Z8L1B9R%1G@.STGN)E\$^.COK!9F5EG7R(_Z:1*6CT*-KV^
M]3ZJQ[)E+-I9L]YD/"YE8#3<NAUV4>5+O93Q?>RM.M(^& 7B4-@SKT<C9U'&
MLH#NH$UFHLANOSE0Y()&8"%2%SIW&=J7@VL^+LH:;1UE_:Z+4,6Q3%7VZ HJ
MA@=C])\^]\\<VAL/[]R1#\M.A1;B=88>"LEHFHEF.-L68 SP?G-.NE5ZV2-S
M22C4GC=&A8P$SF!<SK*T"+(>4L1 G+F;<N=LX4SX-@:N<?^D=+2ZI.[6F24N
MO%HG<=(A+8Q1W@="; UAZNA$4@?J_M9CM>^E3MLW7Y-4CD</G%1<L44H%PWC
MHK",N*?,->=\/YAB6$9MV7"N\#PY^I(:^!*-*+ET6 ?#S@1<:LKGK4P=+!-#
MX& M[\0LIUD@TXG/YM0/?GG\]&H^JM7EJS4.TMR<M !R'#,#=(R^RKAY:D-#
MQV1#EFZGVB6Z'[W.-3R,\AS1G$.=F'Q++UW.!E#MRJ/]26O-!K&&S<Z)^UR/
M^O7.N_FR:W>SI*]>BP^OWK\^O[@0'WX[?W?^YM>@$2ODTWG9/^[B,;2XQF;'
MR6Y4P]F$>)MVNU;28:H0DK-Q='_]<X42F<_ V#;V/LM,QJARG@ \"7,/T?7D
MHE#/[(?GD2X6()B>Z91FB!YZOL3DEE#&QDXNLX4QW$]&@Z.#$=KN)?2FC&SS
MQJP?D%F_7T;=:^/!R=.G&Z\>#(8;KUW6ZN%X,!X=?O5FA^/!\='Q5V]V/#@Z
M/OGJK8Y.!R?'1]=J=I]6C5<.**  6?_W)T=/6ISWV6CQ20PMTV420&;<)@NF
MMB>WN'&/VQMWB"1TCL!\XA>=%2$)O"( MARV-I6="S?,<6>8!SC()[=ZJYGP
MEB-OR-+KWGOW;<Q?><Q7/7/3C74GPI!\L;^LO__NZ4F=<WOU^+=W+(1F5M"_
MXA<9?\QU,;>%ZA<ZF4BN2_\'Z&$W&.\-2&-[I^:Q+O-+N=21>#<0YXNB5#IM
M#/":F_,:"VRT*-"'GL&]!(D4"1S?\ZT3G9TY(]'9V XGH]&!W1#P><A;(A!O
MYX.7]RU-O_Y,WYU^PL1XNY3X0.CMQ1S+?\[)>D*'$:?3Y]]4M>VXE<:\3S;?
MO1O]WZX]U&O?TA2V*TW!>S0DE+4[])1>&LL,YRK")+2SSR*ONQI61ZB3M_"E
M*L)<+ZP+W&)2;*UW\P*/XE8SC.1'2WN"P*S2G(+8/C>R7<;@'WY@L,\3#$W!
M]->'LDXTGNB#;\"BG;G,$QFJBM0.>W!S,X^KIR/F?2'I"<KI"?9,BAJWO7.M
M>Q+EA:ULQMP%QB#E2>!<,%M'9+J&)=V1)E]MH6(.;GA'6_-9'/X\V,8"\A"G
M*B?<3MM:+*L4DX-=/@4GQN$9K%-07C.1 >TD9O;NQM&^=7P9F];1WY_HPZ.3
MR5-U>'(8CD:'PW X&1T?C,='AT,5C0Y/U?'_#9]\.2_'@-.M,?(&!]I:]N\_
M>C<*O_CJ_UTW3^"@:07=K8BXOE]ZRX1=_RK:$BI*,>^+=GUU'N7'=^\R.X>&
MRWG._I@ILHLEW@A_W1ONBPCU0QI(DD6ID@E(J>%1($8'PU.Q@Y+)N%AN);F&
MVGFF2Z"1\#HK>B^%F_1JXURB@]^)E*D@ C,K.9YMZS1OLV>?M6'O;HI 5Q O
M01JO,)VCD^HN&3J35"X+VD[8=G3VEC@:'8C?\=QW5%A>XAEK@7@ADTFNHQE\
M;!:2'(R&X]- _'%QMG4D:O2X^R-0UMCNG@Q[_85W2GPI'1$ O>!S7PK-^GK)
M*"T__O@C ;)L(<78VHG[(YHO$._W)>XHV^7LHEDMTU,C2N=@*3[B*=)3DWW$
M:>:E.7JA>UH:P4W9 W^:2+@(/:'32O&!0HQ'6EAPQR8,5S-,]6"F]O6;#X%X
MC_/[ZYMWYX%!S(/]Y!6<4EY^17!6-<R_P;W@0_=PG@@(DW*0=.J9P;,LX_K4
MI8PKFN5&^X')!0N57EAT5S274;Q1JACG\MNC+A$OH09@Z^"B<@94,RN*@!)0
M[P&K-LY6Q><O5"?/MYGD-SRYX[4;WKG@?]Z8@M/!T3$.^6ZSQ+$;E_CLWL,>
MOWOF.A"ND&#4Y3!X@HH!5*!#:F3T5>C1,[G^K(H2&-[S>^4E1M#V%F&2/X[3
M>_NLCT8!.[/<"O[&XK^K5(GQ =XV&B(":$SP4UF&2.RV'F-SP7(O$J,XM&QJ
MAT"KN-8HP#7Q:H9(;& Y)2,!4X*RQ8QF^.';5"PNU;]Z3C&^1WW"?/B:+'4S
M4?]5N>QE+.^%ATY[+ZSO/:?\9VGD'7#L[;?Q8'AG3/'>RJ9\%GA1HW,[R&>C
MJOR2R9SJ&E\21GG6"0OTH:.BG1WUX*30 >,$309ZU2PW1X)E"W>\ZZ+*P[DL
ME#A^&L!XL;F\ S[OG=V&D XP4UGXT=I.X\.ML)Q>I9I.\OI'?D_&$Q_6;D]S
MYP($/E?>G*$ATU03N%ON2ASJNB.*VO2=^9:B5CWC<[0V+-T-UFPN&7L6#UF#
MEQ#(#9,%=6 J=4YZN,(3%1AYA^CSDTX8(/AOHQ$1"@E#=R9*U"1>$)P(0H!'
ML^4$$"\FLB" *'.Z'DT!1QX7N::#@?D0%0J_P5AVMH:NSG@%B*SNMJC0HRM&
M7&Z0."-I^)WS8%OPNX,<O>Q8 #YKT)AJGB+41TB@AYV@-Q%AZ8!BSXCEO(UE
MVBS,,] K:,A9'H68C.6:CIG'EE,'IMX]8WZ[F,HY=QP'>5]+WUP^N[+>,C+K
MK]'^&O'ILI28H@#*ZEQ/-%^TA7!(2S'//AV,8@\PQ.HZDDFM;3T0OYH8NT1,
M*5M)%V75I&291(Q(I!6J[D4OS<D(=39;760122Q:K3?=3/&@>)M&31TIG9-0
M']31W1&$9^5O"Z_(TW(T?/)7Y'2_R_RC*L7_$,/;D9WCZ[W^[!+S3>T8K\-K
M#=N/[$%]AN$!?S>KV+>KN;=+/%6>(PETO($9O<%X%^.CUAKRT.#5Y9S*5^%2
M'#/V(^M+]H@I*V:H!X$]T=2 P/3U!.:-SXM?VD-.F&_0,8,]$JWS@M8I)$XS
M,6:<R="POC.3A-)&L =15U32!K(:$M*6\-/"TWBPI]@L=F4@SC<0Q!53/!S=
MRA1?0IY]TVPJ[6YKFMLNRB^9YS_8\/8T6%<(ZM2$PL#R9KGO.6R2'<F2YA09
MM X\L\].3X[5I=Z*F>EE<)*I$VT;L1B\&M8$3XY@Y0;8X%018#9A:?/2><TT
MR\ ]#<_04-T[KV^;9#<VTR>_B3#QB.(*"UV]WC&LJT7!#OGH65/-+%[,"?^$
M8[MTS-$5_"RP+9D3#+*JM.BP#JP;IY.[[YU)?$.NBRB(.\.#72H=+?C@Y:O8
MHGB=E>BA<1TR,DK-,LI0TLV2Y39N)$R+6BD^MD4ZG[XA3U17@(UC;\PY>U<H
MPF;0363HQEAMH('/Y\#++ (I7\OIY@R')RY(-EC=G8B7U32:\=YV[48K;+:A
MFUP6IXJT-[.KF%;,VL8JG97NU!&:%Q2!,"-?Y)3QTY%N,??J&FK6>XT'*[U6
M*_$.K(ITD\(UND+A.AG_E^>E_K(4D*^3MOOU4KV^  SLFV/M"L?:ZTR\(:.'
MV>\]V(=\\H0YB*%CPG5/$$++2V!>)_8WLC :)&OX0!UBY^26>(!QX"L!$+K(
M!W625 ONP$+XXIGOJ\V((!O&^UF3=$-$A.<]?. V(!).QX/AT\//@4@X&CR]
M#="!IX/3H\V7/[?9X\'HX'J@ S>;@L.#6YB"D\'XFE-P2P@)=Q?,VEQ\^)DE
M9(\8'N(O6_+W#:E@.\9R[1+V;] $#VHLGXM <9=(!??&EO[:( H/F?\:!0.L
M@4>Q56DX;\(RH]RIIY04=7 [;/?Q(#J\I?1PM "!AYT\%]='>/BF;6UOI[=W
M?_Z5V$T_',<F/^:F[-1;<*;<H]OFEKPTAZ>#PX//\M*<G@Q.#V[D3/ABCG<-
MNKCI/'\+2EPS*+$_R:(U_)F72?SS_P-02P$"% ,4    "  *1%Y1Y-3[#1H)
M  !#/P  &0              @ $     979E;&]Q,S(P,C!E>&AI8FET,S$Q
M+FAT;5!+ 0(4 Q0    (  I$7E%ULY6B- 4  (L?   9              "
M 5$)  !E=F5L;W$S,C R,&5X:&EB:70S,C$N:'1M4$L! A0#%     @ "D1>
M4=<R\]\VF ( F1<7 !$              ( !O X  &5V;&\M,C R,# Y,S N
M:'1M4$L! A0#%     @ "D1>44I "7A=#P  /9P  !$              ( !
M(:<" &5V;&\M,C R,# Y,S N>'-D4$L! A0#%     @ "D1>4:@A(L _&0
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F8FET,3 S,C R,'$S+FAT;5!+!08     "@ * )P"  !E<00    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
